id	sid	tid	token	lemma	pos
dpc-1415	1	1	dermatology	dermatology	NOUN
dpc-1415	1	2	:	:	PUNCT
dpc-1415	1	3	practical	practical	ADJ
dpc-1415	1	4	and	and	CCONJ
dpc-1415	1	5	conceptual	conceptual	ADJ
dpc-1415	1	6	review	review	NOUN
dpc-1415	1	7	|	|	ADV
dpc-1415	1	8	dermatol	dermatol	ADJ
dpc-1415	1	9	pract	pract	NOUN
dpc-1415	1	10	concept	concept	NOUN
dpc-1415	1	11	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	1	12	1	1	NUM
dpc-1415	1	13	dermatology	dermatology	NOUN
dpc-1415	1	14	practical	practical	ADJ
dpc-1415	1	15	&	&	CCONJ
dpc-1415	1	16	conceptual	conceptual	ADJ
dpc-1415	1	17	cutaneous	cutaneous	ADJ
dpc-1415	1	18	adverse	adverse	ADJ
dpc-1415	1	19	events	event	NOUN
dpc-1415	1	20	of	of	ADP
dpc-1415	1	21	immune	immune	ADJ
dpc-1415	1	22	checkpoint	checkpoint	NOUN
dpc-1415	1	23	 	 	SPACE
dpc-1415	1	24	inhibitors	inhibitor	NOUN
dpc-1415	1	25	:	:	PUNCT
dpc-1415	1	26	a	a	DET
dpc-1415	1	27	literature	literature	NOUN
dpc-1415	1	28	review	review	NOUN
dpc-1415	1	29	zoe	zoe	PROPN
dpc-1415	1	30	apalla1	apalla1	PROPN
dpc-1415	1	31	,	,	PUNCT
dpc-1415	1	32	chryssoula	chryssoula	PROPN
dpc-1415	1	33	papageorgiou1	papageorgiou1	NOUN
dpc-1415	1	34	,	,	PUNCT
dpc-1415	1	35	aimilios	aimilios	PROPN
dpc-1415	1	36	lallas2	lallas2	NOUN
dpc-1415	1	37	,	,	PUNCT
dpc-1415	1	38	florentina	florentina	PROPN
dpc-1415	1	39	delli3	delli3	PROPN
dpc-1415	1	40	,	,	PUNCT
dpc-1415	1	41	christina	christina	PROPN
dpc-1415	1	42	fotiadou1	fotiadou1	PROPN
dpc-1415	1	43	,	,	PUNCT
dpc-1415	1	44	christina	christina	PROPN
dpc-1415	1	45	kemanetzi1	kemanetzi1	PROPN
dpc-1415	1	46	,	,	PUNCT
dpc-1415	1	47	elizabeth	elizabeth	PROPN
dpc-1415	1	48	lazaridou1	lazaridou1	PROPN
dpc-1415	2	1	1	1	NUM
dpc-1415	2	2	second	second	ADJ
dpc-1415	2	3	dermatology	dermatology	NOUN
dpc-1415	2	4	department	department	NOUN
dpc-1415	2	5	,	,	PUNCT
dpc-1415	2	6	school	school	NOUN
dpc-1415	2	7	of	of	ADP
dpc-1415	2	8	medicine	medicine	NOUN
dpc-1415	2	9	,	,	PUNCT
dpc-1415	2	10	aristotle	aristotle	PROPN
dpc-1415	2	11	university	university	PROPN
dpc-1415	2	12	of	of	ADP
dpc-1415	2	13	thessaloniki	thessaloniki	PROPN
dpc-1415	2	14	,	,	PUNCT
dpc-1415	2	15	greece	greece	PROPN
dpc-1415	2	16	2	2	NUM
dpc-1415	2	17	first	first	ADJ
dpc-1415	2	18	dermatology	dermatology	NOUN
dpc-1415	2	19	department	department	NOUN
dpc-1415	2	20	,	,	PUNCT
dpc-1415	2	21	school	school	NOUN
dpc-1415	2	22	of	of	ADP
dpc-1415	2	23	medicine	medicine	NOUN
dpc-1415	2	24	,	,	PUNCT
dpc-1415	2	25	aristotle	aristotle	PROPN
dpc-1415	2	26	university	university	PROPN
dpc-1415	2	27	of	of	ADP
dpc-1415	2	28	thessaloniki	thessaloniki	PROPN
dpc-1415	2	29	,	,	PUNCT
dpc-1415	2	30	greece	greece	PROPN
dpc-1415	2	31	3	3	NUM
dpc-1415	2	32	state	state	NOUN
dpc-1415	2	33	dermatology	dermatology	NOUN
dpc-1415	2	34	department	department	NOUN
dpc-1415	2	35	,	,	PUNCT
dpc-1415	2	36	hippokratio	hippokratio	NOUN
dpc-1415	2	37	general	general	ADJ
dpc-1415	2	38	hospital	hospital	PROPN
dpc-1415	2	39	of	of	ADP
dpc-1415	2	40	thessaloniki	thessaloniki	PROPN
dpc-1415	2	41	,	,	PUNCT
dpc-1415	2	42	greece	greece	PROPN
dpc-1415	2	43	key	key	ADJ
dpc-1415	2	44	words	word	NOUN
dpc-1415	2	45	:	:	PUNCT
dpc-1415	2	46	immune	immune	ADJ
dpc-1415	2	47	checkpoint	checkpoint	NOUN
dpc-1415	2	48	inhibitors	inhibitor	NOUN
dpc-1415	2	49	,	,	PUNCT
dpc-1415	2	50	skin	skin	NOUN
dpc-1415	2	51	toxicity	toxicity	NOUN
dpc-1415	2	52	,	,	PUNCT
dpc-1415	2	53	adverse	adverse	ADJ
dpc-1415	2	54	effects	effect	NOUN
dpc-1415	2	55	,	,	PUNCT
dpc-1415	2	56	nivolumab	nivolumab	NOUN
dpc-1415	2	57	,	,	PUNCT
dpc-1415	2	58	pembrolizumab	pembrolizumab	NOUN
dpc-1415	2	59	,	,	PUNCT
dpc-1415	2	60	ipilimumab	ipilimumab	ADJ
dpc-1415	2	61	citation	citation	NOUN
dpc-1415	2	62	:	:	PUNCT
dpc-1415	2	63	apalla	apalla	PROPN
dpc-1415	2	64	z	z	PROPN
dpc-1415	2	65	,	,	PUNCT
dpc-1415	2	66	papageorgiou	papageorgiou	NOUN
dpc-1415	2	67	c	c	NOUN
dpc-1415	2	68	,	,	PUNCT
dpc-1415	2	69	lallas	lallas	PROPN
dpc-1415	2	70	a	a	PRON
dpc-1415	2	71	,	,	PUNCT
dpc-1415	2	72	delli	delli	PROPN
dpc-1415	2	73	f	f	NOUN
dpc-1415	2	74	,	,	PUNCT
dpc-1415	2	75	fotiadou	fotiadou	PROPN
dpc-1415	2	76	c	c	PROPN
dpc-1415	2	77	,	,	PUNCT
dpc-1415	2	78	kemanetzi	kemanetzi	NOUN
dpc-1415	2	79	c	c	NOUN
dpc-1415	2	80	,	,	PUNCT
dpc-1415	2	81	lazaridou	lazaridou	PROPN
dpc-1415	2	82	e.	e.	PROPN
dpc-1415	2	83	cutaneous	cutaneous	ADJ
dpc-1415	2	84	adverse	adverse	ADJ
dpc-1415	2	85	events	event	NOUN
dpc-1415	2	86	of	of	ADP
dpc-1415	2	87	immune	immune	ADJ
dpc-1415	2	88	checkpoint	checkpoint	NOUN
dpc-1415	2	89	inhibitors	inhibitor	NOUN
dpc-1415	2	90	:	:	PUNCT
dpc-1415	2	91	a	a	DET
dpc-1415	2	92	literature	literature	NOUN
dpc-1415	2	93	review	review	NOUN
dpc-1415	2	94	.	.	PUNCT
dpc-1415	3	1	dermatol	dermatol	NOUN
dpc-1415	3	2	pract	pract	PROPN
dpc-1415	3	3	concept	concept	NOUN
dpc-1415	3	4	.	.	PUNCT
dpc-1415	4	1	2021;11(1):e2021155	2021;11(1):e2021155	X
dpc-1415	4	2	.	.	X
dpc-1415	4	3	doi	doi	PROPN
dpc-1415	4	4	:	:	PUNCT
dpc-1415	4	5	https://doi.org/10.5826/dpc.1101a155	https://doi.org/10.5826/dpc.1101a155	PROPN
dpc-1415	4	6	accepted	accept	VERB
dpc-1415	4	7	:	:	PUNCT
dpc-1415	4	8	september	september	PROPN
dpc-1415	4	9	28	28	NUM
dpc-1415	4	10	,	,	PUNCT
dpc-1415	4	11	2020	2020	NUM
dpc-1415	4	12	;	;	PUNCT
dpc-1415	4	13	published	publish	VERB
dpc-1415	4	14	:	:	PUNCT
dpc-1415	4	15	january	january	PROPN
dpc-1415	4	16	29	29	NUM
dpc-1415	4	17	,	,	PUNCT
dpc-1415	4	18	2021	2021	NUM
dpc-1415	4	19	copyright	copyright	NOUN
dpc-1415	4	20	:	:	PUNCT
dpc-1415	4	21	©	©	PROPN
dpc-1415	4	22	2021	2021	NUM
dpc-1415	4	23	apalla	apalla	NOUN
dpc-1415	4	24	et	et	PROPN
dpc-1415	4	25	al	al	PROPN
dpc-1415	4	26	.	.	PUNCT
dpc-1415	5	1	this	this	PRON
dpc-1415	5	2	is	be	AUX
dpc-1415	5	3	an	an	DET
dpc-1415	5	4	open	open	ADJ
dpc-1415	5	5	-	-	PUNCT
dpc-1415	5	6	access	access	NOUN
dpc-1415	5	7	article	article	NOUN
dpc-1415	5	8	distributed	distribute	VERB
dpc-1415	5	9	under	under	ADP
dpc-1415	5	10	the	the	DET
dpc-1415	5	11	terms	term	NOUN
dpc-1415	5	12	of	of	ADP
dpc-1415	5	13	the	the	DET
dpc-1415	5	14	creative	creative	ADJ
dpc-1415	5	15	commons	common	NOUN
dpc-1415	5	16	attribution	attribution	NOUN
dpc-1415	5	17	license	license	NOUN
dpc-1415	5	18	by	by	ADP
dpc-1415	5	19	-	-	PUNCT
dpc-1415	5	20	nc-4.0	nc-4.0	NOUN
dpc-1415	5	21	,	,	PUNCT
dpc-1415	5	22	which	which	PRON
dpc-1415	5	23	permits	permit	VERB
dpc-1415	5	24	unrestricted	unrestricted	ADJ
dpc-1415	5	25	noncommercial	noncommercial	ADJ
dpc-1415	5	26	use	use	NOUN
dpc-1415	5	27	,	,	PUNCT
dpc-1415	5	28	distribution	distribution	NOUN
dpc-1415	5	29	,	,	PUNCT
dpc-1415	5	30	and	and	CCONJ
dpc-1415	5	31	reproduction	reproduction	NOUN
dpc-1415	5	32	in	in	ADP
dpc-1415	5	33	any	any	DET
dpc-1415	5	34	medium	medium	NOUN
dpc-1415	5	35	,	,	PUNCT
dpc-1415	5	36	provided	provide	VERB
dpc-1415	5	37	the	the	DET
dpc-1415	5	38	original	original	ADJ
dpc-1415	5	39	author	author	NOUN
dpc-1415	5	40	and	and	CCONJ
dpc-1415	5	41	source	source	NOUN
dpc-1415	5	42	are	be	AUX
dpc-1415	5	43	credited	credit	VERB
dpc-1415	5	44	.	.	PUNCT
dpc-1415	6	1	funding	funding	NOUN
dpc-1415	6	2	:	:	PUNCT
dpc-1415	6	3	none	none	NOUN
dpc-1415	6	4	.	.	PUNCT
dpc-1415	7	1	competing	compete	VERB
dpc-1415	7	2	interests	interest	NOUN
dpc-1415	7	3	:	:	PUNCT
dpc-1415	7	4	the	the	DET
dpc-1415	7	5	authors	author	NOUN
dpc-1415	7	6	have	have	VERB
dpc-1415	7	7	no	no	DET
dpc-1415	7	8	conflicts	conflict	NOUN
dpc-1415	7	9	of	of	ADP
dpc-1415	7	10	interest	interest	NOUN
dpc-1415	7	11	to	to	PART
dpc-1415	7	12	disclose	disclose	VERB
dpc-1415	7	13	.	.	PUNCT
dpc-1415	8	1	authorship	authorship	NOUN
dpc-1415	8	2	:	:	PUNCT
dpc-1415	8	3	z.a	z.a	PROPN
dpc-1415	8	4	.	.	PROPN
dpc-1415	9	1	and	and	CCONJ
dpc-1415	9	2	c.p	c.p	PROPN
dpc-1415	9	3	.	.	PROPN
dpc-1415	9	4	contributed	contribute	VERB
dpc-1415	9	5	equally	equally	ADV
dpc-1415	9	6	to	to	ADP
dpc-1415	9	7	the	the	DET
dpc-1415	9	8	preparation	preparation	NOUN
dpc-1415	9	9	of	of	ADP
dpc-1415	9	10	the	the	DET
dpc-1415	9	11	manuscript	manuscript	NOUN
dpc-1415	9	12	.	.	PUNCT
dpc-1415	10	1	all	all	DET
dpc-1415	10	2	authors	author	NOUN
dpc-1415	10	3	have	have	AUX
dpc-1415	10	4	contributed	contribute	VERB
dpc-1415	10	5	significantly	significantly	ADV
dpc-1415	10	6	to	to	ADP
dpc-1415	10	7	this	this	DET
dpc-1415	10	8	publication	publication	NOUN
dpc-1415	10	9	.	.	PUNCT
dpc-1415	11	1	corresponding	correspond	VERB
dpc-1415	11	2	author	author	NOUN
dpc-1415	11	3	:	:	PUNCT
dpc-1415	11	4	zoe	zoe	NOUN
dpc-1415	11	5	apalla	apalla	PROPN
dpc-1415	11	6	,	,	PUNCT
dpc-1415	11	7	md	md	PROPN
dpc-1415	11	8	,	,	PUNCT
dpc-1415	11	9	phd	phd	NOUN
dpc-1415	11	10	,	,	PUNCT
dpc-1415	11	11	second	second	ADJ
dpc-1415	11	12	dermatology	dermatology	NOUN
dpc-1415	11	13	department	department	NOUN
dpc-1415	11	14	,	,	PUNCT
dpc-1415	11	15	school	school	NOUN
dpc-1415	11	16	of	of	ADP
dpc-1415	11	17	medicine	medicine	NOUN
dpc-1415	11	18	,	,	PUNCT
dpc-1415	11	19	aristotle	aristotle	PROPN
dpc-1415	11	20	university	university	PROPN
dpc-1415	11	21	of	of	ADP
dpc-1415	11	22	thessaloniki	thessaloniki	PROPN
dpc-1415	11	23	,	,	PUNCT
dpc-1415	11	24	anatolis	anatoli	VERB
dpc-1415	11	25	5	5	NUM
dpc-1415	11	26	,	,	PUNCT
dpc-1415	11	27	55535	55535	NUM
dpc-1415	11	28	,	,	PUNCT
dpc-1415	11	29	thessaloniki	thessaloniki	PROPN
dpc-1415	11	30	,	,	PUNCT
dpc-1415	11	31	greece	greece	PROPN
dpc-1415	11	32	.	.	PUNCT
dpc-1415	12	1	email	email	NOUN
dpc-1415	12	2	:	:	PUNCT
dpc-1415	12	3	zoimd@yahoo.gr	zoimd@yahoo.gr	NOUN
dpc-1415	12	4	immune	immune	ADJ
dpc-1415	12	5	checkpoints	checkpoint	NOUN
dpc-1415	12	6	assist	assist	VERB
dpc-1415	12	7	with	with	ADP
dpc-1415	12	8	self	self	NOUN
dpc-1415	12	9	-	-	PUNCT
dpc-1415	12	10	tolerance	tolerance	NOUN
dpc-1415	12	11	and	and	CCONJ
dpc-1415	12	12	minimize	minimize	VERB
dpc-1415	12	13	collateral	collateral	ADJ
dpc-1415	12	14	tissue	tissue	NOUN
dpc-1415	12	15	damage	damage	NOUN
dpc-1415	12	16	when	when	SCONJ
dpc-1415	12	17	immune	immune	ADJ
dpc-1415	12	18	responses	response	NOUN
dpc-1415	12	19	are	be	AUX
dpc-1415	12	20	activated	activate	VERB
dpc-1415	12	21	.	.	PUNCT
dpc-1415	13	1	although	although	SCONJ
dpc-1415	13	2	immune	immune	ADJ
dpc-1415	13	3	checkpoint	checkpoint	NOUN
dpc-1415	13	4	inhibitors	inhibitor	NOUN
dpc-1415	13	5	(	(	PUNCT
dpc-1415	13	6	cpis	cpis	ADJ
dpc-1415	13	7	)	)	PUNCT
dpc-1415	13	8	are	be	AUX
dpc-1415	13	9	characterized	characterize	VERB
dpc-1415	13	10	by	by	ADP
dpc-1415	13	11	a	a	DET
dpc-1415	13	12	favorable	favorable	ADJ
dpc-1415	13	13	risk	risk	NOUN
dpc-1415	13	14	/	/	SYM
dpc-1415	13	15	benefit	benefit	NOUN
dpc-1415	13	16	ratio	ratio	NOUN
dpc-1415	13	17	,	,	PUNCT
dpc-1415	13	18	immune	immune	ADJ
dpc-1415	13	19	checkpoint	checkpoint	NOUN
dpc-1415	13	20	blockade	blockade	NOUN
dpc-1415	13	21	has	have	AUX
dpc-1415	13	22	been	be	AUX
dpc-1415	13	23	associated	associate	VERB
dpc-1415	13	24	with	with	ADP
dpc-1415	13	25	a	a	DET
dpc-1415	13	26	new	new	ADJ
dpc-1415	13	27	subset	subset	NOUN
dpc-1415	13	28	of	of	ADP
dpc-1415	13	29	autoimmunelike	autoimmunelike	ADJ
dpc-1415	13	30	toxicities	toxicity	NOUN
dpc-1415	13	31	,	,	PUNCT
dpc-1415	13	32	named	name	VERB
dpc-1415	13	33	immune	immune	NOUN
dpc-1415	13	34	-	-	PUNCT
dpc-1415	13	35	related	relate	VERB
dpc-1415	13	36	adverse	adverse	ADJ
dpc-1415	13	37	events	event	NOUN
dpc-1415	13	38	(	(	PUNCT
dpc-1415	13	39	iraes	iraes	NOUN
dpc-1415	13	40	)	)	PUNCT
dpc-1415	13	41	.	.	PUNCT
dpc-1415	14	1	dermatologic	dermatologic	ADJ
dpc-1415	14	2	reactions	reaction	NOUN
dpc-1415	14	3	are	be	AUX
dpc-1415	14	4	among	among	ADP
dpc-1415	14	5	the	the	DET
dpc-1415	14	6	most	most	ADV
dpc-1415	14	7	prevalent	prevalent	ADJ
dpc-1415	14	8	iraes	irae	NOUN
dpc-1415	14	9	triggered	trigger	VERB
dpc-1415	14	10	by	by	ADP
dpc-1415	14	11	cpis	cpis	NOUN
dpc-1415	14	12	.	.	PUNCT
dpc-1415	15	1	in	in	ADP
dpc-1415	15	2	a	a	DET
dpc-1415	15	3	majority	majority	NOUN
dpc-1415	15	4	of	of	ADP
dpc-1415	15	5	cases	case	NOUN
dpc-1415	15	6	they	they	PRON
dpc-1415	15	7	are	be	AUX
dpc-1415	15	8	self	self	NOUN
dpc-1415	15	9	-	-	PUNCT
dpc-1415	15	10	limiting	limit	VERB
dpc-1415	15	11	and	and	CCONJ
dpc-1415	15	12	readily	readily	ADV
dpc-1415	15	13	manageable	manageable	ADJ
dpc-1415	15	14	.	.	PUNCT
dpc-1415	16	1	however	however	ADV
dpc-1415	16	2	,	,	PUNCT
dpc-1415	16	3	it	it	PRON
dpc-1415	16	4	is	be	AUX
dpc-1415	16	5	not	not	PART
dpc-1415	16	6	uncommon	uncommon	ADJ
dpc-1415	16	7	that	that	SCONJ
dpc-1415	16	8	they	they	PRON
dpc-1415	16	9	result	result	VERB
dpc-1415	16	10	in	in	ADP
dpc-1415	16	11	severe	severe	ADJ
dpc-1415	16	12	skin	skin	NOUN
dpc-1415	16	13	involvement	involvement	NOUN
dpc-1415	16	14	and	and	CCONJ
dpc-1415	16	15	impairment	impairment	NOUN
dpc-1415	16	16	of	of	ADP
dpc-1415	16	17	patients	patient	NOUN
dpc-1415	16	18	’	'	PUNCT
dpc-1415	16	19	quality	quality	NOUN
dpc-1415	16	20	of	of	ADP
dpc-1415	16	21	life	life	NOUN
dpc-1415	16	22	.	.	PUNCT
dpc-1415	17	1	awareness	awareness	NOUN
dpc-1415	17	2	of	of	ADP
dpc-1415	17	3	the	the	DET
dpc-1415	17	4	spectrum	spectrum	NOUN
dpc-1415	17	5	of	of	ADP
dpc-1415	17	6	cutaneous	cutaneous	ADJ
dpc-1415	17	7	iraes	iraes	NOUN
dpc-1415	17	8	is	be	AUX
dpc-1415	17	9	mandatory	mandatory	ADJ
dpc-1415	17	10	for	for	ADP
dpc-1415	17	11	every	every	DET
dpc-1415	17	12	clinician	clinician	NOUN
dpc-1415	17	13	involved	involve	VERB
dpc-1415	17	14	in	in	ADP
dpc-1415	17	15	the	the	DET
dpc-1415	17	16	management	management	NOUN
dpc-1415	17	17	of	of	ADP
dpc-1415	17	18	oncologic	oncologic	ADJ
dpc-1415	17	19	patients	patient	NOUN
dpc-1415	17	20	.	.	PUNCT
dpc-1415	18	1	the	the	DET
dpc-1415	18	2	role	role	NOUN
dpc-1415	18	3	of	of	ADP
dpc-1415	18	4	the	the	DET
dpc-1415	18	5	dermatologists	dermatologist	NOUN
dpc-1415	18	6	is	be	AUX
dpc-1415	18	7	essential	essential	ADJ
dpc-1415	18	8	because	because	SCONJ
dpc-1415	18	9	early	early	ADJ
dpc-1415	18	10	recognition	recognition	NOUN
dpc-1415	18	11	and	and	CCONJ
dpc-1415	18	12	appropriate	appropriate	ADJ
dpc-1415	18	13	management	management	NOUN
dpc-1415	18	14	of	of	ADP
dpc-1415	18	15	skin	skin	NOUN
dpc-1415	18	16	toxicity	toxicity	NOUN
dpc-1415	18	17	may	may	AUX
dpc-1415	18	18	prevent	prevent	VERB
dpc-1415	18	19	dose	dose	NOUN
dpc-1415	18	20	modifications	modification	NOUN
dpc-1415	18	21	and	and	CCONJ
dpc-1415	18	22	discontinuation	discontinuation	NOUN
dpc-1415	18	23	of	of	ADP
dpc-1415	18	24	cpis	cpis	NOUN
dpc-1415	18	25	.	.	PUNCT
dpc-1415	19	1	the	the	DET
dpc-1415	19	2	latter	latter	ADJ
dpc-1415	19	3	is	be	AUX
dpc-1415	19	4	particularly	particularly	ADV
dpc-1415	19	5	relevant	relevant	ADJ
dpc-1415	19	6	,	,	PUNCT
dpc-1415	19	7	considering	consider	VERB
dpc-1415	19	8	that	that	SCONJ
dpc-1415	19	9	recent	recent	ADJ
dpc-1415	19	10	data	datum	NOUN
dpc-1415	19	11	suggest	suggest	VERB
dpc-1415	19	12	favorable	favorable	ADJ
dpc-1415	19	13	oncologic	oncologic	ADJ
dpc-1415	19	14	response	response	NOUN
dpc-1415	19	15	in	in	ADP
dpc-1415	19	16	patients	patient	NOUN
dpc-1415	19	17	developing	develop	VERB
dpc-1415	19	18	iraes	irae	NOUN
dpc-1415	19	19	.	.	PUNCT
dpc-1415	20	1	abstract	abstract	ADJ
dpc-1415	20	2	2	2	NUM
dpc-1415	20	3	review	review	NOUN
dpc-1415	20	4	|	|	ADV
dpc-1415	20	5	dermatol	dermatol	ADJ
dpc-1415	20	6	pract	pract	NOUN
dpc-1415	20	7	concept	concept	NOUN
dpc-1415	20	8	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	20	9	introduction	introduction	NOUN
dpc-1415	20	10	checkpoint	checkpoint	NOUN
dpc-1415	20	11	inhibitor	inhibitor	NOUN
dpc-1415	20	12	mode	mode	NOUN
dpc-1415	20	13	of	of	ADP
dpc-1415	20	14	action	action	NOUN
dpc-1415	20	15	checkpoint	checkpoint	NOUN
dpc-1415	20	16	inhibitors	inhibitor	NOUN
dpc-1415	20	17	(	(	PUNCT
dpc-1415	20	18	cpis	cpis	ADJ
dpc-1415	20	19	)	)	PUNCT
dpc-1415	20	20	are	be	AUX
dpc-1415	20	21	molecules	molecule	NOUN
dpc-1415	20	22	that	that	PRON
dpc-1415	20	23	increase	increase	VERB
dpc-1415	20	24	the	the	DET
dpc-1415	20	25	endogenous	endogenous	ADJ
dpc-1415	20	26	immune	immune	ADJ
dpc-1415	20	27	response	response	NOUN
dpc-1415	20	28	against	against	ADP
dpc-1415	20	29	tumors	tumor	NOUN
dpc-1415	20	30	by	by	ADP
dpc-1415	20	31	blocking	block	VERB
dpc-1415	20	32	receptors	receptor	NOUN
dpc-1415	20	33	responsible	responsible	ADJ
dpc-1415	20	34	for	for	ADP
dpc-1415	20	35	lymphocyte	lymphocyte	ADJ
dpc-1415	20	36	inactivation	inactivation	NOUN
dpc-1415	20	37	.	.	PUNCT
dpc-1415	21	1	immune	immune	ADJ
dpc-1415	21	2	checkpoints	checkpoint	NOUN
dpc-1415	21	3	include	include	VERB
dpc-1415	21	4	cytotoxic	cytotoxic	ADJ
dpc-1415	21	5	t	t	PROPN
dpc-1415	21	6	-	-	PUNCT
dpc-1415	21	7	lymphocyte	lymphocyte	NOUN
dpc-1415	21	8	antigen	antigen	NOUN
dpc-1415	21	9	4	4	NUM
dpc-1415	21	10	(	(	PUNCT
dpc-1415	21	11	ctla-4	ctla-4	NOUN
dpc-1415	21	12	)	)	PUNCT
dpc-1415	21	13	,	,	PUNCT
dpc-1415	21	14	programmed	program	VERB
dpc-1415	21	15	cell	cell	NOUN
dpc-1415	21	16	death	death	NOUN
dpc-1415	21	17	1	1	NUM
dpc-1415	21	18	(	(	PUNCT
dpc-1415	21	19	pd-1	pd-1	ADV
dpc-1415	21	20	)	)	PUNCT
dpc-1415	21	21	and	and	CCONJ
dpc-1415	21	22	programmed	program	VERB
dpc-1415	21	23	cell	cell	NOUN
dpc-1415	21	24	death	death	NOUN
dpc-1415	21	25	ligand	ligand	NOUN
dpc-1415	21	26	1	1	NUM
dpc-1415	21	27	(	(	PUNCT
dpc-1415	21	28	pd	pd	NOUN
dpc-1415	21	29	-	-	PUNCT
dpc-1415	21	30	l1	l1	PROPN
dpc-1415	21	31	)	)	PUNCT
dpc-1415	21	32	.	.	PUNCT
dpc-1415	22	1	the	the	DET
dpc-1415	22	2	ctla-4	ctla-4	NOUN
dpc-1415	22	3	,	,	PUNCT
dpc-1415	22	4	pd-1	pd-1	ADV
dpc-1415	22	5	,	,	PUNCT
dpc-1415	22	6	and	and	CCONJ
dpc-1415	22	7	pd	pd	PROPN
dpc-1415	22	8	-	-	PROPN
dpc-1415	22	9	l1	l1	PROPN
dpc-1415	22	10	pathways	pathway	NOUN
dpc-1415	22	11	mediate	mediate	VERB
dpc-1415	22	12	immune	immune	ADJ
dpc-1415	22	13	responses	response	NOUN
dpc-1415	22	14	at	at	ADP
dpc-1415	22	15	different	different	ADJ
dpc-1415	22	16	levels	level	NOUN
dpc-1415	22	17	.	.	PUNCT
dpc-1415	23	1	ctla-4	ctla-4	NOUN
dpc-1415	23	2	controls	control	VERB
dpc-1415	23	3	the	the	DET
dpc-1415	23	4	amplitude	amplitude	NOUN
dpc-1415	23	5	of	of	ADP
dpc-1415	23	6	immunologic	immunologic	ADJ
dpc-1415	23	7	response	response	NOUN
dpc-1415	23	8	at	at	ADP
dpc-1415	23	9	early	early	ADJ
dpc-1415	23	10	stages	stage	NOUN
dpc-1415	23	11	of	of	ADP
dpc-1415	23	12	t	t	NOUN
dpc-1415	23	13	cell	cell	NOUN
dpc-1415	23	14	activation	activation	NOUN
dpc-1415	23	15	,	,	PUNCT
dpc-1415	23	16	whereas	whereas	SCONJ
dpc-1415	23	17	pd-1	pd-1	ADV
dpc-1415	23	18	and	and	CCONJ
dpc-1415	23	19	pd	pd	PROPN
dpc-1415	23	20	-	-	PROPN
dpc-1415	23	21	l1	l1	PROPN
dpc-1415	23	22	pathways	pathway	NOUN
dpc-1415	23	23	act	act	VERB
dpc-1415	23	24	at	at	ADP
dpc-1415	23	25	later	later	ADJ
dpc-1415	23	26	stages	stage	NOUN
dpc-1415	23	27	,	,	PUNCT
dpc-1415	23	28	limiting	limit	VERB
dpc-1415	23	29	t	t	NOUN
dpc-1415	23	30	cell	cell	NOUN
dpc-1415	23	31	activity	activity	NOUN
dpc-1415	23	32	in	in	ADP
dpc-1415	23	33	the	the	DET
dpc-1415	23	34	peripheral	peripheral	ADJ
dpc-1415	23	35	tissues	tissue	NOUN
dpc-1415	23	36	.	.	PUNCT
dpc-1415	24	1	by	by	ADP
dpc-1415	24	2	activating	activate	VERB
dpc-1415	24	3	cytotoxic	cytotoxic	ADJ
dpc-1415	24	4	cd4+/	cd4+/	NOUN
dpc-1415	24	5	cd8	cd8	PROPN
dpc-1415	24	6	+	+	PROPN
dpc-1415	24	7	t	t	NOUN
dpc-1415	24	8	cells	cell	NOUN
dpc-1415	24	9	,	,	PUNCT
dpc-1415	24	10	immune	immune	ADJ
dpc-1415	24	11	checkpoint	checkpoint	NOUN
dpc-1415	24	12	blockade	blockade	NOUN
dpc-1415	24	13	therapy	therapy	NOUN
dpc-1415	24	14	shifts	shift	NOUN
dpc-1415	24	15	the	the	DET
dpc-1415	24	16	immune	immune	ADJ
dpc-1415	24	17	system	system	NOUN
dpc-1415	24	18	towards	towards	ADP
dpc-1415	24	19	anti	anti	ADJ
dpc-1415	24	20	-	-	ADJ
dpc-1415	24	21	tumor	tumor	ADJ
dpc-1415	24	22	activity	activity	NOUN
dpc-1415	24	23	[	[	X
dpc-1415	24	24	1,2	1,2	NUM
dpc-1415	24	25	]	]	PUNCT
dpc-1415	24	26	.	.	PUNCT
dpc-1415	25	1	due	due	ADP
dpc-1415	25	2	to	to	ADP
dpc-1415	25	3	their	their	PRON
dpc-1415	25	4	innovative	innovative	ADJ
dpc-1415	25	5	,	,	PUNCT
dpc-1415	25	6	immune	immune	NOUN
dpc-1415	25	7	-	-	PUNCT
dpc-1415	25	8	based	base	VERB
dpc-1415	25	9	mode	mode	NOUN
dpc-1415	25	10	of	of	ADP
dpc-1415	25	11	action	action	NOUN
dpc-1415	25	12	,	,	PUNCT
dpc-1415	25	13	they	they	PRON
dpc-1415	25	14	entail	entail	VERB
dpc-1415	25	15	a	a	DET
dpc-1415	25	16	new	new	ADJ
dpc-1415	25	17	group	group	NOUN
dpc-1415	25	18	of	of	ADP
dpc-1415	25	19	adverse	adverse	ADJ
dpc-1415	25	20	effects	effect	NOUN
dpc-1415	25	21	,	,	PUNCT
dpc-1415	25	22	which	which	PRON
dpc-1415	25	23	are	be	AUX
dpc-1415	25	24	immune	immune	NOUN
dpc-1415	25	25	-	-	PUNCT
dpc-1415	25	26	mediated	mediate	VERB
dpc-1415	25	27	in	in	ADP
dpc-1415	25	28	their	their	PRON
dpc-1415	25	29	nature	nature	NOUN
dpc-1415	25	30	.	.	PUNCT
dpc-1415	26	1	the	the	DET
dpc-1415	26	2	responsible	responsible	ADJ
dpc-1415	26	3	etiopathogenic	etiopathogenic	ADJ
dpc-1415	26	4	mechanism	mechanism	NOUN
dpc-1415	26	5	driving	drive	VERB
dpc-1415	26	6	cutaneous	cutaneous	ADJ
dpc-1415	26	7	immune	immune	NOUN
dpc-1415	26	8	-	-	PUNCT
dpc-1415	26	9	related	relate	VERB
dpc-1415	26	10	adverse	adverse	ADJ
dpc-1415	26	11	events	event	NOUN
dpc-1415	26	12	(	(	PUNCT
dpc-1415	26	13	iraes	iraes	NOUN
dpc-1415	26	14	)	)	PUNCT
dpc-1415	26	15	has	have	AUX
dpc-1415	26	16	not	not	PART
dpc-1415	26	17	been	be	AUX
dpc-1415	26	18	completely	completely	ADV
dpc-1415	26	19	elucidated	elucidated	ADJ
dpc-1415	26	20	.	.	PUNCT
dpc-1415	27	1	however	however	ADV
dpc-1415	27	2	,	,	PUNCT
dpc-1415	27	3	it	it	PRON
dpc-1415	27	4	seems	seem	VERB
dpc-1415	27	5	to	to	PART
dpc-1415	27	6	be	be	AUX
dpc-1415	27	7	connected	connect	VERB
dpc-1415	27	8	to	to	ADP
dpc-1415	27	9	the	the	DET
dpc-1415	27	10	t	t	NOUN
dpc-1415	27	11	cell	cell	NOUN
dpc-1415	27	12	activation	activation	NOUN
dpc-1415	27	13	,	,	PUNCT
dpc-1415	27	14	mediated	mediate	VERB
dpc-1415	27	15	by	by	ADP
dpc-1415	27	16	the	the	DET
dpc-1415	27	17	blockade	blockade	NOUN
dpc-1415	27	18	of	of	ADP
dpc-1415	27	19	pd-1	pd-1	ADP
dpc-1415	27	20	/	/	SYM
dpc-1415	27	21	pd	pd	NOUN
dpc-1415	27	22	-	-	PROPN
dpc-1415	27	23	l1	l1	PROPN
dpc-1415	27	24	and	and	CCONJ
dpc-1415	27	25	ctla-4	ctla-4	NOUN
dpc-1415	27	26	receptors	receptor	NOUN
dpc-1415	27	27	.	.	PUNCT
dpc-1415	28	1	ipilimumab	ipilimumab	ADJ
dpc-1415	28	2	,	,	PUNCT
dpc-1415	28	3	an	an	DET
dpc-1415	28	4	anti	anti	ADJ
dpc-1415	28	5	-	-	ADJ
dpc-1415	28	6	ctla-4	ctla-4	ADJ
dpc-1415	28	7	antibody	antibody	NOUN
dpc-1415	28	8	,	,	PUNCT
dpc-1415	28	9	was	be	AUX
dpc-1415	28	10	the	the	DET
dpc-1415	28	11	first	first	ADJ
dpc-1415	28	12	licensed	licensed	ADJ
dpc-1415	28	13	cpi	cpi	PROPN
dpc-1415	28	14	after	after	ADP
dpc-1415	28	15	demonstrating	demonstrate	VERB
dpc-1415	28	16	improved	improve	VERB
dpc-1415	28	17	overall	overall	ADJ
dpc-1415	28	18	survival	survival	NOUN
dpc-1415	28	19	in	in	ADP
dpc-1415	28	20	patients	patient	NOUN
dpc-1415	28	21	with	with	ADP
dpc-1415	28	22	melanoma	melanoma	NOUN
dpc-1415	28	23	.	.	PUNCT
dpc-1415	29	1	the	the	DET
dpc-1415	29	2	anti	anti	ADJ
dpc-1415	29	3	-	-	ADJ
dpc-1415	29	4	pd-1	pd-1	ADJ
dpc-1415	29	5	monoclonal	monoclonal	NOUN
dpc-1415	29	6	antibodies	antibody	NOUN
dpc-1415	29	7	block	block	VERB
dpc-1415	29	8	the	the	DET
dpc-1415	29	9	pd-1	pd-1	ADJ
dpc-1415	29	10	receptor	receptor	NOUN
dpc-1415	29	11	and	and	CCONJ
dpc-1415	29	12	the	the	DET
dpc-1415	29	13	anti	anti	ADJ
dpc-1415	29	14	-	-	ADJ
dpc-1415	29	15	pd	pd	ADJ
dpc-1415	29	16	-	-	PUNCT
dpc-1415	29	17	l1	l1	PROPN
dpc-1415	29	18	monoclonal	monoclonal	NOUN
dpc-1415	29	19	antibodies	antibody	NOUN
dpc-1415	29	20	block	block	VERB
dpc-1415	29	21	the	the	DET
dpc-1415	29	22	pd	pd	PROPN
dpc-1415	29	23	-	-	PUNCT
dpc-1415	29	24	l1	l1	PROPN
dpc-1415	29	25	receptor	receptor	NOUN
dpc-1415	29	26	.	.	PUNCT
dpc-1415	30	1	in	in	ADP
dpc-1415	30	2	this	this	DET
dpc-1415	30	3	scenario	scenario	NOUN
dpc-1415	30	4	,	,	PUNCT
dpc-1415	30	5	blocking	block	VERB
dpc-1415	30	6	with	with	ADP
dpc-1415	30	7	a	a	DET
dpc-1415	30	8	cpi	cpi	NOUN
dpc-1415	30	9	(	(	PUNCT
dpc-1415	30	10	either	either	CCONJ
dpc-1415	30	11	anti	anti	ADJ
dpc-1415	30	12	-	-	ADJ
dpc-1415	30	13	pd	pd	ADJ
dpc-1415	30	14	-	-	PUNCT
dpc-1415	30	15	l1	l1	PROPN
dpc-1415	30	16	,	,	PUNCT
dpc-1415	30	17	either	either	CCONJ
dpc-1415	30	18	anti	anti	ADJ
dpc-1415	30	19	-	-	ADJ
dpc-1415	30	20	pd-1	pd-1	ADJ
dpc-1415	30	21	)	)	PUNCT
dpc-1415	30	22	the	the	DET
dpc-1415	30	23	binding	binding	NOUN
dpc-1415	30	24	of	of	ADP
dpc-1415	30	25	pd	pd	PROPN
dpc-1415	30	26	-	-	PROPN
dpc-1415	30	27	l1	l1	PROPN
dpc-1415	30	28	to	to	ADP
dpc-1415	30	29	pd-1	pd-1	X
dpc-1415	30	30	,	,	PUNCT
dpc-1415	30	31	the	the	DET
dpc-1415	30	32	t	t	NOUN
dpc-1415	30	33	cells	cell	NOUN
dpc-1415	30	34	are	be	AUX
dpc-1415	30	35	no	no	ADV
dpc-1415	30	36	longer	long	ADV
dpc-1415	30	37	inhibited	inhibited	ADJ
dpc-1415	30	38	and	and	CCONJ
dpc-1415	30	39	therefore	therefore	ADV
dpc-1415	30	40	the	the	DET
dpc-1415	30	41	immune	immune	ADJ
dpc-1415	30	42	response	response	NOUN
dpc-1415	30	43	against	against	ADP
dpc-1415	30	44	the	the	DET
dpc-1415	30	45	tumor	tumor	NOUN
dpc-1415	30	46	is	be	AUX
dpc-1415	30	47	activated	activate	VERB
dpc-1415	31	1	[	[	PUNCT
dpc-1415	31	2	1	1	NUM
dpc-1415	31	3	]	]	PUNCT
dpc-1415	31	4	.	.	PUNCT
dpc-1415	32	1	implication	implication	NOUN
dpc-1415	32	2	of	of	ADP
dpc-1415	32	3	cpi	cpi	PROPN
dpc-1415	32	4	mode	mode	NOUN
dpc-1415	32	5	of	of	ADP
dpc-1415	32	6	action	action	NOUN
dpc-1415	32	7	in	in	ADP
dpc-1415	32	8	the	the	DET
dpc-1415	32	9	development	development	NOUN
dpc-1415	32	10	of	of	ADP
dpc-1415	32	11	cutaneous	cutaneous	ADJ
dpc-1415	32	12	iraes	irae	NOUN
dpc-1415	32	13	due	due	ADP
dpc-1415	32	14	to	to	ADP
dpc-1415	32	15	their	their	PRON
dpc-1415	32	16	unique	unique	ADJ
dpc-1415	32	17	mechanism	mechanism	NOUN
dpc-1415	32	18	of	of	ADP
dpc-1415	32	19	action	action	NOUN
dpc-1415	32	20	,	,	PUNCT
dpc-1415	32	21	cpis	cpis	PROPN
dpc-1415	32	22	result	result	VERB
dpc-1415	32	23	in	in	ADP
dpc-1415	32	24	a	a	DET
dpc-1415	32	25	new	new	ADJ
dpc-1415	32	26	spectrum	spectrum	NOUN
dpc-1415	32	27	of	of	ADP
dpc-1415	32	28	adverse	adverse	ADJ
dpc-1415	32	29	events	event	NOUN
dpc-1415	32	30	referred	refer	VERB
dpc-1415	32	31	to	to	ADP
dpc-1415	32	32	as	as	ADP
dpc-1415	32	33	iraes	irae	NOUN
dpc-1415	32	34	.	.	PUNCT
dpc-1415	33	1	cpis	cpis	PROPN
dpc-1415	33	2	include	include	VERB
dpc-1415	33	3	anti	anti	ADJ
dpc-1415	33	4	-	-	ADJ
dpc-1415	33	5	pd-1	pd-1	ADJ
dpc-1415	33	6	(	(	PUNCT
dpc-1415	33	7	nivolumab	nivolumab	NOUN
dpc-1415	33	8	and	and	CCONJ
dpc-1415	33	9	pembrolizumab	pembrolizumab	NOUN
dpc-1415	33	10	)	)	PUNCT
dpc-1415	33	11	and	and	CCONJ
dpc-1415	33	12	anti	anti	ADJ
dpc-1415	33	13	-	-	ADJ
dpc-1415	33	14	ctla-4	ctla-4	ADJ
dpc-1415	33	15	(	(	PUNCT
dpc-1415	33	16	ipilimumab	ipilimumab	ADJ
dpc-1415	33	17	,	,	PUNCT
dpc-1415	33	18	tremelimumab	tremelimumab	NOUN
dpc-1415	33	19	)	)	PUNCT
dpc-1415	33	20	agents	agent	NOUN
dpc-1415	33	21	,	,	PUNCT
dpc-1415	33	22	as	as	ADV
dpc-1415	33	23	well	well	ADV
dpc-1415	33	24	as	as	ADP
dpc-1415	33	25	the	the	DET
dpc-1415	33	26	newly	newly	ADV
dpc-1415	33	27	developed	develop	VERB
dpc-1415	33	28	anti	anti	ADJ
dpc-1415	33	29	-	-	ADJ
dpc-1415	33	30	pd	pd	ADJ
dpc-1415	33	31	-	-	PUNCT
dpc-1415	33	32	l1	l1	PROPN
dpc-1415	33	33	agents	agent	NOUN
dpc-1415	33	34	(	(	PUNCT
dpc-1415	33	35	atezolizumab	atezolizumab	PROPN
dpc-1415	33	36	,	,	PUNCT
dpc-1415	33	37	durvalumab	durvalumab	NOUN
dpc-1415	33	38	,	,	PUNCT
dpc-1415	33	39	avelumab	avelumab	NOUN
dpc-1415	33	40	)	)	PUNCT
dpc-1415	33	41	.	.	PUNCT
dpc-1415	34	1	cutaneous	cutaneous	ADJ
dpc-1415	34	2	iraes	irae	NOUN
dpc-1415	34	3	occur	occur	VERB
dpc-1415	34	4	in	in	ADP
dpc-1415	34	5	more	more	ADJ
dpc-1415	34	6	than	than	ADP
dpc-1415	34	7	one	one	NUM
dpc-1415	34	8	-	-	PUNCT
dpc-1415	34	9	third	third	NOUN
dpc-1415	34	10	of	of	ADP
dpc-1415	34	11	the	the	DET
dpc-1415	34	12	patients	patient	NOUN
dpc-1415	34	13	treated	treat	VERB
dpc-1415	34	14	with	with	ADP
dpc-1415	34	15	cpis	cpis	NOUN
dpc-1415	34	16	.	.	PUNCT
dpc-1415	35	1	analytically	analytically	ADV
dpc-1415	35	2	,	,	PUNCT
dpc-1415	35	3	50	50	NUM
dpc-1415	35	4	%	%	NOUN
dpc-1415	35	5	of	of	ADP
dpc-1415	35	6	individuals	individual	NOUN
dpc-1415	35	7	receiving	receive	VERB
dpc-1415	35	8	ipilimumab	ipilimumab	NOUN
dpc-1415	35	9	and	and	CCONJ
dpc-1415	35	10	30%-40	30%-40	NUM
dpc-1415	35	11	%	%	NOUN
dpc-1415	35	12	receiving	receive	VERB
dpc-1415	35	13	nivolumab	nivolumab	NOUN
dpc-1415	35	14	or	or	CCONJ
dpc-1415	35	15	pembrolizumab	pembrolizumab	NOUN
dpc-1415	35	16	will	will	AUX
dpc-1415	35	17	experience	experience	VERB
dpc-1415	35	18	dermatologic	dermatologic	ADJ
dpc-1415	35	19	complications	complication	NOUN
dpc-1415	35	20	[	[	X
dpc-1415	35	21	3	3	NUM
dpc-1415	35	22	]	]	PUNCT
dpc-1415	35	23	.	.	PUNCT
dpc-1415	36	1	however	however	ADV
dpc-1415	36	2	,	,	PUNCT
dpc-1415	36	3	severe	severe	ADJ
dpc-1415	36	4	symptoms	symptom	NOUN
dpc-1415	36	5	of	of	ADP
dpc-1415	36	6	dermal	dermal	ADJ
dpc-1415	36	7	toxicity	toxicity	NOUN
dpc-1415	36	8	is	be	AUX
dpc-1415	36	9	reported	report	VERB
dpc-1415	36	10	in	in	ADP
dpc-1415	36	11	<3	<3	NOUN
dpc-1415	36	12	%	%	NOUN
dpc-1415	36	13	cases	case	NOUN
dpc-1415	36	14	with	with	ADP
dpc-1415	36	15	anti	anti	ADJ
dpc-1415	36	16	-	-	ADJ
dpc-1415	36	17	pd-1	pd-1	ADJ
dpc-1415	36	18	monotherapy	monotherapy	NOUN
dpc-1415	36	19	and	and	CCONJ
dpc-1415	36	20	<	<	X
dpc-1415	36	21	5	5	NUM
dpc-1415	36	22	%	%	NOUN
dpc-1415	36	23	in	in	ADP
dpc-1415	36	24	combined	combined	ADJ
dpc-1415	36	25	therapy	therapy	NOUN
dpc-1415	36	26	with	with	ADP
dpc-1415	36	27	anti	anti	ADJ
dpc-1415	36	28	-	-	ADJ
dpc-1415	36	29	ctla-4	ctla-4	NOUN
dpc-1415	36	30	and	and	CCONJ
dpc-1415	36	31	anti	anti	ADJ
dpc-1415	36	32	-	-	ADJ
dpc-1415	36	33	pd1	pd1	NOUN
dpc-1415	36	34	.	.	PUNCT
dpc-1415	37	1	in	in	ADP
dpc-1415	37	2	general	general	ADJ
dpc-1415	37	3	,	,	PUNCT
dpc-1415	37	4	cpis	cpis	PROPN
dpc-1415	37	5	are	be	AUX
dpc-1415	37	6	considered	consider	VERB
dpc-1415	37	7	to	to	PART
dpc-1415	37	8	present	present	VERB
dpc-1415	37	9	an	an	DET
dpc-1415	37	10	acceptable	acceptable	ADJ
dpc-1415	37	11	skin	skin	NOUN
dpc-1415	37	12	toxicity	toxicity	NOUN
dpc-1415	37	13	profile	profile	NOUN
dpc-1415	37	14	.	.	PUNCT
dpc-1415	38	1	time	time	NOUN
dpc-1415	38	2	of	of	ADP
dpc-1415	38	3	onset	onset	ADJ
dpc-1415	38	4	cutaneous	cutaneous	ADJ
dpc-1415	38	5	iraes	irae	NOUN
dpc-1415	38	6	may	may	AUX
dpc-1415	38	7	have	have	VERB
dpc-1415	38	8	a	a	DET
dpc-1415	38	9	delayed	delay	VERB
dpc-1415	38	10	onset	onset	NOUN
dpc-1415	38	11	and	and	CCONJ
dpc-1415	38	12	prolonged	prolonged	ADJ
dpc-1415	38	13	duration	duration	NOUN
dpc-1415	38	14	,	,	PUNCT
dpc-1415	38	15	compared	compare	VERB
dpc-1415	38	16	to	to	ADP
dpc-1415	38	17	adverse	adverse	ADJ
dpc-1415	38	18	events	event	NOUN
dpc-1415	38	19	(	(	PUNCT
dpc-1415	38	20	aes	aes	PROPN
dpc-1415	38	21	)	)	PUNCT
dpc-1415	38	22	resulting	result	VERB
dpc-1415	38	23	from	from	ADP
dpc-1415	38	24	classic	classic	ADJ
dpc-1415	38	25	chemotherapy	chemotherapy	NOUN
dpc-1415	38	26	.	.	PUNCT
dpc-1415	39	1	for	for	ADP
dpc-1415	39	2	most	most	ADJ
dpc-1415	39	3	patients	patient	NOUN
dpc-1415	39	4	,	,	PUNCT
dpc-1415	39	5	dermatologic	dermatologic	ADJ
dpc-1415	39	6	toxicity	toxicity	NOUN
dpc-1415	39	7	is	be	AUX
dpc-1415	39	8	the	the	DET
dpc-1415	39	9	earliest	early	ADJ
dpc-1415	39	10	occurring	occur	VERB
dpc-1415	39	11	irae	irae	NOUN
dpc-1415	40	1	[	[	X
dpc-1415	40	2	4	4	NUM
dpc-1415	40	3	]	]	PUNCT
dpc-1415	40	4	.	.	PUNCT
dpc-1415	41	1	the	the	DET
dpc-1415	41	2	time	time	NOUN
dpc-1415	41	3	of	of	ADP
dpc-1415	41	4	onset	onset	NOUN
dpc-1415	41	5	of	of	ADP
dpc-1415	41	6	a	a	DET
dpc-1415	41	7	dermatologic	dermatologic	ADJ
dpc-1415	41	8	toxicity	toxicity	NOUN
dpc-1415	41	9	ranges	range	VERB
dpc-1415	41	10	from	from	ADP
dpc-1415	41	11	a	a	DET
dpc-1415	41	12	few	few	ADJ
dpc-1415	41	13	weeks	week	NOUN
dpc-1415	41	14	to	to	ADP
dpc-1415	41	15	several	several	ADJ
dpc-1415	41	16	months	month	NOUN
dpc-1415	41	17	from	from	ADP
dpc-1415	41	18	treatment	treatment	NOUN
dpc-1415	41	19	initiation	initiation	NOUN
dpc-1415	41	20	,	,	PUNCT
dpc-1415	41	21	depending	depend	VERB
dpc-1415	41	22	on	on	ADP
dpc-1415	41	23	the	the	DET
dpc-1415	41	24	type	type	NOUN
dpc-1415	41	25	of	of	ADP
dpc-1415	41	26	cutaneous	cutaneous	ADJ
dpc-1415	41	27	irae	irae	NOUN
dpc-1415	41	28	.	.	PUNCT
dpc-1415	42	1	the	the	DET
dpc-1415	42	2	relationship	relationship	NOUN
dpc-1415	42	3	between	between	ADP
dpc-1415	42	4	iraes	irae	NOUN
dpc-1415	42	5	and	and	CCONJ
dpc-1415	42	6	dose	dose	NOUN
dpc-1415	42	7	or	or	CCONJ
dpc-1415	42	8	time	time	NOUN
dpc-1415	42	9	of	of	ADP
dpc-1415	42	10	exposure	exposure	NOUN
dpc-1415	42	11	to	to	PART
dpc-1415	42	12	cpis	cpis	PROPN
dpc-1415	42	13	has	have	AUX
dpc-1415	42	14	not	not	PART
dpc-1415	42	15	been	be	AUX
dpc-1415	42	16	fully	fully	ADV
dpc-1415	42	17	elucidated	elucidated	ADJ
dpc-1415	42	18	[	[	X
dpc-1415	42	19	5	5	NUM
dpc-1415	42	20	]	]	PUNCT
dpc-1415	42	21	.	.	PUNCT
dpc-1415	43	1	in	in	ADP
dpc-1415	43	2	this	this	DET
dpc-1415	43	3	context	context	NOUN
dpc-1415	43	4	,	,	PUNCT
dpc-1415	43	5	clinicians	clinician	NOUN
dpc-1415	43	6	must	must	AUX
dpc-1415	43	7	remain	remain	VERB
dpc-1415	43	8	vigilant	vigilant	ADJ
dpc-1415	43	9	to	to	ADP
dpc-1415	43	10	the	the	DET
dpc-1415	43	11	possibility	possibility	NOUN
dpc-1415	43	12	of	of	ADP
dpc-1415	43	13	late	late	ADJ
dpc-1415	43	14	onset	onset	NOUN
dpc-1415	43	15	of	of	ADP
dpc-1415	43	16	iraes	irae	NOUN
dpc-1415	43	17	that	that	PRON
dpc-1415	43	18	in	in	ADP
dpc-1415	43	19	some	some	DET
dpc-1415	43	20	cases	case	NOUN
dpc-1415	43	21	may	may	AUX
dpc-1415	43	22	extend	extend	VERB
dpc-1415	43	23	to	to	ADP
dpc-1415	43	24	months	month	NOUN
dpc-1415	43	25	,	,	PUNCT
dpc-1415	43	26	or	or	CCONJ
dpc-1415	43	27	even	even	ADV
dpc-1415	43	28	years	year	NOUN
dpc-1415	43	29	,	,	PUNCT
dpc-1415	43	30	after	after	ADP
dpc-1415	43	31	treatment	treatment	NOUN
dpc-1415	43	32	discontinuation	discontinuation	NOUN
dpc-1415	43	33	[	[	X
dpc-1415	43	34	1,2	1,2	NUM
dpc-1415	43	35	]	]	PUNCT
dpc-1415	43	36	.	.	PUNCT
dpc-1415	44	1	classification	classification	NOUN
dpc-1415	44	2	of	of	ADP
dpc-1415	44	3	cutaneous	cutaneous	ADJ
dpc-1415	44	4	iraes	irae	NOUN
dpc-1415	44	5	cpis	cpis	NOUN
dpc-1415	44	6	can	can	AUX
dpc-1415	44	7	induce	induce	VERB
dpc-1415	44	8	a	a	DET
dpc-1415	44	9	wide	wide	ADJ
dpc-1415	44	10	variety	variety	NOUN
dpc-1415	44	11	of	of	ADP
dpc-1415	44	12	skin	skin	NOUN
dpc-1415	44	13	reactions	reaction	NOUN
dpc-1415	44	14	that	that	PRON
dpc-1415	44	15	represent	represent	VERB
dpc-1415	44	16	either	either	CCONJ
dpc-1415	44	17	a	a	DET
dpc-1415	44	18	reactivation	reactivation	NOUN
dpc-1415	44	19	or	or	CCONJ
dpc-1415	44	20	deterioration	deterioration	NOUN
dpc-1415	44	21	of	of	ADP
dpc-1415	44	22	a	a	DET
dpc-1415	44	23	preexisting	preexist	VERB
dpc-1415	44	24	dermatosis	dermatosis	NOUN
dpc-1415	44	25	or	or	CCONJ
dpc-1415	44	26	a	a	DET
dpc-1415	44	27	de	de	X
dpc-1415	44	28	novo	novo	NOUN
dpc-1415	44	29	development	development	NOUN
dpc-1415	44	30	.	.	PUNCT
dpc-1415	45	1	classification	classification	NOUN
dpc-1415	45	2	of	of	ADP
dpc-1415	45	3	cutaneous	cutaneous	ADJ
dpc-1415	45	4	iraes	iraes	NOUN
dpc-1415	45	5	is	be	AUX
dpc-1415	45	6	still	still	ADV
dpc-1415	45	7	vague	vague	ADJ
dpc-1415	45	8	and	and	CCONJ
dpc-1415	45	9	at	at	ADP
dpc-1415	45	10	the	the	DET
dpc-1415	45	11	moment	moment	NOUN
dpc-1415	45	12	is	be	AUX
dpc-1415	45	13	mostly	mostly	ADV
dpc-1415	45	14	based	base	VERB
dpc-1415	45	15	on	on	ADP
dpc-1415	45	16	clinical	clinical	ADJ
dpc-1415	45	17	morphology	morphology	NOUN
dpc-1415	45	18	.	.	PUNCT
dpc-1415	46	1	in	in	ADP
dpc-1415	46	2	this	this	DET
dpc-1415	46	3	context	context	NOUN
dpc-1415	46	4	,	,	PUNCT
dpc-1415	46	5	cpi	cpi	NOUN
dpc-1415	46	6	-	-	PUNCT
dpc-1415	46	7	mediated	mediate	VERB
dpc-1415	46	8	aes	aes	NOUN
dpc-1415	46	9	can	can	AUX
dpc-1415	46	10	be	be	AUX
dpc-1415	46	11	classified	classify	VERB
dpc-1415	46	12	into	into	ADP
dpc-1415	46	13	6	6	NUM
dpc-1415	46	14	main	main	ADJ
dpc-1415	46	15	categories	category	NOUN
dpc-1415	46	16	,	,	PUNCT
dpc-1415	46	17	namely	namely	ADV
dpc-1415	46	18	,	,	PUNCT
dpc-1415	46	19	inflammatory	inflammatory	ADJ
dpc-1415	46	20	dermatoses	dermatosis	NOUN
dpc-1415	46	21	,	,	PUNCT
dpc-1415	46	22	bullous	bullous	ADJ
dpc-1415	46	23	eruptions	eruption	NOUN
dpc-1415	46	24	,	,	PUNCT
dpc-1415	46	25	pruritus	pruritus	NOUN
dpc-1415	46	26	,	,	PUNCT
dpc-1415	46	27	pigmentary	pigmentary	ADJ
dpc-1415	46	28	disorders	disorder	NOUN
dpc-1415	46	29	,	,	PUNCT
dpc-1415	46	30	severe	severe	ADJ
dpc-1415	46	31	cutaneous	cutaneous	ADJ
dpc-1415	46	32	adverse	adverse	ADJ
dpc-1415	46	33	reactions	reaction	NOUN
dpc-1415	46	34	(	(	PUNCT
dpc-1415	46	35	scars)/life	scars)/life	ADV
dpc-1415	46	36	-	-	PUNCT
dpc-1415	46	37	threatening	threaten	VERB
dpc-1415	46	38	drug	drug	NOUN
dpc-1415	46	39	reactions	reaction	NOUN
dpc-1415	46	40	,	,	PUNCT
dpc-1415	46	41	and	and	CCONJ
dpc-1415	46	42	miscellaneous	miscellaneous	ADJ
dpc-1415	46	43	skin	skin	NOUN
dpc-1415	46	44	manifestations	manifestation	NOUN
dpc-1415	46	45	(	(	PUNCT
dpc-1415	46	46	table	table	NOUN
dpc-1415	46	47	1	1	NUM
dpc-1415	46	48	)	)	PUNCT
dpc-1415	46	49	.	.	PUNCT
dpc-1415	47	1	of	of	ADP
dpc-1415	47	2	note	note	NOUN
dpc-1415	47	3	,	,	PUNCT
dpc-1415	47	4	misclassified	misclassified	ADJ
dpc-1415	47	5	cases	case	NOUN
dpc-1415	47	6	do	do	AUX
dpc-1415	47	7	exist	exist	VERB
dpc-1415	47	8	and	and	CCONJ
dpc-1415	47	9	they	they	PRON
dpc-1415	47	10	are	be	AUX
dpc-1415	47	11	attributed	attribute	VERB
dpc-1415	47	12	to	to	ADP
dpc-1415	47	13	various	various	ADJ
dpc-1415	47	14	reasons	reason	NOUN
dpc-1415	47	15	.	.	PUNCT
dpc-1415	48	1	one	one	NUM
dpc-1415	48	2	of	of	ADP
dpc-1415	48	3	them	they	PRON
dpc-1415	48	4	is	be	AUX
dpc-1415	48	5	that	that	SCONJ
dpc-1415	48	6	clinicians	clinician	NOUN
dpc-1415	48	7	other	other	ADJ
dpc-1415	48	8	than	than	ADP
dpc-1415	48	9	dermatologists	dermatologist	NOUN
dpc-1415	48	10	that	that	PRON
dpc-1415	48	11	are	be	AUX
dpc-1415	48	12	not	not	PART
dpc-1415	48	13	sufficiently	sufficiently	ADV
dpc-1415	48	14	trained	train	VERB
dpc-1415	48	15	in	in	ADP
dpc-1415	48	16	dermatology	dermatology	NOUN
dpc-1415	48	17	are	be	AUX
dpc-1415	48	18	involved	involve	VERB
dpc-1415	48	19	in	in	ADP
dpc-1415	48	20	the	the	DET
dpc-1415	48	21	evaluation	evaluation	NOUN
dpc-1415	48	22	and	and	CCONJ
dpc-1415	48	23	management	management	NOUN
dpc-1415	48	24	of	of	ADP
dpc-1415	48	25	skin	skin	NOUN
dpc-1415	48	26	toxicities	toxicity	NOUN
dpc-1415	48	27	.	.	PUNCT
dpc-1415	49	1	apart	apart	ADV
dpc-1415	49	2	from	from	ADP
dpc-1415	49	3	that	that	PRON
dpc-1415	49	4	,	,	PUNCT
dpc-1415	49	5	classification	classification	NOUN
dpc-1415	49	6	systems	system	NOUN
dpc-1415	49	7	are	be	AUX
dpc-1415	49	8	vague	vague	ADJ
dpc-1415	49	9	per	per	ADP
dpc-1415	49	10	se	se	X
dpc-1415	49	11	,	,	PUNCT
dpc-1415	49	12	since	since	SCONJ
dpc-1415	49	13	there	there	PRON
dpc-1415	49	14	is	be	VERB
dpc-1415	49	15	a	a	DET
dpc-1415	49	16	lack	lack	NOUN
dpc-1415	49	17	of	of	ADP
dpc-1415	49	18	histopathological	histopathological	ADJ
dpc-1415	49	19	studies	study	NOUN
dpc-1415	49	20	that	that	PRON
dpc-1415	49	21	precisely	precisely	ADV
dpc-1415	49	22	characterize	characterize	VERB
dpc-1415	49	23	the	the	DET
dpc-1415	49	24	nature	nature	NOUN
dpc-1415	49	25	of	of	ADP
dpc-1415	49	26	these	these	DET
dpc-1415	49	27	rashes	rash	NOUN
dpc-1415	49	28	.	.	PUNCT
dpc-1415	50	1	in	in	ADP
dpc-1415	50	2	this	this	DET
dpc-1415	50	3	context	context	NOUN
dpc-1415	50	4	,	,	PUNCT
dpc-1415	50	5	especially	especially	ADV
dpc-1415	50	6	in	in	ADP
dpc-1415	50	7	atypical	atypical	ADJ
dpc-1415	50	8	cases	case	NOUN
dpc-1415	50	9	,	,	PUNCT
dpc-1415	50	10	misclassification	misclassification	NOUN
dpc-1415	50	11	is	be	AUX
dpc-1415	50	12	not	not	PART
dpc-1415	50	13	an	an	DET
dpc-1415	50	14	unlikely	unlikely	ADJ
dpc-1415	50	15	scenario	scenario	NOUN
dpc-1415	50	16	even	even	ADV
dpc-1415	50	17	for	for	ADP
dpc-1415	50	18	expert	expert	NOUN
dpc-1415	50	19	dermatologist	dermatologist	NOUN
dpc-1415	50	20	.	.	PUNCT
dpc-1415	51	1	in	in	ADP
dpc-1415	51	2	such	such	ADJ
dpc-1415	51	3	cases	case	NOUN
dpc-1415	51	4	,	,	PUNCT
dpc-1415	51	5	only	only	ADV
dpc-1415	51	6	histopathology	histopathology	NOUN
dpc-1415	51	7	can	can	AUX
dpc-1415	51	8	prompt	prompt	VERB
dpc-1415	51	9	an	an	DET
dpc-1415	51	10	accurate	accurate	ADJ
dpc-1415	51	11	diagnosis	diagnosis	NOUN
dpc-1415	51	12	;	;	PUNCT
dpc-1415	51	13	therefore	therefore	ADV
dpc-1415	51	14	,	,	PUNCT
dpc-1415	51	15	if	if	SCONJ
dpc-1415	51	16	it	it	PRON
dpc-1415	51	17	is	be	AUX
dpc-1415	51	18	not	not	PART
dpc-1415	51	19	performed	perform	VERB
dpc-1415	51	20	,	,	PUNCT
dpc-1415	51	21	many	many	ADJ
dpc-1415	51	22	cases	case	NOUN
dpc-1415	51	23	remain	remain	VERB
dpc-1415	51	24	misclassified	misclassified	ADJ
dpc-1415	51	25	and	and	CCONJ
dpc-1415	51	26	influence	influence	VERB
dpc-1415	51	27	the	the	DET
dpc-1415	51	28	overall	overall	ADJ
dpc-1415	51	29	incidence	incidence	NOUN
dpc-1415	51	30	of	of	ADP
dpc-1415	51	31	each	each	DET
dpc-1415	51	32	skin	skin	NOUN
dpc-1415	51	33	reaction	reaction	NOUN
dpc-1415	51	34	[	[	X
dpc-1415	51	35	6	6	NUM
dpc-1415	51	36	]	]	PUNCT
dpc-1415	51	37	.	.	PUNCT
dpc-1415	52	1	the	the	DET
dpc-1415	52	2	last	last	ADJ
dpc-1415	52	3	column	column	NOUN
dpc-1415	52	4	in	in	ADP
dpc-1415	52	5	table	table	NOUN
dpc-1415	52	6	1	1	NUM
dpc-1415	52	7	reports	report	VERB
dpc-1415	52	8	the	the	DET
dpc-1415	52	9	frequency	frequency	NOUN
dpc-1415	52	10	of	of	ADP
dpc-1415	52	11	cutaneous	cutaneous	ADJ
dpc-1415	52	12	reactions	reaction	NOUN
dpc-1415	52	13	to	to	PART
dpc-1415	52	14	give	give	VERB
dpc-1415	52	15	better	well	ADJ
dpc-1415	52	16	guidance	guidance	NOUN
dpc-1415	52	17	to	to	ADP
dpc-1415	52	18	clinicians	clinician	NOUN
dpc-1415	52	19	.	.	PUNCT
dpc-1415	53	1	a.	a.	NOUN
dpc-1415	53	2	inflammatory	inflammatory	ADJ
dpc-1415	53	3	skin	skin	NOUN
dpc-1415	53	4	reactions	reaction	NOUN
dpc-1415	53	5	several	several	ADJ
dpc-1415	53	6	skin	skin	NOUN
dpc-1415	53	7	rashes	rash	NOUN
dpc-1415	53	8	belong	belong	VERB
dpc-1415	53	9	to	to	ADP
dpc-1415	53	10	this	this	DET
dpc-1415	53	11	group	group	NOUN
dpc-1415	53	12	,	,	PUNCT
dpc-1415	53	13	including	include	VERB
dpc-1415	53	14	maculopapular	maculopapular	ADJ
dpc-1415	53	15	,	,	PUNCT
dpc-1415	53	16	lichenoid	lichenoid	PROPN
dpc-1415	53	17	,	,	PUNCT
dpc-1415	53	18	psoriasiform	psoriasiform	NOUN
dpc-1415	53	19	and	and	CCONJ
dpc-1415	53	20	eczematous	eczematous	ADJ
dpc-1415	53	21	rashes	rash	NOUN
dpc-1415	53	22	,	,	PUNCT
dpc-1415	53	23	as	as	ADV
dpc-1415	53	24	well	well	ADV
dpc-1415	53	25	as	as	ADP
dpc-1415	53	26	classical	classical	ADJ
dpc-1415	53	27	skin	skin	NOUN
dpc-1415	53	28	iraes	irae	NOUN
dpc-1415	53	29	like	like	ADP
dpc-1415	53	30	erythema	erythema	ADJ
dpc-1415	53	31	multiforme	multiforme	NOUN
dpc-1415	53	32	(	(	PUNCT
dpc-1415	53	33	em	em	PRON
dpc-1415	53	34	)	)	PUNCT
dpc-1415	53	35	,	,	PUNCT
dpc-1415	53	36	palmoplantar	palmoplantar	NOUN
dpc-1415	53	37	erythrodysesthesia	erythrodysesthesia	PROPN
dpc-1415	53	38	and	and	CCONJ
dpc-1415	53	39	neutrophilic	neutrophilic	PROPN
dpc-1415	53	40	dermatoses	dermatosis	NOUN
dpc-1415	53	41	,	,	PUNCT
dpc-1415	53	42	such	such	ADJ
dpc-1415	53	43	as	as	ADP
dpc-1415	53	44	sweet	sweet	ADJ
dpc-1415	53	45	syndrome	syndrome	NOUN
dpc-1415	54	1	[	[	X
dpc-1415	54	2	6	6	NUM
dpc-1415	54	3	]	]	PUNCT
dpc-1415	54	4	.	.	PUNCT
dpc-1415	55	1	figure	figure	NOUN
dpc-1415	55	2	1	1	NUM
dpc-1415	55	3	illustrates	illustrate	VERB
dpc-1415	55	4	typical	typical	ADJ
dpc-1415	55	5	examples	example	NOUN
dpc-1415	55	6	of	of	ADP
dpc-1415	55	7	common	common	ADJ
dpc-1415	55	8	cutaneous	cutaneous	ADJ
dpc-1415	55	9	iraes	irae	NOUN
dpc-1415	55	10	.	.	PUNCT
dpc-1415	56	1	1	1	X
dpc-1415	56	2	.	.	NUM
dpc-1415	56	3	maculopapular	maculopapular	ADJ
dpc-1415	56	4	(	(	PUNCT
dpc-1415	56	5	morbilliform	morbilliform	NOUN
dpc-1415	56	6	)	)	PUNCT
dpc-1415	56	7	rashes	rashe	VERB
dpc-1415	56	8	the	the	DET
dpc-1415	56	9	pruritic	pruritic	ADJ
dpc-1415	56	10	maculopapular	maculopapular	ADJ
dpc-1415	56	11	rash	rash	NOUN
dpc-1415	56	12	(	(	PUNCT
dpc-1415	56	13	figure	figure	NOUN
dpc-1415	56	14	1a	1a	NOUN
dpc-1415	56	15	)	)	PUNCT
dpc-1415	56	16	is	be	AUX
dpc-1415	56	17	the	the	DET
dpc-1415	56	18	main	main	ADJ
dpc-1415	56	19	representative	representative	NOUN
dpc-1415	56	20	of	of	ADP
dpc-1415	56	21	this	this	DET
dpc-1415	56	22	category	category	NOUN
dpc-1415	56	23	,	,	PUNCT
dpc-1415	56	24	as	as	SCONJ
dpc-1415	56	25	it	it	PRON
dpc-1415	56	26	is	be	AUX
dpc-1415	56	27	the	the	DET
dpc-1415	56	28	most	most	ADV
dpc-1415	56	29	frequent	frequent	ADJ
dpc-1415	56	30	cutaneous	cutaneous	ADJ
dpc-1415	56	31	irae	irae	NOUN
dpc-1415	56	32	observed	observe	VERB
dpc-1415	56	33	with	with	ADP
dpc-1415	56	34	both	both	DET
dpc-1415	56	35	pd-1	pd-1	NOUN
dpc-1415	56	36	/	/	SYM
dpc-1415	56	37	pd	pd	NOUN
dpc-1415	56	38	-	-	PROPN
dpc-1415	56	39	l1	l1	PROPN
dpc-1415	56	40	and	and	CCONJ
dpc-1415	56	41	ctla-4	ctla-4	NOUN
dpc-1415	56	42	inhibitors	inhibitor	NOUN
dpc-1415	56	43	.	.	PUNCT
dpc-1415	57	1	despite	despite	SCONJ
dpc-1415	57	2	its	its	PRON
dpc-1415	57	3	high	high	ADJ
dpc-1415	57	4	incidence	incidence	NOUN
dpc-1415	57	5	,	,	PUNCT
dpc-1415	57	6	the	the	DET
dpc-1415	57	7	rate	rate	NOUN
dpc-1415	57	8	of	of	ADP
dpc-1415	57	9	grade	grade	NOUN
dpc-1415	57	10	≥3	≥3	PROPN
dpc-1415	57	11	rash	rash	NOUN
dpc-1415	57	12	is	be	AUX
dpc-1415	57	13	rather	rather	ADV
dpc-1415	57	14	uncommon	uncommon	ADJ
dpc-1415	57	15	.	.	PUNCT
dpc-1415	58	1	it	it	PRON
dpc-1415	58	2	mainly	mainly	ADV
dpc-1415	58	3	involves	involve	VERB
dpc-1415	58	4	the	the	DET
dpc-1415	58	5	trunk	trunk	NOUN
dpc-1415	58	6	,	,	PUNCT
dpc-1415	58	7	and	and	CCONJ
dpc-1415	58	8	to	to	ADP
dpc-1415	58	9	a	a	DET
dpc-1415	58	10	lesser	less	ADJ
dpc-1415	58	11	degree	degree	NOUN
dpc-1415	58	12	the	the	DET
dpc-1415	58	13	upper	upper	ADJ
dpc-1415	58	14	extremities	extremity	NOUN
dpc-1415	58	15	,	,	PUNCT
dpc-1415	58	16	while	while	SCONJ
dpc-1415	58	17	the	the	DET
dpc-1415	58	18	face	face	NOUN
dpc-1415	58	19	is	be	AUX
dpc-1415	58	20	usually	usually	ADV
dpc-1415	58	21	spared	spare	VERB
dpc-1415	58	22	.	.	PUNCT
dpc-1415	59	1	review	review	VERB
dpc-1415	59	2	|	|	ADV
dpc-1415	59	3	dermatol	dermatol	ADJ
dpc-1415	59	4	pract	pract	NOUN
dpc-1415	59	5	concept	concept	NOUN
dpc-1415	59	6	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	59	7	3	3	NUM
dpc-1415	59	8	pruritus	pruritus	NOUN
dpc-1415	59	9	,	,	PUNCT
dpc-1415	59	10	typically	typically	ADV
dpc-1415	59	11	developing	develop	VERB
dpc-1415	59	12	concomitantly	concomitantly	ADV
dpc-1415	59	13	with	with	ADP
dpc-1415	59	14	the	the	DET
dpc-1415	59	15	rash	rash	NOUN
dpc-1415	59	16	,	,	PUNCT
dpc-1415	59	17	or	or	CCONJ
dpc-1415	59	18	preceding	precede	VERB
dpc-1415	59	19	the	the	DET
dpc-1415	59	20	skin	skin	NOUN
dpc-1415	59	21	alterations	alteration	NOUN
dpc-1415	59	22	,	,	PUNCT
dpc-1415	59	23	can	can	AUX
dpc-1415	59	24	be	be	AUX
dpc-1415	59	25	also	also	ADV
dpc-1415	59	26	present	present	ADJ
dpc-1415	59	27	as	as	ADP
dpc-1415	59	28	an	an	DET
dpc-1415	59	29	independent	independent	ADJ
dpc-1415	59	30	symptom	symptom	NOUN
dpc-1415	59	31	in	in	ADP
dpc-1415	59	32	otherwise	otherwise	ADV
dpc-1415	59	33	normal	normal	ADV
dpc-1415	59	34	-	-	PUNCT
dpc-1415	59	35	appearing	appear	VERB
dpc-1415	59	36	skin.t	skin.t	PUNCT
dpc-1415	59	37	he	he	PRON
dpc-1415	59	38	rash	rash	NOUN
dpc-1415	59	39	usually	usually	ADV
dpc-1415	59	40	appears	appear	VERB
dpc-1415	59	41	early	early	ADV
dpc-1415	59	42	after	after	ADP
dpc-1415	59	43	treatment	treatment	NOUN
dpc-1415	59	44	initiation	initiation	NOUN
dpc-1415	59	45	in	in	ADP
dpc-1415	59	46	a	a	DET
dpc-1415	59	47	timeframe	timeframe	NOUN
dpc-1415	59	48	that	that	PRON
dpc-1415	59	49	ranges	range	VERB
dpc-1415	59	50	from	from	ADP
dpc-1415	59	51	a	a	DET
dpc-1415	59	52	few	few	ADJ
dpc-1415	59	53	days	day	NOUN
dpc-1415	59	54	or	or	CCONJ
dpc-1415	59	55	weeks	week	NOUN
dpc-1415	59	56	(	(	PUNCT
dpc-1415	59	57	sometimes	sometimes	ADV
dpc-1415	59	58	immediately	immediately	ADV
dpc-1415	59	59	after	after	ADP
dpc-1415	59	60	the	the	DET
dpc-1415	59	61	first	first	ADJ
dpc-1415	59	62	cycle	cycle	NOUN
dpc-1415	59	63	)	)	PUNCT
dpc-1415	59	64	to	to	ADP
dpc-1415	59	65	a	a	DET
dpc-1415	59	66	few	few	ADJ
dpc-1415	59	67	months	month	NOUN
dpc-1415	59	68	,	,	PUNCT
dpc-1415	59	69	but	but	CCONJ
dpc-1415	59	70	delayed	delay	VERB
dpc-1415	59	71	eruptions	eruption	NOUN
dpc-1415	59	72	have	have	AUX
dpc-1415	59	73	also	also	ADV
dpc-1415	59	74	been	be	AUX
dpc-1415	59	75	reported	report	VERB
dpc-1415	59	76	.	.	PUNCT
dpc-1415	60	1	the	the	DET
dpc-1415	60	2	onset	onset	NOUN
dpc-1415	60	3	is	be	AUX
dpc-1415	60	4	slightly	slightly	ADV
dpc-1415	60	5	earlier	early	ADJ
dpc-1415	60	6	with	with	ADP
dpc-1415	60	7	ipilimumab	ipilimumab	NOUN
dpc-1415	60	8	or	or	CCONJ
dpc-1415	60	9	when	when	SCONJ
dpc-1415	60	10	cpis	cpis	PROPN
dpc-1415	60	11	are	be	AUX
dpc-1415	60	12	prescribed	prescribe	VERB
dpc-1415	60	13	in	in	ADP
dpc-1415	60	14	combination	combination	NOUN
dpc-1415	60	15	.	.	PUNCT
dpc-1415	61	1	it	it	PRON
dpc-1415	61	2	is	be	AUX
dpc-1415	61	3	not	not	PART
dpc-1415	61	4	uncommon	uncommon	ADJ
dpc-1415	61	5	for	for	SCONJ
dpc-1415	61	6	this	this	DET
dpc-1415	61	7	nonspecific	nonspecific	ADJ
dpc-1415	61	8	rash	rash	NOUN
dpc-1415	61	9	to	to	PART
dpc-1415	61	10	represent	represent	VERB
dpc-1415	61	11	the	the	DET
dpc-1415	61	12	initial	initial	ADJ
dpc-1415	61	13	manifestation	manifestation	NOUN
dpc-1415	61	14	of	of	ADP
dpc-1415	61	15	other	other	ADJ
dpc-1415	61	16	cpi	cpi	PROPN
dpc-1415	61	17	-	-	PUNCT
dpc-1415	61	18	induced	induce	VERB
dpc-1415	61	19	dermatoses	dermatosis	NOUN
dpc-1415	61	20	,	,	PUNCT
dpc-1415	61	21	such	such	ADJ
dpc-1415	61	22	as	as	ADP
dpc-1415	61	23	lichenoid	lichenoid	PROPN
dpc-1415	61	24	reactions	reaction	NOUN
dpc-1415	61	25	,	,	PUNCT
dpc-1415	61	26	psoriasis	psoriasis	NOUN
dpc-1415	61	27	,	,	PUNCT
dpc-1415	61	28	grover	grover	NOUN
dpc-1415	61	29	disease	disease	NOUN
dpc-1415	61	30	,	,	PUNCT
dpc-1415	61	31	bullous	bullous	ADJ
dpc-1415	61	32	pemphigoid	pemphigoid	NOUN
dpc-1415	61	33	or	or	CCONJ
dpc-1415	61	34	even	even	ADV
dpc-1415	61	35	scars	scar	NOUN
dpc-1415	61	36	.	.	PUNCT
dpc-1415	62	1	considering	consider	VERB
dpc-1415	62	2	that	that	DET
dpc-1415	62	3	iraes	irae	NOUN
dpc-1415	62	4	represent	represent	VERB
dpc-1415	62	5	a	a	DET
dpc-1415	62	6	newly	newly	ADV
dpc-1415	62	7	introduced	introduce	VERB
dpc-1415	62	8	group	group	NOUN
dpc-1415	62	9	of	of	ADP
dpc-1415	62	10	skin	skin	NOUN
dpc-1415	62	11	reactions	reaction	NOUN
dpc-1415	62	12	,	,	PUNCT
dpc-1415	62	13	a	a	DET
dpc-1415	62	14	skin	skin	NOUN
dpc-1415	62	15	biopsy	biopsy	NOUN
dpc-1415	62	16	with	with	ADP
dpc-1415	62	17	histological	histological	ADJ
dpc-1415	62	18	examination	examination	NOUN
dpc-1415	62	19	is	be	AUX
dpc-1415	62	20	highly	highly	ADV
dpc-1415	62	21	recommended	recommend	VERB
dpc-1415	62	22	in	in	ADP
dpc-1415	62	23	order	order	NOUN
dpc-1415	62	24	to	to	PART
dpc-1415	62	25	establish	establish	VERB
dpc-1415	62	26	the	the	DET
dpc-1415	62	27	correct	correct	ADJ
dpc-1415	62	28	diagnosis	diagnosis	NOUN
dpc-1415	62	29	.	.	PUNCT
dpc-1415	63	1	apart	apart	ADV
dpc-1415	63	2	from	from	ADP
dpc-1415	63	3	that	that	PRON
dpc-1415	63	4	,	,	PUNCT
dpc-1415	63	5	close	close	ADJ
dpc-1415	63	6	monitoring	monitoring	NOUN
dpc-1415	63	7	on	on	ADP
dpc-1415	63	8	a	a	DET
dpc-1415	63	9	weekly	weekly	ADJ
dpc-1415	63	10	or	or	CCONJ
dpc-1415	63	11	every	every	DET
dpc-1415	63	12	2	2	NUM
dpc-1415	63	13	-	-	PUNCT
dpc-1415	63	14	week	week	NOUN
dpc-1415	63	15	basis	basis	NOUN
dpc-1415	63	16	facilitates	facilitate	VERB
dpc-1415	63	17	adequate	adequate	ADJ
dpc-1415	63	18	management	management	NOUN
dpc-1415	63	19	.	.	PUNCT
dpc-1415	64	1	even	even	ADV
dpc-1415	64	2	though	though	SCONJ
dpc-1415	64	3	histological	histological	ADJ
dpc-1415	64	4	studies	study	NOUN
dpc-1415	64	5	of	of	ADP
dpc-1415	64	6	cutaneous	cutaneous	ADJ
dpc-1415	64	7	iraes	irae	NOUN
dpc-1415	64	8	are	be	AUX
dpc-1415	64	9	scarce	scarce	ADJ
dpc-1415	64	10	in	in	ADP
dpc-1415	64	11	the	the	DET
dpc-1415	64	12	literature	literature	NOUN
dpc-1415	64	13	,	,	PUNCT
dpc-1415	64	14	it	it	PRON
dpc-1415	64	15	seems	seem	VERB
dpc-1415	64	16	that	that	SCONJ
dpc-1415	64	17	the	the	DET
dpc-1415	64	18	histologic	histologic	ADJ
dpc-1415	64	19	alterations	alteration	NOUN
dpc-1415	64	20	observed	observe	VERB
dpc-1415	64	21	in	in	ADP
dpc-1415	64	22	maculopapular	maculopapular	ADJ
dpc-1415	64	23	rash	rash	NOUN
dpc-1415	64	24	include	include	VERB
dpc-1415	64	25	eczemalike	eczemalike	PROPN
dpc-1415	64	26	spongiotic	spongiotic	ADJ
dpc-1415	64	27	dermatitis	dermatitis	NOUN
dpc-1415	64	28	and	and	CCONJ
dpc-1415	64	29	histologic	histologic	NOUN
dpc-1415	64	30	features	feature	NOUN
dpc-1415	64	31	reminiscent	reminiscent	ADJ
dpc-1415	64	32	of	of	ADP
dpc-1415	64	33	dermal	dermal	ADJ
dpc-1415	64	34	hypersensitivity	hypersensitivity	NOUN
dpc-1415	64	35	reactions	reaction	NOUN
dpc-1415	64	36	[	[	X
dpc-1415	64	37	6,7	6,7	NUM
dpc-1415	64	38	]	]	PUNCT
dpc-1415	64	39	.	.	PUNCT
dpc-1415	65	1	in	in	ADP
dpc-1415	65	2	the	the	DET
dpc-1415	65	3	management	management	NOUN
dpc-1415	65	4	of	of	ADP
dpc-1415	65	5	mild	mild	ADJ
dpc-1415	65	6	(	(	PUNCT
dpc-1415	65	7	<	<	X
dpc-1415	65	8	10	10	NUM
dpc-1415	65	9	%	%	NOUN
dpc-1415	65	10	of	of	ADP
dpc-1415	65	11	body	body	NOUN
dpc-1415	65	12	surface	surface	NOUN
dpc-1415	65	13	area	area	NOUN
dpc-1415	65	14	[	[	X
dpc-1415	65	15	bsa	bsa	X
dpc-1415	65	16	]	]	X
dpc-1415	65	17	)	)	PUNCT
dpc-1415	65	18	or	or	CCONJ
dpc-1415	65	19	moderate	moderate	ADJ
dpc-1415	65	20	(	(	PUNCT
dpc-1415	65	21	10%-30	10%-30	NUM
dpc-1415	65	22	%	%	NOUN
dpc-1415	65	23	bsa	bsa	NOUN
dpc-1415	65	24	)	)	PUNCT
dpc-1415	65	25	maculopapular	maculopapular	ADJ
dpc-1415	65	26	eruption	eruption	NOUN
dpc-1415	65	27	with	with	ADP
dpc-1415	65	28	or	or	CCONJ
dpc-1415	65	29	without	without	ADP
dpc-1415	65	30	symptoms	symptom	NOUN
dpc-1415	65	31	such	such	ADJ
dpc-1415	65	32	as	as	ADP
dpc-1415	65	33	pruritus	pruritus	NOUN
dpc-1415	65	34	,	,	PUNCT
dpc-1415	65	35	burning	burning	NOUN
dpc-1415	65	36	,	,	PUNCT
dpc-1415	65	37	tightness	tightness	NOUN
dpc-1415	65	38	,	,	PUNCT
dpc-1415	65	39	cpi	cpi	NOUN
dpc-1415	65	40	therapy	therapy	NOUN
dpc-1415	65	41	can	can	AUX
dpc-1415	65	42	be	be	AUX
dpc-1415	65	43	maintained	maintain	VERB
dpc-1415	65	44	.	.	PUNCT
dpc-1415	66	1	the	the	DET
dpc-1415	66	2	rash	rash	NOUN
dpc-1415	66	3	should	should	AUX
dpc-1415	66	4	be	be	AUX
dpc-1415	66	5	treated	treat	VERB
dpc-1415	66	6	with	with	ADP
dpc-1415	66	7	topical	topical	ADJ
dpc-1415	66	8	moisturizing	moisturizing	NOUN
dpc-1415	66	9	emollients	emollient	NOUN
dpc-1415	66	10	,	,	PUNCT
dpc-1415	66	11	oral	oral	ADJ
dpc-1415	66	12	antihistamines	antihistamine	NOUN
dpc-1415	66	13	for	for	ADP
dpc-1415	66	14	pruritus	pruritus	PROPN
dpc-1415	66	15	and	and	CCONJ
dpc-1415	66	16	mediumto	mediumto	VERB
dpc-1415	66	17	highpotency	highpotency	NOUN
dpc-1415	66	18	topical	topical	ADJ
dpc-1415	66	19	corticosteroids	corticosteroid	NOUN
dpc-1415	66	20	.	.	PUNCT
dpc-1415	67	1	systemic	systemic	ADJ
dpc-1415	67	2	prednisone	prednisone	NOUN
dpc-1415	67	3	should	should	AUX
dpc-1415	67	4	be	be	AUX
dpc-1415	67	5	preserved	preserve	VERB
dpc-1415	67	6	for	for	ADP
dpc-1415	67	7	persistent	persistent	ADJ
dpc-1415	67	8	and	and	CCONJ
dpc-1415	67	9	severe	severe	ADJ
dpc-1415	67	10	cases	case	NOUN
dpc-1415	67	11	(	(	PUNCT
dpc-1415	67	12	>	>	SYM
dpc-1415	67	13	30	30	NUM
dpc-1415	67	14	%	%	NOUN
dpc-1415	67	15	bsa	bsa	NOUN
dpc-1415	67	16	,	,	PUNCT
dpc-1415	67	17	with	with	ADP
dpc-1415	67	18	or	or	CCONJ
dpc-1415	67	19	without	without	ADP
dpc-1415	67	20	associated	associated	ADJ
dpc-1415	67	21	symptoms	symptom	NOUN
dpc-1415	67	22	and	and	CCONJ
dpc-1415	67	23	limiting	limit	VERB
dpc-1415	67	24	self	self	NOUN
dpc-1415	67	25	-	-	PUNCT
dpc-1415	67	26	care	care	NOUN
dpc-1415	67	27	,	,	PUNCT
dpc-1415	67	28	or	or	CCONJ
dpc-1415	67	29	instrumental	instrumental	ADJ
dpc-1415	67	30	activities	activity	NOUN
dpc-1415	67	31	of	of	ADP
dpc-1415	67	32	daily	daily	ADJ
dpc-1415	67	33	living	living	NOUN
dpc-1415	67	34	)	)	PUNCT
dpc-1415	67	35	.	.	PUNCT
dpc-1415	68	1	a	a	DET
dpc-1415	68	2	multidisciplinary	multidisciplinary	ADJ
dpc-1415	68	3	team	team	NOUN
dpc-1415	68	4	,	,	PUNCT
dpc-1415	68	5	consisting	consist	VERB
dpc-1415	68	6	of	of	ADP
dpc-1415	68	7	oncologists	oncologist	NOUN
dpc-1415	68	8	and	and	CCONJ
dpc-1415	68	9	dermatologists	dermatologist	NOUN
dpc-1415	68	10	,	,	PUNCT
dpc-1415	68	11	should	should	AUX
dpc-1415	68	12	decide	decide	VERB
dpc-1415	68	13	on	on	ADP
dpc-1415	68	14	the	the	DET
dpc-1415	68	15	optimal	optimal	ADJ
dpc-1415	68	16	management	management	NOUN
dpc-1415	68	17	of	of	ADP
dpc-1415	68	18	patients	patient	NOUN
dpc-1415	68	19	with	with	ADP
dpc-1415	68	20	severe	severe	ADJ
dpc-1415	68	21	iraes	irae	NOUN
dpc-1415	68	22	.	.	PUNCT
dpc-1415	69	1	in	in	ADP
dpc-1415	69	2	this	this	DET
dpc-1415	69	3	scenario	scenario	NOUN
dpc-1415	69	4	,	,	PUNCT
dpc-1415	69	5	the	the	DET
dpc-1415	69	6	withholding	withholding	NOUN
dpc-1415	69	7	immunotherapy	immunotherapy	NOUN
dpc-1415	69	8	might	might	AUX
dpc-1415	69	9	be	be	AUX
dpc-1415	69	10	warranted	warrant	VERB
dpc-1415	69	11	.	.	PUNCT
dpc-1415	70	1	table	table	NOUN
dpc-1415	70	2	1	1	NUM
dpc-1415	70	3	.	.	PUNCT
dpc-1415	71	1	classification	classification	NOUN
dpc-1415	71	2	of	of	ADP
dpc-1415	71	3	skin	skin	NOUN
dpc-1415	71	4	toxicities	toxicity	NOUN
dpc-1415	71	5	induced	induce	VERB
dpc-1415	71	6	by	by	ADP
dpc-1415	71	7	checkpoint	checkpoint	NOUN
dpc-1415	71	8	inhibitors	inhibitor	NOUN
dpc-1415	71	9	category	category	NOUN
dpc-1415	71	10	skin	skin	NOUN
dpc-1415	71	11	disorder	disorder	NOUN
dpc-1415	71	12	frequency	frequency	NOUN
dpc-1415	71	13	skin	skin	NOUN
dpc-1415	71	14	rashes	rash	NOUN
dpc-1415	71	15	/	/	SYM
dpc-1415	71	16	inflammatory	inflammatory	ADJ
dpc-1415	71	17	dermatitis	dermatitis	NOUN
dpc-1415	71	18	bullous	bullous	ADJ
dpc-1415	71	19	eruptions	eruption	NOUN
dpc-1415	71	20	pruritus	pruritus	PROPN
dpc-1415	71	21	pigmentary	pigmentary	NOUN
dpc-1415	71	22	disorders	disorder	NOUN
dpc-1415	71	23	severe	severe	ADJ
dpc-1415	71	24	cutaneous	cutaneous	ADJ
dpc-1415	71	25	adverse	adverse	ADJ
dpc-1415	71	26	reactions	reaction	NOUN
dpc-1415	71	27	/	/	SYM
dpc-1415	71	28	life	life	NOUN
dpc-1415	71	29	-	-	PUNCT
dpc-1415	71	30	threatening	threaten	VERB
dpc-1415	71	31	drug	drug	NOUN
dpc-1415	71	32	reactions	reaction	NOUN
dpc-1415	71	33	miscellaneous	miscellaneous	VERB
dpc-1415	71	34	maculopapular	maculopapular	ADJ
dpc-1415	71	35	lichenoid	lichenoid	PROPN
dpc-1415	71	36	psoriasiform	psoriasiform	NOUN
dpc-1415	71	37	eczematous	eczematous	ADJ
dpc-1415	71	38	neutrophilic	neutrophilic	ADJ
dpc-1415	71	39	dermatoses	dermatose	VERB
dpc-1415	71	40	bullous	bullous	ADJ
dpc-1415	71	41	pemphigoid	pemphigoid	ADJ
dpc-1415	71	42	,	,	PUNCT
dpc-1415	71	43	bullous	bullous	ADJ
dpc-1415	71	44	lichen	lichen	NOUN
dpc-1415	71	45	,	,	PUNCT
dpc-1415	71	46	lichen	lichen	NOUN
dpc-1415	71	47	pemphigoides	pemphigoide	NOUN
dpc-1415	71	48	,	,	PUNCT
dpc-1415	71	49	linear	linear	PROPN
dpc-1415	71	50	iga	iga	PROPN
dpc-1415	71	51	bullous	bullous	ADJ
dpc-1415	71	52	dermatosis	dermatosis	NOUN
dpc-1415	71	53	,	,	PUNCT
dpc-1415	71	54	bullous	bullous	ADJ
dpc-1415	71	55	drug	drug	NOUN
dpc-1415	71	56	eruption	eruption	NOUN
dpc-1415	71	57	isolated	isolate	VERB
dpc-1415	71	58	or	or	CCONJ
dpc-1415	71	59	in	in	ADP
dpc-1415	71	60	association	association	NOUN
dpc-1415	71	61	with	with	ADP
dpc-1415	71	62	skin	skin	NOUN
dpc-1415	71	63	rashes	rash	NOUN
dpc-1415	71	64	vitiligo	vitiligo	VERB
dpc-1415	71	65	regression	regression	NOUN
dpc-1415	71	66	of	of	ADP
dpc-1415	71	67	melanocytic	melanocytic	ADJ
dpc-1415	71	68	nevi	nevi	NOUN
dpc-1415	71	69	and	and	CCONJ
dpc-1415	71	70	other	other	ADJ
dpc-1415	71	71	pigmented	pigmented	ADJ
dpc-1415	71	72	lesions	lesion	NOUN
dpc-1415	71	73	drug	drug	NOUN
dpc-1415	71	74	reaction	reaction	NOUN
dpc-1415	71	75	with	with	ADP
dpc-1415	71	76	eosinophilia	eosinophilia	PROPN
dpc-1415	71	77	and	and	CCONJ
dpc-1415	71	78	systemic	systemic	ADJ
dpc-1415	71	79	symptoms	symptom	NOUN
dpc-1415	71	80	(	(	PUNCT
dpc-1415	71	81	dress)/	dress)/	NOUN
dpc-1415	71	82	drug	drug	NOUN
dpc-1415	71	83	-	-	PUNCT
dpc-1415	71	84	induced	induce	VERB
dpc-1415	71	85	hypersensitivity	hypersensitivity	NOUN
dpc-1415	71	86	syndrome	syndrome	NOUN
dpc-1415	71	87	(	(	PUNCT
dpc-1415	71	88	dihs	dihs	NOUN
dpc-1415	71	89	)	)	PUNCT
dpc-1415	71	90	steven	steven	PROPN
dpc-1415	71	91	-	-	PUNCT
dpc-1415	71	92	johnson	johnson	PROPN
dpc-1415	71	93	syndrome	syndrome	PROPN
dpc-1415	71	94	(	(	PUNCT
dpc-1415	71	95	sjs	sjs	PROPN
dpc-1415	71	96	)	)	PUNCT
dpc-1415	71	97	toxic	toxic	ADJ
dpc-1415	71	98	epidermal	epidermal	ADJ
dpc-1415	71	99	necrolysis	necrolysis	NOUN
dpc-1415	71	100	(	(	PUNCT
dpc-1415	71	101	ten	ten	NUM
dpc-1415	71	102	)	)	PUNCT
dpc-1415	71	103	acute	acute	NOUN
dpc-1415	71	104	generalized	generalize	VERB
dpc-1415	71	105	exanthematous	exanthematous	ADJ
dpc-1415	71	106	pustulosis	pustulosis	NOUN
dpc-1415	71	107	(	(	PUNCT
dpc-1415	71	108	agep	agep	NOUN
dpc-1415	71	109	)	)	PUNCT
dpc-1415	71	110	grover	grover	NOUN
dpc-1415	71	111	disease	disease	NOUN
dpc-1415	71	112	vasculitis	vasculiti	VERB
dpc-1415	71	113	dermatomyositis	dermatomyositis	PROPN
dpc-1415	71	114	sjögren	sjögren	VERB
dpc-1415	71	115	syndrome	syndrome	NOUN
dpc-1415	71	116	sarcoidosis	sarcoidosis	NOUN
dpc-1415	71	117	urticaria	urticaria	NOUN
dpc-1415	71	118	acneiform	acneiform	VERB
dpc-1415	71	119	/	/	SYM
dpc-1415	71	120	papulopustular	papulopustular	ADJ
dpc-1415	71	121	rocasea	rocasea	NOUN
dpc-1415	71	122	prurigo	prurigo	PROPN
dpc-1415	71	123	simplex	simplex	NOUN
dpc-1415	71	124	/	/	SYM
dpc-1415	71	125	nodularis	nodularis	NOUN
dpc-1415	71	126	nail	nail	NOUN
dpc-1415	71	127	,	,	PUNCT
dpc-1415	71	128	hair	hair	NOUN
dpc-1415	71	129	,	,	PUNCT
dpc-1415	71	130	oral	oral	ADJ
dpc-1415	71	131	mucosa	mucosa	NOUN
dpc-1415	71	132	frequent	frequent	ADJ
dpc-1415	71	133	frequent	frequent	ADJ
dpc-1415	71	134	frequent	frequent	ADJ
dpc-1415	71	135	frequent	frequent	ADJ
dpc-1415	71	136	rare	rare	ADJ
dpc-1415	71	137	rare	rare	ADJ
dpc-1415	71	138	frequent	frequent	ADJ
dpc-1415	71	139	frequent	frequent	ADJ
dpc-1415	71	140	less	less	ADV
dpc-1415	71	141	frequent	frequent	ADJ
dpc-1415	71	142	(	(	PUNCT
dpc-1415	71	143	pigmentary	pigmentary	ADJ
dpc-1415	71	144	disorders	disorder	NOUN
dpc-1415	71	145	are	be	AUX
dpc-1415	71	146	mainly	mainly	ADV
dpc-1415	71	147	seen	see	VERB
dpc-1415	71	148	among	among	ADP
dpc-1415	71	149	melanoma	melanoma	NOUN
dpc-1415	71	150	patients	patient	NOUN
dpc-1415	71	151	while	while	SCONJ
dpc-1415	71	152	it	it	PRON
dpc-1415	71	153	is	be	AUX
dpc-1415	71	154	rare	rare	ADJ
dpc-1415	71	155	in	in	ADP
dpc-1415	71	156	other	other	ADJ
dpc-1415	71	157	tumors	tumor	NOUN
dpc-1415	71	158	)	)	PUNCT
dpc-1415	71	159	rare	rare	ADJ
dpc-1415	71	160	rare	rare	ADJ
dpc-1415	71	161	rare	rare	ADJ
dpc-1415	71	162	rare	rare	ADJ
dpc-1415	71	163	rare	rare	ADJ
dpc-1415	71	164	less	less	ADV
dpc-1415	71	165	frequent	frequent	ADJ
dpc-1415	71	166	rare	rare	ADJ
dpc-1415	71	167	rare	rare	ADJ
dpc-1415	71	168	rare	rare	ADJ
dpc-1415	71	169	less	less	ADV
dpc-1415	71	170	frequent	frequent	ADJ
dpc-1415	71	171	4	4	NUM
dpc-1415	71	172	review	review	NOUN
dpc-1415	71	173	|	|	ADV
dpc-1415	71	174	dermatol	dermatol	ADJ
dpc-1415	71	175	pract	pract	NOUN
dpc-1415	71	176	concept	concept	NOUN
dpc-1415	71	177	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	71	178	when	when	SCONJ
dpc-1415	71	179	skin	skin	NOUN
dpc-1415	71	180	toxicity	toxicity	NOUN
dpc-1415	71	181	is	be	AUX
dpc-1415	71	182	resolved	resolve	VERB
dpc-1415	71	183	and	and	CCONJ
dpc-1415	71	184	corticosteroids	corticosteroid	NOUN
dpc-1415	71	185	are	be	AUX
dpc-1415	71	186	reduced	reduce	VERB
dpc-1415	71	187	at	at	ADP
dpc-1415	71	188	a	a	DET
dpc-1415	71	189	prednisone	prednisone	NOUN
dpc-1415	71	190	dose	dose	NOUN
dpc-1415	71	191	equivalent	equivalent	NOUN
dpc-1415	71	192	to	to	ADP
dpc-1415	71	193	less	less	ADJ
dpc-1415	71	194	than	than	ADP
dpc-1415	71	195	10	10	NUM
dpc-1415	71	196	mg	mg	NUM
dpc-1415	71	197	/	/	SYM
dpc-1415	71	198	day	day	NOUN
dpc-1415	71	199	,	,	PUNCT
dpc-1415	71	200	cpi	cpi	PROPN
dpc-1415	71	201	therapy	therapy	NOUN
dpc-1415	71	202	can	can	AUX
dpc-1415	71	203	be	be	AUX
dpc-1415	71	204	resumed	resume	VERB
dpc-1415	71	205	[	[	PUNCT
dpc-1415	71	206	6	6	NUM
dpc-1415	71	207	-	-	SYM
dpc-1415	71	208	8	8	NUM
dpc-1415	71	209	]	]	PUNCT
dpc-1415	71	210	.	.	PUNCT
dpc-1415	72	1	2	2	X
dpc-1415	72	2	.	.	X
dpc-1415	72	3	lichenoid	lichenoid	NOUN
dpc-1415	72	4	rashes	rashes	PROPN
dpc-1415	72	5	lichenoid	lichenoid	PROPN
dpc-1415	72	6	drug	drug	NOUN
dpc-1415	72	7	eruption	eruption	NOUN
dpc-1415	72	8	(	(	PUNCT
dpc-1415	72	9	figure	figure	NOUN
dpc-1415	72	10	1c	1c	NOUN
dpc-1415	72	11	)	)	PUNCT
dpc-1415	72	12	is	be	AUX
dpc-1415	72	13	another	another	DET
dpc-1415	72	14	common	common	ADJ
dpc-1415	72	15	skin	skin	NOUN
dpc-1415	72	16	reaction	reaction	NOUN
dpc-1415	72	17	triggered	trigger	VERB
dpc-1415	72	18	by	by	ADP
dpc-1415	72	19	cpis	cpis	NOUN
dpc-1415	72	20	.	.	PUNCT
dpc-1415	73	1	the	the	DET
dpc-1415	73	2	incidence	incidence	NOUN
dpc-1415	73	3	of	of	ADP
dpc-1415	73	4	lichenoid	lichenoid	PROPN
dpc-1415	73	5	reactions	reaction	NOUN
dpc-1415	73	6	is	be	AUX
dpc-1415	73	7	probably	probably	ADV
dpc-1415	73	8	underreported	underreported	ADJ
dpc-1415	73	9	,	,	PUNCT
dpc-1415	73	10	and	and	CCONJ
dpc-1415	73	11	many	many	ADJ
dpc-1415	73	12	authors	author	NOUN
dpc-1415	73	13	strongly	strongly	ADV
dpc-1415	73	14	believe	believe	VERB
dpc-1415	73	15	that	that	SCONJ
dpc-1415	73	16	the	the	DET
dpc-1415	73	17	lichenoid	lichenoid	PROPN
dpc-1415	73	18	rash	rash	NOUN
dpc-1415	73	19	is	be	AUX
dpc-1415	73	20	even	even	ADV
dpc-1415	73	21	more	more	ADV
dpc-1415	73	22	frequent	frequent	ADJ
dpc-1415	73	23	than	than	ADP
dpc-1415	73	24	the	the	DET
dpc-1415	73	25	maculopapular	maculopapular	ADJ
dpc-1415	73	26	rash	rash	NOUN
dpc-1415	73	27	,	,	PUNCT
dpc-1415	73	28	which	which	PRON
dpc-1415	73	29	is	be	AUX
dpc-1415	73	30	also	also	ADV
dpc-1415	73	31	observed	observe	VERB
dpc-1415	73	32	in	in	ADP
dpc-1415	73	33	high	high	ADJ
dpc-1415	73	34	rates	rate	NOUN
dpc-1415	73	35	among	among	ADP
dpc-1415	73	36	individuals	individual	NOUN
dpc-1415	73	37	treated	treat	VERB
dpc-1415	73	38	with	with	ADP
dpc-1415	73	39	cpis	cpis	NOUN
dpc-1415	73	40	.	.	PUNCT
dpc-1415	74	1	in	in	ADP
dpc-1415	74	2	doubtful	doubtful	ADJ
dpc-1415	74	3	cases	case	NOUN
dpc-1415	74	4	,	,	PUNCT
dpc-1415	74	5	dermoscopy	dermoscopy	NOUN
dpc-1415	74	6	might	might	AUX
dpc-1415	74	7	prove	prove	VERB
dpc-1415	74	8	helpful	helpful	ADJ
dpc-1415	74	9	,	,	PUNCT
dpc-1415	74	10	since	since	SCONJ
dpc-1415	74	11	it	it	PRON
dpc-1415	74	12	highlights	highlight	VERB
dpc-1415	74	13	the	the	DET
dpc-1415	74	14	wickham	wickham	PROPN
dpc-1415	74	15	striae	striae	NOUN
dpc-1415	74	16	,	,	PUNCT
dpc-1415	74	17	facilitating	facilitate	VERB
dpc-1415	74	18	the	the	DET
dpc-1415	74	19	diagnosis	diagnosis	NOUN
dpc-1415	74	20	of	of	ADP
dpc-1415	74	21	lichenoid	lichenoid	PROPN
dpc-1415	74	22	eruptions	eruption	NOUN
dpc-1415	74	23	(	(	PUNCT
dpc-1415	74	24	figure	figure	NOUN
dpc-1415	74	25	2	2	NUM
dpc-1415	74	26	,	,	PUNCT
dpc-1415	74	27	a	a	PRON
dpc-1415	74	28	and	and	CCONJ
dpc-1415	74	29	b	b	NOUN
dpc-1415	74	30	)	)	PUNCT
dpc-1415	74	31	.	.	PUNCT
dpc-1415	75	1	the	the	DET
dpc-1415	75	2	responsible	responsible	ADJ
dpc-1415	75	3	immunologic	immunologic	ADJ
dpc-1415	75	4	mechanism	mechanism	NOUN
dpc-1415	75	5	figure	figure	NOUN
dpc-1415	75	6	2	2	NUM
dpc-1415	75	7	.	.	PUNCT
dpc-1415	76	1	(	(	PUNCT
dpc-1415	76	2	a	a	X
dpc-1415	76	3	)	)	PUNCT
dpc-1415	76	4	a	a	DET
dpc-1415	76	5	lichenoid	lichenoid	PROPN
dpc-1415	76	6	eruption	eruption	NOUN
dpc-1415	76	7	in	in	ADP
dpc-1415	76	8	a	a	DET
dpc-1415	76	9	patient	patient	NOUN
dpc-1415	76	10	with	with	ADP
dpc-1415	76	11	merkel	merkel	NOUN
dpc-1415	76	12	cell	cell	NOUN
dpc-1415	76	13	carcinoma	carcinoma	NOUN
dpc-1415	76	14	treated	treat	VERB
dpc-1415	76	15	with	with	ADP
dpc-1415	76	16	pembrolizumab	pembrolizumab	NOUN
dpc-1415	76	17	.	.	PUNCT
dpc-1415	77	1	(	(	PUNCT
dpc-1415	77	2	b	b	X
dpc-1415	77	3	)	)	PUNCT
dpc-1415	77	4	dermoscopy	dermoscopy	NOUN
dpc-1415	77	5	highlights	highlight	NOUN
dpc-1415	77	6	the	the	DET
dpc-1415	77	7	wickham	wickham	PROPN
dpc-1415	77	8	striae	striae	NOUN
dpc-1415	77	9	,	,	PUNCT
dpc-1415	77	10	facilitating	facilitate	VERB
dpc-1415	77	11	the	the	DET
dpc-1415	77	12	diagnosis	diagnosis	NOUN
dpc-1415	77	13	.	.	PUNCT
dpc-1415	78	1	a	a	DET
dpc-1415	78	2	b	b	NUM
dpc-1415	78	3	figure	figure	NOUN
dpc-1415	78	4	1	1	NUM
dpc-1415	78	5	.	.	PUNCT
dpc-1415	79	1	the	the	DET
dpc-1415	79	2	most	most	ADV
dpc-1415	79	3	common	common	ADJ
dpc-1415	79	4	skin	skin	NOUN
dpc-1415	79	5	toxicities	toxicity	NOUN
dpc-1415	79	6	during	during	ADP
dpc-1415	79	7	the	the	DET
dpc-1415	79	8	course	course	NOUN
dpc-1415	79	9	of	of	ADP
dpc-1415	79	10	immunotherapy	immunotherapy	NOUN
dpc-1415	79	11	include	include	VERB
dpc-1415	79	12	(	(	PUNCT
dpc-1415	79	13	a	a	DET
dpc-1415	79	14	)	)	PUNCT
dpc-1415	79	15	maculopapular	maculopapular	NOUN
dpc-1415	79	16	,	,	PUNCT
dpc-1415	79	17	(	(	PUNCT
dpc-1415	79	18	b	b	NOUN
dpc-1415	79	19	)	)	PUNCT
dpc-1415	79	20	psoriasiform	psoriasiform	NOUN
dpc-1415	79	21	and	and	CCONJ
dpc-1415	79	22	(	(	PUNCT
dpc-1415	79	23	c	c	NOUN
dpc-1415	79	24	)	)	PUNCT
dpc-1415	79	25	lichenoid	lichenoid	PROPN
dpc-1415	79	26	eruptions	eruption	NOUN
dpc-1415	79	27	.	.	PUNCT
dpc-1415	80	1	a	a	DET
dpc-1415	80	2	b	b	X
dpc-1415	80	3	c	c	X
dpc-1415	80	4	review	review	NOUN
dpc-1415	80	5	|	|	ADV
dpc-1415	80	6	dermatol	dermatol	ADJ
dpc-1415	80	7	pract	pract	NOUN
dpc-1415	80	8	concept	concept	NOUN
dpc-1415	80	9	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	80	10	5	5	NUM
dpc-1415	80	11	is	be	AUX
dpc-1415	80	12	not	not	PART
dpc-1415	80	13	completely	completely	ADV
dpc-1415	80	14	elucidated	elucidated	ADJ
dpc-1415	80	15	.	.	PUNCT
dpc-1415	81	1	however	however	ADV
dpc-1415	81	2	,	,	PUNCT
dpc-1415	81	3	it	it	PRON
dpc-1415	81	4	is	be	AUX
dpc-1415	81	5	assumed	assume	VERB
dpc-1415	81	6	that	that	SCONJ
dpc-1415	81	7	the	the	DET
dpc-1415	81	8	inhibition	inhibition	NOUN
dpc-1415	81	9	of	of	ADP
dpc-1415	81	10	pd-1	pd-1	ADP
dpc-1415	81	11	,	,	PUNCT
dpc-1415	81	12	pd	pd	PROPN
dpc-1415	81	13	-	-	PROPN
dpc-1415	81	14	l1	l1	PROPN
dpc-1415	81	15	,	,	PUNCT
dpc-1415	81	16	or	or	CCONJ
dpc-1415	81	17	ctla-4	ctla-4	NOUN
dpc-1415	81	18	results	result	NOUN
dpc-1415	81	19	in	in	ADP
dpc-1415	81	20	impaired	impaired	ADJ
dpc-1415	81	21	t	t	NOUN
dpc-1415	81	22	cell	cell	NOUN
dpc-1415	81	23	homeostasis	homeostasis	NOUN
dpc-1415	81	24	in	in	ADP
dpc-1415	81	25	the	the	DET
dpc-1415	81	26	skin	skin	NOUN
dpc-1415	81	27	,	,	PUNCT
dpc-1415	81	28	thus	thus	ADV
dpc-1415	81	29	facilitating	facilitate	VERB
dpc-1415	81	30	such	such	ADJ
dpc-1415	81	31	cytotoxic	cytotoxic	ADJ
dpc-1415	81	32	inflammatory	inflammatory	ADJ
dpc-1415	81	33	reactions	reaction	NOUN
dpc-1415	81	34	.	.	PUNCT
dpc-1415	82	1	the	the	DET
dpc-1415	82	2	onset	onset	NOUN
dpc-1415	82	3	of	of	ADP
dpc-1415	82	4	lichenoid	lichenoid	PROPN
dpc-1415	82	5	dermatologic	dermatologic	ADJ
dpc-1415	82	6	toxicity	toxicity	NOUN
dpc-1415	82	7	to	to	PART
dpc-1415	82	8	cpis	cpis	VERB
dpc-1415	82	9	usually	usually	ADV
dpc-1415	82	10	develops	develop	VERB
dpc-1415	82	11	several	several	ADJ
dpc-1415	82	12	weeks	week	NOUN
dpc-1415	82	13	to	to	ADP
dpc-1415	82	14	months	month	NOUN
dpc-1415	82	15	after	after	ADP
dpc-1415	82	16	treatment	treatment	NOUN
dpc-1415	82	17	initiation	initiation	NOUN
dpc-1415	82	18	.	.	PUNCT
dpc-1415	83	1	the	the	DET
dpc-1415	83	2	lesions	lesion	NOUN
dpc-1415	83	3	may	may	AUX
dpc-1415	83	4	resemble	resemble	VERB
dpc-1415	83	5	those	those	PRON
dpc-1415	83	6	seen	see	VERB
dpc-1415	83	7	in	in	ADP
dpc-1415	83	8	typical	typical	ADJ
dpc-1415	83	9	lichen	lichen	NOUN
dpc-1415	83	10	planus	planus	NOUN
dpc-1415	83	11	or	or	CCONJ
dpc-1415	83	12	may	may	AUX
dpc-1415	83	13	be	be	AUX
dpc-1415	83	14	hypertrophic	hypertrophic	ADJ
dpc-1415	83	15	,	,	PUNCT
dpc-1415	83	16	papulosquamous	papulosquamous	ADJ
dpc-1415	83	17	,	,	PUNCT
dpc-1415	83	18	or	or	CCONJ
dpc-1415	83	19	even	even	ADV
dpc-1415	83	20	bullous	bullous	ADJ
dpc-1415	83	21	.	.	PUNCT
dpc-1415	84	1	sites	site	NOUN
dpc-1415	84	2	of	of	ADP
dpc-1415	84	3	predilection	predilection	NOUN
dpc-1415	84	4	are	be	AUX
dpc-1415	84	5	the	the	DET
dpc-1415	84	6	trunk	trunk	NOUN
dpc-1415	84	7	and	and	CCONJ
dpc-1415	84	8	extremities	extremity	NOUN
dpc-1415	84	9	.	.	PUNCT
dpc-1415	85	1	pruritus	pruritus	PROPN
dpc-1415	85	2	is	be	AUX
dpc-1415	85	3	frequent	frequent	ADJ
dpc-1415	85	4	and	and	CCONJ
dpc-1415	85	5	in	in	ADP
dpc-1415	85	6	some	some	DET
dpc-1415	85	7	instances	instance	NOUN
dpc-1415	85	8	can	can	AUX
dpc-1415	85	9	be	be	AUX
dpc-1415	85	10	so	so	ADV
dpc-1415	85	11	severe	severe	ADJ
dpc-1415	85	12	profoundly	profoundly	ADV
dpc-1415	85	13	diminishing	diminish	VERB
dpc-1415	85	14	patients	patient	NOUN
dpc-1415	85	15	’	'	PUNCT
dpc-1415	85	16	quality	quality	NOUN
dpc-1415	85	17	of	of	ADP
dpc-1415	85	18	life	life	NOUN
dpc-1415	86	1	[	[	X
dpc-1415	86	2	6,7	6,7	NUM
dpc-1415	86	3	]	]	PUNCT
dpc-1415	86	4	.	.	PUNCT
dpc-1415	87	1	oral	oral	ADJ
dpc-1415	87	2	and	and	CCONJ
dpc-1415	87	3	genital	genital	ADJ
dpc-1415	87	4	mucosa	mucosa	NOUN
dpc-1415	87	5	may	may	AUX
dpc-1415	87	6	also	also	ADV
dpc-1415	87	7	be	be	AUX
dpc-1415	87	8	involved	involve	VERB
dpc-1415	87	9	[	[	PUNCT
dpc-1415	87	10	9	9	NUM
dpc-1415	87	11	]	]	PUNCT
dpc-1415	87	12	.	.	PUNCT
dpc-1415	88	1	severe	severe	ADJ
dpc-1415	88	2	forms	form	NOUN
dpc-1415	88	3	need	need	VERB
dpc-1415	88	4	to	to	PART
dpc-1415	88	5	be	be	AUX
dpc-1415	88	6	differentiated	differentiate	VERB
dpc-1415	88	7	from	from	ADP
dpc-1415	88	8	other	other	ADJ
dpc-1415	88	9	severe	severe	ADJ
dpc-1415	88	10	cutaneous	cutaneous	ADJ
dpc-1415	88	11	toxicities	toxicity	NOUN
dpc-1415	88	12	,	,	PUNCT
dpc-1415	88	13	such	such	ADJ
dpc-1415	88	14	as	as	ADP
dpc-1415	88	15	stevens	stevens	PROPN
dpc-1415	88	16	-	-	PUNCT
dpc-1415	88	17	johnson	johnson	PROPN
dpc-1415	88	18	syndrome/	syndrome/	NUM
dpc-1415	88	19	toxic	toxic	ADJ
dpc-1415	88	20	epidermal	epidermal	ADJ
dpc-1415	88	21	necrolysis	necrolysis	NOUN
dpc-1415	88	22	(	(	PUNCT
dpc-1415	88	23	sjs	sjs	PROPN
dpc-1415	88	24	/	/	SYM
dpc-1415	88	25	ten	ten	NUM
dpc-1415	88	26	)	)	PUNCT
dpc-1415	88	27	.	.	PUNCT
dpc-1415	89	1	in	in	ADP
dpc-1415	89	2	consideration	consideration	NOUN
dpc-1415	89	3	of	of	ADP
dpc-1415	89	4	the	the	DET
dpc-1415	89	5	aforementioned	aforementioned	ADJ
dpc-1415	89	6	morphologic	morphologic	ADJ
dpc-1415	89	7	diversity	diversity	NOUN
dpc-1415	89	8	,	,	PUNCT
dpc-1415	89	9	histopathologic	histopathologic	ADJ
dpc-1415	89	10	examination	examination	NOUN
dpc-1415	89	11	is	be	AUX
dpc-1415	89	12	of	of	ADP
dpc-1415	89	13	paramount	paramount	ADJ
dpc-1415	89	14	importance	importance	NOUN
dpc-1415	89	15	to	to	ADP
dpc-1415	89	16	establishing	establish	VERB
dpc-1415	89	17	a	a	DET
dpc-1415	89	18	definite	definite	ADJ
dpc-1415	89	19	diagnosis	diagnosis	NOUN
dpc-1415	89	20	.	.	PUNCT
dpc-1415	90	1	a	a	DET
dpc-1415	90	2	dense	dense	ADJ
dpc-1415	90	3	band	band	NOUN
dpc-1415	90	4	-	-	PUNCT
dpc-1415	90	5	like	like	ADJ
dpc-1415	90	6	lymphohistiocytic	lymphohistiocytic	NOUN
dpc-1415	90	7	infiltrate	infiltrate	NOUN
dpc-1415	90	8	along	along	ADP
dpc-1415	90	9	the	the	DET
dpc-1415	90	10	dermal	dermal	NOUN
dpc-1415	90	11	–	–	PUNCT
dpc-1415	90	12	epidermal	epidermal	ADJ
dpc-1415	90	13	junction	junction	NOUN
dpc-1415	90	14	,	,	PUNCT
dpc-1415	90	15	with	with	ADP
dpc-1415	90	16	patchy	patchy	ADJ
dpc-1415	90	17	-	-	PUNCT
dpc-1415	90	18	toflorid	toflorid	VERB
dpc-1415	90	19	vacuolar	vacuolar	ADJ
dpc-1415	90	20	interface	interface	NOUN
dpc-1415	90	21	dermatitis	dermatitis	NOUN
dpc-1415	90	22	and	and	CCONJ
dpc-1415	90	23	basilar	basilar	ADJ
dpc-1415	90	24	/	/	SYM
dpc-1415	90	25	suprabasilar	suprabasilar	ADJ
dpc-1415	90	26	apoptotic	apoptotic	ADJ
dpc-1415	90	27	keratinocytes	keratinocyte	NOUN
dpc-1415	90	28	compose	compose	VERB
dpc-1415	90	29	the	the	DET
dpc-1415	90	30	histopathologic	histopathologic	ADJ
dpc-1415	90	31	pattern	pattern	NOUN
dpc-1415	90	32	of	of	ADP
dpc-1415	90	33	cpi	cpi	NOUN
dpc-1415	90	34	-	-	PUNCT
dpc-1415	90	35	mediated	mediate	VERB
dpc-1415	90	36	lichenoid	lichenoid	NOUN
dpc-1415	90	37	rash	rash	NOUN
dpc-1415	90	38	[	[	X
dpc-1415	90	39	10	10	NUM
dpc-1415	90	40	]	]	PUNCT
dpc-1415	90	41	.	.	PUNCT
dpc-1415	91	1	therapeutic	therapeutic	ADJ
dpc-1415	91	2	management	management	NOUN
dpc-1415	91	3	includes	include	VERB
dpc-1415	91	4	topical	topical	ADJ
dpc-1415	91	5	steroids	steroid	NOUN
dpc-1415	91	6	and	and	CCONJ
dpc-1415	91	7	,	,	PUNCT
dpc-1415	91	8	rarely	rarely	ADV
dpc-1415	91	9	,	,	PUNCT
dpc-1415	91	10	oral	oral	ADJ
dpc-1415	91	11	corticosteroids	corticosteroid	NOUN
dpc-1415	91	12	,	,	PUNCT
dpc-1415	91	13	phototherapy	phototherapy	NOUN
dpc-1415	91	14	,	,	PUNCT
dpc-1415	91	15	or	or	CCONJ
dpc-1415	91	16	acitretin	acitretin	NOUN
dpc-1415	91	17	.	.	PUNCT
dpc-1415	92	1	cpi	cpi	PROPN
dpc-1415	92	2	treatment	treatment	NOUN
dpc-1415	92	3	is	be	AUX
dpc-1415	92	4	usually	usually	ADV
dpc-1415	92	5	maintained	maintain	VERB
dpc-1415	92	6	[	[	PUNCT
dpc-1415	92	7	6	6	NUM
dpc-1415	92	8	-	-	SYM
dpc-1415	92	9	8	8	NUM
dpc-1415	92	10	]	]	PUNCT
dpc-1415	92	11	.	.	PUNCT
dpc-1415	93	1	3	3	X
dpc-1415	93	2	.	.	X
dpc-1415	93	3	psoriasiform	psoriasiform	NOUN
dpc-1415	93	4	rashes	rash	NOUN
dpc-1415	93	5	cpis	cpis	NOUN
dpc-1415	93	6	may	may	AUX
dpc-1415	93	7	trigger	trigger	VERB
dpc-1415	93	8	a	a	DET
dpc-1415	93	9	psoriasiform	psoriasiform	NOUN
dpc-1415	93	10	rash	rash	NOUN
dpc-1415	93	11	,	,	PUNCT
dpc-1415	93	12	or	or	CCONJ
dpc-1415	93	13	may	may	AUX
dpc-1415	93	14	exacerbate	exacerbate	VERB
dpc-1415	93	15	a	a	DET
dpc-1415	93	16	preexisting	preexist	VERB
dpc-1415	93	17	psoriasis	psoriasis	NOUN
dpc-1415	93	18	(	(	PUNCT
dpc-1415	93	19	figure	figure	NOUN
dpc-1415	93	20	3	3	NUM
dpc-1415	93	21	,	,	PUNCT
dpc-1415	93	22	a	a	DET
dpc-1415	93	23	-	-	PUNCT
dpc-1415	93	24	c	c	NOUN
dpc-1415	93	25	)	)	PUNCT
dpc-1415	93	26	.	.	PUNCT
dpc-1415	94	1	it	it	PRON
dpc-1415	94	2	is	be	AUX
dpc-1415	94	3	well	well	ADV
dpc-1415	94	4	known	know	VERB
dpc-1415	94	5	that	that	SCONJ
dpc-1415	94	6	psoriasis	psoriasis	NOUN
dpc-1415	94	7	is	be	AUX
dpc-1415	94	8	a	a	DET
dpc-1415	94	9	chronic	chronic	NOUN
dpc-1415	94	10	,	,	PUNCT
dpc-1415	94	11	immune	immune	NOUN
dpc-1415	94	12	-	-	PUNCT
dpc-1415	94	13	mediated	mediate	VERB
dpc-1415	94	14	,	,	PUNCT
dpc-1415	94	15	inflammatory	inflammatory	ADJ
dpc-1415	94	16	skin	skin	NOUN
dpc-1415	94	17	disease	disease	NOUN
dpc-1415	95	1	[	[	X
dpc-1415	95	2	11,12	11,12	NOUN
dpc-1415	95	3	]	]	PUNCT
dpc-1415	95	4	.	.	PUNCT
dpc-1415	96	1	the	the	DET
dpc-1415	96	2	pathogenetic	pathogenetic	ADJ
dpc-1415	96	3	mechanism	mechanism	NOUN
dpc-1415	96	4	responsible	responsible	ADJ
dpc-1415	96	5	for	for	ADP
dpc-1415	96	6	psoriasis	psoriasis	NOUN
dpc-1415	96	7	in	in	ADP
dpc-1415	96	8	patients	patient	NOUN
dpc-1415	96	9	treated	treat	VERB
dpc-1415	96	10	with	with	ADP
dpc-1415	96	11	cpis	cpis	PROPN
dpc-1415	96	12	has	have	AUX
dpc-1415	96	13	not	not	PART
dpc-1415	96	14	yet	yet	ADV
dpc-1415	96	15	been	be	AUX
dpc-1415	96	16	completely	completely	ADV
dpc-1415	96	17	elucidated	elucidated	ADJ
dpc-1415	96	18	.	.	PUNCT
dpc-1415	97	1	however	however	ADV
dpc-1415	97	2	,	,	PUNCT
dpc-1415	97	3	it	it	PRON
dpc-1415	97	4	is	be	AUX
dpc-1415	97	5	deemed	deem	VERB
dpc-1415	97	6	to	to	PART
dpc-1415	97	7	be	be	AUX
dpc-1415	97	8	immunemediated	immunemediate	VERB
dpc-1415	97	9	,	,	PUNCT
dpc-1415	97	10	resulting	result	VERB
dpc-1415	97	11	by	by	ADP
dpc-1415	97	12	the	the	DET
dpc-1415	97	13	t	t	PROPN
dpc-1415	97	14	-	-	PUNCT
dpc-1415	97	15	cell	cell	NOUN
dpc-1415	97	16	activation	activation	NOUN
dpc-1415	97	17	of	of	ADP
dpc-1415	97	18	cytotoxic	cytotoxic	ADJ
dpc-1415	97	19	cd4+/cd8	cd4+/cd8	NOUN
dpc-1415	97	20	+	+	X
dpc-1415	98	1	[	[	X
dpc-1415	98	2	13,14,15	13,14,15	NUM
dpc-1415	98	3	]	]	PUNCT
dpc-1415	98	4	.	.	PUNCT
dpc-1415	99	1	well	well	ADV
dpc-1415	99	2	-	-	PUNCT
dpc-1415	99	3	demarcated	demarcate	VERB
dpc-1415	99	4	,	,	PUNCT
dpc-1415	99	5	erythematous	erythematous	ADJ
dpc-1415	99	6	,	,	PUNCT
dpc-1415	99	7	scaly	scaly	NOUN
dpc-1415	99	8	papules	papule	NOUN
dpc-1415	99	9	and	and	CCONJ
dpc-1415	99	10	plaques	plaque	NOUN
dpc-1415	99	11	,	,	PUNCT
dpc-1415	99	12	reminiscent	reminiscent	ADJ
dpc-1415	99	13	of	of	ADP
dpc-1415	99	14	classic	classic	ADJ
dpc-1415	99	15	plaque	plaque	NOUN
dpc-1415	99	16	psoriasis	psoriasis	NOUN
dpc-1415	99	17	,	,	PUNCT
dpc-1415	99	18	is	be	AUX
dpc-1415	99	19	the	the	DET
dpc-1415	99	20	commonest	commonest	NOUN
dpc-1415	99	21	presentation	presentation	NOUN
dpc-1415	99	22	.	.	PUNCT
dpc-1415	100	1	in	in	ADP
dpc-1415	100	2	addition	addition	NOUN
dpc-1415	100	3	,	,	PUNCT
dpc-1415	100	4	guttate	guttate	ADJ
dpc-1415	100	5	,	,	PUNCT
dpc-1415	100	6	pustular	pustular	ADJ
dpc-1415	100	7	,	,	PUNCT
dpc-1415	100	8	and	and	CCONJ
dpc-1415	100	9	inverse	inverse	NOUN
dpc-1415	100	10	psoriasis	psoriasis	NOUN
dpc-1415	100	11	have	have	AUX
dpc-1415	100	12	also	also	ADV
dpc-1415	100	13	been	be	AUX
dpc-1415	100	14	reported	report	VERB
dpc-1415	100	15	[	[	X
dpc-1415	100	16	16,17	16,17	NUM
dpc-1415	100	17	]	]	PUNCT
dpc-1415	100	18	.	.	PUNCT
dpc-1415	101	1	importantly	importantly	ADV
dpc-1415	101	2	,	,	PUNCT
dpc-1415	101	3	exacerbation	exacerbation	NOUN
dpc-1415	101	4	or	or	CCONJ
dpc-1415	101	5	de	de	ADJ
dpc-1415	101	6	-	-	ADJ
dpc-1415	101	7	novo	novo	ADJ
dpc-1415	101	8	occurrence	occurrence	NOUN
dpc-1415	101	9	of	of	ADP
dpc-1415	101	10	psoriatic	psoriatic	ADJ
dpc-1415	101	11	arthritis	arthritis	NOUN
dpc-1415	101	12	(	(	PUNCT
dpc-1415	101	13	figure	figure	NOUN
dpc-1415	101	14	3c	3c	NUM
dpc-1415	101	15	)	)	PUNCT
dpc-1415	101	16	,	,	PUNCT
dpc-1415	101	17	with	with	ADP
dpc-1415	101	18	or	or	CCONJ
dpc-1415	101	19	without	without	ADP
dpc-1415	101	20	skin	skin	NOUN
dpc-1415	101	21	psoriasis	psoriasis	NOUN
dpc-1415	101	22	,	,	PUNCT
dpc-1415	101	23	has	have	AUX
dpc-1415	101	24	also	also	ADV
dpc-1415	101	25	been	be	AUX
dpc-1415	101	26	described	describe	VERB
dpc-1415	101	27	[	[	X
dpc-1415	101	28	18	18	NUM
dpc-1415	101	29	]	]	PUNCT
dpc-1415	101	30	.	.	PUNCT
dpc-1415	102	1	the	the	DET
dpc-1415	102	2	histopathologic	histopathologic	PROPN
dpc-1415	102	3	findings	finding	NOUN
dpc-1415	102	4	are	be	AUX
dpc-1415	102	5	similar	similar	ADJ
dpc-1415	102	6	to	to	ADP
dpc-1415	102	7	those	those	PRON
dpc-1415	102	8	seen	see	VERB
dpc-1415	102	9	in	in	ADP
dpc-1415	102	10	classic	classic	ADJ
dpc-1415	102	11	plaque	plaque	NOUN
dpc-1415	102	12	psoriatic	psoriatic	ADJ
dpc-1415	102	13	cases	case	NOUN
dpc-1415	102	14	.	.	PUNCT
dpc-1415	103	1	topical	topical	ADJ
dpc-1415	103	2	treatment	treatment	NOUN
dpc-1415	103	3	does	do	AUX
dpc-1415	103	4	not	not	PART
dpc-1415	103	5	differ	differ	VERB
dpc-1415	103	6	from	from	ADP
dpc-1415	103	7	the	the	DET
dpc-1415	103	8	treatment	treatment	NOUN
dpc-1415	103	9	of	of	ADP
dpc-1415	103	10	classic	classic	ADJ
dpc-1415	103	11	psoriasis	psoriasis	NOUN
dpc-1415	103	12	and	and	CCONJ
dpc-1415	103	13	includes	include	VERB
dpc-1415	103	14	vitamin	vitamin	NOUN
dpc-1415	103	15	d	d	NOUN
dpc-1415	103	16	analogues	analogue	NOUN
dpc-1415	103	17	and	and	CCONJ
dpc-1415	103	18	topical	topical	ADJ
dpc-1415	103	19	steroids	steroid	NOUN
dpc-1415	103	20	.	.	PUNCT
dpc-1415	104	1	among	among	ADP
dpc-1415	104	2	the	the	DET
dpc-1415	104	3	systemic	systemic	ADJ
dpc-1415	104	4	treatments	treatment	NOUN
dpc-1415	104	5	,	,	PUNCT
dpc-1415	104	6	retinoids	retinoid	NOUN
dpc-1415	104	7	,	,	PUNCT
dpc-1415	104	8	uvb	uvb	ADJ
dpc-1415	104	9	therapy	therapy	NOUN
dpc-1415	104	10	,	,	PUNCT
dpc-1415	104	11	apremilast	apremilast	VERB
dpc-1415	104	12	and	and	CCONJ
dpc-1415	104	13	methotrexate	methotrexate	NOUN
dpc-1415	104	14	are	be	AUX
dpc-1415	104	15	preferable	preferable	ADJ
dpc-1415	104	16	.	.	PUNCT
dpc-1415	105	1	with	with	ADP
dpc-1415	105	2	the	the	DET
dpc-1415	105	3	exception	exception	NOUN
dpc-1415	105	4	of	of	ADP
dpc-1415	105	5	erythrodermic	erythrodermic	ADJ
dpc-1415	105	6	and	and	CCONJ
dpc-1415	105	7	generalized	generalized	ADJ
dpc-1415	105	8	pustular	pustular	ADJ
dpc-1415	105	9	psoriasis	psoriasis	NOUN
dpc-1415	105	10	,	,	PUNCT
dpc-1415	105	11	cpi	cpi	NOUN
dpc-1415	105	12	therapy	therapy	NOUN
dpc-1415	105	13	is	be	AUX
dpc-1415	105	14	usually	usually	ADV
dpc-1415	105	15	maintained	maintain	VERB
dpc-1415	105	16	.	.	PUNCT
dpc-1415	106	1	early	early	ADJ
dpc-1415	106	2	recognition	recognition	NOUN
dpc-1415	106	3	and	and	CCONJ
dpc-1415	106	4	adequate	adequate	ADJ
dpc-1415	106	5	management	management	NOUN
dpc-1415	106	6	of	of	ADP
dpc-1415	106	7	cpi	cpi	NOUN
dpc-1415	106	8	-	-	PUNCT
dpc-1415	106	9	mediated	mediate	VERB
dpc-1415	106	10	psoriasis	psoriasis	NOUN
dpc-1415	106	11	are	be	AUX
dpc-1415	106	12	challenging	challenge	VERB
dpc-1415	106	13	,	,	PUNCT
dpc-1415	106	14	especially	especially	ADV
dpc-1415	106	15	considering	consider	VERB
dpc-1415	106	16	the	the	DET
dpc-1415	106	17	lack	lack	NOUN
dpc-1415	106	18	of	of	ADP
dpc-1415	106	19	evidence	evidence	NOUN
dpc-1415	106	20	-	-	PUNCT
dpc-1415	106	21	based	base	VERB
dpc-1415	106	22	guidelines	guideline	NOUN
dpc-1415	106	23	.	.	PUNCT
dpc-1415	107	1	in	in	ADP
dpc-1415	107	2	any	any	DET
dpc-1415	107	3	case	case	NOUN
dpc-1415	107	4	,	,	PUNCT
dpc-1415	107	5	a	a	DET
dpc-1415	107	6	multidisciplinary	multidisciplinary	ADJ
dpc-1415	107	7	approach	approach	NOUN
dpc-1415	107	8	is	be	AUX
dpc-1415	107	9	necessary	necessary	ADJ
dpc-1415	107	10	.	.	PUNCT
dpc-1415	108	1	4	4	X
dpc-1415	108	2	.	.	X
dpc-1415	108	3	eczematous	eczematous	ADJ
dpc-1415	108	4	rashes	rash	NOUN
dpc-1415	108	5	eczematous	eczematous	ADJ
dpc-1415	108	6	rashes	rash	NOUN
dpc-1415	108	7	are	be	AUX
dpc-1415	108	8	also	also	ADV
dpc-1415	108	9	common	common	ADJ
dpc-1415	108	10	in	in	ADP
dpc-1415	108	11	patients	patient	NOUN
dpc-1415	108	12	treated	treat	VERB
dpc-1415	108	13	with	with	ADP
dpc-1415	108	14	cpis	cpis	NOUN
dpc-1415	108	15	.	.	PUNCT
dpc-1415	109	1	they	they	PRON
dpc-1415	109	2	are	be	AUX
dpc-1415	109	3	characterized	characterize	VERB
dpc-1415	109	4	by	by	ADP
dpc-1415	109	5	pruritic	pruritic	ADJ
dpc-1415	109	6	,	,	PUNCT
dpc-1415	109	7	erythematous	erythematous	ADJ
dpc-1415	109	8	,	,	PUNCT
dpc-1415	109	9	scaly	scaly	NOUN
dpc-1415	109	10	,	,	PUNCT
dpc-1415	109	11	or	or	CCONJ
dpc-1415	109	12	crusted	crust	VERB
dpc-1415	109	13	macules	macule	NOUN
dpc-1415	109	14	and	and	CCONJ
dpc-1415	109	15	papules	papule	NOUN
dpc-1415	109	16	that	that	PRON
dpc-1415	109	17	may	may	AUX
dpc-1415	109	18	coalesce	coalesce	VERB
dpc-1415	109	19	into	into	ADP
dpc-1415	109	20	plaques	plaque	NOUN
dpc-1415	109	21	.	.	PUNCT
dpc-1415	110	1	diverse	diverse	ADJ
dpc-1415	110	2	clinical	clinical	ADJ
dpc-1415	110	3	presentation	presentation	NOUN
dpc-1415	110	4	,	,	PUNCT
dpc-1415	110	5	including	include	VERB
dpc-1415	110	6	localized	localized	ADJ
dpc-1415	110	7	or	or	CCONJ
dpc-1415	110	8	generalized	generalized	ADJ
dpc-1415	110	9	patches	patch	NOUN
dpc-1415	110	10	/	/	SYM
dpc-1415	110	11	plaques	plaque	NOUN
dpc-1415	110	12	of	of	ADP
dpc-1415	110	13	classic	classic	ADJ
dpc-1415	110	14	dermatitis	dermatitis	NOUN
dpc-1415	110	15	,	,	PUNCT
dpc-1415	110	16	as	as	ADV
dpc-1415	110	17	well	well	ADV
dpc-1415	110	18	as	as	ADP
dpc-1415	110	19	nummular	nummular	ADJ
dpc-1415	110	20	,	,	PUNCT
dpc-1415	110	21	dyshidrotic	dyshidrotic	ADJ
dpc-1415	110	22	and	and	CCONJ
dpc-1415	110	23	asteatotic	asteatotic	ADJ
dpc-1415	110	24	eczema	eczema	NOUN
dpc-1415	110	25	may	may	AUX
dpc-1415	110	26	be	be	AUX
dpc-1415	110	27	observed	observe	VERB
dpc-1415	110	28	.	.	PUNCT
dpc-1415	111	1	the	the	DET
dpc-1415	111	2	time	time	NOUN
dpc-1415	111	3	of	of	ADP
dpc-1415	111	4	onset	onset	NOUN
dpc-1415	111	5	ranges	range	VERB
dpc-1415	111	6	from	from	ADP
dpc-1415	111	7	4	4	NUM
dpc-1415	111	8	-	-	SYM
dpc-1415	111	9	18	18	NUM
dpc-1415	111	10	months	month	NOUN
dpc-1415	111	11	after	after	ADP
dpc-1415	111	12	treatment	treatment	NOUN
dpc-1415	111	13	initiation	initiation	NOUN
dpc-1415	111	14	.	.	PUNCT
dpc-1415	112	1	5	5	X
dpc-1415	112	2	.	.	X
dpc-1415	112	3	neutrophilic	neutrophilic	PROPN
dpc-1415	112	4	dermatoses	dermatose	VERB
dpc-1415	112	5	the	the	DET
dpc-1415	112	6	spectrum	spectrum	NOUN
dpc-1415	112	7	of	of	ADP
dpc-1415	112	8	neutrophilic	neutrophilic	PROPN
dpc-1415	112	9	dermatoses	dermatosis	NOUN
dpc-1415	112	10	secondary	secondary	ADJ
dpc-1415	112	11	to	to	PART
dpc-1415	112	12	cpis	cpis	VERB
dpc-1415	112	13	includes	include	VERB
dpc-1415	112	14	sweet	sweet	ADJ
dpc-1415	112	15	syndrome	syndrome	NOUN
dpc-1415	112	16	,	,	PUNCT
dpc-1415	112	17	pustular	pustular	ADJ
dpc-1415	112	18	eruptions	eruption	NOUN
dpc-1415	112	19	,	,	PUNCT
dpc-1415	112	20	bullous	bullous	ADJ
dpc-1415	112	21	lupus	lupus	PROPN
dpc-1415	112	22	erythematosus	erythematosus	NOUN
dpc-1415	112	23	,	,	PUNCT
dpc-1415	112	24	and	and	CCONJ
dpc-1415	112	25	pyoderma	pyoderma	NOUN
dpc-1415	112	26	gangrenosum	gangrenosum	NOUN
dpc-1415	112	27	.	.	PUNCT
dpc-1415	113	1	they	they	PRON
dpc-1415	113	2	are	be	AUX
dpc-1415	113	3	considered	consider	VERB
dpc-1415	113	4	rare	rare	ADJ
dpc-1415	113	5	,	,	PUNCT
dpc-1415	113	6	with	with	SCONJ
dpc-1415	113	7	only	only	ADV
dpc-1415	113	8	few	few	ADJ
dpc-1415	113	9	cases	case	NOUN
dpc-1415	113	10	reported	report	VERB
dpc-1415	113	11	[	[	X
dpc-1415	113	12	19	19	NUM
dpc-1415	113	13	]	]	PUNCT
dpc-1415	113	14	.	.	PUNCT
dpc-1415	114	1	the	the	DET
dpc-1415	114	2	onset	onset	ADJ
dpc-1415	114	3	figure	figure	NOUN
dpc-1415	114	4	3	3	NUM
dpc-1415	114	5	.	.	PUNCT
dpc-1415	115	1	(	(	PUNCT
dpc-1415	115	2	a	a	X
dpc-1415	115	3	)	)	PUNCT
dpc-1415	115	4	a	a	DET
dpc-1415	115	5	patient	patient	NOUN
dpc-1415	115	6	with	with	ADP
dpc-1415	115	7	non	non	ADJ
dpc-1415	115	8	-	-	ADJ
dpc-1415	115	9	small	small	ADJ
dpc-1415	115	10	cell	cell	NOUN
dpc-1415	115	11	lung	lung	NOUN
dpc-1415	115	12	carcinoma	carcinoma	NOUN
dpc-1415	115	13	who	who	PRON
dpc-1415	115	14	was	be	AUX
dpc-1415	115	15	treated	treat	VERB
dpc-1415	115	16	with	with	ADP
dpc-1415	115	17	a	a	DET
dpc-1415	115	18	combination	combination	NOUN
dpc-1415	115	19	of	of	ADP
dpc-1415	115	20	nivolumab	nivolumab	NOUN
dpc-1415	115	21	and	and	CCONJ
dpc-1415	115	22	ipilimumab	ipilimumab	VERB
dpc-1415	115	23	developed	develop	VERB
dpc-1415	115	24	palmoplantar	palmoplantar	NOUN
dpc-1415	115	25	pustulosis	pustulosis	NOUN
dpc-1415	115	26	after	after	ADP
dpc-1415	115	27	the	the	DET
dpc-1415	115	28	third	third	ADJ
dpc-1415	115	29	cycle	cycle	NOUN
dpc-1415	115	30	.	.	PUNCT
dpc-1415	116	1	(	(	PUNCT
dpc-1415	116	2	b	b	X
dpc-1415	116	3	)	)	PUNCT
dpc-1415	116	4	significant	significant	ADJ
dpc-1415	116	5	improvement	improvement	NOUN
dpc-1415	116	6	of	of	ADP
dpc-1415	116	7	the	the	DET
dpc-1415	116	8	skin	skin	NOUN
dpc-1415	116	9	after	after	ADP
dpc-1415	116	10	2	2	NUM
dpc-1415	116	11	months	month	NOUN
dpc-1415	116	12	of	of	ADP
dpc-1415	116	13	treatment	treatment	NOUN
dpc-1415	116	14	.	.	PUNCT
dpc-1415	117	1	(	(	PUNCT
dpc-1415	117	2	c	c	X
dpc-1415	117	3	)	)	PUNCT
dpc-1415	117	4	however	however	ADV
dpc-1415	117	5	,	,	PUNCT
dpc-1415	117	6	the	the	DET
dpc-1415	117	7	patient	patient	NOUN
dpc-1415	117	8	experienced	experience	VERB
dpc-1415	117	9	severe	severe	ADJ
dpc-1415	117	10	psoriatic	psoriatic	ADJ
dpc-1415	117	11	arthritis	arthritis	NOUN
dpc-1415	117	12	and	and	CCONJ
dpc-1415	117	13	was	be	AUX
dpc-1415	117	14	switched	switch	VERB
dpc-1415	117	15	to	to	PART
dpc-1415	117	16	apremilast	apremilast	VERB
dpc-1415	117	17	.	.	PUNCT
dpc-1415	118	1	a	a	DET
dpc-1415	118	2	b	b	NOUN
dpc-1415	118	3	c	c	NOUN
dpc-1415	118	4	6	6	NUM
dpc-1415	118	5	review	review	NOUN
dpc-1415	118	6	|	|	ADV
dpc-1415	118	7	dermatol	dermatol	ADJ
dpc-1415	118	8	pract	pract	NOUN
dpc-1415	118	9	concept	concept	NOUN
dpc-1415	118	10	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	118	11	of	of	ADP
dpc-1415	118	12	neutrophilic	neutrophilic	ADJ
dpc-1415	118	13	dermatoses	dermatosis	NOUN
dpc-1415	118	14	seems	seem	VERB
dpc-1415	118	15	to	to	PART
dpc-1415	118	16	be	be	AUX
dpc-1415	118	17	relatively	relatively	ADV
dpc-1415	118	18	delayed	delay	VERB
dpc-1415	118	19	,	,	PUNCT
dpc-1415	118	20	ranging	range	VERB
dpc-1415	118	21	from	from	ADP
dpc-1415	118	22	weeks	week	NOUN
dpc-1415	118	23	to	to	ADP
dpc-1415	118	24	months	month	NOUN
dpc-1415	118	25	.	.	PUNCT
dpc-1415	119	1	interestingly	interestingly	ADV
dpc-1415	119	2	,	,	PUNCT
dpc-1415	119	3	most	most	ADJ
dpc-1415	119	4	of	of	ADP
dpc-1415	119	5	the	the	DET
dpc-1415	119	6	cases	case	NOUN
dpc-1415	119	7	of	of	ADP
dpc-1415	119	8	sweet	sweet	ADJ
dpc-1415	119	9	syndrome	syndrome	NOUN
dpc-1415	119	10	and	and	CCONJ
dpc-1415	119	11	all	all	DET
dpc-1415	119	12	cases	case	NOUN
dpc-1415	119	13	of	of	ADP
dpc-1415	119	14	pyoderma	pyoderma	NOUN
dpc-1415	119	15	gangrenosum	gangrenosum	NOUN
dpc-1415	119	16	reported	report	VERB
dpc-1415	119	17	in	in	ADP
dpc-1415	119	18	the	the	DET
dpc-1415	119	19	literature	literature	NOUN
dpc-1415	119	20	were	be	AUX
dpc-1415	119	21	induced	induce	VERB
dpc-1415	119	22	by	by	ADP
dpc-1415	119	23	ipilimumab	ipilimumab	NOUN
dpc-1415	119	24	(	(	PUNCT
dpc-1415	119	25	antictla-4	antictla-4	NOUN
dpc-1415	119	26	)	)	PUNCT
dpc-1415	120	1	[	[	X
dpc-1415	120	2	20	20	NUM
dpc-1415	120	3	]	]	PUNCT
dpc-1415	120	4	.	.	PUNCT
dpc-1415	121	1	b.	b.	PROPN
dpc-1415	121	2	bullous	bullous	ADJ
dpc-1415	121	3	eruptions	eruption	NOUN
dpc-1415	121	4	compared	compare	VERB
dpc-1415	121	5	with	with	ADP
dpc-1415	121	6	other	other	ADJ
dpc-1415	121	7	dermatoses	dermatosis	NOUN
dpc-1415	121	8	,	,	PUNCT
dpc-1415	121	9	autoimmune	autoimmune	ADJ
dpc-1415	121	10	bullous	bullous	ADJ
dpc-1415	121	11	diseases	disease	NOUN
dpc-1415	121	12	in	in	ADP
dpc-1415	121	13	association	association	NOUN
dpc-1415	121	14	with	with	ADP
dpc-1415	121	15	immunotherapy	immunotherapy	NOUN
dpc-1415	121	16	are	be	AUX
dpc-1415	121	17	less	less	ADV
dpc-1415	121	18	common	common	ADJ
dpc-1415	121	19	and	and	CCONJ
dpc-1415	121	20	they	they	PRON
dpc-1415	121	21	are	be	AUX
dpc-1415	121	22	scarcely	scarcely	ADV
dpc-1415	121	23	reported	report	VERB
dpc-1415	121	24	in	in	ADP
dpc-1415	121	25	the	the	DET
dpc-1415	121	26	literature	literature	NOUN
dpc-1415	121	27	(	(	PUNCT
dpc-1415	121	28	figure	figure	NOUN
dpc-1415	121	29	 	 	SPACE
dpc-1415	121	30	4	4	NUM
dpc-1415	121	31	)	)	PUNCT
dpc-1415	121	32	.	.	PUNCT
dpc-1415	122	1	interestingly	interestingly	ADV
dpc-1415	122	2	,	,	PUNCT
dpc-1415	122	3	the	the	DET
dpc-1415	122	4	risk	risk	NOUN
dpc-1415	122	5	of	of	ADP
dpc-1415	122	6	a	a	DET
dpc-1415	122	7	bullous	bullous	ADJ
dpc-1415	122	8	eruption	eruption	NOUN
dpc-1415	122	9	seems	seem	VERB
dpc-1415	122	10	to	to	PART
dpc-1415	122	11	be	be	AUX
dpc-1415	122	12	higher	high	ADJ
dpc-1415	122	13	when	when	SCONJ
dpc-1415	122	14	treated	treat	VERB
dpc-1415	122	15	with	with	ADP
dpc-1415	122	16	anti	anti	ADJ
dpc-1415	122	17	-	-	ADJ
dpc-1415	122	18	pd-1	pd-1	ADJ
dpc-1415	122	19	or	or	CCONJ
dpc-1415	122	20	anti	anti	ADJ
dpc-1415	122	21	-	-	ADJ
dpc-1415	122	22	pd	pd	ADJ
dpc-1415	122	23	-	-	PUNCT
dpc-1415	122	24	l1	l1	PROPN
dpc-1415	122	25	rather	rather	ADV
dpc-1415	122	26	than	than	ADP
dpc-1415	122	27	anti	anti	ADJ
dpc-1415	122	28	-	-	NOUN
dpc-1415	122	29	ctla-4	ctla-4	NOUN
dpc-1415	122	30	.	.	PUNCT
dpc-1415	123	1	in	in	ADP
dpc-1415	123	2	the	the	DET
dpc-1415	123	3	analysis	analysis	NOUN
dpc-1415	123	4	of	of	ADP
dpc-1415	123	5	a	a	DET
dpc-1415	123	6	database	database	NOUN
dpc-1415	123	7	including	include	VERB
dpc-1415	123	8	853	853	NUM
dpc-1415	123	9	patients	patient	NOUN
dpc-1415	123	10	receiving	receive	VERB
dpc-1415	123	11	anti	anti	ADJ
dpc-1415	123	12	-	-	ADJ
dpc-1415	123	13	pd-1	pd-1	ADJ
dpc-1415	123	14	/	/	SYM
dpc-1415	123	15	pd	pd	NOUN
dpc-1415	123	16	-	-	PUNCT
dpc-1415	123	17	l1	l1	PROPN
dpc-1415	123	18	,	,	PUNCT
dpc-1415	123	19	the	the	DET
dpc-1415	123	20	rate	rate	NOUN
dpc-1415	123	21	of	of	ADP
dpc-1415	123	22	bullous	bullous	ADJ
dpc-1415	123	23	skin	skin	NOUN
dpc-1415	123	24	toxicity	toxicity	NOUN
dpc-1415	123	25	was	be	AUX
dpc-1415	123	26	about	about	ADV
dpc-1415	123	27	1	1	NUM
dpc-1415	123	28	%	%	NOUN
dpc-1415	123	29	in	in	ADP
dpc-1415	123	30	the	the	DET
dpc-1415	123	31	studied	studied	ADJ
dpc-1415	123	32	population	population	NOUN
dpc-1415	124	1	[	[	X
dpc-1415	124	2	21	21	NUM
dpc-1415	124	3	]	]	PUNCT
dpc-1415	124	4	.	.	PUNCT
dpc-1415	125	1	of	of	ADP
dpc-1415	125	2	note	note	NOUN
dpc-1415	125	3	,	,	PUNCT
dpc-1415	125	4	most	most	ADJ
dpc-1415	125	5	of	of	ADP
dpc-1415	125	6	them	they	PRON
dpc-1415	125	7	developed	develop	VERB
dpc-1415	125	8	bullous	bullous	ADJ
dpc-1415	125	9	pemphigoid	pemphigoid	NOUN
dpc-1415	125	10	(	(	PUNCT
dpc-1415	125	11	bp	bp	PROPN
dpc-1415	125	12	)	)	PUNCT
dpc-1415	125	13	.	.	PUNCT
dpc-1415	126	1	in	in	ADP
dpc-1415	126	2	addition	addition	NOUN
dpc-1415	126	3	,	,	PUNCT
dpc-1415	126	4	a	a	DET
dpc-1415	126	5	case	case	NOUN
dpc-1415	126	6	of	of	ADP
dpc-1415	126	7	bullous	bullous	ADJ
dpc-1415	126	8	lichenoid	lichenoid	PROPN
dpc-1415	126	9	dermatitis	dermatitis	NOUN
dpc-1415	126	10	and	and	CCONJ
dpc-1415	126	11	a	a	DET
dpc-1415	126	12	case	case	NOUN
dpc-1415	126	13	of	of	ADP
dpc-1415	126	14	linear	linear	PROPN
dpc-1415	126	15	iga	iga	PROPN
dpc-1415	126	16	bullous	bullous	ADJ
dpc-1415	126	17	dermatosis	dermatosis	NOUN
dpc-1415	126	18	were	be	AUX
dpc-1415	126	19	also	also	ADV
dpc-1415	126	20	reported	report	VERB
dpc-1415	126	21	.	.	PUNCT
dpc-1415	127	1	in	in	ADP
dpc-1415	127	2	another	another	DET
dpc-1415	127	3	retrospective	retrospective	ADJ
dpc-1415	127	4	analysis	analysis	NOUN
dpc-1415	127	5	,	,	PUNCT
dpc-1415	127	6	the	the	DET
dpc-1415	127	7	incidence	incidence	NOUN
dpc-1415	127	8	of	of	ADP
dpc-1415	127	9	bullous	bullous	ADJ
dpc-1415	127	10	disorders	disorder	NOUN
dpc-1415	127	11	was	be	AUX
dpc-1415	127	12	higher	high	ADJ
dpc-1415	127	13	(	(	PUNCT
dpc-1415	127	14	8	8	NUM
dpc-1415	127	15	%	%	NOUN
dpc-1415	127	16	)	)	PUNCT
dpc-1415	127	17	and	and	CCONJ
dpc-1415	127	18	all	all	DET
dpc-1415	127	19	cases	case	NOUN
dpc-1415	127	20	were	be	AUX
dpc-1415	127	21	secondary	secondary	ADJ
dpc-1415	127	22	to	to	ADP
dpc-1415	127	23	anti	anti	ADJ
dpc-1415	127	24	-	-	ADJ
dpc-1415	127	25	pd1	pd1	VERB
dpc-1415	127	26	/	/	SYM
dpc-1415	127	27	pd	pd	NOUN
dpc-1415	127	28	-	-	PROPN
dpc-1415	127	29	l1	l1	PROPN
dpc-1415	127	30	therapy	therapy	NOUN
dpc-1415	128	1	[	[	X
dpc-1415	128	2	22	22	NUM
dpc-1415	128	3	]	]	PUNCT
dpc-1415	128	4	.	.	PUNCT
dpc-1415	129	1	the	the	DET
dpc-1415	129	2	clinical	clinical	ADJ
dpc-1415	129	3	presentation	presentation	NOUN
dpc-1415	129	4	of	of	ADP
dpc-1415	129	5	bullous	bullous	ADJ
dpc-1415	129	6	disorders	disorder	NOUN
dpc-1415	129	7	includes	include	VERB
dpc-1415	129	8	pruritus	pruritus	NOUN
dpc-1415	129	9	,	,	PUNCT
dpc-1415	129	10	tense	tense	ADJ
dpc-1415	129	11	vesicles	vesicle	NOUN
dpc-1415	129	12	/	/	SYM
dpc-1415	129	13	bullae	bullae	NOUN
dpc-1415	129	14	on	on	ADP
dpc-1415	129	15	the	the	DET
dpc-1415	129	16	trunk	trunk	NOUN
dpc-1415	129	17	and	and	CCONJ
dpc-1415	129	18	extremities	extremity	NOUN
dpc-1415	129	19	as	as	ADV
dpc-1415	129	20	well	well	ADV
dpc-1415	129	21	as	as	ADP
dpc-1415	129	22	oral	oral	ADJ
dpc-1415	129	23	erosions	erosion	NOUN
dpc-1415	129	24	,	,	PUNCT
dpc-1415	129	25	and	and	CCONJ
dpc-1415	129	26	urticarial	urticarial	ADJ
dpc-1415	129	27	lesions	lesion	NOUN
dpc-1415	129	28	.	.	PUNCT
dpc-1415	130	1	the	the	DET
dpc-1415	130	2	eruption	eruption	NOUN
dpc-1415	130	3	may	may	AUX
dpc-1415	130	4	appear	appear	VERB
dpc-1415	130	5	either	either	CCONJ
dpc-1415	130	6	early	early	ADJ
dpc-1415	130	7	after	after	ADP
dpc-1415	130	8	initiation	initiation	NOUN
dpc-1415	130	9	of	of	ADP
dpc-1415	130	10	therapy	therapy	NOUN
dpc-1415	130	11	or	or	CCONJ
dpc-1415	130	12	only	only	ADV
dpc-1415	130	13	after	after	ADP
dpc-1415	130	14	several	several	ADJ
dpc-1415	130	15	months	month	NOUN
dpc-1415	130	16	of	of	ADP
dpc-1415	130	17	treatment	treatment	NOUN
dpc-1415	130	18	.	.	PUNCT
dpc-1415	131	1	interestingly	interestingly	ADV
dpc-1415	131	2	,	,	PUNCT
dpc-1415	131	3	the	the	DET
dpc-1415	131	4	anti	anti	ADJ
dpc-1415	131	5	-	-	ADJ
dpc-1415	131	6	pd-1	pd-1	ADJ
dpc-1415	131	7	/	/	SYM
dpc-1415	131	8	pd	pd	NOUN
dpc-1415	131	9	-	-	PUNCT
dpc-1415	131	10	l1induced	l1induce	VERB
dpc-1415	131	11	bp	bp	PROPN
dpc-1415	131	12	may	may	AUX
dpc-1415	131	13	persist	persist	VERB
dpc-1415	131	14	for	for	ADP
dpc-1415	131	15	several	several	ADJ
dpc-1415	131	16	months	month	NOUN
dpc-1415	131	17	after	after	ADP
dpc-1415	131	18	discontinuation	discontinuation	NOUN
dpc-1415	131	19	of	of	ADP
dpc-1415	131	20	the	the	DET
dpc-1415	131	21	treatment	treatment	NOUN
dpc-1415	131	22	in	in	ADP
dpc-1415	131	23	contrast	contrast	NOUN
dpc-1415	131	24	to	to	ADP
dpc-1415	131	25	the	the	DET
dpc-1415	131	26	classic	classic	ADJ
dpc-1415	131	27	bp	bp	NOUN
dpc-1415	131	28	that	that	PRON
dpc-1415	131	29	usually	usually	ADV
dpc-1415	131	30	disappears	disappear	VERB
dpc-1415	131	31	immediately	immediately	ADV
dpc-1415	131	32	after	after	ADP
dpc-1415	131	33	discontinuation	discontinuation	NOUN
dpc-1415	131	34	of	of	ADP
dpc-1415	131	35	the	the	DET
dpc-1415	131	36	causative	causative	ADJ
dpc-1415	131	37	agent	agent	NOUN
dpc-1415	131	38	[	[	X
dpc-1415	131	39	23	23	NUM
dpc-1415	131	40	]	]	PUNCT
dpc-1415	131	41	.	.	PUNCT
dpc-1415	132	1	the	the	DET
dpc-1415	132	2	diagnosis	diagnosis	NOUN
dpc-1415	132	3	is	be	AUX
dpc-1415	132	4	established	establish	VERB
dpc-1415	132	5	by	by	ADP
dpc-1415	132	6	the	the	DET
dpc-1415	132	7	combination	combination	NOUN
dpc-1415	132	8	of	of	ADP
dpc-1415	132	9	clinical	clinical	ADJ
dpc-1415	132	10	features	feature	NOUN
dpc-1415	132	11	,	,	PUNCT
dpc-1415	132	12	histopathologic	histopathologic	ADJ
dpc-1415	132	13	and	and	CCONJ
dpc-1415	132	14	immunohistochemical	immunohistochemical	ADJ
dpc-1415	132	15	findings	finding	NOUN
dpc-1415	132	16	,	,	PUNCT
dpc-1415	132	17	and	and	CCONJ
dpc-1415	132	18	direct	direct	ADJ
dpc-1415	132	19	and	and	CCONJ
dpc-1415	132	20	indirect	indirect	ADJ
dpc-1415	132	21	immunofluorescence	immunofluorescence	NOUN
dpc-1415	132	22	.	.	PUNCT
dpc-1415	133	1	in	in	ADP
dpc-1415	133	2	a	a	DET
dpc-1415	133	3	literature	literature	NOUN
dpc-1415	133	4	review	review	NOUN
dpc-1415	133	5	of	of	ADP
dpc-1415	133	6	bp	bp	PROPN
dpc-1415	133	7	associated	associate	VERB
dpc-1415	133	8	with	with	ADP
dpc-1415	133	9	pd-1	pd-1	ADJ
dpc-1415	133	10	and	and	CCONJ
dpc-1415	133	11	pd	pd	PROPN
dpc-1415	133	12	-	-	PUNCT
dpc-1415	133	13	l1	l1	PROPN
dpc-1415	133	14	inhibitors	inhibitor	NOUN
dpc-1415	133	15	,	,	PUNCT
dpc-1415	133	16	including	include	VERB
dpc-1415	133	17	all	all	DET
dpc-1415	133	18	the	the	DET
dpc-1415	133	19	publications	publication	NOUN
dpc-1415	133	20	up	up	ADP
dpc-1415	133	21	to	to	ADP
dpc-1415	133	22	july	july	PROPN
dpc-1415	133	23	2017	2017	NUM
dpc-1415	133	24	,	,	PUNCT
dpc-1415	133	25	the	the	DET
dpc-1415	133	26	authors	author	NOUN
dpc-1415	133	27	identified	identify	VERB
dpc-1415	133	28	21	21	NUM
dpc-1415	133	29	cases	case	NOUN
dpc-1415	133	30	[	[	X
dpc-1415	133	31	24	24	NUM
dpc-1415	133	32	]	]	PUNCT
dpc-1415	133	33	.	.	PUNCT
dpc-1415	134	1	twelve	twelve	NUM
dpc-1415	134	2	of	of	ADP
dpc-1415	134	3	them	they	PRON
dpc-1415	134	4	experienced	experience	VERB
dpc-1415	134	5	nonspecific	nonspecific	ADJ
dpc-1415	134	6	cutaneous	cutaneous	ADJ
dpc-1415	134	7	features	feature	NOUN
dpc-1415	134	8	with	with	ADP
dpc-1415	134	9	pruritus	pruritus	PROPN
dpc-1415	134	10	before	before	ADP
dpc-1415	134	11	or	or	CCONJ
dpc-1415	134	12	along	along	ADP
dpc-1415	134	13	with	with	ADP
dpc-1415	134	14	the	the	DET
dpc-1415	134	15	clinical	clinical	ADJ
dpc-1415	134	16	appearance	appearance	NOUN
dpc-1415	134	17	of	of	ADP
dpc-1415	134	18	the	the	DET
dpc-1415	134	19	blisters	blister	NOUN
dpc-1415	134	20	,	,	PUNCT
dpc-1415	134	21	and	and	CCONJ
dpc-1415	134	22	16/21	16/21	NUM
dpc-1415	134	23	necessitated	necessitate	VERB
dpc-1415	134	24	discontinuation	discontinuation	NOUN
dpc-1415	134	25	of	of	ADP
dpc-1415	134	26	pd-1	pd-1	ADP
dpc-1415	134	27	/	/	SYM
dpc-1415	134	28	pd	pd	ADJ
dpc-1415	134	29	-	-	PUNCT
dpc-1415	134	30	l1	l1	PROPN
dpc-1415	134	31	inhibitor	inhibitor	NOUN
dpc-1415	134	32	due	due	ADP
dpc-1415	134	33	to	to	ADP
dpc-1415	134	34	bp	bp	PROPN
dpc-1415	134	35	.	.	PUNCT
dpc-1415	135	1	the	the	DET
dpc-1415	135	2	latter	latter	ADJ
dpc-1415	135	3	was	be	AUX
dpc-1415	135	4	mainly	mainly	ADV
dpc-1415	135	5	managed	manage	VERB
dpc-1415	135	6	with	with	ADP
dpc-1415	135	7	diverse	diverse	ADJ
dpc-1415	135	8	doses	dose	NOUN
dpc-1415	135	9	of	of	ADP
dpc-1415	135	10	systemic	systemic	ADJ
dpc-1415	135	11	steroids	steroid	NOUN
dpc-1415	135	12	that	that	PRON
dpc-1415	135	13	were	be	AUX
dpc-1415	135	14	used	use	VERB
dpc-1415	135	15	either	either	CCONJ
dpc-1415	135	16	as	as	ADP
dpc-1415	135	17	monotherapy	monotherapy	NOUN
dpc-1415	135	18	or	or	CCONJ
dpc-1415	135	19	in	in	ADP
dpc-1415	135	20	combination	combination	NOUN
dpc-1415	135	21	with	with	ADP
dpc-1415	135	22	other	other	ADJ
dpc-1415	135	23	systemic	systemic	ADJ
dpc-1415	135	24	agents	agent	NOUN
dpc-1415	135	25	,	,	PUNCT
dpc-1415	135	26	including	include	VERB
dpc-1415	135	27	antihistamines	antihistamine	NOUN
dpc-1415	135	28	,	,	PUNCT
dpc-1415	135	29	doxycycline	doxycycline	NOUN
dpc-1415	135	30	,	,	PUNCT
dpc-1415	135	31	niacinamide	niacinamide	NOUN
dpc-1415	135	32	,	,	PUNCT
dpc-1415	135	33	methotrexate	methotrexate	NOUN
dpc-1415	135	34	,	,	PUNCT
dpc-1415	135	35	omalizumab	omalizumab	NOUN
dpc-1415	135	36	and	and	CCONJ
dpc-1415	135	37	rituximab	rituximab	NOUN
dpc-1415	135	38	.	.	PUNCT
dpc-1415	136	1	additionally	additionally	ADV
dpc-1415	136	2	,	,	PUNCT
dpc-1415	136	3	topical	topical	ADJ
dpc-1415	136	4	treatment	treatment	NOUN
dpc-1415	136	5	was	be	AUX
dpc-1415	136	6	applied	apply	VERB
dpc-1415	136	7	in	in	ADP
dpc-1415	136	8	most	most	ADJ
dpc-1415	136	9	cases	case	NOUN
dpc-1415	136	10	.	.	PUNCT
dpc-1415	137	1	as	as	ADP
dpc-1415	137	2	for	for	ADP
dpc-1415	137	3	the	the	DET
dpc-1415	137	4	treatment	treatment	NOUN
dpc-1415	137	5	strategy	strategy	NOUN
dpc-1415	137	6	of	of	ADP
dpc-1415	137	7	immunobullous	immunobullous	ADJ
dpc-1415	137	8	dermatoses	dermatosis	NOUN
dpc-1415	137	9	,	,	PUNCT
dpc-1415	137	10	according	accord	VERB
dpc-1415	137	11	to	to	ADP
dpc-1415	137	12	the	the	DET
dpc-1415	137	13	existing	exist	VERB
dpc-1415	137	14	guidelines	guideline	NOUN
dpc-1415	137	15	[	[	X
dpc-1415	137	16	6	6	NUM
dpc-1415	137	17	-	-	SYM
dpc-1415	137	18	8	8	NUM
dpc-1415	137	19	]	]	PUNCT
dpc-1415	137	20	,	,	PUNCT
dpc-1415	137	21	when	when	SCONJ
dpc-1415	137	22	symptoms	symptom	NOUN
dpc-1415	137	23	are	be	AUX
dpc-1415	137	24	mild	mild	ADJ
dpc-1415	137	25	(	(	PUNCT
dpc-1415	137	26	blisters	blister	NOUN
dpc-1415	137	27	covering	cover	VERB
dpc-1415	137	28	<	<	NOUN
dpc-1415	137	29	10	10	NUM
dpc-1415	137	30	%	%	NOUN
dpc-1415	137	31	bsa	bsa	NOUN
dpc-1415	137	32	)	)	PUNCT
dpc-1415	137	33	,	,	PUNCT
dpc-1415	137	34	high	high	ADJ
dpc-1415	137	35	-	-	PUNCT
dpc-1415	137	36	potency	potency	NOUN
dpc-1415	137	37	topical	topical	ADJ
dpc-1415	137	38	steroids	steroid	NOUN
dpc-1415	137	39	may	may	AUX
dpc-1415	137	40	be	be	AUX
dpc-1415	137	41	applied	apply	VERB
dpc-1415	137	42	to	to	ADP
dpc-1415	137	43	the	the	DET
dpc-1415	137	44	affected	affect	VERB
dpc-1415	137	45	areas	area	NOUN
dpc-1415	137	46	and	and	CCONJ
dpc-1415	137	47	immunotherapy	immunotherapy	NOUN
dpc-1415	137	48	should	should	AUX
dpc-1415	137	49	be	be	AUX
dpc-1415	137	50	withheld	withhold	VERB
dpc-1415	137	51	.	.	PUNCT
dpc-1415	138	1	in	in	ADP
dpc-1415	138	2	moderate	moderate	ADJ
dpc-1415	138	3	cases	case	NOUN
dpc-1415	138	4	(	(	PUNCT
dpc-1415	138	5	blisters	blister	NOUN
dpc-1415	138	6	covering	cover	VERB
dpc-1415	138	7	10%-30	10%-30	NUM
dpc-1415	138	8	%	%	NOUN
dpc-1415	138	9	bsa	bsa	NOUN
dpc-1415	138	10	;	;	PUNCT
dpc-1415	138	11	painful	painful	ADJ
dpc-1415	138	12	blisters	blister	NOUN
dpc-1415	138	13	limiting	limit	VERB
dpc-1415	138	14	instrumental	instrumental	ADJ
dpc-1415	138	15	activities	activity	NOUN
dpc-1415	138	16	of	of	ADP
dpc-1415	138	17	daily	daily	ADJ
dpc-1415	138	18	living	living	NOUN
dpc-1415	138	19	)	)	PUNCT
dpc-1415	138	20	,	,	PUNCT
dpc-1415	138	21	prednisone	prednisone	NOUN
dpc-1415	138	22	/	/	SYM
dpc-1415	138	23	methylprednisolone	methylprednisolone	NOUN
dpc-1415	138	24	0.5	0.5	NUM
dpc-1415	138	25	-	-	SYM
dpc-1415	138	26	1	1	NUM
dpc-1415	138	27	mg	mg	PROPN
dpc-1415	138	28	/	/	SYM
dpc-1415	138	29	kg	kg	NOUN
dpc-1415	138	30	per	per	ADP
dpc-1415	138	31	day	day	NOUN
dpc-1415	138	32	should	should	AUX
dpc-1415	138	33	be	be	AUX
dpc-1415	138	34	added	add	VERB
dpc-1415	138	35	.	.	PUNCT
dpc-1415	139	1	in	in	ADP
dpc-1415	139	2	severe	severe	ADJ
dpc-1415	139	3	cases	case	NOUN
dpc-1415	139	4	(	(	PUNCT
dpc-1415	139	5	blisters	blister	NOUN
dpc-1415	139	6	covering	cover	VERB
dpc-1415	139	7	>	>	SYM
dpc-1415	139	8	30	30	NUM
dpc-1415	139	9	%	%	NOUN
dpc-1415	139	10	bsa	bsa	NOUN
dpc-1415	139	11	limiting	limit	VERB
dpc-1415	139	12	instrumental	instrumental	ADJ
dpc-1415	139	13	activities	activity	NOUN
dpc-1415	139	14	of	of	ADP
dpc-1415	139	15	daily	daily	ADJ
dpc-1415	139	16	living	living	NOUN
dpc-1415	139	17	)	)	PUNCT
dpc-1415	139	18	,	,	PUNCT
dpc-1415	139	19	immunotherapy	immunotherapy	NOUN
dpc-1415	139	20	should	should	AUX
dpc-1415	139	21	be	be	AUX
dpc-1415	139	22	discontinued	discontinue	VERB
dpc-1415	139	23	and	and	CCONJ
dpc-1415	139	24	hospitalization	hospitalization	NOUN
dpc-1415	139	25	should	should	AUX
dpc-1415	139	26	be	be	AUX
dpc-1415	139	27	considered	consider	VERB
dpc-1415	139	28	,	,	PUNCT
dpc-1415	139	29	along	along	ADP
dpc-1415	139	30	with	with	ADP
dpc-1415	139	31	dermatologic	dermatologic	ADJ
dpc-1415	139	32	and	and	CCONJ
dpc-1415	139	33	other	other	ADJ
dpc-1415	139	34	appropriate	appropriate	ADJ
dpc-1415	139	35	consulting	consulting	NOUN
dpc-1415	139	36	services	service	NOUN
dpc-1415	139	37	(	(	PUNCT
dpc-1415	139	38	eg	eg	NOUN
dpc-1415	139	39	,	,	PUNCT
dpc-1415	139	40	ophthalmology	ophthalmology	NOUN
dpc-1415	139	41	;	;	PUNCT
dpc-1415	139	42	urology	urology	NOUN
dpc-1415	139	43	;	;	PUNCT
dpc-1415	139	44	gynecology	gynecology	NOUN
dpc-1415	139	45	;	;	PUNCT
dpc-1415	139	46	etc	etc	X
dpc-1415	139	47	)	)	PUNCT
dpc-1415	139	48	if	if	SCONJ
dpc-1415	139	49	needed	need	VERB
dpc-1415	139	50	.	.	PUNCT
dpc-1415	140	1	in	in	ADP
dpc-1415	140	2	these	these	DET
dpc-1415	140	3	cases	case	NOUN
dpc-1415	140	4	,	,	PUNCT
dpc-1415	140	5	prednisone/	prednisone/	NUM
dpc-1415	140	6	methylprednisolone	methylprednisolone	ADJ
dpc-1415	140	7	1	1	NUM
dpc-1415	140	8	-	-	SYM
dpc-1415	140	9	2	2	NUM
dpc-1415	140	10	mg	mg	PROPN
dpc-1415	140	11	/	/	SYM
dpc-1415	140	12	kg	kg	NOUN
dpc-1415	140	13	per	per	ADP
dpc-1415	140	14	day	day	NOUN
dpc-1415	140	15	should	should	AUX
dpc-1415	140	16	be	be	AUX
dpc-1415	140	17	administered	administer	VERB
dpc-1415	140	18	,	,	PUNCT
dpc-1415	140	19	and	and	CCONJ
dpc-1415	140	20	if	if	SCONJ
dpc-1415	140	21	no	no	DET
dpc-1415	140	22	improvement	improvement	NOUN
dpc-1415	140	23	is	be	AUX
dpc-1415	140	24	noted	note	VERB
dpc-1415	140	25	after	after	ADP
dpc-1415	140	26	3	3	NUM
dpc-1415	140	27	days	day	NOUN
dpc-1415	140	28	,	,	PUNCT
dpc-1415	140	29	adding	add	VERB
dpc-1415	140	30	rituximab	rituximab	NOUN
dpc-1415	140	31	should	should	AUX
dpc-1415	140	32	be	be	AUX
dpc-1415	140	33	considered	consider	VERB
dpc-1415	140	34	.	.	PUNCT
dpc-1415	141	1	general	general	ADJ
dpc-1415	141	2	recommendations	recommendation	NOUN
dpc-1415	141	3	include	include	VERB
dpc-1415	141	4	topical	topical	ADJ
dpc-1415	141	5	wound	wound	NOUN
dpc-1415	141	6	care	care	NOUN
dpc-1415	141	7	with	with	ADP
dpc-1415	141	8	petrolatum	petrolatum	NOUN
dpc-1415	141	9	ointments	ointment	NOUN
dpc-1415	141	10	and	and	CCONJ
dpc-1415	141	11	gauzes	gauze	VERB
dpc-1415	141	12	over	over	ADP
dpc-1415	141	13	erosions	erosion	NOUN
dpc-1415	141	14	and	and	CCONJ
dpc-1415	141	15	avoidance	avoidance	NOUN
dpc-1415	141	16	of	of	ADP
dpc-1415	141	17	sun	sun	NOUN
dpc-1415	141	18	exposure	exposure	NOUN
dpc-1415	141	19	.	.	PUNCT
dpc-1415	142	1	total	total	ADJ
dpc-1415	142	2	body	body	NOUN
dpc-1415	142	3	skin	skin	NOUN
dpc-1415	142	4	examination	examination	NOUN
dpc-1415	142	5	that	that	PRON
dpc-1415	142	6	includes	include	VERB
dpc-1415	142	7	all	all	DET
dpc-1415	142	8	skin	skin	NOUN
dpc-1415	142	9	surfaces	surface	NOUN
dpc-1415	142	10	and	and	CCONJ
dpc-1415	142	11	mucous	mucous	ADJ
dpc-1415	142	12	membranes	membrane	NOUN
dpc-1415	142	13	is	be	AUX
dpc-1415	142	14	highly	highly	ADV
dpc-1415	142	15	recommended	recommend	VERB
dpc-1415	142	16	.	.	PUNCT
dpc-1415	143	1	in	in	ADP
dpc-1415	143	2	addition	addition	NOUN
dpc-1415	143	3	,	,	PUNCT
dpc-1415	143	4	lymphadenopathy	lymphadenopathy	ADJ
dpc-1415	143	5	,	,	PUNCT
dpc-1415	143	6	facial	facial	ADJ
dpc-1415	143	7	or	or	CCONJ
dpc-1415	143	8	distal	distal	ADJ
dpc-1415	143	9	extremity	extremity	NOUN
dpc-1415	143	10	swelling	swelling	NOUN
dpc-1415	143	11	,	,	PUNCT
dpc-1415	143	12	and	and	CCONJ
dpc-1415	143	13	nikolsky	nikolsky	ADJ
dpc-1415	143	14	sign	sign	NOUN
dpc-1415	143	15	should	should	AUX
dpc-1415	143	16	be	be	AUX
dpc-1415	143	17	assessed	assess	VERB
dpc-1415	143	18	,	,	PUNCT
dpc-1415	143	19	as	as	SCONJ
dpc-1415	143	20	they	they	PRON
dpc-1415	143	21	may	may	AUX
dpc-1415	143	22	be	be	AUX
dpc-1415	143	23	signs	sign	NOUN
dpc-1415	143	24	of	of	ADP
dpc-1415	143	25	drug	drug	NOUN
dpc-1415	143	26	-	-	PUNCT
dpc-1415	143	27	induced	induce	VERB
dpc-1415	143	28	hypersensitivity	hypersensitivity	NOUN
dpc-1415	143	29	syndrome	syndrome	NOUN
dpc-1415	143	30	(	(	PUNCT
dpc-1415	143	31	dihs	dihs	NOUN
dpc-1415	143	32	)	)	PUNCT
dpc-1415	143	33	,	,	PUNCT
dpc-1415	143	34	dress	dress	NOUN
dpc-1415	143	35	or	or	CCONJ
dpc-1415	143	36	sjs	sjs	PROPN
dpc-1415	143	37	and	and	CCONJ
dpc-1415	143	38	ten	ten	NUM
dpc-1415	143	39	.	.	PUNCT
dpc-1415	144	1	in	in	ADP
dpc-1415	144	2	any	any	DET
dpc-1415	144	3	case	case	NOUN
dpc-1415	144	4	,	,	PUNCT
dpc-1415	144	5	patients	patient	NOUN
dpc-1415	144	6	should	should	AUX
dpc-1415	144	7	be	be	AUX
dpc-1415	144	8	closely	closely	ADV
dpc-1415	144	9	monitored	monitor	VERB
dpc-1415	144	10	and	and	CCONJ
dpc-1415	144	11	close	close	ADJ
dpc-1415	144	12	collaboration	collaboration	NOUN
dpc-1415	144	13	between	between	ADP
dpc-1415	144	14	dermatologists	dermatologist	NOUN
dpc-1415	144	15	and	and	CCONJ
dpc-1415	144	16	oncologists	oncologist	NOUN
dpc-1415	144	17	is	be	AUX
dpc-1415	144	18	essential	essential	ADJ
dpc-1415	144	19	for	for	ADP
dpc-1415	144	20	the	the	DET
dpc-1415	144	21	optimal	optimal	ADJ
dpc-1415	144	22	treatment	treatment	NOUN
dpc-1415	144	23	decision	decision	NOUN
dpc-1415	144	24	[	[	X
dpc-1415	144	25	25	25	NUM
dpc-1415	144	26	]	]	PUNCT
dpc-1415	144	27	.	.	PUNCT
dpc-1415	145	1	whether	whether	SCONJ
dpc-1415	145	2	the	the	DET
dpc-1415	145	3	appearance	appearance	NOUN
dpc-1415	145	4	of	of	ADP
dpc-1415	145	5	bp	bp	PROPN
dpc-1415	145	6	indicates	indicate	VERB
dpc-1415	145	7	a	a	DET
dpc-1415	145	8	favorable	favorable	ADJ
dpc-1415	145	9	response	response	NOUN
dpc-1415	145	10	to	to	ADP
dpc-1415	145	11	immunotherapy	immunotherapy	NOUN
dpc-1415	145	12	or	or	CCONJ
dpc-1415	145	13	not	not	PART
dpc-1415	145	14	remains	remain	VERB
dpc-1415	145	15	unknown	unknown	ADJ
dpc-1415	145	16	.	.	PUNCT
dpc-1415	146	1	howfigure	howfigure	NOUN
dpc-1415	146	2	4	4	NUM
dpc-1415	146	3	.	.	PUNCT
dpc-1415	147	1	uncommon	uncommon	ADJ
dpc-1415	147	2	skin	skin	NOUN
dpc-1415	147	3	toxicities	toxicity	NOUN
dpc-1415	147	4	include	include	VERB
dpc-1415	147	5	bullous	bullous	ADJ
dpc-1415	147	6	disorders	disorder	NOUN
dpc-1415	147	7	like	like	ADP
dpc-1415	147	8	(	(	PUNCT
dpc-1415	147	9	a	a	NOUN
dpc-1415	147	10	)	)	PUNCT
dpc-1415	147	11	bullous	bullous	ADJ
dpc-1415	147	12	pemphigoid	pemphigoid	NOUN
dpc-1415	147	13	and	and	CCONJ
dpc-1415	147	14	(	(	PUNCT
dpc-1415	147	15	b	b	NOUN
dpc-1415	147	16	)	)	PUNCT
dpc-1415	147	17	bullous	bullous	ADJ
dpc-1415	147	18	lichen	lichen	NOUN
dpc-1415	147	19	planus	planus	NOUN
dpc-1415	147	20	.	.	PUNCT
dpc-1415	148	1	a	a	DET
dpc-1415	148	2	b	b	X
dpc-1415	148	3	review	review	NOUN
dpc-1415	148	4	|	|	ADV
dpc-1415	148	5	dermatol	dermatol	ADJ
dpc-1415	148	6	pract	pract	NOUN
dpc-1415	148	7	concept	concept	NOUN
dpc-1415	148	8	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	148	9	7	7	NUM
dpc-1415	148	10	ever	ever	ADV
dpc-1415	148	11	,	,	PUNCT
dpc-1415	148	12	in	in	ADP
dpc-1415	148	13	a	a	DET
dpc-1415	148	14	recently	recently	ADV
dpc-1415	148	15	published	publish	VERB
dpc-1415	148	16	study	study	NOUN
dpc-1415	148	17	,	,	PUNCT
dpc-1415	148	18	the	the	DET
dpc-1415	148	19	authors	author	NOUN
dpc-1415	148	20	reported	report	VERB
dpc-1415	148	21	improved	improved	ADJ
dpc-1415	148	22	outcomes	outcome	NOUN
dpc-1415	148	23	in	in	ADP
dpc-1415	148	24	the	the	DET
dpc-1415	148	25	group	group	NOUN
dpc-1415	148	26	of	of	ADP
dpc-1415	148	27	patients	patient	NOUN
dpc-1415	148	28	that	that	PRON
dpc-1415	148	29	developed	develop	VERB
dpc-1415	148	30	bp	bp	PROPN
dpc-1415	148	31	compared	compare	VERB
dpc-1415	148	32	to	to	ADP
dpc-1415	148	33	controls	control	NOUN
dpc-1415	148	34	[	[	X
dpc-1415	148	35	26	26	NUM
dpc-1415	148	36	]	]	PUNCT
dpc-1415	148	37	.	.	PUNCT
dpc-1415	149	1	c.	c.	PROPN
dpc-1415	149	2	pruritus	pruritus	PROPN
dpc-1415	149	3	pruritus	pruritus	PROPN
dpc-1415	149	4	is	be	AUX
dpc-1415	149	5	one	one	NUM
dpc-1415	149	6	of	of	ADP
dpc-1415	149	7	the	the	DET
dpc-1415	149	8	most	most	ADV
dpc-1415	149	9	common	common	ADJ
dpc-1415	149	10	iraes	iraes	NOUN
dpc-1415	149	11	during	during	ADP
dpc-1415	149	12	therapy	therapy	NOUN
dpc-1415	149	13	with	with	ADP
dpc-1415	149	14	cpis	cpis	NOUN
dpc-1415	149	15	.	.	PUNCT
dpc-1415	150	1	the	the	DET
dpc-1415	150	2	incidence	incidence	NOUN
dpc-1415	150	3	ranges	range	VERB
dpc-1415	150	4	from	from	ADP
dpc-1415	150	5	14	14	NUM
dpc-1415	150	6	%	%	NOUN
dpc-1415	150	7	to	to	PART
dpc-1415	150	8	21	21	NUM
dpc-1415	150	9	%	%	NOUN
dpc-1415	150	10	in	in	ADP
dpc-1415	150	11	patients	patient	NOUN
dpc-1415	150	12	receiving	receive	VERB
dpc-1415	150	13	anti	anti	NOUN
dpc-1415	150	14	-	-	ADJ
dpc-1415	150	15	pd-1	pd-1	ADP
dpc-1415	150	16	,	,	PUNCT
dpc-1415	150	17	which	which	PRON
dpc-1415	150	18	is	be	AUX
dpc-1415	150	19	higher	high	ADJ
dpc-1415	150	20	compared	compare	VERB
dpc-1415	150	21	to	to	ADP
dpc-1415	150	22	anti	anti	ADJ
dpc-1415	150	23	-	-	NOUN
dpc-1415	150	24	ctla-4	ctla-4	NOUN
dpc-1415	150	25	.	.	PUNCT
dpc-1415	150	26	combination	combination	NOUN
dpc-1415	150	27	treatment	treatment	NOUN
dpc-1415	150	28	with	with	ADP
dpc-1415	150	29	nivolumab	nivolumab	NOUN
dpc-1415	150	30	and	and	CCONJ
dpc-1415	150	31	ipilimumab	ipilimumab	VERB
dpc-1415	150	32	further	further	ADJ
dpc-1415	150	33	increases	increase	VERB
dpc-1415	150	34	the	the	DET
dpc-1415	150	35	occurrence	occurrence	NOUN
dpc-1415	150	36	of	of	ADP
dpc-1415	150	37	pruritus	pruritus	PROPN
dpc-1415	150	38	.	.	PUNCT
dpc-1415	151	1	however	however	ADV
dpc-1415	151	2	,	,	PUNCT
dpc-1415	151	3	the	the	DET
dpc-1415	151	4	incidence	incidence	NOUN
dpc-1415	151	5	of	of	ADP
dpc-1415	151	6	severe	severe	ADJ
dpc-1415	151	7	cases	case	NOUN
dpc-1415	151	8	is	be	AUX
dpc-1415	151	9	low	low	ADJ
dpc-1415	151	10	[	[	PUNCT
dpc-1415	151	11	27	27	NUM
dpc-1415	151	12	-	-	SYM
dpc-1415	151	13	31	31	NUM
dpc-1415	151	14	]	]	PUNCT
dpc-1415	151	15	.	.	PUNCT
dpc-1415	152	1	the	the	DET
dpc-1415	152	2	lower	low	ADJ
dpc-1415	152	3	incidence	incidence	NOUN
dpc-1415	152	4	of	of	ADP
dpc-1415	152	5	pruritus	pruritus	PROPN
dpc-1415	152	6	is	be	AUX
dpc-1415	152	7	recorded	record	VERB
dpc-1415	152	8	with	with	ADP
dpc-1415	152	9	anti	anti	ADJ
dpc-1415	152	10	-	-	ADJ
dpc-1415	152	11	pd	pd	ADJ
dpc-1415	152	12	-	-	ADJ
dpc-1415	152	13	l1	l1	PROPN
dpc-1415	152	14	treatment	treatment	NOUN
dpc-1415	152	15	[	[	X
dpc-1415	152	16	32	32	NUM
dpc-1415	152	17	]	]	PUNCT
dpc-1415	152	18	.	.	PUNCT
dpc-1415	153	1	pruritus	pruritus	PROPN
dpc-1415	153	2	may	may	AUX
dpc-1415	153	3	develop	develop	VERB
dpc-1415	153	4	either	either	CCONJ
dpc-1415	153	5	per	per	ADP
dpc-1415	153	6	se	se	X
dpc-1415	153	7	or	or	CCONJ
dpc-1415	153	8	may	may	AUX
dpc-1415	153	9	be	be	AUX
dpc-1415	153	10	associated	associate	VERB
dpc-1415	153	11	with	with	ADP
dpc-1415	153	12	skin	skin	NOUN
dpc-1415	153	13	rashes	rash	NOUN
dpc-1415	153	14	,	,	PUNCT
dpc-1415	153	15	irritation	irritation	NOUN
dpc-1415	153	16	and	and	CCONJ
dpc-1415	153	17	xerosis	xerosis	NOUN
dpc-1415	153	18	,	,	PUNCT
dpc-1415	153	19	and	and	CCONJ
dpc-1415	153	20	early	early	ADV
dpc-1415	153	21	after	after	ADP
dpc-1415	153	22	immunotherapy	immunotherapy	NOUN
dpc-1415	153	23	initiation	initiation	NOUN
dpc-1415	153	24	.	.	PUNCT
dpc-1415	154	1	in	in	ADP
dpc-1415	154	2	any	any	DET
dpc-1415	154	3	case	case	NOUN
dpc-1415	154	4	,	,	PUNCT
dpc-1415	154	5	it	it	PRON
dpc-1415	154	6	can	can	AUX
dpc-1415	154	7	highly	highly	ADV
dpc-1415	154	8	aggravate	aggravate	VERB
dpc-1415	154	9	a	a	DET
dpc-1415	154	10	patient	patient	NOUN
dpc-1415	154	11	’s	’s	PART
dpc-1415	154	12	quality	quality	NOUN
dpc-1415	154	13	of	of	ADP
dpc-1415	154	14	life	life	NOUN
dpc-1415	154	15	and	and	CCONJ
dpc-1415	154	16	psychological	psychological	ADJ
dpc-1415	154	17	status	status	NOUN
dpc-1415	154	18	,	,	PUNCT
dpc-1415	154	19	making	make	VERB
dpc-1415	154	20	the	the	DET
dpc-1415	154	21	need	need	NOUN
dpc-1415	154	22	for	for	ADP
dpc-1415	154	23	relief	relief	NOUN
dpc-1415	154	24	therapy	therapy	NOUN
dpc-1415	154	25	mandatory	mandatory	ADJ
dpc-1415	154	26	.	.	PUNCT
dpc-1415	155	1	guidelines	guideline	NOUN
dpc-1415	155	2	for	for	ADP
dpc-1415	155	3	management	management	NOUN
dpc-1415	155	4	of	of	ADP
dpc-1415	155	5	mild	mild	ADJ
dpc-1415	155	6	or	or	CCONJ
dpc-1415	155	7	moderate	moderate	ADJ
dpc-1415	155	8	pruritus	pruritus	NOUN
dpc-1415	155	9	recommend	recommend	VERB
dpc-1415	155	10	oral	oral	ADJ
dpc-1415	155	11	antihistamines	antihistamine	NOUN
dpc-1415	155	12	and	and	CCONJ
dpc-1415	155	13	topical	topical	ADJ
dpc-1415	155	14	steroids	steroid	NOUN
dpc-1415	155	15	of	of	ADP
dpc-1415	155	16	mild	mild	ADJ
dpc-1415	155	17	and	and	CCONJ
dpc-1415	155	18	high	high	ADJ
dpc-1415	155	19	potency	potency	NOUN
dpc-1415	155	20	,	,	PUNCT
dpc-1415	155	21	while	while	SCONJ
dpc-1415	155	22	prednisone	prednisone	NOUN
dpc-1415	155	23	/	/	SYM
dpc-1415	155	24	methylprednisolone	methylprednisolone	PROPN
dpc-1415	155	25	and	and	CCONJ
dpc-1415	155	26	gaba	gaba	PROPN
dpc-1415	155	27	agonists	agonist	NOUN
dpc-1415	155	28	are	be	AUX
dpc-1415	155	29	preserved	preserve	VERB
dpc-1415	155	30	for	for	ADP
dpc-1415	155	31	more	more	ADV
dpc-1415	155	32	severe	severe	ADJ
dpc-1415	155	33	cases	case	NOUN
dpc-1415	155	34	.	.	PUNCT
dpc-1415	156	1	in	in	ADP
dpc-1415	156	2	the	the	DET
dpc-1415	156	3	end	end	NOUN
dpc-1415	156	4	,	,	PUNCT
dpc-1415	156	5	aprepitant	aprepitant	ADJ
dpc-1415	156	6	or	or	CCONJ
dpc-1415	156	7	omalizumab	omalizumab	NOUN
dpc-1415	156	8	may	may	AUX
dpc-1415	156	9	be	be	AUX
dpc-1415	156	10	considered	consider	VERB
dpc-1415	156	11	for	for	ADP
dpc-1415	156	12	refractory	refractory	NOUN
dpc-1415	156	13	cases	case	NOUN
dpc-1415	156	14	[	[	X
dpc-1415	156	15	8,33	8,33	NUM
dpc-1415	156	16	]	]	PUNCT
dpc-1415	156	17	.	.	PUNCT
dpc-1415	157	1	d.	d.	PROPN
dpc-1415	157	2	pigmentary	pigmentary	PROPN
dpc-1415	157	3	disorders	disorder	NOUN
dpc-1415	157	4	vitiligo	vitiligo	VERB
dpc-1415	157	5	represents	represent	VERB
dpc-1415	157	6	another	another	DET
dpc-1415	157	7	common	common	ADJ
dpc-1415	157	8	cutaneous	cutaneous	ADJ
dpc-1415	157	9	irae	irae	NOUN
dpc-1415	157	10	,	,	PUNCT
dpc-1415	157	11	particularly	particularly	ADV
dpc-1415	157	12	reported	report	VERB
dpc-1415	157	13	in	in	ADP
dpc-1415	157	14	melanoma	melanoma	NOUN
dpc-1415	157	15	patients	patient	NOUN
dpc-1415	157	16	treated	treat	VERB
dpc-1415	157	17	with	with	ADP
dpc-1415	157	18	cpis	cpis	NOUN
dpc-1415	157	19	.	.	PUNCT
dpc-1415	158	1	only	only	ADV
dpc-1415	158	2	exceptional	exceptional	ADJ
dpc-1415	158	3	cases	case	NOUN
dpc-1415	158	4	have	have	AUX
dpc-1415	158	5	been	be	AUX
dpc-1415	158	6	described	describe	VERB
dpc-1415	158	7	in	in	ADP
dpc-1415	158	8	patients	patient	NOUN
dpc-1415	158	9	with	with	ADP
dpc-1415	158	10	tumors	tumor	NOUN
dpc-1415	158	11	other	other	ADJ
dpc-1415	158	12	than	than	ADP
dpc-1415	158	13	melanoma	melanoma	NOUN
dpc-1415	158	14	[	[	X
dpc-1415	158	15	34,35	34,35	NOUN
dpc-1415	158	16	]	]	PUNCT
dpc-1415	158	17	.	.	PUNCT
dpc-1415	159	1	the	the	DET
dpc-1415	159	2	incidence	incidence	NOUN
dpc-1415	159	3	of	of	ADP
dpc-1415	159	4	vitiligo	vitiligo	NOUN
dpc-1415	159	5	ranges	range	VERB
dpc-1415	159	6	from	from	ADP
dpc-1415	159	7	7.5	7.5	NUM
dpc-1415	159	8	%	%	NOUN
dpc-1415	159	9	to	to	PART
dpc-1415	159	10	25	25	NUM
dpc-1415	159	11	%	%	NOUN
dpc-1415	159	12	in	in	ADP
dpc-1415	159	13	patients	patient	NOUN
dpc-1415	159	14	treated	treat	VERB
dpc-1415	159	15	with	with	ADP
dpc-1415	159	16	anti	anti	ADJ
dpc-1415	159	17	-	-	ADJ
dpc-1415	159	18	pd-1	pd-1	ADJ
dpc-1415	159	19	,	,	PUNCT
dpc-1415	159	20	and	and	CCONJ
dpc-1415	159	21	it	it	PRON
dpc-1415	159	22	is	be	AUX
dpc-1415	159	23	less	less	ADV
dpc-1415	159	24	frequent	frequent	ADJ
dpc-1415	159	25	with	with	ADP
dpc-1415	159	26	the	the	DET
dpc-1415	159	27	use	use	NOUN
dpc-1415	159	28	of	of	ADP
dpc-1415	159	29	anti	anti	ADJ
dpc-1415	159	30	-	-	ADJ
dpc-1415	159	31	ctla-4	ctla-4	ADJ
dpc-1415	159	32	agents	agent	NOUN
dpc-1415	159	33	.	.	PUNCT
dpc-1415	160	1	the	the	DET
dpc-1415	160	2	exact	exact	ADJ
dpc-1415	160	3	mechanism	mechanism	NOUN
dpc-1415	160	4	of	of	ADP
dpc-1415	160	5	vitiligo	vitiligo	NOUN
dpc-1415	160	6	remains	remain	VERB
dpc-1415	160	7	unclear	unclear	ADJ
dpc-1415	160	8	.	.	PUNCT
dpc-1415	161	1	however	however	ADV
dpc-1415	161	2	,	,	PUNCT
dpc-1415	161	3	taking	take	VERB
dpc-1415	161	4	into	into	ADP
dpc-1415	161	5	account	account	NOUN
dpc-1415	161	6	its	its	PRON
dpc-1415	161	7	strong	strong	ADJ
dpc-1415	161	8	association	association	NOUN
dpc-1415	161	9	with	with	ADP
dpc-1415	161	10	melanoma	melanoma	NOUN
dpc-1415	161	11	,	,	PUNCT
dpc-1415	161	12	an	an	DET
dpc-1415	161	13	autoimmune	autoimmune	ADJ
dpc-1415	161	14	mechanism	mechanism	NOUN
dpc-1415	161	15	has	have	AUX
dpc-1415	161	16	been	be	AUX
dpc-1415	161	17	hypothesized	hypothesize	VERB
dpc-1415	161	18	.	.	PUNCT
dpc-1415	162	1	specifically	specifically	ADV
dpc-1415	162	2	,	,	PUNCT
dpc-1415	162	3	melanoma	melanoma	NOUN
dpc-1415	162	4	shares	share	VERB
dpc-1415	162	5	common	common	ADJ
dpc-1415	162	6	antigens	antigen	NOUN
dpc-1415	162	7	with	with	ADP
dpc-1415	162	8	healthy	healthy	ADJ
dpc-1415	162	9	melanocytes	melanocyte	NOUN
dpc-1415	162	10	that	that	PRON
dpc-1415	162	11	are	be	AUX
dpc-1415	162	12	involved	involve	VERB
dpc-1415	162	13	in	in	ADP
dpc-1415	162	14	melanin	melanin	NOUN
dpc-1415	162	15	synthesis	synthesis	NOUN
dpc-1415	162	16	.	.	PUNCT
dpc-1415	163	1	therefore	therefore	ADV
dpc-1415	163	2	,	,	PUNCT
dpc-1415	163	3	the	the	DET
dpc-1415	163	4	antibodies	antibody	NOUN
dpc-1415	163	5	directed	direct	VERB
dpc-1415	163	6	to	to	ADP
dpc-1415	163	7	these	these	DET
dpc-1415	163	8	melanoma	melanoma	NOUN
dpc-1415	163	9	-	-	PUNCT
dpc-1415	163	10	associated	associate	VERB
dpc-1415	163	11	antigens	antigen	NOUN
dpc-1415	163	12	also	also	ADV
dpc-1415	163	13	target	target	VERB
dpc-1415	163	14	healthy	healthy	ADJ
dpc-1415	163	15	melanocytes	melanocyte	NOUN
dpc-1415	163	16	.	.	PUNCT
dpc-1415	164	1	this	this	PRON
dpc-1415	164	2	,	,	PUNCT
dpc-1415	164	3	along	along	ADP
dpc-1415	164	4	with	with	ADP
dpc-1415	164	5	the	the	DET
dpc-1415	164	6	cytotoxic	cytotoxic	ADJ
dpc-1415	164	7	t	t	NOUN
dpc-1415	164	8	cell	cell	NOUN
dpc-1415	164	9	-	-	PUNCT
dpc-1415	164	10	mediated	mediate	VERB
dpc-1415	164	11	response	response	NOUN
dpc-1415	164	12	induced	induce	VERB
dpc-1415	164	13	by	by	ADP
dpc-1415	164	14	immunotherapy	immunotherapy	NOUN
dpc-1415	164	15	,	,	PUNCT
dpc-1415	164	16	finally	finally	ADV
dpc-1415	164	17	result	result	VERB
dpc-1415	164	18	in	in	ADP
dpc-1415	164	19	depigmentation	depigmentation	NOUN
dpc-1415	164	20	[	[	X
dpc-1415	164	21	36	36	NUM
dpc-1415	164	22	]	]	PUNCT
dpc-1415	164	23	.	.	PUNCT
dpc-1415	165	1	vitiligo	vitiligo	PROPN
dpc-1415	165	2	develops	develop	VERB
dpc-1415	165	3	progressively	progressively	ADV
dpc-1415	165	4	after	after	ADP
dpc-1415	165	5	several	several	ADJ
dpc-1415	165	6	months	month	NOUN
dpc-1415	165	7	of	of	ADP
dpc-1415	165	8	immunotherapy	immunotherapy	NOUN
dpc-1415	165	9	and	and	CCONJ
dpc-1415	165	10	in	in	ADP
dpc-1415	165	11	most	most	ADJ
dpc-1415	165	12	cases	case	NOUN
dpc-1415	165	13	does	do	AUX
dpc-1415	165	14	not	not	PART
dpc-1415	165	15	resolve	resolve	VERB
dpc-1415	165	16	even	even	ADV
dpc-1415	165	17	after	after	ADP
dpc-1415	165	18	treatment	treatment	NOUN
dpc-1415	165	19	discontinuation	discontinuation	NOUN
dpc-1415	165	20	.	.	PUNCT
dpc-1415	166	1	the	the	DET
dpc-1415	166	2	lesions	lesion	NOUN
dpc-1415	166	3	are	be	AUX
dpc-1415	166	4	usually	usually	ADV
dpc-1415	166	5	distributed	distribute	VERB
dpc-1415	166	6	bilaterally	bilaterally	ADV
dpc-1415	166	7	and	and	CCONJ
dpc-1415	166	8	tend	tend	VERB
dpc-1415	166	9	to	to	PART
dpc-1415	166	10	be	be	AUX
dpc-1415	166	11	generalized	generalize	VERB
dpc-1415	166	12	.	.	PUNCT
dpc-1415	167	1	however	however	ADV
dpc-1415	167	2	,	,	PUNCT
dpc-1415	167	3	focal	focal	ADJ
dpc-1415	167	4	or	or	CCONJ
dpc-1415	167	5	localized	localized	ADJ
dpc-1415	167	6	depigmentation	depigmentation	NOUN
dpc-1415	167	7	,	,	PUNCT
dpc-1415	167	8	sometimes	sometimes	ADV
dpc-1415	167	9	surrounding	surround	VERB
dpc-1415	167	10	cutaneous	cutaneous	ADJ
dpc-1415	167	11	metastases	metastasis	NOUN
dpc-1415	167	12	,	,	PUNCT
dpc-1415	167	13	may	may	AUX
dpc-1415	167	14	be	be	AUX
dpc-1415	167	15	also	also	ADV
dpc-1415	167	16	observed	observe	VERB
dpc-1415	167	17	[	[	PUNCT
dpc-1415	167	18	37	37	NUM
dpc-1415	167	19	]	]	PUNCT
dpc-1415	167	20	.	.	PUNCT
dpc-1415	168	1	fading	fade	VERB
dpc-1415	168	2	and	and	CCONJ
dpc-1415	168	3	disappearance	disappearance	NOUN
dpc-1415	168	4	of	of	ADP
dpc-1415	168	5	nevi	nevi	ADJ
dpc-1415	168	6	and	and	CCONJ
dpc-1415	168	7	other	other	ADJ
dpc-1415	168	8	pigmented	pigmented	ADJ
dpc-1415	168	9	lesions	lesion	NOUN
dpc-1415	168	10	,	,	PUNCT
dpc-1415	168	11	such	such	ADJ
dpc-1415	168	12	as	as	ADP
dpc-1415	168	13	solar	solar	ADJ
dpc-1415	168	14	lentigines	lentigo	NOUN
dpc-1415	168	15	and	and	CCONJ
dpc-1415	168	16	seborrheic	seborrheic	ADJ
dpc-1415	168	17	keratosis	keratosis	NOUN
dpc-1415	168	18	,	,	PUNCT
dpc-1415	168	19	can	can	AUX
dpc-1415	168	20	also	also	ADV
dpc-1415	168	21	occur	occur	VERB
dpc-1415	168	22	[	[	X
dpc-1415	168	23	38	38	NUM
dpc-1415	168	24	]	]	PUNCT
dpc-1415	168	25	.	.	PUNCT
dpc-1415	169	1	interestingly	interestingly	ADV
dpc-1415	169	2	,	,	PUNCT
dpc-1415	169	3	the	the	DET
dpc-1415	169	4	development	development	NOUN
dpc-1415	169	5	of	of	ADP
dpc-1415	169	6	new	new	ADJ
dpc-1415	169	7	nevi	nevi	NOUN
dpc-1415	169	8	has	have	AUX
dpc-1415	169	9	also	also	ADV
dpc-1415	169	10	been	be	AUX
dpc-1415	169	11	described	describe	VERB
dpc-1415	169	12	[	[	PUNCT
dpc-1415	169	13	39	39	NUM
dpc-1415	169	14	]	]	PUNCT
dpc-1415	169	15	.	.	PUNCT
dpc-1415	170	1	hair	hair	NOUN
dpc-1415	170	2	involvement	involvement	NOUN
dpc-1415	170	3	,	,	PUNCT
dpc-1415	170	4	with	with	ADP
dpc-1415	170	5	whitening	whitening	NOUN
dpc-1415	170	6	of	of	ADP
dpc-1415	170	7	the	the	DET
dpc-1415	170	8	eyelashes	eyelash	NOUN
dpc-1415	170	9	,	,	PUNCT
dpc-1415	170	10	eyebrows	eyebrow	NOUN
dpc-1415	170	11	,	,	PUNCT
dpc-1415	170	12	or	or	CCONJ
dpc-1415	170	13	scalp	scalp	NOUN
dpc-1415	170	14	hair	hair	NOUN
dpc-1415	170	15	is	be	AUX
dpc-1415	170	16	not	not	PART
dpc-1415	170	17	unusual	unusual	ADJ
dpc-1415	170	18	.	.	PUNCT
dpc-1415	171	1	although	although	SCONJ
dpc-1415	171	2	vitiligo	vitiligo	NOUN
dpc-1415	171	3	may	may	AUX
dpc-1415	171	4	affect	affect	VERB
dpc-1415	171	5	the	the	DET
dpc-1415	171	6	patient	patient	NOUN
dpc-1415	171	7	’s	’s	PART
dpc-1415	171	8	psychological	psychological	ADJ
dpc-1415	171	9	status	status	NOUN
dpc-1415	171	10	,	,	PUNCT
dpc-1415	171	11	other	other	ADJ
dpc-1415	171	12	than	than	ADP
dpc-1415	171	13	sun	sun	NOUN
dpc-1415	171	14	protection	protection	NOUN
dpc-1415	171	15	,	,	PUNCT
dpc-1415	171	16	it	it	PRON
dpc-1415	171	17	requires	require	VERB
dpc-1415	171	18	no	no	DET
dpc-1415	171	19	treatment	treatment	NOUN
dpc-1415	171	20	.	.	PUNCT
dpc-1415	172	1	importantly	importantly	ADV
dpc-1415	172	2	,	,	PUNCT
dpc-1415	172	3	the	the	DET
dpc-1415	172	4	coexistence	coexistence	NOUN
dpc-1415	172	5	of	of	ADP
dpc-1415	172	6	vitiligo	vitiligo	NOUN
dpc-1415	172	7	with	with	ADP
dpc-1415	172	8	other	other	ADJ
dpc-1415	172	9	cutaneous	cutaneous	ADJ
dpc-1415	172	10	iraes	iraes	NOUN
dpc-1415	172	11	is	be	AUX
dpc-1415	172	12	not	not	PART
dpc-1415	172	13	uncommon	uncommon	ADJ
dpc-1415	172	14	(	(	PUNCT
dpc-1415	172	15	figure	figure	NOUN
dpc-1415	172	16	5	5	NUM
dpc-1415	172	17	)	)	PUNCT
dpc-1415	172	18	.	.	PUNCT
dpc-1415	173	1	figure	figure	NOUN
dpc-1415	173	2	5	5	NUM
dpc-1415	173	3	.	.	PUNCT
dpc-1415	174	1	concomitant	concomitant	ADJ
dpc-1415	174	2	development	development	NOUN
dpc-1415	174	3	of	of	ADP
dpc-1415	174	4	more	more	ADJ
dpc-1415	174	5	than	than	ADP
dpc-1415	174	6	one	one	NUM
dpc-1415	174	7	skin	skin	NOUN
dpc-1415	174	8	toxicity	toxicity	NOUN
dpc-1415	174	9	is	be	AUX
dpc-1415	174	10	not	not	PART
dpc-1415	174	11	unusual	unusual	ADJ
dpc-1415	174	12	.	.	PUNCT
dpc-1415	175	1	the	the	DET
dpc-1415	175	2	patient	patient	NOUN
dpc-1415	175	3	illustrated	illustrate	VERB
dpc-1415	175	4	in	in	ADP
dpc-1415	175	5	(	(	PUNCT
dpc-1415	175	6	a	a	X
dpc-1415	175	7	)	)	PUNCT
dpc-1415	175	8	experienced	experienced	ADJ
dpc-1415	175	9	vitiligo	vitiligo	NOUN
dpc-1415	175	10	and	and	CCONJ
dpc-1415	175	11	psoriasis	psoriasis	NOUN
dpc-1415	175	12	(	(	PUNCT
dpc-1415	175	13	see	see	VERB
dpc-1415	175	14	figure	figure	NOUN
dpc-1415	175	15	1b	1b	NUM
dpc-1415	175	16	)	)	PUNCT
dpc-1415	175	17	and	and	CCONJ
dpc-1415	175	18	the	the	DET
dpc-1415	175	19	patient	patient	NOUN
dpc-1415	175	20	in	in	ADP
dpc-1415	175	21	(	(	PUNCT
dpc-1415	175	22	b	b	NOUN
dpc-1415	175	23	)	)	PUNCT
dpc-1415	175	24	experienced	experienced	ADJ
dpc-1415	175	25	vitiligo	vitiligo	NOUN
dpc-1415	175	26	and	and	CCONJ
dpc-1415	175	27	bullous	bullous	ADJ
dpc-1415	175	28	pemphigoid	pemphigoid	NOUN
dpc-1415	175	29	,	,	PUNCT
dpc-1415	175	30	both	both	CCONJ
dpc-1415	175	31	during	during	ADP
dpc-1415	175	32	treatment	treatment	NOUN
dpc-1415	175	33	with	with	ADP
dpc-1415	175	34	nivolumab	nivolumab	NOUN
dpc-1415	175	35	for	for	ADP
dpc-1415	175	36	advanced	advanced	ADJ
dpc-1415	175	37	melanoma	melanoma	NOUN
dpc-1415	175	38	.	.	PUNCT
dpc-1415	176	1	a	a	DET
dpc-1415	176	2	b	b	NUM
dpc-1415	176	3	8	8	NUM
dpc-1415	176	4	review	review	NOUN
dpc-1415	176	5	|	|	ADV
dpc-1415	176	6	dermatol	dermatol	ADJ
dpc-1415	176	7	pract	pract	NOUN
dpc-1415	176	8	concept	concept	NOUN
dpc-1415	176	9	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	176	10	recently	recently	ADV
dpc-1415	176	11	published	publish	VERB
dpc-1415	176	12	data	datum	NOUN
dpc-1415	176	13	show	show	VERB
dpc-1415	176	14	that	that	SCONJ
dpc-1415	176	15	the	the	DET
dpc-1415	176	16	development	development	NOUN
dpc-1415	176	17	of	of	ADP
dpc-1415	176	18	vitiligo	vitiligo	NOUN
dpc-1415	176	19	-	-	PUNCT
dpc-1415	176	20	like	like	ADJ
dpc-1415	176	21	depigmentation	depigmentation	NOUN
dpc-1415	176	22	suggests	suggest	VERB
dpc-1415	176	23	a	a	DET
dpc-1415	176	24	favorable	favorable	ADJ
dpc-1415	176	25	response	response	NOUN
dpc-1415	176	26	to	to	ADP
dpc-1415	176	27	treatment	treatment	NOUN
dpc-1415	176	28	in	in	ADP
dpc-1415	176	29	patients	patient	NOUN
dpc-1415	176	30	receiving	receive	VERB
dpc-1415	176	31	pembrolizumab	pembrolizumab	NOUN
dpc-1415	176	32	or	or	CCONJ
dpc-1415	176	33	nivolumab	nivolumab	NOUN
dpc-1415	176	34	[	[	X
dpc-1415	176	35	36,40	36,40	NUM
dpc-1415	176	36	-	-	SYM
dpc-1415	176	37	43	43	NUM
dpc-1415	176	38	]	]	PUNCT
dpc-1415	176	39	.	.	PUNCT
dpc-1415	177	1	specifically	specifically	ADV
dpc-1415	177	2	,	,	PUNCT
dpc-1415	177	3	it	it	PRON
dpc-1415	177	4	has	have	AUX
dpc-1415	177	5	been	be	AUX
dpc-1415	177	6	associated	associate	VERB
dpc-1415	177	7	with	with	ADP
dpc-1415	177	8	prolonged	prolonged	ADJ
dpc-1415	177	9	progression	progression	NOUN
dpc-1415	177	10	-	-	PUNCT
dpc-1415	177	11	free	free	ADJ
dpc-1415	177	12	survival	survival	NOUN
dpc-1415	177	13	and	and	CCONJ
dpc-1415	177	14	overall	overall	ADJ
dpc-1415	177	15	survival	survival	NOUN
dpc-1415	177	16	and	and	CCONJ
dpc-1415	177	17	could	could	AUX
dpc-1415	177	18	probably	probably	ADV
dpc-1415	177	19	serve	serve	VERB
dpc-1415	177	20	as	as	ADP
dpc-1415	177	21	a	a	DET
dpc-1415	177	22	positive	positive	ADJ
dpc-1415	177	23	prognostic	prognostic	ADJ
dpc-1415	177	24	factor	factor	NOUN
dpc-1415	177	25	of	of	ADP
dpc-1415	177	26	the	the	DET
dpc-1415	177	27	oncologic	oncologic	ADJ
dpc-1415	177	28	outcome	outcome	NOUN
dpc-1415	177	29	.	.	PUNCT
dpc-1415	178	1	however	however	ADV
dpc-1415	178	2	,	,	PUNCT
dpc-1415	178	3	further	further	ADJ
dpc-1415	178	4	studies	study	NOUN
dpc-1415	178	5	are	be	AUX
dpc-1415	178	6	required	require	VERB
dpc-1415	178	7	to	to	PART
dpc-1415	178	8	validate	validate	VERB
dpc-1415	178	9	these	these	DET
dpc-1415	178	10	results	result	NOUN
dpc-1415	178	11	.	.	PUNCT
dpc-1415	179	1	e.	e.	PROPN
dpc-1415	179	2	severe	severe	ADJ
dpc-1415	179	3	cutaneous	cutaneous	ADJ
dpc-1415	179	4	adverse	adverse	ADJ
dpc-1415	179	5	reactions	reaction	NOUN
dpc-1415	179	6	(	(	PUNCT
dpc-1415	179	7	scars)/	scars)/	NOUN
dpc-1415	179	8	life	life	NOUN
dpc-1415	179	9	-	-	PUNCT
dpc-1415	179	10	threatening	threaten	VERB
dpc-1415	179	11	drug	drug	NOUN
dpc-1415	179	12	reactions	reaction	NOUN
dpc-1415	179	13	scars	scar	NOUN
dpc-1415	179	14	encompass	encompass	VERB
dpc-1415	179	15	dress/	dress/	NUM
dpc-1415	179	16	dihs	dihs	NOUN
dpc-1415	179	17	,	,	PUNCT
dpc-1415	179	18	sjs	sjs	PROPN
dpc-1415	179	19	,	,	PUNCT
dpc-1415	179	20	ten	ten	NUM
dpc-1415	179	21	,	,	PUNCT
dpc-1415	179	22	and	and	CCONJ
dpc-1415	179	23	acute	acute	ADJ
dpc-1415	179	24	generalized	generalize	VERB
dpc-1415	179	25	exanthematous	exanthematous	ADJ
dpc-1415	179	26	pustulosis	pustulosis	NOUN
dpc-1415	179	27	[	[	X
dpc-1415	179	28	44	44	NUM
dpc-1415	179	29	]	]	PUNCT
dpc-1415	179	30	.	.	PUNCT
dpc-1415	180	1	scars	scar	NOUN
dpc-1415	180	2	are	be	AUX
dpc-1415	180	3	scarcely	scarcely	ADV
dpc-1415	180	4	reported	report	VERB
dpc-1415	180	5	with	with	ADP
dpc-1415	180	6	cpis	cpis	PROPN
dpc-1415	180	7	[	[	X
dpc-1415	180	8	45	45	NUM
dpc-1415	180	9	-	-	SYM
dpc-1415	180	10	51	51	NUM
dpc-1415	180	11	]	]	PUNCT
dpc-1415	180	12	.	.	PUNCT
dpc-1415	181	1	considering	consider	VERB
dpc-1415	181	2	that	that	SCONJ
dpc-1415	181	3	a	a	DET
dpc-1415	181	4	maculopapular	maculopapular	NOUN
dpc-1415	181	5	or	or	CCONJ
dpc-1415	181	6	a	a	DET
dpc-1415	181	7	nonspecific	nonspecific	ADJ
dpc-1415	181	8	rash	rash	NOUN
dpc-1415	181	9	may	may	AUX
dpc-1415	181	10	precede	precede	VERB
dpc-1415	181	11	life	life	NOUN
dpc-1415	181	12	-	-	PUNCT
dpc-1415	181	13	threatening	threaten	VERB
dpc-1415	181	14	reactions	reaction	NOUN
dpc-1415	181	15	,	,	PUNCT
dpc-1415	181	16	dermatologic	dermatologic	ADJ
dpc-1415	181	17	consultation	consultation	NOUN
dpc-1415	181	18	and	and	CCONJ
dpc-1415	181	19	possibly	possibly	ADV
dpc-1415	181	20	a	a	DET
dpc-1415	181	21	skin	skin	NOUN
dpc-1415	181	22	biopsy	biopsy	NOUN
dpc-1415	181	23	is	be	AUX
dpc-1415	181	24	recommended	recommend	VERB
dpc-1415	181	25	.	.	PUNCT
dpc-1415	182	1	in	in	ADP
dpc-1415	182	2	case	case	NOUN
dpc-1415	182	3	of	of	ADP
dpc-1415	182	4	a	a	DET
dpc-1415	182	5	scar	scar	NOUN
dpc-1415	182	6	,	,	PUNCT
dpc-1415	182	7	cpi	cpi	PROPN
dpc-1415	182	8	therapy	therapy	NOUN
dpc-1415	182	9	must	must	AUX
dpc-1415	182	10	be	be	AUX
dpc-1415	182	11	withheld	withhold	VERB
dpc-1415	182	12	or	or	CCONJ
dpc-1415	182	13	permanently	permanently	ADV
dpc-1415	182	14	discontinued	discontinue	VERB
dpc-1415	182	15	and	and	CCONJ
dpc-1415	182	16	hospitalization	hospitalization	NOUN
dpc-1415	182	17	maybe	maybe	ADV
dpc-1415	182	18	needed	need	VERB
dpc-1415	182	19	for	for	ADP
dpc-1415	182	20	appropriate	appropriate	ADJ
dpc-1415	182	21	management	management	NOUN
dpc-1415	182	22	[	[	X
dpc-1415	182	23	7,8	7,8	NUM
dpc-1415	182	24	]	]	PUNCT
dpc-1415	182	25	.	.	PUNCT
dpc-1415	183	1	f.	f.	PROPN
dpc-1415	183	2	miscellaneous	miscellaneous	PROPN
dpc-1415	183	3	skin	skin	NOUN
dpc-1415	183	4	manifestations	manifestation	NOUN
dpc-1415	183	5	this	this	DET
dpc-1415	183	6	category	category	NOUN
dpc-1415	183	7	encompasses	encompass	VERB
dpc-1415	183	8	a	a	DET
dpc-1415	183	9	series	series	NOUN
dpc-1415	183	10	of	of	ADP
dpc-1415	183	11	rare	rare	ADJ
dpc-1415	183	12	skin	skin	NOUN
dpc-1415	183	13	complications	complication	NOUN
dpc-1415	183	14	that	that	PRON
dpc-1415	183	15	may	may	AUX
dpc-1415	183	16	occur	occur	VERB
dpc-1415	183	17	during	during	ADP
dpc-1415	183	18	cpi	cpi	PROPN
dpc-1415	183	19	therapy	therapy	NOUN
dpc-1415	183	20	.	.	PUNCT
dpc-1415	184	1	grover	grover	NOUN
dpc-1415	184	2	disease	disease	NOUN
dpc-1415	184	3	may	may	AUX
dpc-1415	184	4	present	present	VERB
dpc-1415	184	5	as	as	ADP
dpc-1415	184	6	pruritic	pruritic	ADJ
dpc-1415	184	7	erythematous	erythematous	ADJ
dpc-1415	184	8	papules	papule	NOUN
dpc-1415	184	9	or	or	CCONJ
dpc-1415	184	10	keratotic	keratotic	ADJ
dpc-1415	184	11	papules	papule	NOUN
dpc-1415	184	12	,	,	PUNCT
dpc-1415	184	13	papulovesicles	papulovesicle	NOUN
dpc-1415	184	14	,	,	PUNCT
dpc-1415	184	15	and	and	CCONJ
dpc-1415	184	16	vesicles	vesicle	NOUN
dpc-1415	184	17	[	[	X
dpc-1415	184	18	52	52	NUM
dpc-1415	184	19	]	]	PUNCT
dpc-1415	184	20	the	the	DET
dpc-1415	184	21	lesions	lesion	NOUN
dpc-1415	184	22	may	may	AUX
dpc-1415	184	23	be	be	AUX
dpc-1415	184	24	distributed	distribute	VERB
dpc-1415	184	25	on	on	ADP
dpc-1415	184	26	the	the	DET
dpc-1415	184	27	trunk	trunk	NOUN
dpc-1415	184	28	and	and	CCONJ
dpc-1415	184	29	chest	chest	NOUN
dpc-1415	184	30	or	or	CCONJ
dpc-1415	184	31	may	may	AUX
dpc-1415	184	32	be	be	AUX
dpc-1415	184	33	more	more	ADV
dpc-1415	184	34	diffuse	diffuse	ADJ
dpc-1415	184	35	,	,	PUNCT
dpc-1415	184	36	usually	usually	ADV
dpc-1415	184	37	appearing	appear	VERB
dpc-1415	184	38	early	early	ADV
dpc-1415	184	39	after	after	ADP
dpc-1415	184	40	the	the	DET
dpc-1415	184	41	cpis	cpis	PROPN
dpc-1415	184	42	initiation	initiation	NOUN
dpc-1415	184	43	and	and	CCONJ
dpc-1415	184	44	may	may	AUX
dpc-1415	184	45	last	last	VERB
dpc-1415	184	46	several	several	ADJ
dpc-1415	184	47	weeks	week	NOUN
dpc-1415	184	48	or	or	CCONJ
dpc-1415	184	49	months	month	NOUN
dpc-1415	184	50	after	after	ADP
dpc-1415	184	51	their	their	PRON
dpc-1415	184	52	discontinuation	discontinuation	NOUN
dpc-1415	184	53	[	[	X
dpc-1415	184	54	53,54	53,54	NUM
dpc-1415	184	55	]	]	X
dpc-1415	184	56	.	.	PUNCT
dpc-1415	185	1	a	a	DET
dpc-1415	185	2	skin	skin	NOUN
dpc-1415	185	3	biopsy	biopsy	NOUN
dpc-1415	185	4	is	be	AUX
dpc-1415	185	5	mandatory	mandatory	ADJ
dpc-1415	185	6	for	for	ADP
dpc-1415	185	7	diagnostic	diagnostic	ADJ
dpc-1415	185	8	purposes	purpose	NOUN
dpc-1415	185	9	.	.	PUNCT
dpc-1415	186	1	rare	rare	ADJ
dpc-1415	186	2	autoimmune	autoimmune	ADJ
dpc-1415	186	3	disorders	disorder	NOUN
dpc-1415	186	4	,	,	PUNCT
dpc-1415	186	5	such	such	ADJ
dpc-1415	186	6	as	as	ADP
dpc-1415	186	7	vasculitis	vasculitis	PROPN
dpc-1415	186	8	,	,	PUNCT
dpc-1415	186	9	dermatomyositis	dermatomyositis	NOUN
dpc-1415	186	10	and	and	CCONJ
dpc-1415	186	11	sjögren	sjögren	VERB
dpc-1415	186	12	syndrome	syndrome	NOUN
dpc-1415	186	13	during	during	ADP
dpc-1415	186	14	anti	anti	ADJ
dpc-1415	186	15	-	-	ADJ
dpc-1415	186	16	pd-1/	pd-1/	ADJ
dpc-1415	186	17	anti	anti	ADJ
dpc-1415	186	18	-	-	ADJ
dpc-1415	186	19	pd	pd	ADJ
dpc-1415	186	20	-	-	PUNCT
dpc-1415	186	21	l1	l1	PROPN
dpc-1415	186	22	and	and	CCONJ
dpc-1415	186	23	anti	anti	ADJ
dpc-1415	186	24	-	-	ADJ
dpc-1415	186	25	ctla-4	ctla-4	NOUN
dpc-1415	186	26	therapy	therapy	NOUN
dpc-1415	186	27	have	have	AUX
dpc-1415	186	28	been	be	AUX
dpc-1415	186	29	sporadically	sporadically	ADV
dpc-1415	186	30	reported	report	VERB
dpc-1415	186	31	[	[	PUNCT
dpc-1415	186	32	55	55	NUM
dpc-1415	186	33	-	-	SYM
dpc-1415	186	34	59	59	NUM
dpc-1415	186	35	]	]	PUNCT
dpc-1415	186	36	.	.	PUNCT
dpc-1415	187	1	in	in	ADP
dpc-1415	187	2	such	such	ADJ
dpc-1415	187	3	cases	case	NOUN
dpc-1415	187	4	,	,	PUNCT
dpc-1415	187	5	laboratory	laboratory	NOUN
dpc-1415	187	6	tests	test	NOUN
dpc-1415	187	7	should	should	AUX
dpc-1415	187	8	be	be	AUX
dpc-1415	187	9	performed	perform	VERB
dpc-1415	187	10	and	and	CCONJ
dpc-1415	187	11	systemic	systemic	ADJ
dpc-1415	187	12	involvement	involvement	NOUN
dpc-1415	187	13	should	should	AUX
dpc-1415	187	14	be	be	AUX
dpc-1415	187	15	excluded	exclude	VERB
dpc-1415	187	16	.	.	PUNCT
dpc-1415	188	1	furthermore	furthermore	ADV
dpc-1415	188	2	,	,	PUNCT
dpc-1415	188	3	de	de	ADJ
dpc-1415	188	4	-	-	ADJ
dpc-1415	188	5	novo	novo	ADJ
dpc-1415	188	6	development	development	NOUN
dpc-1415	188	7	or	or	CCONJ
dpc-1415	188	8	exacerbation	exacerbation	NOUN
dpc-1415	188	9	of	of	ADP
dpc-1415	188	10	preexisting	preexist	VERB
dpc-1415	188	11	sarcoidosis	sarcoidosis	NOUN
dpc-1415	188	12	,	,	PUNCT
dpc-1415	188	13	urticaria	urticaria	NOUN
dpc-1415	188	14	,	,	PUNCT
dpc-1415	188	15	rocasea	rocasea	NOUN
dpc-1415	188	16	,	,	PUNCT
dpc-1415	188	17	or	or	CCONJ
dpc-1415	188	18	prurigo	prurigo	VERB
dpc-1415	188	19	simplex/	simplex/	NUM
dpc-1415	188	20	nodularis	nodularis	NOUN
dpc-1415	188	21	,	,	PUNCT
dpc-1415	188	22	may	may	AUX
dpc-1415	188	23	occur	occur	VERB
dpc-1415	188	24	[	[	X
dpc-1415	188	25	22,60,61	22,60,61	NUM
dpc-1415	188	26	]	]	PUNCT
dpc-1415	188	27	.	.	PUNCT
dpc-1415	189	1	sarcoidosis	sarcoidosis	NOUN
dpc-1415	189	2	is	be	AUX
dpc-1415	189	3	not	not	PART
dpc-1415	189	4	uncommon	uncommon	ADJ
dpc-1415	189	5	and	and	CCONJ
dpc-1415	189	6	its	its	PRON
dpc-1415	189	7	clinical	clinical	ADJ
dpc-1415	189	8	presentation	presentation	NOUN
dpc-1415	189	9	may	may	AUX
dpc-1415	189	10	vary	vary	VERB
dpc-1415	189	11	from	from	ADP
dpc-1415	189	12	papules	papule	NOUN
dpc-1415	189	13	or	or	CCONJ
dpc-1415	189	14	plaques	plaque	NOUN
dpc-1415	189	15	to	to	PART
dpc-1415	189	16	erythema	erythema	ADV
dpc-1415	189	17	nodosum	nodosum	VERB
dpc-1415	189	18	,	,	PUNCT
dpc-1415	189	19	with	with	ADP
dpc-1415	189	20	or	or	CCONJ
dpc-1415	189	21	without	without	ADP
dpc-1415	189	22	pulmonary	pulmonary	ADJ
dpc-1415	189	23	or	or	CCONJ
dpc-1415	189	24	other	other	ADJ
dpc-1415	189	25	organ	organ	NOUN
dpc-1415	189	26	involvement	involvement	NOUN
dpc-1415	189	27	[	[	X
dpc-1415	189	28	62	62	NUM
dpc-1415	189	29	-	-	SYM
dpc-1415	189	30	65	65	NUM
dpc-1415	189	31	]	]	PUNCT
dpc-1415	189	32	.	.	PUNCT
dpc-1415	190	1	systemic	systemic	ADJ
dpc-1415	190	2	or	or	CCONJ
dpc-1415	190	3	topical	topical	ADJ
dpc-1415	190	4	steroids	steroid	NOUN
dpc-1415	190	5	may	may	AUX
dpc-1415	190	6	be	be	AUX
dpc-1415	190	7	applied	apply	VERB
dpc-1415	190	8	for	for	ADP
dpc-1415	190	9	the	the	DET
dpc-1415	190	10	treatment	treatment	NOUN
dpc-1415	190	11	of	of	ADP
dpc-1415	190	12	the	the	DET
dpc-1415	190	13	skin	skin	NOUN
dpc-1415	190	14	lesions	lesion	NOUN
dpc-1415	190	15	.	.	PUNCT
dpc-1415	191	1	in	in	ADP
dpc-1415	191	2	the	the	DET
dpc-1415	191	3	end	end	NOUN
dpc-1415	191	4	,	,	PUNCT
dpc-1415	191	5	oral	oral	ADJ
dpc-1415	191	6	mucosa	mucosa	NOUN
dpc-1415	191	7	alterations	alteration	NOUN
dpc-1415	191	8	and	and	CCONJ
dpc-1415	191	9	nonspecific	nonspecific	ADJ
dpc-1415	191	10	nail	nail	NOUN
dpc-1415	191	11	and	and	CCONJ
dpc-1415	191	12	hair	hair	NOUN
dpc-1415	191	13	alterations	alteration	NOUN
dpc-1415	191	14	,	,	PUNCT
dpc-1415	191	15	like	like	ADP
dpc-1415	191	16	onychodystrophy	onychodystrophy	NOUN
dpc-1415	191	17	,	,	PUNCT
dpc-1415	191	18	paronychia	paronychia	NOUN
dpc-1415	191	19	,	,	PUNCT
dpc-1415	191	20	alopecia	alopecia	NOUN
dpc-1415	191	21	and	and	CCONJ
dpc-1415	191	22	dysgeusia	dysgeusia	NOUN
dpc-1415	191	23	can	can	AUX
dpc-1415	191	24	be	be	AUX
dpc-1415	191	25	observed	observe	VERB
dpc-1415	191	26	.	.	PUNCT
dpc-1415	192	1	alopecia	alopecia	NOUN
dpc-1415	192	2	is	be	AUX
dpc-1415	192	3	usually	usually	ADV
dpc-1415	192	4	non	non	ADJ
dpc-1415	192	5	-	-	ADJ
dpc-1415	192	6	scarring	scarring	ADJ
dpc-1415	192	7	,	,	PUNCT
dpc-1415	192	8	is	be	AUX
dpc-1415	192	9	mainly	mainly	ADV
dpc-1415	192	10	of	of	ADP
dpc-1415	192	11	alopecia	alopecia	NOUN
dpc-1415	192	12	areata	areata	ADJ
dpc-1415	192	13	type	type	NOUN
dpc-1415	192	14	,	,	PUNCT
dpc-1415	192	15	and	and	CCONJ
dpc-1415	192	16	can	can	AUX
dpc-1415	192	17	be	be	AUX
dpc-1415	192	18	partial	partial	ADJ
dpc-1415	192	19	or	or	CCONJ
dpc-1415	192	20	diffuse	diffuse	VERB
dpc-1415	192	21	.	.	PUNCT
dpc-1415	193	1	the	the	DET
dpc-1415	193	2	underlying	underlying	ADJ
dpc-1415	193	3	mechanism	mechanism	NOUN
dpc-1415	193	4	involves	involve	VERB
dpc-1415	193	5	an	an	DET
dpc-1415	193	6	immune	immune	ADJ
dpc-1415	193	7	attack	attack	NOUN
dpc-1415	193	8	operated	operate	VERB
dpc-1415	193	9	by	by	ADP
dpc-1415	193	10	cytotoxic	cytotoxic	ADJ
dpc-1415	193	11	cd8	cd8	PROPN
dpc-1415	193	12	+	+	PROPN
dpc-1415	193	13	cells	cell	NOUN
dpc-1415	193	14	on	on	ADP
dpc-1415	193	15	the	the	DET
dpc-1415	193	16	hair	hair	NOUN
dpc-1415	193	17	bulb	bulb	NOUN
dpc-1415	194	1	[	[	X
dpc-1415	194	2	66	66	NUM
dpc-1415	194	3	]	]	PUNCT
dpc-1415	194	4	.	.	PUNCT
dpc-1415	195	1	treatment	treatment	NOUN
dpc-1415	195	2	strategy	strategy	NOUN
dpc-1415	195	3	in	in	ADP
dpc-1415	195	4	most	most	ADJ
dpc-1415	195	5	cases	case	NOUN
dpc-1415	195	6	,	,	PUNCT
dpc-1415	195	7	cutaneous	cutaneous	ADJ
dpc-1415	195	8	iraes	irae	NOUN
dpc-1415	195	9	are	be	AUX
dpc-1415	195	10	mild	mild	ADJ
dpc-1415	195	11	(	(	PUNCT
dpc-1415	195	12	grade	grade	NOUN
dpc-1415	195	13	1	1	NUM
dpc-1415	195	14	,	,	PUNCT
dpc-1415	195	15	2	2	NUM
dpc-1415	195	16	)	)	PUNCT
dpc-1415	195	17	and	and	CCONJ
dpc-1415	195	18	usually	usually	ADV
dpc-1415	195	19	manageable	manageable	ADJ
dpc-1415	195	20	with	with	ADP
dpc-1415	195	21	topical	topical	ADJ
dpc-1415	195	22	treatment	treatment	NOUN
dpc-1415	195	23	,	,	PUNCT
dpc-1415	195	24	including	include	VERB
dpc-1415	195	25	steroids	steroid	NOUN
dpc-1415	195	26	,	,	PUNCT
dpc-1415	195	27	calcineurin	calcineurin	ADJ
dpc-1415	195	28	inhibitors	inhibitor	NOUN
dpc-1415	195	29	and	and	CCONJ
dpc-1415	195	30	phototherapy	phototherapy	NOUN
dpc-1415	195	31	.	.	PUNCT
dpc-1415	196	1	skin	skin	NOUN
dpc-1415	196	2	toxicity	toxicity	NOUN
dpc-1415	196	3	grade	grade	NOUN
dpc-1415	196	4	≥3	≥3	PROPN
dpc-1415	196	5	,	,	PUNCT
dpc-1415	196	6	usually	usually	ADV
dpc-1415	196	7	requires	require	VERB
dpc-1415	196	8	systemic	systemic	ADJ
dpc-1415	196	9	immunomodulating	immunomodulating	ADJ
dpc-1415	196	10	and	and	CCONJ
dpc-1415	196	11	immunosuppressive	immunosuppressive	ADJ
dpc-1415	196	12	drugs	drug	NOUN
dpc-1415	196	13	.	.	PUNCT
dpc-1415	197	1	systemic	systemic	ADJ
dpc-1415	197	2	steroids	steroid	NOUN
dpc-1415	197	3	,	,	PUNCT
dpc-1415	197	4	though	though	SCONJ
dpc-1415	197	5	highly	highly	ADV
dpc-1415	197	6	efficacious	efficacious	ADJ
dpc-1415	197	7	and	and	CCONJ
dpc-1415	197	8	widely	widely	ADV
dpc-1415	197	9	used	use	VERB
dpc-1415	197	10	in	in	ADP
dpc-1415	197	11	cutaneous	cutaneous	ADJ
dpc-1415	197	12	drug	drug	NOUN
dpc-1415	197	13	reactions	reaction	NOUN
dpc-1415	197	14	,	,	PUNCT
dpc-1415	197	15	raise	raise	VERB
dpc-1415	197	16	practical	practical	ADJ
dpc-1415	197	17	difficulties	difficulty	NOUN
dpc-1415	197	18	when	when	SCONJ
dpc-1415	197	19	used	use	VERB
dpc-1415	197	20	in	in	ADP
dpc-1415	197	21	high	high	ADJ
dpc-1415	197	22	doses	dose	NOUN
dpc-1415	197	23	,	,	PUNCT
dpc-1415	197	24	since	since	SCONJ
dpc-1415	197	25	they	they	PRON
dpc-1415	197	26	may	may	AUX
dpc-1415	197	27	impede	impede	VERB
dpc-1415	197	28	the	the	DET
dpc-1415	197	29	action	action	NOUN
dpc-1415	197	30	of	of	ADP
dpc-1415	197	31	immunotherapy	immunotherapy	NOUN
dpc-1415	197	32	.	.	PUNCT
dpc-1415	198	1	in	in	ADP
dpc-1415	198	2	this	this	DET
dpc-1415	198	3	context	context	NOUN
dpc-1415	198	4	,	,	PUNCT
dpc-1415	198	5	involvement	involvement	NOUN
dpc-1415	198	6	of	of	ADP
dpc-1415	198	7	qualified	qualified	ADJ
dpc-1415	198	8	dermatologists	dermatologist	NOUN
dpc-1415	198	9	that	that	PRON
dpc-1415	198	10	may	may	AUX
dpc-1415	198	11	apply	apply	VERB
dpc-1415	198	12	organ	organ	NOUN
dpc-1415	198	13	-	-	PUNCT
dpc-1415	198	14	specific	specific	ADJ
dpc-1415	198	15	therapeutic	therapeutic	ADJ
dpc-1415	198	16	modalities	modality	NOUN
dpc-1415	198	17	and	and	CCONJ
dpc-1415	198	18	avoiding	avoid	VERB
dpc-1415	198	19	immunosuppressive	immunosuppressive	ADJ
dpc-1415	198	20	agents	agent	NOUN
dpc-1415	198	21	is	be	AUX
dpc-1415	198	22	crucial	crucial	ADJ
dpc-1415	198	23	for	for	ADP
dpc-1415	198	24	immunotherapy	immunotherapy	NOUN
dpc-1415	198	25	survival	survival	NOUN
dpc-1415	198	26	.	.	PUNCT
dpc-1415	199	1	furthermore	furthermore	ADV
dpc-1415	199	2	,	,	PUNCT
dpc-1415	199	3	considering	consider	VERB
dpc-1415	199	4	that	that	SCONJ
dpc-1415	199	5	the	the	DET
dpc-1415	199	6	impact	impact	NOUN
dpc-1415	199	7	of	of	ADP
dpc-1415	199	8	various	various	ADJ
dpc-1415	199	9	immunomodulating	immunomodulating	ADJ
dpc-1415	199	10	drugs	drug	NOUN
dpc-1415	199	11	on	on	ADP
dpc-1415	199	12	the	the	DET
dpc-1415	199	13	anti	anti	ADJ
dpc-1415	199	14	-	-	ADJ
dpc-1415	199	15	tumor	tumor	ADJ
dpc-1415	199	16	effect	effect	NOUN
dpc-1415	199	17	of	of	ADP
dpc-1415	199	18	immunotherapy	immunotherapy	NOUN
dpc-1415	199	19	has	have	AUX
dpc-1415	199	20	not	not	PART
dpc-1415	199	21	been	be	AUX
dpc-1415	199	22	fully	fully	ADV
dpc-1415	199	23	elucidated	elucidated	ADJ
dpc-1415	199	24	,	,	PUNCT
dpc-1415	199	25	close	close	ADJ
dpc-1415	199	26	collaboration	collaboration	NOUN
dpc-1415	199	27	between	between	ADP
dpc-1415	199	28	oncologists	oncologist	NOUN
dpc-1415	199	29	and	and	CCONJ
dpc-1415	199	30	dermatologists	dermatologist	NOUN
dpc-1415	199	31	is	be	AUX
dpc-1415	199	32	mandatory	mandatory	ADJ
dpc-1415	199	33	for	for	ADP
dpc-1415	199	34	the	the	DET
dpc-1415	199	35	optimization	optimization	NOUN
dpc-1415	199	36	of	of	ADP
dpc-1415	199	37	treatment	treatment	NOUN
dpc-1415	199	38	strategy	strategy	NOUN
dpc-1415	199	39	(	(	PUNCT
dpc-1415	199	40	eg	eg	NOUN
dpc-1415	199	41	,	,	PUNCT
dpc-1415	199	42	doses	dose	NOUN
dpc-1415	199	43	,	,	PUNCT
dpc-1415	199	44	dosage	dosage	NOUN
dpc-1415	199	45	modifications	modification	NOUN
dpc-1415	199	46	,	,	PUNCT
dpc-1415	199	47	discontinuation	discontinuation	NOUN
dpc-1415	199	48	or	or	CCONJ
dpc-1415	199	49	not	not	PART
dpc-1415	199	50	of	of	ADP
dpc-1415	199	51	immunotherapy	immunotherapy	NOUN
dpc-1415	199	52	)	)	PUNCT
dpc-1415	199	53	that	that	PRON
dpc-1415	199	54	will	will	AUX
dpc-1415	199	55	finally	finally	ADV
dpc-1415	199	56	benefit	benefit	VERB
dpc-1415	199	57	the	the	DET
dpc-1415	199	58	patient	patient	NOUN
dpc-1415	199	59	.	.	PUNCT
dpc-1415	200	1	in	in	ADP
dpc-1415	200	2	a	a	DET
dpc-1415	200	3	recent	recent	ADJ
dpc-1415	200	4	commentary	commentary	NOUN
dpc-1415	200	5	,	,	PUNCT
dpc-1415	200	6	the	the	DET
dpc-1415	200	7	authors	author	NOUN
dpc-1415	200	8	proposed	propose	VERB
dpc-1415	200	9	an	an	DET
dpc-1415	200	10	algorithm	algorithm	NOUN
dpc-1415	200	11	that	that	PRON
dpc-1415	200	12	could	could	AUX
dpc-1415	200	13	serve	serve	VERB
dpc-1415	200	14	as	as	ADP
dpc-1415	200	15	a	a	DET
dpc-1415	200	16	guide	guide	NOUN
dpc-1415	200	17	for	for	ADP
dpc-1415	200	18	treatment	treatment	NOUN
dpc-1415	200	19	decisions	decision	NOUN
dpc-1415	200	20	of	of	ADP
dpc-1415	200	21	both	both	DET
dpc-1415	200	22	dermatologists	dermatologist	NOUN
dpc-1415	200	23	and	and	CCONJ
dpc-1415	200	24	oncologists	oncologist	NOUN
dpc-1415	200	25	[	[	X
dpc-1415	200	26	67	67	NUM
dpc-1415	200	27	]	]	PUNCT
dpc-1415	200	28	.	.	PUNCT
dpc-1415	201	1	conclusions	conclusion	NOUN
dpc-1415	201	2	in	in	ADP
dpc-1415	201	3	conclusion	conclusion	NOUN
dpc-1415	201	4	,	,	PUNCT
dpc-1415	201	5	the	the	DET
dpc-1415	201	6	immune	immune	NOUN
dpc-1415	201	7	-	-	PUNCT
dpc-1415	201	8	based	base	VERB
dpc-1415	201	9	mechanism	mechanism	NOUN
dpc-1415	201	10	of	of	ADP
dpc-1415	201	11	cpis	cpis	PROPN
dpc-1415	201	12	results	result	NOUN
dpc-1415	201	13	in	in	ADP
dpc-1415	201	14	a	a	DET
dpc-1415	201	15	novel	novel	ADJ
dpc-1415	201	16	toxicity	toxicity	NOUN
dpc-1415	201	17	profile	profile	NOUN
dpc-1415	201	18	that	that	PRON
dpc-1415	201	19	differs	differ	VERB
dpc-1415	201	20	from	from	ADP
dpc-1415	201	21	the	the	DET
dpc-1415	201	22	one	one	NUM
dpc-1415	201	23	observed	observe	VERB
dpc-1415	201	24	by	by	ADP
dpc-1415	201	25	traditional	traditional	ADJ
dpc-1415	201	26	cytotoxic	cytotoxic	ADJ
dpc-1415	201	27	therapies	therapy	NOUN
dpc-1415	201	28	.	.	PUNCT
dpc-1415	202	1	overall	overall	ADV
dpc-1415	202	2	,	,	PUNCT
dpc-1415	202	3	the	the	DET
dpc-1415	202	4	cpi	cpi	PROPN
dpc-1415	202	5	profile	profile	NOUN
dpc-1415	202	6	is	be	AUX
dpc-1415	202	7	favorable	favorable	ADJ
dpc-1415	202	8	when	when	SCONJ
dpc-1415	202	9	compared	compare	VERB
dpc-1415	202	10	with	with	ADP
dpc-1415	202	11	standard	standard	ADJ
dpc-1415	202	12	anti	anti	ADJ
dpc-1415	202	13	-	-	ADJ
dpc-1415	202	14	cancer	cancer	ADJ
dpc-1415	202	15	agents	agent	NOUN
dpc-1415	202	16	,	,	PUNCT
dpc-1415	202	17	such	such	ADJ
dpc-1415	202	18	as	as	ADP
dpc-1415	202	19	chemotherapy	chemotherapy	NOUN
dpc-1415	202	20	and	and	CCONJ
dpc-1415	202	21	targeted	target	VERB
dpc-1415	202	22	therapy	therapy	NOUN
dpc-1415	202	23	.	.	PUNCT
dpc-1415	203	1	however	however	ADV
dpc-1415	203	2	,	,	PUNCT
dpc-1415	203	3	close	close	ADJ
dpc-1415	203	4	monitoring	monitoring	NOUN
dpc-1415	203	5	for	for	ADP
dpc-1415	203	6	symptoms	symptom	NOUN
dpc-1415	203	7	of	of	ADP
dpc-1415	203	8	 	 	SPACE
dpc-1415	203	9	iraes	iraes	NOUN
dpc-1415	203	10	when	when	SCONJ
dpc-1415	203	11	prescribing	prescribing	NOUN
dpc-1415	203	12	cpis	cpis	NOUN
dpc-1415	203	13	is	be	AUX
dpc-1415	203	14	mandatory	mandatory	ADJ
dpc-1415	203	15	.	.	PUNCT
dpc-1415	204	1	the	the	DET
dpc-1415	204	2	most	most	ADV
dpc-1415	204	3	common	common	ADJ
dpc-1415	204	4	cutaneous	cutaneous	ADJ
dpc-1415	204	5	aes	aes	NOUN
dpc-1415	204	6	include	include	VERB
dpc-1415	204	7	maculopapular	maculopapular	ADJ
dpc-1415	204	8	,	,	PUNCT
dpc-1415	204	9	lichenoid	lichenoid	PROPN
dpc-1415	204	10	,	,	PUNCT
dpc-1415	204	11	psoriasiform	psoriasiform	NOUN
dpc-1415	204	12	and	and	CCONJ
dpc-1415	204	13	eczematous	eczematous	ADJ
dpc-1415	204	14	skin	skin	NOUN
dpc-1415	204	15	rashes	rash	NOUN
dpc-1415	204	16	,	,	PUNCT
dpc-1415	204	17	pruritus	pruritus	NOUN
dpc-1415	204	18	,	,	PUNCT
dpc-1415	204	19	and	and	CCONJ
dpc-1415	204	20	pigmentary	pigmentary	ADJ
dpc-1415	204	21	disorders	disorder	NOUN
dpc-1415	204	22	.	.	PUNCT
dpc-1415	205	1	skin	skin	NOUN
dpc-1415	205	2	toxicities	toxicity	NOUN
dpc-1415	205	3	usually	usually	ADV
dpc-1415	205	4	occur	occur	VERB
dpc-1415	205	5	early	early	ADV
dpc-1415	205	6	in	in	ADP
dpc-1415	205	7	the	the	DET
dpc-1415	205	8	course	course	NOUN
dpc-1415	205	9	of	of	ADP
dpc-1415	205	10	treatment	treatment	NOUN
dpc-1415	205	11	,	,	PUNCT
dpc-1415	205	12	and	and	CCONJ
dpc-1415	205	13	in	in	ADP
dpc-1415	205	14	general	general	ADJ
dpc-1415	205	15	,	,	PUNCT
dpc-1415	205	16	tend	tend	VERB
dpc-1415	205	17	to	to	PART
dpc-1415	205	18	be	be	AUX
dpc-1415	205	19	less	less	ADV
dpc-1415	205	20	severe	severe	ADJ
dpc-1415	205	21	during	during	ADP
dpc-1415	205	22	therapy	therapy	NOUN
dpc-1415	205	23	with	with	ADP
dpc-1415	205	24	anti	anti	ADJ
dpc-1415	205	25	-	-	ADJ
dpc-1415	205	26	pd-1/	pd-1/	ADJ
dpc-1415	205	27	anti	anti	ADJ
dpc-1415	205	28	-	-	ADJ
dpc-1415	205	29	pd	pd	ADJ
dpc-1415	205	30	-	-	PUNCT
dpc-1415	205	31	l1	l1	PROPN
dpc-1415	205	32	agents	agent	NOUN
dpc-1415	205	33	compared	compare	VERB
dpc-1415	205	34	to	to	ADP
dpc-1415	205	35	ctla-4	ctla-4	NOUN
dpc-1415	205	36	inhibitors	inhibitor	NOUN
dpc-1415	205	37	or	or	CCONJ
dpc-1415	205	38	combinations	combination	NOUN
dpc-1415	205	39	.	.	PUNCT
dpc-1415	206	1	in	in	ADP
dpc-1415	206	2	all	all	DET
dpc-1415	206	3	cases	case	NOUN
dpc-1415	206	4	,	,	PUNCT
dpc-1415	206	5	early	early	ADJ
dpc-1415	206	6	recognition	recognition	NOUN
dpc-1415	206	7	of	of	ADP
dpc-1415	206	8	cutaneous	cutaneous	ADJ
dpc-1415	206	9	immunotherapy	immunotherapy	NOUN
dpc-1415	206	10	-	-	PUNCT
dpc-1415	206	11	driven	drive	VERB
dpc-1415	206	12	aes	aes	NOUN
dpc-1415	206	13	is	be	AUX
dpc-1415	206	14	of	of	ADP
dpc-1415	206	15	paramount	paramount	ADJ
dpc-1415	206	16	importance	importance	NOUN
dpc-1415	206	17	for	for	ADP
dpc-1415	206	18	the	the	DET
dpc-1415	206	19	patient	patient	NOUN
dpc-1415	206	20	,	,	PUNCT
dpc-1415	206	21	as	as	SCONJ
dpc-1415	206	22	it	it	PRON
dpc-1415	206	23	allows	allow	VERB
dpc-1415	206	24	adequate	adequate	ADJ
dpc-1415	206	25	control	control	NOUN
dpc-1415	206	26	of	of	ADP
dpc-1415	206	27	the	the	DET
dpc-1415	206	28	toxicity	toxicity	NOUN
dpc-1415	206	29	and	and	CCONJ
dpc-1415	206	30	increased	increase	VERB
dpc-1415	206	31	survival	survival	NOUN
dpc-1415	206	32	of	of	ADP
dpc-1415	206	33	immunotherapy	immunotherapy	NOUN
dpc-1415	206	34	.	.	PUNCT
dpc-1415	207	1	in	in	ADP
dpc-1415	207	2	this	this	DET
dpc-1415	207	3	context	context	NOUN
dpc-1415	207	4	,	,	PUNCT
dpc-1415	207	5	a	a	DET
dpc-1415	207	6	multidisciplinary	multidisciplinary	ADJ
dpc-1415	207	7	team	team	NOUN
dpc-1415	207	8	,	,	PUNCT
dpc-1415	207	9	including	include	VERB
dpc-1415	207	10	specialized	specialized	ADJ
dpc-1415	207	11	dermatologists	dermatologist	NOUN
dpc-1415	207	12	and	and	CCONJ
dpc-1415	207	13	oncologists	oncologist	NOUN
dpc-1415	207	14	,	,	PUNCT
dpc-1415	207	15	is	be	AUX
dpc-1415	207	16	desirable	desirable	ADJ
dpc-1415	207	17	for	for	ADP
dpc-1415	207	18	optimal	optimal	ADJ
dpc-1415	207	19	management	management	NOUN
dpc-1415	207	20	.	.	PUNCT
dpc-1415	208	1	finally	finally	ADV
dpc-1415	208	2	,	,	PUNCT
dpc-1415	208	3	large	large	ADJ
dpc-1415	208	4	-	-	PUNCT
dpc-1415	208	5	scale	scale	NOUN
dpc-1415	208	6	studies	study	NOUN
dpc-1415	208	7	will	will	AUX
dpc-1415	208	8	elucidate	elucidate	VERB
dpc-1415	208	9	certain	certain	ADJ
dpc-1415	208	10	aspects	aspect	NOUN
dpc-1415	208	11	in	in	ADP
dpc-1415	208	12	cutaneous	cutaneous	ADJ
dpc-1415	208	13	iraes	iraes	NOUN
dpc-1415	208	14	pathogenesis	pathogenesis	NOUN
dpc-1415	208	15	,	,	PUNCT
dpc-1415	208	16	prognostic	prognostic	ADJ
dpc-1415	208	17	factors	factor	NOUN
dpc-1415	208	18	for	for	ADP
dpc-1415	208	19	their	their	PRON
dpc-1415	208	20	development	development	NOUN
dpc-1415	208	21	,	,	PUNCT
dpc-1415	208	22	their	their	PRON
dpc-1415	208	23	prognostic	prognostic	ADJ
dpc-1415	208	24	value	value	NOUN
dpc-1415	208	25	for	for	ADP
dpc-1415	208	26	the	the	DET
dpc-1415	208	27	oncologic	oncologic	ADJ
dpc-1415	208	28	outcome	outcome	NOUN
dpc-1415	208	29	,	,	PUNCT
dpc-1415	208	30	and	and	CCONJ
dpc-1415	208	31	optimal	optimal	ADJ
dpc-1415	208	32	management	management	NOUN
dpc-1415	208	33	strategies	strategy	NOUN
dpc-1415	208	34	.	.	PUNCT
dpc-1415	209	1	furthermore	furthermore	ADV
dpc-1415	209	2	,	,	PUNCT
dpc-1415	209	3	the	the	DET
dpc-1415	209	4	impact	impact	NOUN
dpc-1415	209	5	of	of	ADP
dpc-1415	209	6	systematic	systematic	ADJ
dpc-1415	209	7	therapies	therapy	NOUN
dpc-1415	209	8	(	(	PUNCT
dpc-1415	209	9	eg	eg	NOUN
dpc-1415	209	10	,	,	PUNCT
dpc-1415	209	11	corticosteroids	corticosteroid	NOUN
dpc-1415	209	12	and	and	CCONJ
dpc-1415	209	13	immunosuppressive	immunosuppressive	ADJ
dpc-1415	209	14	drugs	drug	NOUN
dpc-1415	209	15	)	)	PUNCT
dpc-1415	209	16	that	that	PRON
dpc-1415	209	17	are	be	AUX
dpc-1415	209	18	usually	usually	ADV
dpc-1415	209	19	used	use	VERB
dpc-1415	209	20	to	to	PART
dpc-1415	209	21	treat	treat	VERB
dpc-1415	209	22	severe	severe	ADJ
dpc-1415	209	23	skin	skin	NOUN
dpc-1415	209	24	reactions	reaction	NOUN
dpc-1415	209	25	on	on	ADP
dpc-1415	209	26	the	the	DET
dpc-1415	209	27	anti	anti	ADJ
dpc-1415	209	28	-	-	ADJ
dpc-1415	209	29	tumor	tumor	ADJ
dpc-1415	209	30	effect	effect	NOUN
dpc-1415	209	31	of	of	ADP
dpc-1415	209	32	immunotherapy	immunotherapy	NOUN
dpc-1415	209	33	is	be	AUX
dpc-1415	209	34	largely	largely	ADV
dpc-1415	209	35	unknown	unknown	ADJ
dpc-1415	209	36	and	and	CCONJ
dpc-1415	209	37	requires	require	VERB
dpc-1415	209	38	further	further	ADJ
dpc-1415	209	39	research	research	NOUN
dpc-1415	209	40	.	.	PUNCT
dpc-1415	210	1	review	review	VERB
dpc-1415	210	2	|	|	ADV
dpc-1415	210	3	dermatol	dermatol	ADJ
dpc-1415	210	4	pract	pract	NOUN
dpc-1415	210	5	concept	concept	NOUN
dpc-1415	210	6	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	210	7	9	9	NUM
dpc-1415	210	8	references	reference	NOUN
dpc-1415	210	9	1	1	NUM
dpc-1415	210	10	.	.	PUNCT
dpc-1415	210	11	pennock	pennock	PROPN
dpc-1415	210	12	gk	gk	PROPN
dpc-1415	210	13	,	,	PUNCT
dpc-1415	210	14	chow	chow	PROPN
dpc-1415	210	15	lq	lq	PROPN
dpc-1415	210	16	.	.	PUNCT
dpc-1415	211	1	the	the	DET
dpc-1415	211	2	evolving	evolve	VERB
dpc-1415	211	3	role	role	NOUN
dpc-1415	211	4	of	of	ADP
dpc-1415	211	5	immune	immune	ADJ
dpc-1415	211	6	checkpoint	checkpoint	NOUN
dpc-1415	211	7	inhibitors	inhibitor	NOUN
dpc-1415	211	8	in	in	ADP
dpc-1415	211	9	cancer	cancer	NOUN
dpc-1415	211	10	treatment	treatment	NOUN
dpc-1415	211	11	.	.	PUNCT
dpc-1415	212	1	oncologist	oncologist	NOUN
dpc-1415	212	2	.	.	PUNCT
dpc-1415	213	1	2015;20(7):812	2015;20(7):812	NUM
dpc-1415	213	2	-	-	PUNCT
dpc-1415	213	3	822	822	NUM
dpc-1415	213	4	.	.	PUNCT
dpc-1415	214	1	doi	doi	NOUN
dpc-1415	214	2	:	:	PUNCT
dpc-1415	214	3	10.1634	10.1634	NUM
dpc-1415	214	4	/	/	SYM
dpc-1415	214	5	theoncologist.2014	theoncologist.2014	PROPN
dpc-1415	214	6	-	-	PUNCT
dpc-1415	214	7	0422	0422	NUM
dpc-1415	214	8	.	.	PUNCT
dpc-1415	215	1	pmid	pmid	NOUN
dpc-1415	215	2	:	:	PUNCT
dpc-1415	215	3	26069281	26069281	NUM
dpc-1415	215	4	.	.	PUNCT
dpc-1415	216	1	2	2	X
dpc-1415	216	2	.	.	X
dpc-1415	216	3	luke	luke	PROPN
dpc-1415	216	4	jj	jj	PROPN
dpc-1415	216	5	,	,	PUNCT
dpc-1415	216	6	ott	ott	PROPN
dpc-1415	216	7	pa	pa	PROPN
dpc-1415	216	8	.	.	PROPN
dpc-1415	216	9	pd-1	pd-1	ADP
dpc-1415	216	10	pathway	pathway	NOUN
dpc-1415	216	11	inhibitors	inhibitor	NOUN
dpc-1415	216	12	:	:	PUNCT
dpc-1415	216	13	the	the	DET
dpc-1415	216	14	next	next	ADJ
dpc-1415	216	15	generation	generation	NOUN
dpc-1415	216	16	of	of	ADP
dpc-1415	216	17	immunotherapy	immunotherapy	NOUN
dpc-1415	216	18	for	for	ADP
dpc-1415	216	19	advanced	advanced	ADJ
dpc-1415	216	20	melanoma	melanoma	NOUN
dpc-1415	216	21	.	.	PUNCT
dpc-1415	217	1	oncotarget	oncotarget	NOUN
dpc-1415	217	2	.	.	PUNCT
dpc-1415	218	1	2015;6(6):3479	2015;6(6):3479	NUM
dpc-1415	218	2	-	-	SYM
dpc-1415	218	3	3492	3492	NUM
dpc-1415	218	4	.	.	PUNCT
dpc-1415	219	1	doi	doi	NOUN
dpc-1415	219	2	:	:	PUNCT
dpc-1415	219	3	10.18632	10.18632	NUM
dpc-1415	219	4	/	/	SYM
dpc-1415	219	5	oncotarget.2980	oncotarget.2980	PROPN
dpc-1415	219	6	.	.	PUNCT
dpc-1415	219	7	pmid	pmid	NOUN
dpc-1415	219	8	:	:	PUNCT
dpc-1415	219	9	25682878	25682878	NUM
dpc-1415	219	10	.	.	PUNCT
dpc-1415	220	1	3	3	X
dpc-1415	220	2	.	.	PROPN
dpc-1415	220	3	naidoo	naidoo	PROPN
dpc-1415	220	4	j	j	PROPN
dpc-1415	220	5	,	,	PUNCT
dpc-1415	220	6	page	page	NOUN
dpc-1415	220	7	db	db	PROPN
dpc-1415	220	8	,	,	PUNCT
dpc-1415	220	9	li	li	PROPN
dpc-1415	220	10	bt	bt	PROPN
dpc-1415	220	11	,	,	PUNCT
dpc-1415	220	12	et	et	PROPN
dpc-1415	220	13	al	al	PROPN
dpc-1415	220	14	.	.	PUNCT
dpc-1415	221	1	toxicities	toxicity	NOUN
dpc-1415	221	2	of	of	ADP
dpc-1415	221	3	the	the	DET
dpc-1415	221	4	anti	anti	NOUN
dpc-1415	221	5	-	-	ADJ
dpc-1415	221	6	pd-1	pd-1	ADJ
dpc-1415	221	7	and	and	CCONJ
dpc-1415	221	8	anti	anti	ADJ
dpc-1415	221	9	-	-	ADJ
dpc-1415	221	10	pd	pd	ADJ
dpc-1415	221	11	-	-	ADJ
dpc-1415	221	12	l1	l1	PROPN
dpc-1415	221	13	immune	immune	ADJ
dpc-1415	221	14	checkpoint	checkpoint	NOUN
dpc-1415	221	15	antibodies	antibodie	VERB
dpc-1415	221	16	.	.	PUNCT
dpc-1415	222	1	ann	ann	PROPN
dpc-1415	222	2	oncol	oncol	PROPN
dpc-1415	222	3	.	.	PUNCT
dpc-1415	223	1	2015;26(12):2375	2015;26(12):2375	NUM
dpc-1415	223	2	-	-	PUNCT
dpc-1415	223	3	2391	2391	NUM
dpc-1415	223	4	.	.	PUNCT
dpc-1415	224	1	doi	doi	NOUN
dpc-1415	224	2	:	:	PUNCT
dpc-1415	224	3	10.1093	10.1093	NUM
dpc-1415	224	4	/	/	SYM
dpc-1415	224	5	annonc	annonc	VERB
dpc-1415	224	6	/	/	SYM
dpc-1415	224	7	mdv383	mdv383	PROPN
dpc-1415	224	8	.	.	PUNCT
dpc-1415	225	1	pmid	pmid	NOUN
dpc-1415	225	2	:	:	PUNCT
dpc-1415	225	3	26371282	26371282	NUM
dpc-1415	225	4	4	4	NUM
dpc-1415	225	5	.	.	PUNCT
dpc-1415	225	6	weber	weber	PROPN
dpc-1415	225	7	js	js	PROPN
dpc-1415	225	8	,	,	PUNCT
dpc-1415	225	9	kähler	kähler	PROPN
dpc-1415	225	10	kc	kc	PROPN
dpc-1415	225	11	,	,	PUNCT
dpc-1415	225	12	hauschild	hauschild	PROPN
dpc-1415	225	13	a.	a.	NOUN
dpc-1415	225	14	management	management	NOUN
dpc-1415	225	15	of	of	ADP
dpc-1415	225	16	immune	immune	NOUN
dpc-1415	225	17	-	-	PUNCT
dpc-1415	225	18	related	relate	VERB
dpc-1415	225	19	adverse	adverse	ADJ
dpc-1415	225	20	events	event	NOUN
dpc-1415	225	21	and	and	CCONJ
dpc-1415	225	22	kinetics	kinetic	NOUN
dpc-1415	225	23	of	of	ADP
dpc-1415	225	24	response	response	NOUN
dpc-1415	225	25	with	with	ADP
dpc-1415	225	26	ipilimumab	ipilimumab	NOUN
dpc-1415	225	27	.	.	PUNCT
dpc-1415	226	1	j	j	PROPN
dpc-1415	226	2	clin	clin	PROPN
dpc-1415	226	3	oncol	oncol	PROPN
dpc-1415	226	4	.	.	PUNCT
dpc-1415	227	1	2012;30(21):2691	2012;30(21):2691	NUM
dpc-1415	227	2	-	-	SYM
dpc-1415	227	3	2697	2697	NUM
dpc-1415	227	4	.	.	PUNCT
dpc-1415	228	1	doi	doi	NOUN
dpc-1415	228	2	:	:	PUNCT
dpc-1415	228	3	10.1200/	10.1200/	NUM
dpc-1415	228	4	jco.2012.41.6750	jco.2012.41.6750	PROPN
dpc-1415	228	5	.	.	PUNCT
dpc-1415	229	1	pmid	pmid	PROPN
dpc-1415	229	2	:	:	PUNCT
dpc-1415	229	3	22614989	22614989	NUM
dpc-1415	229	4	5	5	NUM
dpc-1415	229	5	.	.	PUNCT
dpc-1415	229	6	ernstoff	ernstoff	PROPN
dpc-1415	229	7	ms	ms	PROPN
dpc-1415	229	8	,	,	PUNCT
dpc-1415	229	9	gandhi	gandhi	PROPN
dpc-1415	229	10	s	s	PROPN
dpc-1415	229	11	,	,	PUNCT
dpc-1415	229	12	pandey	pandey	PROPN
dpc-1415	229	13	m	m	PROPN
dpc-1415	229	14	,	,	PUNCT
dpc-1415	229	15	et	et	PROPN
dpc-1415	229	16	al	al	PROPN
dpc-1415	230	1	.	.	PUNCT
dpc-1415	230	2	challenges	challenge	NOUN
dpc-1415	230	3	faced	face	VERB
dpc-1415	230	4	when	when	SCONJ
dpc-1415	230	5	identifying	identify	VERB
dpc-1415	230	6	patients	patient	NOUN
dpc-1415	230	7	for	for	ADP
dpc-1415	230	8	combination	combination	NOUN
dpc-1415	230	9	immunotherapy	immunotherapy	NOUN
dpc-1415	230	10	.	.	PUNCT
dpc-1415	231	1	future	future	ADJ
dpc-1415	231	2	oncol	oncol	ADJ
dpc-1415	231	3	.	.	PUNCT
dpc-1415	232	1	2017;13(18):1607–1618	2017;13(18):1607–1618	X
dpc-1415	232	2	.	.	PUNCT
dpc-1415	233	1	doi	doi	NOUN
dpc-1415	233	2	:	:	PUNCT
dpc-1415	233	3	10.2217	10.2217	NUM
dpc-1415	233	4	/	/	SYM
dpc-1415	233	5	fon-2017	fon-2017	NOUN
dpc-1415	233	6	-	-	PUNCT
dpc-1415	233	7	0218	0218	NUM
dpc-1415	233	8	.	.	PUNCT
dpc-1415	234	1	pmid	pmid	NOUN
dpc-1415	234	2	:	:	PUNCT
dpc-1415	234	3	28835114	28835114	NUM
dpc-1415	234	4	.	.	PUNCT
dpc-1415	235	1	6	6	NUM
dpc-1415	235	2	.	.	NUM
dpc-1415	235	3	gomes	gomes	PROPN
dpc-1415	235	4	n	n	CCONJ
dpc-1415	235	5	,	,	PUNCT
dpc-1415	235	6	sibaud	sibaud	NOUN
dpc-1415	235	7	v	v	NOUN
dpc-1415	235	8	,	,	PUNCT
dpc-1415	235	9	azevedo	azevedo	PROPN
dpc-1415	235	10	f	f	PROPN
dpc-1415	235	11	,	,	PUNCT
dpc-1415	235	12	magina	magina	PROPN
dpc-1415	235	13	s.	s.	PROPN
dpc-1415	236	1	[	[	X
dpc-1415	236	2	cutaneous	cutaneous	ADJ
dpc-1415	236	3	toxicity	toxicity	NOUN
dpc-1415	236	4	of	of	ADP
dpc-1415	236	5	immune	immune	ADJ
dpc-1415	236	6	checkpoint	checkpoint	NOUN
dpc-1415	236	7	inhibitors	inhibitor	NOUN
dpc-1415	236	8	:	:	PUNCT
dpc-1415	236	9	a	a	DET
dpc-1415	236	10	narrative	narrative	NOUN
dpc-1415	236	11	review	review	NOUN
dpc-1415	236	12	]	]	PUNCT
dpc-1415	236	13	.	.	PUNCT
dpc-1415	237	1	acta	acta	PROPN
dpc-1415	237	2	med	med	PROPN
dpc-1415	237	3	port	port	NOUN
dpc-1415	237	4	.	.	PUNCT
dpc-1415	238	1	2020;33(5):335	2020;33(5):335	NUM
dpc-1415	238	2	-	-	SYM
dpc-1415	238	3	343	343	NUM
dpc-1415	238	4	.	.	PUNCT
dpc-1415	239	1	doi	doi	NOUN
dpc-1415	239	2	:	:	PUNCT
dpc-1415	239	3	10.20344	10.20344	NUM
dpc-1415	239	4	/	/	SYM
dpc-1415	239	5	amp.12424	amp.12424	PROPN
dpc-1415	239	6	.	.	PUNCT
dpc-1415	239	7	pmid	pmid	NOUN
dpc-1415	239	8	:	:	PUNCT
dpc-1415	239	9	32416756	32416756	NUM
dpc-1415	239	10	.	.	PUNCT
dpc-1415	240	1	7	7	X
dpc-1415	240	2	.	.	X
dpc-1415	240	3	brahmer	brahmer	PROPN
dpc-1415	240	4	jr	jr	PROPN
dpc-1415	240	5	,	,	PUNCT
dpc-1415	240	6	lacchetti	lacchetti	VERB
dpc-1415	240	7	c	c	X
dpc-1415	240	8	,	,	PUNCT
dpc-1415	240	9	schneider	schneider	NOUN
dpc-1415	240	10	bj	bj	PROPN
dpc-1415	240	11	,	,	PUNCT
dpc-1415	240	12	et	et	PROPN
dpc-1415	240	13	al	al	PROPN
dpc-1415	240	14	.	.	PUNCT
dpc-1415	240	15	management	management	NOUN
dpc-1415	240	16	of	of	ADP
dpc-1415	240	17	immune	immune	NOUN
dpc-1415	240	18	-	-	PUNCT
dpc-1415	240	19	related	relate	VERB
dpc-1415	240	20	adverse	adverse	ADJ
dpc-1415	240	21	events	event	NOUN
dpc-1415	240	22	in	in	ADP
dpc-1415	240	23	patients	patient	NOUN
dpc-1415	240	24	treated	treat	VERB
dpc-1415	240	25	with	with	ADP
dpc-1415	240	26	immune	immune	ADJ
dpc-1415	240	27	checkpoint	checkpoint	NOUN
dpc-1415	240	28	inhibitor	inhibitor	NOUN
dpc-1415	240	29	therapy	therapy	NOUN
dpc-1415	240	30	:	:	PUNCT
dpc-1415	240	31	american	american	ADJ
dpc-1415	240	32	society	society	NOUN
dpc-1415	240	33	of	of	ADP
dpc-1415	240	34	clinical	clinical	ADJ
dpc-1415	240	35	oncology	oncology	NOUN
dpc-1415	240	36	clinical	clinical	ADJ
dpc-1415	240	37	practice	practice	NOUN
dpc-1415	240	38	guideline	guideline	NOUN
dpc-1415	240	39	.	.	PUNCT
dpc-1415	241	1	j	j	PROPN
dpc-1415	241	2	clin	clin	PROPN
dpc-1415	241	3	oncol	oncol	PROPN
dpc-1415	241	4	.	.	PUNCT
dpc-1415	242	1	2018;36(17):1714	2018;36(17):1714	PROPN
dpc-1415	242	2	-	-	PROPN
dpc-1415	242	3	1768	1768	NUM
dpc-1415	242	4	.	.	PUNCT
dpc-1415	243	1	doi	doi	NOUN
dpc-1415	243	2	:	:	PUNCT
dpc-1415	243	3	10.1200	10.1200	NUM
dpc-1415	243	4	/	/	SYM
dpc-1415	243	5	jco.2017.77.6385	jco.2017.77.6385	PROPN
dpc-1415	243	6	.	.	PUNCT
dpc-1415	244	1	pmid	pmid	NOUN
dpc-1415	244	2	:	:	PUNCT
dpc-1415	244	3	29442540	29442540	NUM
dpc-1415	244	4	.	.	PUNCT
dpc-1415	245	1	8	8	X
dpc-1415	245	2	.	.	X
dpc-1415	245	3	thompson	thompson	PROPN
dpc-1415	245	4	ja	ja	PROPN
dpc-1415	245	5	,	,	PUNCT
dpc-1415	245	6	schneider	schneider	PROPN
dpc-1415	245	7	bj	bj	PROPN
dpc-1415	245	8	,	,	PUNCT
dpc-1415	245	9	brahmer	brahmer	PROPN
dpc-1415	245	10	j	j	PROPN
dpc-1415	245	11	,	,	PUNCT
dpc-1415	245	12	et	et	PROPN
dpc-1415	245	13	al	al	PROPN
dpc-1415	245	14	.	.	PROPN
dpc-1415	246	1	nccn	nccn	PROPN
dpc-1415	246	2	guidelines	guideline	NOUN
dpc-1415	246	3	insights	insight	NOUN
dpc-1415	246	4	:	:	PUNCT
dpc-1415	246	5	management	management	NOUN
dpc-1415	246	6	of	of	ADP
dpc-1415	246	7	immunotherapy	immunotherapy	NOUN
dpc-1415	246	8	-	-	PUNCT
dpc-1415	246	9	related	relate	VERB
dpc-1415	246	10	toxicities	toxicity	NOUN
dpc-1415	246	11	,	,	PUNCT
dpc-1415	246	12	version	version	NOUN
dpc-1415	246	13	1.2020	1.2020	NUM
dpc-1415	246	14	.	.	PUNCT
dpc-1415	247	1	j	j	PROPN
dpc-1415	247	2	natl	natl	PROPN
dpc-1415	247	3	compr	compr	PROPN
dpc-1415	247	4	canc	canc	PROPN
dpc-1415	247	5	netw	netw	PROPN
dpc-1415	247	6	.	.	PUNCT
dpc-1415	248	1	2020;18(3):230–241	2020;18(3):230–241	X
dpc-1415	248	2	.	.	PUNCT
dpc-1415	249	1	doi	doi	NOUN
dpc-1415	249	2	:	:	PUNCT
dpc-1415	249	3	10.6004	10.6004	NUM
dpc-1415	249	4	/	/	SYM
dpc-1415	249	5	jnccn.2020.0012	jnccn.2020.0012	PROPN
dpc-1415	249	6	.	.	PUNCT
dpc-1415	250	1	pmid	pmid	NOUN
dpc-1415	250	2	:	:	PUNCT
dpc-1415	250	3	32135517	32135517	NUM
dpc-1415	250	4	.	.	PUNCT
dpc-1415	251	1	9	9	X
dpc-1415	251	2	.	.	X
dpc-1415	251	3	lage	lage	PROPN
dpc-1415	251	4	d	d	PROPN
dpc-1415	251	5	,	,	PUNCT
dpc-1415	251	6	juliano	juliano	PROPN
dpc-1415	251	7	pb	pb	PROPN
dpc-1415	251	8	,	,	PUNCT
dpc-1415	251	9	metze	metze	PROPN
dpc-1415	251	10	k	k	PROPN
dpc-1415	251	11	,	,	PUNCT
dpc-1415	251	12	et	et	PROPN
dpc-1415	251	13	al	al	PROPN
dpc-1415	251	14	.	.	PUNCT
dpc-1415	252	1	lichen	lichen	PROPN
dpc-1415	252	2	planus	planus	PROPN
dpc-1415	252	3	and	and	CCONJ
dpc-1415	252	4	lichenoid	lichenoid	NOUN
dpc-1415	252	5	drug	drug	NOUN
dpc-1415	252	6	-	-	PUNCT
dpc-1415	252	7	induced	induce	VERB
dpc-1415	252	8	eruption	eruption	NOUN
dpc-1415	252	9	:	:	PUNCT
dpc-1415	252	10	a	a	DET
dpc-1415	252	11	histological	histological	ADJ
dpc-1415	252	12	and	and	CCONJ
dpc-1415	252	13	immunohistochemical	immunohistochemical	ADJ
dpc-1415	252	14	study	study	NOUN
dpc-1415	252	15	.	.	PUNCT
dpc-1415	253	1	int	int	NOUN
dpc-1415	253	2	j	j	PROPN
dpc-1415	253	3	dermatol	dermatol	NOUN
dpc-1415	253	4	.	.	PUNCT
dpc-1415	254	1	2012;51(10):1199	2012;51(10):1199	NUM
dpc-1415	254	2	-	-	SYM
dpc-1415	254	3	1205	1205	NUM
dpc-1415	254	4	.	.	PUNCT
dpc-1415	255	1	doi	doi	NOUN
dpc-1415	255	2	:	:	PUNCT
dpc-1415	255	3	10.1111	10.1111	NUM
dpc-1415	255	4	/	/	SYM
dpc-1415	255	5	j.1365	j.1365	NOUN
dpc-1415	255	6	-	-	PUNCT
dpc-1415	255	7	4632.2011.05113.x	4632.2011.05113.x	NUM
dpc-1415	255	8	.	.	PUNCT
dpc-1415	256	1	pmid	pmid	NOUN
dpc-1415	256	2	:	:	PUNCT
dpc-1415	256	3	22416968	22416968	NUM
dpc-1415	256	4	.	.	PUNCT
dpc-1415	257	1	10	10	NUM
dpc-1415	257	2	.	.	PUNCT
dpc-1415	257	3	tetzlaff	tetzlaff	PROPN
dpc-1415	257	4	mt	mt	PROPN
dpc-1415	257	5	,	,	PUNCT
dpc-1415	257	6	nagarajan	nagarajan	NOUN
dpc-1415	257	7	p	p	PROPN
dpc-1415	257	8	,	,	PUNCT
dpc-1415	257	9	chon	chon	PROPN
dpc-1415	257	10	s	s	PROPN
dpc-1415	257	11	,	,	PUNCT
dpc-1415	257	12	et	et	PROPN
dpc-1415	257	13	al	al	PROPN
dpc-1415	257	14	.	.	PUNCT
dpc-1415	258	1	lichenoid	lichenoid	PROPN
dpc-1415	258	2	dermatologic	dermatologic	ADJ
dpc-1415	258	3	toxicity	toxicity	NOUN
dpc-1415	258	4	from	from	ADP
dpc-1415	258	5	immune	immune	ADJ
dpc-1415	258	6	checkpoint	checkpoint	NOUN
dpc-1415	258	7	blockade	blockade	NOUN
dpc-1415	258	8	therapy	therapy	NOUN
dpc-1415	258	9	:	:	PUNCT
dpc-1415	258	10	a	a	DET
dpc-1415	258	11	detailed	detailed	ADJ
dpc-1415	258	12	examination	examination	NOUN
dpc-1415	258	13	of	of	ADP
dpc-1415	258	14	the	the	DET
dpc-1415	258	15	clinicopathologic	clinicopathologic	ADJ
dpc-1415	258	16	features	feature	NOUN
dpc-1415	258	17	.	.	PUNCT
dpc-1415	259	1	am	be	AUX
dpc-1415	259	2	j	j	PROPN
dpc-1415	259	3	dermatopathol	dermatopathol	NOUN
dpc-1415	259	4	.	.	PUNCT
dpc-1415	260	1	2017;39(2):121	2017;39(2):121	NUM
dpc-1415	260	2	-	-	SYM
dpc-1415	260	3	129	129	NUM
dpc-1415	260	4	.	.	PUNCT
dpc-1415	261	1	doi	doi	NOUN
dpc-1415	261	2	:	:	PUNCT
dpc-1415	261	3	10.1097	10.1097	NUM
dpc-1415	261	4	/	/	SYM
dpc-1415	261	5	dad.0000000000000688	dad.0000000000000688	NOUN
dpc-1415	261	6	.	.	PUNCT
dpc-1415	262	1	pmid	pmid	NOUN
dpc-1415	262	2	:	:	PUNCT
dpc-1415	262	3	28134729	28134729	NUM
dpc-1415	262	4	.	.	PUNCT
dpc-1415	263	1	11	11	NUM
dpc-1415	263	2	.	.	PUNCT
dpc-1415	263	3	soumelis	soumeli	NOUN
dpc-1415	263	4	v.	v.	ADP
dpc-1415	263	5	molecular	molecular	ADJ
dpc-1415	263	6	and	and	CCONJ
dpc-1415	263	7	cellular	cellular	ADJ
dpc-1415	263	8	discoveries	discovery	NOUN
dpc-1415	263	9	in	in	ADP
dpc-1415	263	10	inflammatory	inflammatory	ADJ
dpc-1415	263	11	dermatoses	dermatosis	NOUN
dpc-1415	263	12	.	.	PUNCT
dpc-1415	264	1	j	j	PROPN
dpc-1415	264	2	eur	eur	PROPN
dpc-1415	264	3	acad	acad	PROPN
dpc-1415	264	4	dermatol	dermatol	NOUN
dpc-1415	264	5	venereol	venereol	NOUN
dpc-1415	264	6	.	.	PUNCT
dpc-1415	265	1	2017;31suppl	2017;31suppl	PROPN
dpc-1415	265	2	5:3–7	5:3–7	NUM
dpc-1415	265	3	.	.	PUNCT
dpc-1415	266	1	doi	doi	NOUN
dpc-1415	266	2	:	:	PUNCT
dpc-1415	266	3	10.1111	10.1111	NUM
dpc-1415	266	4	/	/	SYM
dpc-1415	266	5	jdv.14373	jdv.14373	PROPN
dpc-1415	266	6	.	.	PUNCT
dpc-1415	267	1	pmid	pmid	NOUN
dpc-1415	267	2	:	:	PUNCT
dpc-1415	267	3	28805939	28805939	NUM
dpc-1415	267	4	.	.	PUNCT
dpc-1415	268	1	12	12	NUM
dpc-1415	268	2	.	.	PUNCT
dpc-1415	269	1	eyerich	eyerich	PROPN
dpc-1415	269	2	s	s	PROPN
dpc-1415	269	3	,	,	PUNCT
dpc-1415	269	4	onken	onken	VERB
dpc-1415	269	5	at	at	ADP
dpc-1415	269	6	,	,	PUNCT
dpc-1415	269	7	weidinger	weidinger	NOUN
dpc-1415	269	8	s	s	PROPN
dpc-1415	269	9	,	,	PUNCT
dpc-1415	269	10	et	et	PROPN
dpc-1415	269	11	al	al	PROPN
dpc-1415	269	12	.	.	PROPN
dpc-1415	270	1	mutual	mutual	ADJ
dpc-1415	270	2	antagonism	antagonism	NOUN
dpc-1415	270	3	of	of	ADP
dpc-1415	270	4	t	t	NOUN
dpc-1415	270	5	cells	cell	NOUN
dpc-1415	270	6	causing	cause	VERB
dpc-1415	270	7	psoriasis	psoriasis	NOUN
dpc-1415	270	8	and	and	CCONJ
dpc-1415	270	9	atopic	atopic	NOUN
dpc-1415	270	10	eczema	eczema	NOUN
dpc-1415	270	11	.	.	PUNCT
dpc-1415	271	1	n	n	PRON
dpc-1415	271	2	engl	engl	PROPN
dpc-1415	271	3	j	j	PROPN
dpc-1415	271	4	med	med	PROPN
dpc-1415	271	5	.	.	PUNCT
dpc-1415	272	1	2011;365(3):231–238	2011;365(3):231–238	NUM
dpc-1415	272	2	.	.	PUNCT
dpc-1415	272	3	doi	doi	NOUN
dpc-1415	272	4	:	:	PUNCT
dpc-1415	272	5	10.1056	10.1056	NUM
dpc-1415	272	6	/	/	SYM
dpc-1415	272	7	nejmoa1104200	nejmoa1104200	PROPN
dpc-1415	272	8	.	.	PUNCT
dpc-1415	273	1	pmid	pmid	NOUN
dpc-1415	273	2	:	:	PUNCT
dpc-1415	273	3	21774711	21774711	NUM
dpc-1415	273	4	.	.	PUNCT
dpc-1415	274	1	13	13	NUM
dpc-1415	274	2	.	.	PUNCT
dpc-1415	275	1	mahil	mahil	NOUN
dpc-1415	275	2	sk	sk	PROPN
dpc-1415	275	3	,	,	PUNCT
dpc-1415	275	4	capon	capon	NOUN
dpc-1415	275	5	f	f	PROPN
dpc-1415	275	6	,	,	PUNCT
dpc-1415	275	7	barker	barker	PROPN
dpc-1415	276	1	jn	jn	PROPN
dpc-1415	276	2	.	.	PROPN
dpc-1415	276	3	update	update	NOUN
dpc-1415	276	4	on	on	ADP
dpc-1415	276	5	psoriasis	psoriasis	NOUN
dpc-1415	276	6	immunopathogenesis	immunopathogenesis	NOUN
dpc-1415	276	7	and	and	CCONJ
dpc-1415	276	8	targeted	target	VERB
dpc-1415	276	9	immunotherapy	immunotherapy	NOUN
dpc-1415	276	10	.	.	PUNCT
dpc-1415	277	1	semin	semin	PROPN
dpc-1415	277	2	immunopathol	immunopathol	PROPN
dpc-1415	277	3	.	.	PUNCT
dpc-1415	278	1	2016;38(1):11–27	2016;38(1):11–27	X
dpc-1415	278	2	.	.	PUNCT
dpc-1415	279	1	doi	doi	NOUN
dpc-1415	279	2	:	:	PUNCT
dpc-1415	279	3	10.1007	10.1007	NUM
dpc-1415	279	4	/	/	SYM
dpc-1415	279	5	s00281	s00281	NOUN
dpc-1415	279	6	-	-	PUNCT
dpc-1415	279	7	015	015	NUM
dpc-1415	279	8	-	-	PUNCT
dpc-1415	279	9	0539	0539	NUM
dpc-1415	279	10	-	-	SYM
dpc-1415	279	11	8	8	NUM
dpc-1415	279	12	.	.	PUNCT
dpc-1415	280	1	pmid	pmid	NOUN
dpc-1415	280	2	:	:	PUNCT
dpc-1415	280	3	26573299	26573299	NUM
dpc-1415	280	4	.	.	PUNCT
dpc-1415	281	1	14	14	NUM
dpc-1415	281	2	.	.	PUNCT
dpc-1415	282	1	matsumura	matsumura	PROPN
dpc-1415	282	2	n	n	CCONJ
dpc-1415	282	3	,	,	PUNCT
dpc-1415	282	4	ohtsuka	ohtsuka	PROPN
dpc-1415	282	5	m	m	PROPN
dpc-1415	282	6	,	,	PUNCT
dpc-1415	282	7	kikuchi	kikuchi	PROPN
dpc-1415	282	8	n	n	CCONJ
dpc-1415	282	9	,	,	PUNCT
dpc-1415	282	10	et	et	PROPN
dpc-1415	282	11	al	al	PROPN
dpc-1415	282	12	.	.	PUNCT
dpc-1415	282	13	exacerbation	exacerbation	NOUN
dpc-1415	282	14	of	of	ADP
dpc-1415	282	15	psoriasis	psoriasis	NOUN
dpc-1415	282	16	during	during	ADP
dpc-1415	282	17	nivolumab	nivolumab	NOUN
dpc-1415	282	18	therapy	therapy	NOUN
dpc-1415	282	19	for	for	ADP
dpc-1415	282	20	metastatic	metastatic	ADJ
dpc-1415	282	21	melanoma	melanoma	NOUN
dpc-1415	282	22	.	.	PUNCT
dpc-1415	283	1	acta	acta	PROPN
dpc-1415	283	2	derm	derm	PROPN
dpc-1415	283	3	venereol	venereol	NOUN
dpc-1415	283	4	.	.	PUNCT
dpc-1415	284	1	2016;96(2):259–260	2016;96(2):259–260	X
dpc-1415	284	2	.	.	PUNCT
dpc-1415	284	3	doi	doi	NOUN
dpc-1415	284	4	:	:	PUNCT
dpc-1415	284	5	10.2340/000155552212	10.2340/000155552212	NUM
dpc-1415	284	6	.	.	PUNCT
dpc-1415	285	1	pmid	pmid	NOUN
dpc-1415	285	2	:	:	PUNCT
dpc-1415	285	3	26270860	26270860	NUM
dpc-1415	285	4	.	.	PUNCT
dpc-1415	286	1	15	15	NUM
dpc-1415	286	2	.	.	PUNCT
dpc-1415	287	1	fattore	fattore	NOUN
dpc-1415	287	2	d	d	PROPN
dpc-1415	287	3	,	,	PUNCT
dpc-1415	287	4	annunziata	annunziata	PROPN
dpc-1415	287	5	mc	mc	PROPN
dpc-1415	287	6	,	,	PUNCT
dpc-1415	287	7	panariello	panariello	PROPN
dpc-1415	287	8	l	l	PROPN
dpc-1415	287	9	,	,	PUNCT
dpc-1415	287	10	et	et	PROPN
dpc-1415	287	11	al	al	PROPN
dpc-1415	287	12	.	.	PROPN
dpc-1415	288	1	successful	successful	ADJ
dpc-1415	288	2	treatment	treatment	NOUN
dpc-1415	288	3	of	of	ADP
dpc-1415	288	4	psoriasis	psoriasis	NOUN
dpc-1415	288	5	induced	induce	VERB
dpc-1415	288	6	by	by	ADP
dpc-1415	288	7	immune	immune	ADJ
dpc-1415	288	8	checkpoint	checkpoint	NOUN
dpc-1415	288	9	inhibitor	inhibitor	NOUN
dpc-1415	288	10	with	with	ADP
dpc-1415	288	11	apremilast	apremilast	ADJ
dpc-1415	288	12	.	.	PUNCT
dpc-1415	289	1	eur	eur	PROPN
dpc-1415	289	2	j	j	PROPN
dpc-1415	289	3	cancer	cancer	NOUN
dpc-1415	289	4	.	.	PUNCT
dpc-1415	290	1	2019;110:107–109	2019;110:107–109	NUM
dpc-1415	290	2	.	.	PUNCT
dpc-1415	291	1	doi	doi	NOUN
dpc-1415	291	2	:	:	PUNCT
dpc-1415	291	3	10.1016	10.1016	NUM
dpc-1415	291	4	/	/	SYM
dpc-1415	291	5	j.	j.	PROPN
dpc-1415	291	6	ejca.2019.01.010	ejca.2019.01.010	PROPN
dpc-1415	291	7	.	.	PUNCT
dpc-1415	292	1	pmid	pmid	NOUN
dpc-1415	292	2	:	:	PUNCT
dpc-1415	292	3	30785013	30785013	NUM
dpc-1415	292	4	.	.	PUNCT
dpc-1415	293	1	16	16	NUM
dpc-1415	293	2	.	.	PUNCT
dpc-1415	294	1	bonigen	bonigen	PROPN
dpc-1415	294	2	j	j	PROPN
dpc-1415	294	3	,	,	PUNCT
dpc-1415	294	4	raynaud	raynaud	PROPN
dpc-1415	294	5	-	-	PUNCT
dpc-1415	294	6	donzel	donzel	PROPN
dpc-1415	294	7	c	c	PROPN
dpc-1415	294	8	,	,	PUNCT
dpc-1415	294	9	hureaux	hureaux	PROPN
dpc-1415	294	10	j	j	PROPN
dpc-1415	294	11	,	,	PUNCT
dpc-1415	294	12	et	et	PROPN
dpc-1415	294	13	al	al	PROPN
dpc-1415	294	14	.	.	PUNCT
dpc-1415	295	1	anti	anti	ADJ
dpc-1415	295	2	-	-	ADJ
dpc-1415	295	3	pd1	pd1	ADJ
dpc-1415	295	4	induced	induce	VERB
dpc-1415	295	5	psoriasis	psoriasis	NOUN
dpc-1415	295	6	:	:	PUNCT
dpc-1415	295	7	a	a	DET
dpc-1415	295	8	study	study	NOUN
dpc-1415	295	9	of	of	ADP
dpc-1415	295	10	21	21	NUM
dpc-1415	295	11	patients	patient	NOUN
dpc-1415	295	12	.	.	PUNCT
dpc-1415	296	1	j	j	PROPN
dpc-1415	296	2	eur	eur	PROPN
dpc-1415	296	3	acad	acad	PROPN
dpc-1415	296	4	dermatol	dermatol	NOUN
dpc-1415	296	5	venereol	venereol	NOUN
dpc-1415	296	6	.	.	PUNCT
dpc-1415	297	1	2017;31(5):e254	2017;31(5):e254	NUM
dpc-1415	297	2	–	–	PUNCT
dpc-1415	297	3	e257	e257	PROPN
dpc-1415	297	4	.	.	PUNCT
dpc-1415	297	5	doi	doi	NOUN
dpc-1415	297	6	:	:	PUNCT
dpc-1415	297	7	10.1111	10.1111	NUM
dpc-1415	297	8	/	/	SYM
dpc-1415	297	9	jdv.14011	jdv.14011	PROPN
dpc-1415	297	10	.	.	PUNCT
dpc-1415	298	1	pmid	pmid	NOUN
dpc-1415	298	2	:	:	PUNCT
dpc-1415	298	3	27739129	27739129	NUM
dpc-1415	298	4	.	.	PUNCT
dpc-1415	299	1	17	17	NUM
dpc-1415	299	2	.	.	PUNCT
dpc-1415	300	1	phadke	phadke	ADJ
dpc-1415	300	2	sd	sd	PROPN
dpc-1415	300	3	,	,	PUNCT
dpc-1415	300	4	ghabour	ghabour	PROPN
dpc-1415	300	5	r	r	PROPN
dpc-1415	300	6	,	,	PUNCT
dpc-1415	300	7	swick	swick	PROPN
dpc-1415	300	8	bl	bl	PROPN
dpc-1415	300	9	,	,	PUNCT
dpc-1415	300	10	et	et	PROPN
dpc-1415	300	11	al	al	PROPN
dpc-1415	300	12	.	.	PROPN
dpc-1415	300	13	pembrolizumab	pembrolizumab	NOUN
dpc-1415	300	14	therapy	therapy	NOUN
dpc-1415	300	15	triggering	trigger	VERB
dpc-1415	300	16	an	an	DET
dpc-1415	300	17	exacerbation	exacerbation	NOUN
dpc-1415	300	18	of	of	ADP
dpc-1415	300	19	preexisting	preexist	VERB
dpc-1415	300	20	autoimmune	autoimmune	ADJ
dpc-1415	300	21	disease	disease	NOUN
dpc-1415	300	22	:	:	PUNCT
dpc-1415	300	23	a	a	DET
dpc-1415	300	24	report	report	NOUN
dpc-1415	300	25	of	of	ADP
dpc-1415	300	26	2	2	NUM
dpc-1415	300	27	patient	patient	ADJ
dpc-1415	300	28	cases	case	NOUN
dpc-1415	300	29	.	.	PUNCT
dpc-1415	301	1	j	j	PROPN
dpc-1415	301	2	investig	investig	NOUN
dpc-1415	301	3	med	med	ADJ
dpc-1415	301	4	high	high	ADJ
dpc-1415	301	5	impact	impact	NOUN
dpc-1415	301	6	case	case	NOUN
dpc-1415	301	7	rep	rep	PROPN
dpc-1415	301	8	.	.	PROPN
dpc-1415	301	9	2016;4(4):2324709616674316	2016;4(4):2324709616674316	NUM
dpc-1415	301	10	.	.	PUNCT
dpc-1415	302	1	doi	doi	NOUN
dpc-1415	302	2	:	:	PUNCT
dpc-1415	302	3	10.1177/2324709616674316	10.1177/2324709616674316	NUM
dpc-1415	302	4	.	.	PUNCT
dpc-1415	302	5	pmid	pmid	PROPN
dpc-1415	302	6	:	:	PUNCT
dpc-1415	302	7	27826593	27826593	NUM
dpc-1415	302	8	.	.	PUNCT
dpc-1415	303	1	18	18	NUM
dpc-1415	303	2	.	.	PUNCT
dpc-1415	304	1	menzies	menzies	PROPN
dpc-1415	304	2	am	be	AUX
dpc-1415	304	3	,	,	PUNCT
dpc-1415	304	4	johnson	johnson	PROPN
dpc-1415	304	5	db	db	PROPN
dpc-1415	304	6	,	,	PUNCT
dpc-1415	304	7	ramanujam	ramanujam	VERB
dpc-1415	304	8	s	s	PROPN
dpc-1415	304	9	,	,	PUNCT
dpc-1415	304	10	et	et	PROPN
dpc-1415	304	11	al	al	PROPN
dpc-1415	304	12	.	.	PUNCT
dpc-1415	305	1	anti	anti	ADJ
dpc-1415	305	2	-	-	ADJ
dpc-1415	305	3	pd-1	pd-1	ADJ
dpc-1415	305	4	therapy	therapy	NOUN
dpc-1415	305	5	in	in	ADP
dpc-1415	305	6	patients	patient	NOUN
dpc-1415	305	7	with	with	ADP
dpc-1415	305	8	advanced	advanced	ADJ
dpc-1415	305	9	melanoma	melanoma	NOUN
dpc-1415	305	10	and	and	CCONJ
dpc-1415	305	11	preexisting	preexist	VERB
dpc-1415	305	12	autoimmune	autoimmune	ADJ
dpc-1415	305	13	disorders	disorder	NOUN
dpc-1415	305	14	or	or	CCONJ
dpc-1415	305	15	major	major	ADJ
dpc-1415	305	16	toxicity	toxicity	NOUN
dpc-1415	305	17	with	with	ADP
dpc-1415	305	18	ipilimumab	ipilimumab	NOUN
dpc-1415	305	19	.	.	PUNCT
dpc-1415	306	1	ann	ann	PROPN
dpc-1415	306	2	oncol	oncol	PROPN
dpc-1415	306	3	.	.	PUNCT
dpc-1415	307	1	2017;28(2):368	2017;28(2):368	NUM
dpc-1415	307	2	-	-	SYM
dpc-1415	307	3	376	376	NUM
dpc-1415	307	4	.	.	PUNCT
dpc-1415	308	1	doi	doi	NOUN
dpc-1415	308	2	:	:	PUNCT
dpc-1415	308	3	10.1093	10.1093	NUM
dpc-1415	308	4	/	/	SYM
dpc-1415	308	5	annonc	annonc	ADJ
dpc-1415	308	6	/	/	SYM
dpc-1415	308	7	mdw443	mdw443	NOUN
dpc-1415	308	8	.	.	PUNCT
dpc-1415	309	1	pmid	pmid	NOUN
dpc-1415	309	2	:	:	PUNCT
dpc-1415	309	3	27687304	27687304	NUM
dpc-1415	309	4	.	.	PUNCT
dpc-1415	310	1	19	19	NUM
dpc-1415	310	2	.	.	X
dpc-1415	311	1	ravi	ravi	PROPN
dpc-1415	311	2	v	v	PROPN
dpc-1415	311	3	,	,	PUNCT
dpc-1415	311	4	maloney	maloney	PROPN
dpc-1415	311	5	nj	nj	PROPN
dpc-1415	311	6	,	,	PUNCT
dpc-1415	311	7	worswick	worswick	PROPN
dpc-1415	311	8	s.	s.	PROPN
dpc-1415	311	9	neutrophilic	neutrophilic	PROPN
dpc-1415	311	10	dermatoses	dermatose	VERB
dpc-1415	311	11	as	as	ADP
dpc-1415	311	12	adverse	adverse	ADJ
dpc-1415	311	13	effects	effect	NOUN
dpc-1415	311	14	of	of	ADP
dpc-1415	311	15	checkpoint	checkpoint	NOUN
dpc-1415	311	16	inhibitors	inhibitor	NOUN
dpc-1415	311	17	:	:	PUNCT
dpc-1415	311	18	a	a	DET
dpc-1415	311	19	review	review	NOUN
dpc-1415	311	20	.	.	PUNCT
dpc-1415	312	1	dermatol	dermatol	NOUN
dpc-1415	312	2	ther	ther	ADV
dpc-1415	312	3	.	.	PUNCT
dpc-1415	313	1	2019;32(5):e13074	2019;32(5):e13074	NUM
dpc-1415	313	2	.	.	PUNCT
dpc-1415	314	1	doi	doi	NOUN
dpc-1415	314	2	:	:	PUNCT
dpc-1415	314	3	10.1111	10.1111	NUM
dpc-1415	314	4	/	/	SYM
dpc-1415	314	5	dth.13074	dth.13074	PROPN
dpc-1415	314	6	.	.	PUNCT
dpc-1415	315	1	pmid	pmid	NOUN
dpc-1415	315	2	:	:	PUNCT
dpc-1415	315	3	31444856	31444856	NUM
dpc-1415	315	4	.	.	PUNCT
dpc-1415	316	1	20	20	NUM
dpc-1415	316	2	.	.	PUNCT
dpc-1415	317	1	pintova	pintova	PROPN
dpc-1415	317	2	s	s	PROPN
dpc-1415	317	3	,	,	PUNCT
dpc-1415	317	4	sidhu	sidhu	PROPN
dpc-1415	317	5	h	h	PROPN
dpc-1415	317	6	,	,	PUNCT
dpc-1415	317	7	friedlander	friedlander	PROPN
dpc-1415	317	8	pa	pa	PROPN
dpc-1415	317	9	,	,	PUNCT
dpc-1415	317	10	et	et	PROPN
dpc-1415	317	11	al	al	PROPN
dpc-1415	317	12	.	.	PROPN
dpc-1415	317	13	sweet	sweet	PROPN
dpc-1415	317	14	’s	’s	PART
dpc-1415	317	15	syndrome	syndrome	NOUN
dpc-1415	317	16	in	in	ADP
dpc-1415	317	17	a	a	DET
dpc-1415	317	18	patient	patient	NOUN
dpc-1415	317	19	with	with	ADP
dpc-1415	317	20	metastatic	metastatic	ADJ
dpc-1415	317	21	melanoma	melanoma	NOUN
dpc-1415	317	22	after	after	ADP
dpc-1415	317	23	ipilimumab	ipilimumab	NOUN
dpc-1415	317	24	.	.	PUNCT
dpc-1415	318	1	melanoma	melanoma	NOUN
dpc-1415	318	2	res	re	NOUN
dpc-1415	318	3	.	.	PUNCT
dpc-1415	319	1	2013;23(6):498	2013;23(6):498	NOUN
dpc-1415	319	2	-	-	PUNCT
dpc-1415	319	3	501	501	NUM
dpc-1415	319	4	.	.	PUNCT
dpc-1415	320	1	doi	doi	NOUN
dpc-1415	320	2	:	:	PUNCT
dpc-1415	320	3	10.1097	10.1097	NUM
dpc-1415	320	4	/	/	SYM
dpc-1415	320	5	cmr.0000000000000017	cmr.0000000000000017	X
dpc-1415	320	6	.	.	PUNCT
dpc-1415	321	1	pmid	pmid	NOUN
dpc-1415	321	2	:	:	PUNCT
dpc-1415	321	3	24113862	24113862	NUM
dpc-1415	321	4	.	.	PUNCT
dpc-1415	322	1	21	21	NUM
dpc-1415	322	2	.	.	PUNCT
dpc-1415	323	1	siegel	siegel	PROPN
dpc-1415	323	2	j	j	PROPN
dpc-1415	323	3	,	,	PUNCT
dpc-1415	323	4	totonchy	totonchy	PROPN
dpc-1415	323	5	m	m	PROPN
dpc-1415	323	6	,	,	PUNCT
dpc-1415	323	7	damsky	damsky	PROPN
dpc-1415	323	8	w	w	PROPN
dpc-1415	323	9	,	,	PUNCT
dpc-1415	323	10	et	et	PROPN
dpc-1415	323	11	al	al	PROPN
dpc-1415	323	12	.	.	PUNCT
dpc-1415	324	1	bullous	bullous	ADJ
dpc-1415	324	2	disorders	disorder	NOUN
dpc-1415	324	3	associated	associate	VERB
dpc-1415	324	4	with	with	ADP
dpc-1415	324	5	anti	anti	ADJ
dpc-1415	324	6	-	-	ADJ
dpc-1415	324	7	pd-1	pd-1	ADJ
dpc-1415	324	8	and	and	CCONJ
dpc-1415	324	9	anti	anti	ADJ
dpc-1415	324	10	-	-	ADJ
dpc-1415	324	11	pd	pd	ADJ
dpc-1415	324	12	-	-	PUNCT
dpc-1415	324	13	l1	l1	PROPN
dpc-1415	324	14	therapy	therapy	NOUN
dpc-1415	324	15	:	:	PUNCT
dpc-1415	324	16	a	a	DET
dpc-1415	324	17	retrospective	retrospective	ADJ
dpc-1415	324	18	analysis	analysis	NOUN
dpc-1415	324	19	evaluating	evaluate	VERB
dpc-1415	324	20	the	the	DET
dpc-1415	324	21	clinical	clinical	ADJ
dpc-1415	324	22	and	and	CCONJ
dpc-1415	324	23	histopathologic	histopathologic	NOUN
dpc-1415	324	24	features	feature	NOUN
dpc-1415	324	25	,	,	PUNCT
dpc-1415	324	26	frequency	frequency	NOUN
dpc-1415	324	27	,	,	PUNCT
dpc-1415	324	28	and	and	CCONJ
dpc-1415	324	29	impact	impact	NOUN
dpc-1415	324	30	on	on	ADP
dpc-1415	324	31	cancer	cancer	NOUN
dpc-1415	324	32	therapy	therapy	NOUN
dpc-1415	324	33	.	.	PUNCT
dpc-1415	325	1	j	j	PROPN
dpc-1415	325	2	am	be	AUX
dpc-1415	325	3	acad	acad	ADJ
dpc-1415	325	4	dermatol	dermatol	NOUN
dpc-1415	325	5	.	.	PUNCT
dpc-1415	326	1	2018;79(6):1081	2018;79(6):1081	NUM
dpc-1415	326	2	–	–	PUNCT
dpc-1415	326	3	1088	1088	NUM
dpc-1415	326	4	.	.	PUNCT
dpc-1415	327	1	doi	doi	NOUN
dpc-1415	327	2	:	:	PUNCT
dpc-1415	327	3	10.1016	10.1016	NUM
dpc-1415	327	4	/	/	SYM
dpc-1415	327	5	j.jaad.2018.07.008	j.jaad.2018.07.008	PROPN
dpc-1415	327	6	.	.	PUNCT
dpc-1415	328	1	pmid	pmid	NOUN
dpc-1415	328	2	:	:	PUNCT
dpc-1415	328	3	30025829	30025829	NUM
dpc-1415	328	4	.	.	PUNCT
dpc-1415	329	1	22	22	NUM
dpc-1415	329	2	.	.	PUNCT
dpc-1415	330	1	coleman	coleman	PROPN
dpc-1415	330	2	e	e	PROPN
dpc-1415	330	3	,	,	PUNCT
dpc-1415	330	4	ko	ko	PROPN
dpc-1415	330	5	c	c	PROPN
dpc-1415	330	6	,	,	PUNCT
dpc-1415	330	7	dai	dai	PROPN
dpc-1415	330	8	f	f	PROPN
dpc-1415	330	9	,	,	PUNCT
dpc-1415	330	10	et	et	PROPN
dpc-1415	330	11	al	al	PROPN
dpc-1415	330	12	.	.	PUNCT
dpc-1415	330	13	inflammatory	inflammatory	ADJ
dpc-1415	330	14	eruptions	eruption	NOUN
dpc-1415	330	15	associated	associate	VERB
dpc-1415	330	16	with	with	ADP
dpc-1415	330	17	immune	immune	ADJ
dpc-1415	330	18	checkpoint	checkpoint	NOUN
dpc-1415	330	19	inhibitor	inhibitor	NOUN
dpc-1415	330	20	therapy	therapy	NOUN
dpc-1415	330	21	:	:	PUNCT
dpc-1415	330	22	a	a	DET
dpc-1415	330	23	single	single	ADJ
dpc-1415	330	24	-	-	PUNCT
dpc-1415	330	25	institution	institution	NOUN
dpc-1415	330	26	retrospective	retrospective	ADJ
dpc-1415	330	27	analysis	analysis	NOUN
dpc-1415	330	28	with	with	ADP
dpc-1415	330	29	stratification	stratification	NOUN
dpc-1415	330	30	of	of	ADP
dpc-1415	330	31	reactions	reaction	NOUN
dpc-1415	330	32	by	by	ADP
dpc-1415	330	33	toxicity	toxicity	NOUN
dpc-1415	330	34	and	and	CCONJ
dpc-1415	330	35	implications	implication	NOUN
dpc-1415	330	36	for	for	ADP
dpc-1415	330	37	management	management	NOUN
dpc-1415	330	38	.	.	PUNCT
dpc-1415	331	1	j	j	PROPN
dpc-1415	331	2	am	be	AUX
dpc-1415	331	3	acad	acad	ADJ
dpc-1415	331	4	dermatol	dermatol	NOUN
dpc-1415	331	5	.	.	PUNCT
dpc-1415	332	1	2019;80(4):990–997	2019;80(4):990–997	X
dpc-1415	332	2	.	.	PUNCT
dpc-1415	332	3	doi	doi	NOUN
dpc-1415	332	4	:	:	PUNCT
dpc-1415	332	5	10.1016	10.1016	NUM
dpc-1415	332	6	/	/	SYM
dpc-1415	332	7	j.jaad.2018.10.062	j.jaad.2018.10.062	PROPN
dpc-1415	332	8	.	.	PUNCT
dpc-1415	333	1	pmid	pmid	NOUN
dpc-1415	333	2	:	:	PUNCT
dpc-1415	333	3	30399387	30399387	NUM
dpc-1415	333	4	.	.	PUNCT
dpc-1415	334	1	23	23	NUM
dpc-1415	334	2	.	.	PUNCT
dpc-1415	334	3	naidoo	naidoo	PROPN
dpc-1415	334	4	j	j	PROPN
dpc-1415	334	5	,	,	PUNCT
dpc-1415	334	6	schindler	schindler	PROPN
dpc-1415	334	7	k	k	PROPN
dpc-1415	334	8	,	,	PUNCT
dpc-1415	334	9	querfeld	querfeld	VERB
dpc-1415	334	10	c	c	NOUN
dpc-1415	334	11	,	,	PUNCT
dpc-1415	334	12	et	et	PROPN
dpc-1415	334	13	al	al	PROPN
dpc-1415	334	14	.	.	PROPN
dpc-1415	334	15	autoimmune	autoimmune	PROPN
dpc-1415	334	16	bullous	bullous	ADJ
dpc-1415	334	17	skin	skin	NOUN
dpc-1415	334	18	disorders	disorder	NOUN
dpc-1415	334	19	with	with	ADP
dpc-1415	334	20	immune	immune	ADJ
dpc-1415	334	21	checkpoint	checkpoint	NOUN
dpc-1415	334	22	inhibitors	inhibitor	NOUN
dpc-1415	334	23	targeting	target	VERB
dpc-1415	334	24	pd-1	pd-1	ADP
dpc-1415	334	25	and	and	CCONJ
dpc-1415	334	26	pd	pd	PROPN
dpc-1415	334	27	-	-	PROPN
dpc-1415	334	28	l1	l1	PROPN
dpc-1415	334	29	.	.	PUNCT
dpc-1415	335	1	cancer	cancer	NOUN
dpc-1415	335	2	immunol	immunol	NOUN
dpc-1415	335	3	res	re	NOUN
dpc-1415	335	4	.	.	PUNCT
dpc-1415	336	1	2016;4(5):383	2016;4(5):383	NOUN
dpc-1415	336	2	-	-	SYM
dpc-1415	336	3	389	389	NUM
dpc-1415	336	4	.	.	PUNCT
dpc-1415	337	1	doi	doi	NOUN
dpc-1415	337	2	:	:	PUNCT
dpc-1415	337	3	10.1158/2326	10.1158/2326	NUM
dpc-1415	337	4	-	-	PUNCT
dpc-1415	337	5	6066.cir-15	6066.cir-15	NUM
dpc-1415	337	6	-	-	PUNCT
dpc-1415	337	7	0123	0123	NUM
dpc-1415	337	8	.	.	PUNCT
dpc-1415	338	1	pmid	pmid	NOUN
dpc-1415	338	2	:	:	PUNCT
dpc-1415	338	3	26928461	26928461	NUM
dpc-1415	338	4	.	.	PUNCT
dpc-1415	339	1	24	24	NUM
dpc-1415	339	2	.	.	PUNCT
dpc-1415	339	3	lopez	lopez	PROPN
dpc-1415	339	4	at	at	ADP
dpc-1415	339	5	,	,	PUNCT
dpc-1415	339	6	khanna	khanna	PROPN
dpc-1415	339	7	t	t	PROPN
dpc-1415	339	8	,	,	PUNCT
dpc-1415	339	9	antonov	antonov	PROPN
dpc-1415	339	10	n	n	CCONJ
dpc-1415	339	11	,	,	PUNCT
dpc-1415	339	12	et	et	PROPN
dpc-1415	339	13	al	al	PROPN
dpc-1415	339	14	.	.	PUNCT
dpc-1415	340	1	a	a	DET
dpc-1415	340	2	review	review	NOUN
dpc-1415	340	3	of	of	ADP
dpc-1415	340	4	bullous	bullous	ADJ
dpc-1415	340	5	pemphigoid	pemphigoid	NOUN
dpc-1415	340	6	associated	associate	VERB
dpc-1415	340	7	with	with	ADP
dpc-1415	340	8	pd-1	pd-1	ADJ
dpc-1415	340	9	and	and	CCONJ
dpc-1415	340	10	pd	pd	PROPN
dpc-1415	340	11	-	-	PUNCT
dpc-1415	340	12	l1	l1	PROPN
dpc-1415	340	13	inhibitors	inhibitor	NOUN
dpc-1415	340	14	.	.	PUNCT
dpc-1415	341	1	int	int	NOUN
dpc-1415	341	2	j	j	PROPN
dpc-1415	341	3	dermatol	dermatol	NOUN
dpc-1415	341	4	.	.	PUNCT
dpc-1415	342	1	2018;57(6):664–669	2018;57(6):664–669	NUM
dpc-1415	342	2	.	.	X
dpc-1415	343	1	doi	doi	NOUN
dpc-1415	343	2	:	:	PUNCT
dpc-1415	343	3	10.1111	10.1111	NUM
dpc-1415	343	4	/	/	SYM
dpc-1415	343	5	ijd.13984	ijd.13984	PROPN
dpc-1415	343	6	.	.	PUNCT
dpc-1415	344	1	pmid	pmid	NOUN
dpc-1415	344	2	:	:	PUNCT
dpc-1415	344	3	29630716	29630716	NUM
dpc-1415	344	4	.	.	PUNCT
dpc-1415	345	1	25	25	NUM
dpc-1415	345	2	.	.	PUNCT
dpc-1415	346	1	apalla	apalla	PROPN
dpc-1415	346	2	z	z	PROPN
dpc-1415	346	3	,	,	PUNCT
dpc-1415	346	4	lallas	lallas	PROPN
dpc-1415	346	5	a	a	PRON
dpc-1415	346	6	,	,	PUNCT
dpc-1415	346	7	delli	delli	PROPN
dpc-1415	346	8	f	f	NOUN
dpc-1415	346	9	,	,	PUNCT
dpc-1415	346	10	et	et	PROPN
dpc-1415	346	11	al	al	PROPN
dpc-1415	346	12	.	.	PUNCT
dpc-1415	346	13	management	management	NOUN
dpc-1415	346	14	of	of	ADP
dpc-1415	346	15	immune	immune	ADJ
dpc-1415	346	16	checkpoint	checkpoint	NOUN
dpc-1415	346	17	inhibitor	inhibitor	NOUN
dpc-1415	346	18	-	-	PUNCT
dpc-1415	346	19	induced	induce	VERB
dpc-1415	346	20	bullous	bullous	ADJ
dpc-1415	346	21	pemphigoid	pemphigoid	NOUN
dpc-1415	346	22	.	.	PUNCT
dpc-1415	347	1	j	j	PROPN
dpc-1415	347	2	am	be	AUX
dpc-1415	347	3	acad	acad	ADJ
dpc-1415	347	4	dermatol	dermatol	NOUN
dpc-1415	347	5	.	.	PUNCT
dpc-1415	348	1	2020	2020	NUM
dpc-1415	348	2	may	may	AUX
dpc-1415	348	3	16	16	NUM
dpc-1415	348	4	:	:	PUNCT
dpc-1415	348	5	s0190	s0190	VERB
dpc-1415	348	6	-	-	PUNCT
dpc-1415	348	7	9622(20)30910	9622(20)30910	NUM
dpc-1415	348	8	-	-	SYM
dpc-1415	348	9	5	5	NUM
dpc-1415	348	10	.	.	PUNCT
dpc-1415	348	11	doi	doi	NOUN
dpc-1415	348	12	:	:	PUNCT
dpc-1415	348	13	10.1016	10.1016	NUM
dpc-1415	348	14	/	/	SYM
dpc-1415	348	15	j.	j.	PROPN
dpc-1415	348	16	jaad.2020.05.045	jaad.2020.05.045	PROPN
dpc-1415	348	17	.	.	PUNCT
dpc-1415	349	1	pmid	pmid	PROPN
dpc-1415	349	2	:	:	PUNCT
dpc-1415	349	3	32428613	32428613	NUM
dpc-1415	349	4	.	.	PUNCT
dpc-1415	350	1	26	26	NUM
dpc-1415	350	2	.	.	PUNCT
dpc-1415	351	1	apalla	apalla	PROPN
dpc-1415	351	2	z	z	PROPN
dpc-1415	351	3	,	,	PUNCT
dpc-1415	351	4	lazaridou	lazaridou	PROPN
dpc-1415	351	5	e	e	NOUN
dpc-1415	351	6	,	,	PUNCT
dpc-1415	351	7	lallas	lallas	PROPN
dpc-1415	351	8	a.	a.	NOUN
dpc-1415	351	9	comment	comment	NOUN
dpc-1415	351	10	on	on	ADP
dpc-1415	351	11	:	:	PUNCT
dpc-1415	351	12	bullous	bullous	ADJ
dpc-1415	351	13	pemphigoid	pemphigoid	NOUN
dpc-1415	351	14	after	after	ADP
dpc-1415	351	15	anti	anti	ADJ
dpc-1415	351	16	-	-	ADJ
dpc-1415	351	17	pd-1	pd-1	ADJ
dpc-1415	351	18	therapy	therapy	NOUN
dpc-1415	351	19	:	:	PUNCT
dpc-1415	351	20	a	a	DET
dpc-1415	351	21	retrospective	retrospective	ADJ
dpc-1415	351	22	case	case	NOUN
dpc-1415	351	23	-	-	PUNCT
dpc-1415	351	24	control	control	NOUN
dpc-1415	351	25	study	study	NOUN
dpc-1415	351	26	evaluating	evaluating	NOUN
dpc-1415	351	27	impact	impact	NOUN
dpc-1415	351	28	on	on	ADP
dpc-1415	351	29	tumor	tumor	NOUN
dpc-1415	351	30	response	response	NOUN
dpc-1415	351	31	and	and	CCONJ
dpc-1415	351	32	survival	survival	NOUN
dpc-1415	351	33	outcomes	outcome	NOUN
dpc-1415	351	34	.	.	PUNCT
dpc-1415	352	1	j	j	PROPN
dpc-1415	352	2	am	be	AUX
dpc-1415	352	3	acad	acad	ADJ
dpc-1415	352	4	dermatol	dermatol	NOUN
dpc-1415	352	5	.	.	PUNCT
dpc-1415	353	1	2020	2020	NUM
dpc-1415	353	2	may	may	AUX
dpc-1415	353	3	12	12	NUM
dpc-1415	353	4	:	:	PUNCT
dpc-1415	353	5	s0190	s0190	VERB
dpc-1415	353	6	-	-	PUNCT
dpc-1415	353	7	9622(20)30851	9622(20)30851	NOUN
dpc-1415	353	8	-	-	PUNCT
dpc-1415	353	9	3	3	NUM
dpc-1415	353	10	.	.	PUNCT
dpc-1415	354	1	doi	doi	NOUN
dpc-1415	354	2	:	:	PUNCT
dpc-1415	354	3	10.1016	10.1016	NUM
dpc-1415	354	4	/	/	SYM
dpc-1415	354	5	j.jaad.2020.04.174	j.jaad.2020.04.174	PROPN
dpc-1415	354	6	.	.	PUNCT
dpc-1415	355	1	27	27	NUM
dpc-1415	355	2	.	.	PUNCT
dpc-1415	356	1	hassel	hassel	PROPN
dpc-1415	356	2	jc	jc	PROPN
dpc-1415	356	3	,	,	PUNCT
dpc-1415	356	4	heinzerling	heinzerle	VERB
dpc-1415	356	5	l	l	NOUN
dpc-1415	356	6	,	,	PUNCT
dpc-1415	356	7	aberle	aberle	VERB
dpc-1415	356	8	j	j	PROPN
dpc-1415	356	9	,	,	PUNCT
dpc-1415	356	10	et	et	PROPN
dpc-1415	356	11	al	al	PROPN
dpc-1415	356	12	.	.	PROPN
dpc-1415	357	1	combined	combine	VERB
dpc-1415	357	2	immune	immune	ADJ
dpc-1415	357	3	checkpoint	checkpoint	NOUN
dpc-1415	357	4	blockade	blockade	NOUN
dpc-1415	357	5	(	(	PUNCT
dpc-1415	357	6	anti	anti	ADJ
dpc-1415	357	7	-	-	ADJ
dpc-1415	357	8	pd-1	pd-1	ADJ
dpc-1415	357	9	/	/	SYM
dpc-1415	357	10	anti	anti	ADJ
dpc-1415	357	11	-	-	ADJ
dpc-1415	357	12	ctla-4	ctla-4	NOUN
dpc-1415	357	13	):	):	PUNCT
dpc-1415	357	14	evaluation	evaluation	NOUN
dpc-1415	357	15	and	and	CCONJ
dpc-1415	357	16	management	management	NOUN
dpc-1415	357	17	of	of	ADP
dpc-1415	357	18	adverse	adverse	ADJ
dpc-1415	357	19	drug	drug	NOUN
dpc-1415	357	20	reactions	reaction	NOUN
dpc-1415	357	21	.	.	PUNCT
dpc-1415	358	1	cancer	cancer	NOUN
dpc-1415	358	2	treat	treat	PROPN
dpc-1415	358	3	rev	rev	VERB
dpc-1415	358	4	.	.	PUNCT
dpc-1415	359	1	2017;57:36	2017;57:36	NUM
dpc-1415	359	2	-	-	SYM
dpc-1415	359	3	49	49	NUM
dpc-1415	359	4	.	.	PUNCT
dpc-1415	360	1	doi	doi	NOUN
dpc-1415	360	2	:	:	PUNCT
dpc-1415	360	3	10.1016	10.1016	NUM
dpc-1415	360	4	/	/	SYM
dpc-1415	360	5	j.ctrv.2017.05.003	j.ctrv.2017.05.003	PROPN
dpc-1415	360	6	.	.	PUNCT
dpc-1415	361	1	pmid	pmid	NOUN
dpc-1415	361	2	:	:	PUNCT
dpc-1415	361	3	28550712	28550712	NUM
dpc-1415	361	4	.	.	PUNCT
dpc-1415	362	1	28	28	NUM
dpc-1415	362	2	.	.	PUNCT
dpc-1415	363	1	belum	belum	PROPN
dpc-1415	363	2	vr	vr	PROPN
dpc-1415	363	3	,	,	PUNCT
dpc-1415	363	4	benhuri	benhuri	PROPN
dpc-1415	363	5	b	b	PROPN
dpc-1415	363	6	,	,	PUNCT
dpc-1415	363	7	postow	postow	PROPN
dpc-1415	363	8	ma	ma	PROPN
dpc-1415	363	9	,	,	PUNCT
dpc-1415	363	10	et	et	PROPN
dpc-1415	363	11	al	al	PROPN
dpc-1415	363	12	.	.	PROPN
dpc-1415	363	13	characterisation	characterisation	NOUN
dpc-1415	363	14	and	and	CCONJ
dpc-1415	363	15	management	management	NOUN
dpc-1415	363	16	of	of	ADP
dpc-1415	363	17	dermatologic	dermatologic	ADJ
dpc-1415	363	18	adverse	adverse	ADJ
dpc-1415	363	19	events	event	NOUN
dpc-1415	363	20	to	to	ADP
dpc-1415	363	21	agents	agent	NOUN
dpc-1415	363	22	targeting	target	VERB
dpc-1415	363	23	10	10	NUM
dpc-1415	363	24	review	review	NOUN
dpc-1415	363	25	|	|	ADV
dpc-1415	363	26	dermatol	dermatol	ADJ
dpc-1415	363	27	pract	pract	NOUN
dpc-1415	363	28	concept	concept	NOUN
dpc-1415	363	29	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	363	30	the	the	DET
dpc-1415	363	31	pd-1	pd-1	ADJ
dpc-1415	363	32	receptor	receptor	NOUN
dpc-1415	363	33	.	.	PUNCT
dpc-1415	364	1	eur	eur	PROPN
dpc-1415	364	2	j	j	PROPN
dpc-1415	364	3	cancer	cancer	NOUN
dpc-1415	364	4	.	.	PUNCT
dpc-1415	365	1	2016;60:12	2016;60:12	NUM
dpc-1415	365	2	-	-	SYM
dpc-1415	365	3	25	25	NUM
dpc-1415	365	4	.	.	PUNCT
dpc-1415	365	5	doi	doi	NOUN
dpc-1415	365	6	:	:	PUNCT
dpc-1415	365	7	10.1016	10.1016	NUM
dpc-1415	365	8	/	/	SYM
dpc-1415	365	9	j.	j.	PROPN
dpc-1415	365	10	ejca.2016.02.010	ejca.2016.02.010	PROPN
dpc-1415	365	11	.	.	PUNCT
dpc-1415	366	1	pmid	pmid	NOUN
dpc-1415	366	2	:	:	PUNCT
dpc-1415	366	3	27043866	27043866	NUM
dpc-1415	366	4	.	.	PUNCT
dpc-1415	367	1	29	29	NUM
dpc-1415	367	2	.	.	PUNCT
dpc-1415	368	1	larkin	larkin	PROPN
dpc-1415	368	2	j	j	PROPN
dpc-1415	368	3	,	,	PUNCT
dpc-1415	368	4	chiarion	chiarion	NOUN
dpc-1415	368	5	-	-	PUNCT
dpc-1415	368	6	sileni	sileni	NOUN
dpc-1415	368	7	v	v	NOUN
dpc-1415	368	8	,	,	PUNCT
dpc-1415	368	9	gonzalez	gonzalez	PROPN
dpc-1415	368	10	r	r	PROPN
dpc-1415	368	11	,	,	PUNCT
dpc-1415	368	12	et	et	PROPN
dpc-1415	368	13	al	al	PROPN
dpc-1415	368	14	.	.	PROPN
dpc-1415	369	1	combined	combine	VERB
dpc-1415	369	2	nivolumab	nivolumab	NOUN
dpc-1415	369	3	and	and	CCONJ
dpc-1415	369	4	ipilimumab	ipilimumab	VERB
dpc-1415	369	5	or	or	CCONJ
dpc-1415	369	6	monotherapy	monotherapy	NOUN
dpc-1415	369	7	in	in	ADP
dpc-1415	369	8	untreated	untreated	ADJ
dpc-1415	369	9	melanoma	melanoma	NOUN
dpc-1415	369	10	.	.	PUNCT
dpc-1415	370	1	n	n	PRON
dpc-1415	370	2	engl	engl	PROPN
dpc-1415	370	3	j	j	PROPN
dpc-1415	370	4	med	med	PROPN
dpc-1415	370	5	.	.	PUNCT
dpc-1415	371	1	2015;373(1):23	2015;373(1):23	X
dpc-1415	371	2	-	-	SYM
dpc-1415	371	3	34	34	NUM
dpc-1415	371	4	.	.	PUNCT
dpc-1415	372	1	doi	doi	NOUN
dpc-1415	372	2	:	:	PUNCT
dpc-1415	372	3	10.1056	10.1056	NUM
dpc-1415	372	4	/	/	SYM
dpc-1415	372	5	nejmoa1504030	nejmoa1504030	PROPN
dpc-1415	372	6	.	.	PUNCT
dpc-1415	373	1	pmid	pmid	NOUN
dpc-1415	373	2	:	:	PUNCT
dpc-1415	373	3	26027431	26027431	NUM
dpc-1415	373	4	.	.	PUNCT
dpc-1415	374	1	30	30	NUM
dpc-1415	374	2	.	.	PUNCT
dpc-1415	375	1	robert	robert	PROPN
dpc-1415	375	2	c	c	PROPN
dpc-1415	375	3	,	,	PUNCT
dpc-1415	375	4	schachter	schachter	PROPN
dpc-1415	375	5	j	j	PROPN
dpc-1415	375	6	,	,	PUNCT
dpc-1415	375	7	long	long	ADV
dpc-1415	375	8	gv	gv	ADP
dpc-1415	375	9	,	,	PUNCT
dpc-1415	375	10	et	et	PROPN
dpc-1415	375	11	al	al	PROPN
dpc-1415	375	12	.	.	PROPN
dpc-1415	375	13	pembrolizumab	pembrolizumab	NOUN
dpc-1415	375	14	versus	versus	ADP
dpc-1415	375	15	ipilimumab	ipilimumab	NOUN
dpc-1415	375	16	in	in	ADP
dpc-1415	375	17	advanced	advanced	ADJ
dpc-1415	375	18	melanoma	melanoma	NOUN
dpc-1415	375	19	.	.	PUNCT
dpc-1415	376	1	n	n	PRON
dpc-1415	376	2	engl	engl	PROPN
dpc-1415	376	3	j	j	PROPN
dpc-1415	376	4	med	med	PROPN
dpc-1415	376	5	.	.	PUNCT
dpc-1415	377	1	2015;372(26):2521	2015;372(26):2521	NUM
dpc-1415	377	2	-	-	SYM
dpc-1415	377	3	2532	2532	NUM
dpc-1415	377	4	.	.	PUNCT
dpc-1415	378	1	doi	doi	NOUN
dpc-1415	378	2	:	:	PUNCT
dpc-1415	378	3	10.1056	10.1056	NUM
dpc-1415	378	4	/	/	SYM
dpc-1415	378	5	nejmoa1503093	nejmoa1503093	PROPN
dpc-1415	378	6	.	.	PUNCT
dpc-1415	379	1	pmid	pmid	NOUN
dpc-1415	379	2	:	:	PUNCT
dpc-1415	379	3	25891173	25891173	NUM
dpc-1415	379	4	.	.	PUNCT
dpc-1415	380	1	31	31	NUM
dpc-1415	380	2	.	.	PUNCT
dpc-1415	381	1	postow	postow	PROPN
dpc-1415	381	2	ma	ma	PROPN
dpc-1415	381	3	,	,	PUNCT
dpc-1415	381	4	chesney	chesney	PROPN
dpc-1415	381	5	j	j	PROPN
dpc-1415	381	6	,	,	PUNCT
dpc-1415	381	7	pavlick	pavlick	PROPN
dpc-1415	381	8	ac	ac	PROPN
dpc-1415	381	9	,	,	PUNCT
dpc-1415	381	10	et	et	PROPN
dpc-1415	381	11	al	al	PROPN
dpc-1415	381	12	.	.	PROPN
dpc-1415	381	13	nivolumab	nivolumab	NOUN
dpc-1415	381	14	and	and	CCONJ
dpc-1415	381	15	ipilimumab	ipilimumab	VERB
dpc-1415	381	16	versus	versus	ADP
dpc-1415	381	17	ipilimumab	ipilimumab	NOUN
dpc-1415	381	18	in	in	ADP
dpc-1415	381	19	untreated	untreated	ADJ
dpc-1415	381	20	melanoma	melanoma	NOUN
dpc-1415	381	21	.	.	PUNCT
dpc-1415	382	1	n	n	PRON
dpc-1415	382	2	engl	engl	PROPN
dpc-1415	382	3	j	j	PROPN
dpc-1415	382	4	med	med	PROPN
dpc-1415	382	5	.	.	PUNCT
dpc-1415	383	1	2015;372(21):2006	2015;372(21):2006	NUM
dpc-1415	383	2	-	-	SYM
dpc-1415	383	3	2017	2017	NUM
dpc-1415	383	4	.	.	PUNCT
dpc-1415	384	1	doi	doi	NOUN
dpc-1415	384	2	:	:	PUNCT
dpc-1415	384	3	10.1056	10.1056	NUM
dpc-1415	384	4	/	/	SYM
dpc-1415	384	5	nejmoa1414428	nejmoa1414428	PROPN
dpc-1415	384	6	.	.	PUNCT
dpc-1415	385	1	pmid	pmid	NOUN
dpc-1415	385	2	:	:	PUNCT
dpc-1415	385	3	25891304	25891304	NUM
dpc-1415	385	4	.	.	PUNCT
dpc-1415	386	1	32	32	NUM
dpc-1415	386	2	.	.	PUNCT
dpc-1415	387	1	balar	balar	PROPN
dpc-1415	387	2	av	av	PROPN
dpc-1415	387	3	,	,	PUNCT
dpc-1415	387	4	galsky	galsky	PROPN
dpc-1415	387	5	md	md	PROPN
dpc-1415	387	6	,	,	PUNCT
dpc-1415	387	7	rosenberg	rosenberg	PROPN
dpc-1415	387	8	je	je	PROPN
dpc-1415	387	9	,	,	PUNCT
dpc-1415	387	10	et	et	PROPN
dpc-1415	387	11	al	al	PROPN
dpc-1415	387	12	.	.	PROPN
dpc-1415	387	13	atezolizumab	atezolizumab	PROPN
dpc-1415	387	14	as	as	ADP
dpc-1415	387	15	firstline	firstline	ADJ
dpc-1415	387	16	treatment	treatment	NOUN
dpc-1415	387	17	in	in	ADP
dpc-1415	387	18	cisplatin	cisplatin	NOUN
dpc-1415	387	19	-	-	PUNCT
dpc-1415	387	20	ineligible	ineligible	ADJ
dpc-1415	387	21	patients	patient	NOUN
dpc-1415	387	22	with	with	ADP
dpc-1415	387	23	locally	locally	ADV
dpc-1415	387	24	advanced	advanced	ADJ
dpc-1415	387	25	and	and	CCONJ
dpc-1415	387	26	metastatic	metastatic	ADJ
dpc-1415	387	27	urothelialcarcinoma	urothelialcarcinoma	NOUN
dpc-1415	387	28	:	:	PUNCT
dpc-1415	387	29	a	a	DET
dpc-1415	387	30	single	single	ADJ
dpc-1415	387	31	-	-	PUNCT
dpc-1415	387	32	arm	arm	NOUN
dpc-1415	387	33	,	,	PUNCT
dpc-1415	387	34	multicentre	multicentre	NOUN
dpc-1415	387	35	,	,	PUNCT
dpc-1415	387	36	phase	phase	NOUN
dpc-1415	387	37	2	2	NUM
dpc-1415	387	38	trial	trial	NOUN
dpc-1415	387	39	.	.	PUNCT
dpc-1415	388	1	lancet	lancet	NOUN
dpc-1415	388	2	.	.	PUNCT
dpc-1415	389	1	2017;389(10064):67	2017;389(10064):67	PROPN
dpc-1415	389	2	-	-	PUNCT
dpc-1415	389	3	76	76	NUM
dpc-1415	389	4	.	.	PUNCT
dpc-1415	390	1	doi	doi	NOUN
dpc-1415	390	2	:	:	PUNCT
dpc-1415	390	3	10.1016/	10.1016/	NUM
dpc-1415	390	4	s0140	s0140	PROPN
dpc-1415	390	5	-	-	PUNCT
dpc-1415	390	6	6736(16)32455	6736(16)32455	ADP
dpc-1415	390	7	-	-	PUNCT
dpc-1415	390	8	2	2	NUM
dpc-1415	390	9	.	.	NOUN
dpc-1415	390	10	33	33	NUM
dpc-1415	390	11	.	.	PUNCT
dpc-1415	391	1	puzanov	puzanov	PROPN
dpc-1415	391	2	i	i	PROPN
dpc-1415	391	3	,	,	PUNCT
dpc-1415	391	4	diab	diab	PROPN
dpc-1415	391	5	a	a	PROPN
dpc-1415	391	6	,	,	PUNCT
dpc-1415	391	7	abdallah	abdallah	PROPN
dpc-1415	391	8	k	k	PROPN
dpc-1415	391	9	,	,	PUNCT
dpc-1415	391	10	et	et	PROPN
dpc-1415	391	11	al	al	PROPN
dpc-1415	391	12	.	.	PUNCT
dpc-1415	392	1	managing	manage	VERB
dpc-1415	392	2	toxicities	toxicity	NOUN
dpc-1415	392	3	associated	associate	VERB
dpc-1415	392	4	with	with	ADP
dpc-1415	392	5	immune	immune	ADJ
dpc-1415	392	6	checkpoint	checkpoint	NOUN
dpc-1415	392	7	inhibitors	inhibitor	NOUN
dpc-1415	392	8	:	:	PUNCT
dpc-1415	392	9	consensus	consensus	NOUN
dpc-1415	392	10	recommendations	recommendation	NOUN
dpc-1415	392	11	from	from	ADP
dpc-1415	392	12	the	the	DET
dpc-1415	392	13	society	society	NOUN
dpc-1415	392	14	for	for	ADP
dpc-1415	392	15	immunotherapy	immunotherapy	NOUN
dpc-1415	392	16	of	of	ADP
dpc-1415	392	17	cancer	cancer	NOUN
dpc-1415	392	18	(	(	PUNCT
dpc-1415	392	19	sitc	sitc	NOUN
dpc-1415	392	20	)	)	PUNCT
dpc-1415	392	21	toxicity	toxicity	NOUN
dpc-1415	392	22	management	management	NOUN
dpc-1415	392	23	working	working	NOUN
dpc-1415	392	24	group	group	NOUN
dpc-1415	392	25	.	.	PUNCT
dpc-1415	393	1	j	j	PROPN
dpc-1415	393	2	immunother	immunother	ADJ
dpc-1415	393	3	cancer	cancer	NOUN
dpc-1415	393	4	.	.	PUNCT
dpc-1415	394	1	2017;5(1):95	2017;5(1):95	X
dpc-1415	394	2	.	.	PUNCT
dpc-1415	394	3	doi	doi	NOUN
dpc-1415	394	4	:	:	PUNCT
dpc-1415	394	5	10.1186	10.1186	NUM
dpc-1415	394	6	/	/	SYM
dpc-1415	394	7	s40425	s40425	NOUN
dpc-1415	394	8	-	-	PUNCT
dpc-1415	394	9	017	017	NUM
dpc-1415	394	10	-	-	PUNCT
dpc-1415	394	11	0300	0300	NUM
dpc-1415	394	12	-	-	PUNCT
dpc-1415	394	13	z.	z.	NOUN
dpc-1415	394	14	pmid	pmid	PROPN
dpc-1415	394	15	:	:	PUNCT
dpc-1415	394	16	29162153	29162153	NUM
dpc-1415	394	17	.	.	PUNCT
dpc-1415	395	1	34	34	NUM
dpc-1415	395	2	.	.	X
dpc-1415	395	3	yin	yin	PROPN
dpc-1415	395	4	es	es	PROPN
dpc-1415	395	5	,	,	PUNCT
dpc-1415	395	6	totonchy	totonchy	ADJ
dpc-1415	395	7	mb	mb	NOUN
dpc-1415	395	8	,	,	PUNCT
dpc-1415	395	9	leventhal	leventhal	PROPN
dpc-1415	395	10	js	js	PROPN
dpc-1415	395	11	.	.	PUNCT
dpc-1415	395	12	nivolumab	nivolumab	ADV
dpc-1415	395	13	-	-	PUNCT
dpc-1415	395	14	associated	associate	VERB
dpc-1415	395	15	vitiligo	vitiligo	NOUN
dpc-1415	395	16	-	-	PUNCT
dpc-1415	395	17	like	like	ADJ
dpc-1415	395	18	depigmentation	depigmentation	NOUN
dpc-1415	395	19	in	in	ADP
dpc-1415	395	20	a	a	DET
dpc-1415	395	21	patient	patient	NOUN
dpc-1415	395	22	with	with	ADP
dpc-1415	395	23	acute	acute	ADJ
dpc-1415	395	24	myeloid	myeloid	ADJ
dpc-1415	395	25	leukemia	leukemia	NOUN
dpc-1415	395	26	:	:	PUNCT
dpc-1415	395	27	a	a	DET
dpc-1415	395	28	novel	novel	ADJ
dpc-1415	395	29	finding	finding	NOUN
dpc-1415	395	30	.	.	PUNCT
dpc-1415	396	1	jaad	jaad	NOUN
dpc-1415	396	2	case	case	NOUN
dpc-1415	396	3	rep	rep	PROPN
dpc-1415	396	4	.	.	PROPN
dpc-1415	396	5	2017;3:90	2017;3:90	NOUN
dpc-1415	396	6	-	-	PUNCT
dpc-1415	396	7	92	92	NUM
dpc-1415	396	8	.	.	PUNCT
dpc-1415	397	1	doi	doi	NOUN
dpc-1415	397	2	:	:	PUNCT
dpc-1415	397	3	10.1016	10.1016	NUM
dpc-1415	397	4	/	/	SYM
dpc-1415	397	5	j.	j.	PROPN
dpc-1415	397	6	jdcr.2016.10.008	jdcr.2016.10.008	PROPN
dpc-1415	397	7	.	.	PUNCT
dpc-1415	398	1	pmid	pmid	NOUN
dpc-1415	398	2	:	:	PUNCT
dpc-1415	398	3	28280766	28280766	NUM
dpc-1415	398	4	.	.	X
dpc-1415	399	1	35	35	NUM
dpc-1415	399	2	.	.	PUNCT
dpc-1415	400	1	uenami	uenami	PROPN
dpc-1415	400	2	t	t	PROPN
dpc-1415	400	3	,	,	PUNCT
dpc-1415	400	4	hosono	hosono	PROPN
dpc-1415	400	5	y	y	PROPN
dpc-1415	400	6	,	,	PUNCT
dpc-1415	400	7	ishijima	ishijima	PROPN
dpc-1415	400	8	m	m	PROPN
dpc-1415	400	9	,	,	PUNCT
dpc-1415	400	10	et	et	PROPN
dpc-1415	400	11	al	al	PROPN
dpc-1415	400	12	.	.	PROPN
dpc-1415	400	13	vitiligo	vitiligo	VERB
dpc-1415	400	14	in	in	ADP
dpc-1415	400	15	a	a	DET
dpc-1415	400	16	patient	patient	NOUN
dpc-1415	400	17	with	with	ADP
dpc-1415	400	18	lung	lung	NOUN
dpc-1415	400	19	adenocarcinoma	adenocarcinoma	NOUN
dpc-1415	400	20	treated	treat	VERB
dpc-1415	400	21	with	with	ADP
dpc-1415	400	22	nivolumab	nivolumab	NOUN
dpc-1415	400	23	:	:	PUNCT
dpc-1415	400	24	a	a	DET
dpc-1415	400	25	case	case	NOUN
dpc-1415	400	26	report	report	NOUN
dpc-1415	400	27	.	.	PUNCT
dpc-1415	401	1	lung	lung	NOUN
dpc-1415	401	2	cancer	cancer	NOUN
dpc-1415	401	3	.	.	PUNCT
dpc-1415	402	1	2017;109:42	2017;109:42	NUM
dpc-1415	402	2	-	-	SYM
dpc-1415	402	3	44	44	NUM
dpc-1415	402	4	.	.	PUNCT
dpc-1415	403	1	doi	doi	NOUN
dpc-1415	403	2	:	:	PUNCT
dpc-1415	403	3	10.1016	10.1016	NUM
dpc-1415	403	4	/	/	SYM
dpc-1415	403	5	j.lungcan.2017.04.019	j.lungcan.2017.04.019	PROPN
dpc-1415	403	6	.	.	PUNCT
dpc-1415	404	1	pmid	pmid	NOUN
dpc-1415	404	2	:	:	PUNCT
dpc-1415	404	3	28577948	28577948	NUM
dpc-1415	404	4	.	.	PUNCT
dpc-1415	405	1	36	36	NUM
dpc-1415	405	2	.	.	PUNCT
dpc-1415	406	1	hua	hua	PROPN
dpc-1415	406	2	c	c	PROPN
dpc-1415	406	3	,	,	PUNCT
dpc-1415	406	4	boussemart	boussemart	PROPN
dpc-1415	406	5	l	l	PROPN
dpc-1415	406	6	,	,	PUNCT
dpc-1415	406	7	mateus	mateus	PROPN
dpc-1415	406	8	c	c	PROPN
dpc-1415	406	9	,	,	PUNCT
dpc-1415	406	10	et	et	PROPN
dpc-1415	406	11	al	al	PROPN
dpc-1415	406	12	.	.	PROPN
dpc-1415	406	13	association	association	PROPN
dpc-1415	406	14	of	of	ADP
dpc-1415	406	15	vitiligo	vitiligo	PROPN
dpc-1415	406	16	with	with	ADP
dpc-1415	406	17	tumor	tumor	NOUN
dpc-1415	406	18	response	response	NOUN
dpc-1415	406	19	in	in	ADP
dpc-1415	406	20	patients	patient	NOUN
dpc-1415	406	21	with	with	ADP
dpc-1415	406	22	metastatic	metastatic	ADJ
dpc-1415	406	23	melanoma	melanoma	NOUN
dpc-1415	406	24	treated	treat	VERB
dpc-1415	406	25	with	with	ADP
dpc-1415	406	26	pembrolizumab	pembrolizumab	NOUN
dpc-1415	406	27	.	.	PUNCT
dpc-1415	407	1	jama	jama	PROPN
dpc-1415	407	2	dermatol	dermatol	NOUN
dpc-1415	407	3	.	.	PUNCT
dpc-1415	408	1	2016	2016	NUM
dpc-1415	408	2	;	;	PUNCT
dpc-1415	408	3	152(1):45	152(1):45	NUM
dpc-1415	408	4	-	-	SYM
dpc-1415	408	5	51	51	NUM
dpc-1415	408	6	.	.	PUNCT
dpc-1415	409	1	doi	doi	NOUN
dpc-1415	409	2	:	:	PUNCT
dpc-1415	409	3	10.1001	10.1001	NUM
dpc-1415	409	4	/	/	SYM
dpc-1415	409	5	jamadermatol.2015.2707	jamadermatol.2015.2707	NOUN
dpc-1415	409	6	.	.	PUNCT
dpc-1415	410	1	pmid	pmid	NOUN
dpc-1415	410	2	:	:	PUNCT
dpc-1415	410	3	26501224	26501224	NUM
dpc-1415	410	4	.	.	PUNCT
dpc-1415	411	1	37	37	NUM
dpc-1415	411	2	.	.	PUNCT
dpc-1415	412	1	sibaud	sibaud	PROPN
dpc-1415	412	2	v	v	PROPN
dpc-1415	412	3	,	,	PUNCT
dpc-1415	412	4	meyer	meyer	PROPN
dpc-1415	412	5	n	n	CCONJ
dpc-1415	412	6	,	,	PUNCT
dpc-1415	412	7	lamant	lamant	PROPN
dpc-1415	412	8	l	l	PROPN
dpc-1415	412	9	,	,	PUNCT
dpc-1415	412	10	et	et	PROPN
dpc-1415	412	11	al	al	PROPN
dpc-1415	412	12	.	.	PUNCT
dpc-1415	413	1	dermatologic	dermatologic	ADJ
dpc-1415	413	2	complications	complication	NOUN
dpc-1415	413	3	of	of	ADP
dpc-1415	413	4	anti	anti	ADJ
dpc-1415	413	5	-	-	ADJ
dpc-1415	413	6	pd-1	pd-1	ADJ
dpc-1415	413	7	/	/	SYM
dpc-1415	413	8	pd	pd	ADJ
dpc-1415	413	9	-	-	PUNCT
dpc-1415	413	10	l1	l1	PROPN
dpc-1415	413	11	immune	immune	ADJ
dpc-1415	413	12	checkpoint	checkpoint	NOUN
dpc-1415	413	13	antibodies	antibodie	VERB
dpc-1415	413	14	.	.	PUNCT
dpc-1415	414	1	curr	curr	PROPN
dpc-1415	414	2	opin	opin	PROPN
dpc-1415	414	3	oncol	oncol	PROPN
dpc-1415	414	4	.	.	PUNCT
dpc-1415	415	1	2016;28(4):254	2016;28(4):254	NUM
dpc-1415	415	2	-	-	SYM
dpc-1415	415	3	263	263	NUM
dpc-1415	415	4	.	.	PUNCT
dpc-1415	416	1	doi	doi	NOUN
dpc-1415	416	2	:	:	PUNCT
dpc-1415	416	3	10.1097/	10.1097/	NUM
dpc-1415	416	4	cco.0000000000000290	cco.0000000000000290	NUM
dpc-1415	416	5	.	.	PUNCT
dpc-1415	417	1	pmid	pmid	NOUN
dpc-1415	417	2	:	:	PUNCT
dpc-1415	417	3	27136138	27136138	NUM
dpc-1415	417	4	.	.	PUNCT
dpc-1415	418	1	38	38	NUM
dpc-1415	418	2	.	.	PUNCT
dpc-1415	418	3	wolner	wolner	PROPN
dpc-1415	418	4	zj	zj	PROPN
dpc-1415	418	5	,	,	PUNCT
dpc-1415	418	6	marghoob	marghoob	VERB
dpc-1415	418	7	aa	aa	PROPN
dpc-1415	418	8	,	,	PUNCT
dpc-1415	418	9	pulitzer	pulitzer	PROPN
dpc-1415	418	10	mp	mp	PROPN
dpc-1415	418	11	,	,	PUNCT
dpc-1415	418	12	et	et	PROPN
dpc-1415	418	13	al	al	PROPN
dpc-1415	418	14	.	.	PUNCT
dpc-1415	419	1	a	a	DET
dpc-1415	419	2	case	case	NOUN
dpc-1415	419	3	report	report	NOUN
dpc-1415	419	4	of	of	ADP
dpc-1415	419	5	disappearing	disappear	VERB
dpc-1415	419	6	pigmented	pigmented	ADJ
dpc-1415	419	7	skin	skin	NOUN
dpc-1415	419	8	lesions	lesion	NOUN
dpc-1415	419	9	associated	associate	VERB
dpc-1415	419	10	with	with	ADP
dpc-1415	419	11	pembrolizumab	pembrolizumab	NOUN
dpc-1415	419	12	treatment	treatment	NOUN
dpc-1415	419	13	for	for	ADP
dpc-1415	419	14	metastatic	metastatic	ADJ
dpc-1415	419	15	melanoma	melanoma	NOUN
dpc-1415	419	16	.	.	PUNCT
dpc-1415	420	1	br	br	PROPN
dpc-1415	420	2	j	j	PROPN
dpc-1415	420	3	dermatol	dermatol	NOUN
dpc-1415	420	4	.	.	PUNCT
dpc-1415	421	1	2018;178(1):265	2018;178(1):265	NUM
dpc-1415	421	2	-	-	SYM
dpc-1415	421	3	269	269	NUM
dpc-1415	421	4	.	.	PUNCT
dpc-1415	421	5	doi	doi	NOUN
dpc-1415	421	6	:	:	PUNCT
dpc-1415	421	7	10.1111	10.1111	NUM
dpc-1415	421	8	/	/	SYM
dpc-1415	421	9	bjd.15354	bjd.15354	PROPN
dpc-1415	421	10	.	.	PUNCT
dpc-1415	422	1	pmid	pmid	NOUN
dpc-1415	422	2	:	:	PUNCT
dpc-1415	422	3	28132411	28132411	NUM
dpc-1415	422	4	.	.	PUNCT
dpc-1415	423	1	39	39	NUM
dpc-1415	423	2	.	.	PUNCT
dpc-1415	424	1	hwang	hwang	PROPN
dpc-1415	424	2	sj	sj	PROPN
dpc-1415	424	3	,	,	PUNCT
dpc-1415	424	4	carlos	carlos	PROPN
dpc-1415	424	5	g	g	PROPN
dpc-1415	424	6	,	,	PUNCT
dpc-1415	424	7	wakade	wakade	NOUN
dpc-1415	424	8	d	d	NOUN
dpc-1415	424	9	,	,	PUNCT
dpc-1415	424	10	et	et	PROPN
dpc-1415	424	11	al	al	PROPN
dpc-1415	424	12	.	.	PUNCT
dpc-1415	425	1	cutaneous	cutaneous	ADJ
dpc-1415	425	2	adverse	adverse	ADJ
dpc-1415	425	3	events	event	NOUN
dpc-1415	425	4	(	(	PUNCT
dpc-1415	425	5	aes	aes	NOUN
dpc-1415	425	6	)	)	PUNCT
dpc-1415	425	7	of	of	ADP
dpc-1415	425	8	anti	anti	ADJ
dpc-1415	425	9	-	-	ADJ
dpc-1415	425	10	programmed	programmed	ADJ
dpc-1415	425	11	cell	cell	NOUN
dpc-1415	425	12	death	death	NOUN
dpc-1415	425	13	(	(	PUNCT
dpc-1415	425	14	pd)-1	pd)-1	NOUN
dpc-1415	425	15	therapy	therapy	NOUN
dpc-1415	425	16	in	in	ADP
dpc-1415	425	17	patients	patient	NOUN
dpc-1415	425	18	with	with	ADP
dpc-1415	425	19	metastatic	metastatic	ADJ
dpc-1415	425	20	melanoma	melanoma	NOUN
dpc-1415	425	21	:	:	PUNCT
dpc-1415	425	22	a	a	DET
dpc-1415	425	23	single	single	ADJ
dpc-1415	425	24	-	-	PUNCT
dpc-1415	425	25	institution	institution	NOUN
dpc-1415	425	26	cohort	cohort	NOUN
dpc-1415	425	27	.	.	PUNCT
dpc-1415	426	1	j	j	PROPN
dpc-1415	426	2	am	be	AUX
dpc-1415	426	3	acad	acad	ADJ
dpc-1415	426	4	dermatol	dermatol	NOUN
dpc-1415	426	5	.	.	PUNCT
dpc-1415	427	1	2016;74(3):455–461.e1	2016;74(3):455–461.e1	X
dpc-1415	427	2	.	.	PUNCT
dpc-1415	428	1	doi	doi	NOUN
dpc-1415	428	2	:	:	PUNCT
dpc-1415	428	3	10.1016	10.1016	NUM
dpc-1415	428	4	/	/	SYM
dpc-1415	428	5	j.	j.	PROPN
dpc-1415	428	6	jaad.2015.10.029	jaad.2015.10.029	PROPN
dpc-1415	428	7	pmid	pmid	PROPN
dpc-1415	428	8	:	:	PUNCT
dpc-1415	428	9	26793994	26793994	NUM
dpc-1415	428	10	40	40	NUM
dpc-1415	428	11	.	.	PUNCT
dpc-1415	429	1	freeman	freeman	PROPN
dpc-1415	429	2	-	-	PUNCT
dpc-1415	429	3	keller	keller	PROPN
dpc-1415	429	4	m	m	PROPN
dpc-1415	429	5	,	,	PUNCT
dpc-1415	429	6	kim	kim	PROPN
dpc-1415	429	7	y	y	PROPN
dpc-1415	429	8	,	,	PUNCT
dpc-1415	429	9	cronin	cronin	PROPN
dpc-1415	429	10	h.	h.	PROPN
dpc-1415	429	11	nivolumab	nivolumab	PROPN
dpc-1415	429	12	in	in	ADP
dpc-1415	429	13	resected	resected	ADJ
dpc-1415	429	14	and	and	CCONJ
dpc-1415	429	15	unresectable	unresectable	ADJ
dpc-1415	429	16	metastatic	metastatic	ADJ
dpc-1415	429	17	melanoma	melanoma	NOUN
dpc-1415	429	18	:	:	PUNCT
dpc-1415	429	19	characteristics	characteristic	NOUN
dpc-1415	429	20	of	of	ADP
dpc-1415	429	21	immune	immune	ADJ
dpc-1415	429	22	related	relate	VERB
dpc-1415	429	23	adverse	adverse	ADJ
dpc-1415	429	24	events	event	NOUN
dpc-1415	429	25	and	and	CCONJ
dpc-1415	429	26	association	association	NOUN
dpc-1415	429	27	with	with	ADP
dpc-1415	429	28	outcomes	outcome	NOUN
dpc-1415	429	29	.	.	PUNCT
dpc-1415	430	1	clin	clin	PROPN
dpc-1415	430	2	cancer	cancer	NOUN
dpc-1415	430	3	res	re	NOUN
dpc-1415	430	4	.	.	PUNCT
dpc-1415	431	1	2016;22(4):886	2016;22(4):886	NUM
dpc-1415	431	2	-	-	SYM
dpc-1415	431	3	894	894	NUM
dpc-1415	431	4	.	.	PUNCT
dpc-1415	432	1	doi	doi	NOUN
dpc-1415	432	2	:	:	PUNCT
dpc-1415	432	3	10.1158/1078	10.1158/1078	NUM
dpc-1415	432	4	-	-	PUNCT
dpc-1415	432	5	0432.ccr-151136	0432.ccr-151136	NOUN
dpc-1415	432	6	.	.	PUNCT
dpc-1415	433	1	pmid	pmid	NOUN
dpc-1415	433	2	:	:	PUNCT
dpc-1415	433	3	26446948	26446948	NUM
dpc-1415	433	4	.	.	PUNCT
dpc-1415	434	1	41	41	NUM
dpc-1415	434	2	.	.	PUNCT
dpc-1415	435	1	nakamura	nakamura	PROPN
dpc-1415	435	2	y	y	PROPN
dpc-1415	435	3	,	,	PUNCT
dpc-1415	435	4	tanaka	tanaka	PROPN
dpc-1415	435	5	r	r	PROPN
dpc-1415	435	6	,	,	PUNCT
dpc-1415	435	7	asami	asami	PROPN
dpc-1415	435	8	y	y	PROPN
dpc-1415	435	9	,	,	PUNCT
dpc-1415	435	10	et	et	PROPN
dpc-1415	435	11	al	al	PROPN
dpc-1415	435	12	.	.	PROPN
dpc-1415	435	13	correlation	correlation	NOUN
dpc-1415	435	14	between	between	ADP
dpc-1415	435	15	vitiligo	vitiligo	NOUN
dpc-1415	435	16	occurrence	occurrence	NOUN
dpc-1415	435	17	and	and	CCONJ
dpc-1415	435	18	clinical	clinical	ADJ
dpc-1415	435	19	benefit	benefit	NOUN
dpc-1415	435	20	in	in	ADP
dpc-1415	435	21	advanced	advanced	ADJ
dpc-1415	435	22	melanoma	melanoma	NOUN
dpc-1415	435	23	patients	patient	NOUN
dpc-1415	435	24	treated	treat	VERB
dpc-1415	435	25	with	with	ADP
dpc-1415	435	26	nivolumab	nivolumab	NOUN
dpc-1415	435	27	:	:	PUNCT
dpc-1415	435	28	a	a	DET
dpc-1415	435	29	multi	multi	ADJ
dpc-1415	435	30	-	-	ADJ
dpc-1415	435	31	institutional	institutional	ADJ
dpc-1415	435	32	retrospective	retrospective	ADJ
dpc-1415	435	33	study	study	NOUN
dpc-1415	435	34	.	.	PUNCT
dpc-1415	436	1	j	j	PROPN
dpc-1415	436	2	dermatol	dermatol	NOUN
dpc-1415	436	3	.	.	PUNCT
dpc-1415	437	1	2017;44(2):117	2017;44(2):117	NUM
dpc-1415	437	2	-	-	SYM
dpc-1415	437	3	122	122	NUM
dpc-1415	437	4	.	.	PUNCT
dpc-1415	438	1	doi	doi	NOUN
dpc-1415	438	2	:	:	PUNCT
dpc-1415	438	3	10.1111/13468138.13520	10.1111/13468138.13520	NUM
dpc-1415	438	4	.	.	PUNCT
dpc-1415	439	1	pmid	pmid	NOUN
dpc-1415	439	2	:	:	PUNCT
dpc-1415	439	3	27510892	27510892	NUM
dpc-1415	439	4	.	.	PUNCT
dpc-1415	440	1	42	42	NUM
dpc-1415	440	2	.	.	PUNCT
dpc-1415	441	1	teulings	teuling	NOUN
dpc-1415	441	2	he	he	PRON
dpc-1415	441	3	,	,	PUNCT
dpc-1415	441	4	limpens	limpens	PROPN
dpc-1415	441	5	j	j	PROPN
dpc-1415	441	6	,	,	PUNCT
dpc-1415	441	7	jansen	jansen	PROPN
dpc-1415	441	8	sn	sn	PROPN
dpc-1415	441	9	,	,	PUNCT
dpc-1415	441	10	et	et	PROPN
dpc-1415	441	11	al	al	PROPN
dpc-1415	441	12	.	.	PROPN
dpc-1415	441	13	vitiligo	vitiligo	PROPN
dpc-1415	441	14	-	-	PUNCT
dpc-1415	441	15	like	like	ADJ
dpc-1415	441	16	depigmentation	depigmentation	NOUN
dpc-1415	441	17	in	in	ADP
dpc-1415	441	18	patients	patient	NOUN
dpc-1415	441	19	with	with	ADP
dpc-1415	441	20	stage	stage	NOUN
dpc-1415	441	21	iii	iii	NOUN
dpc-1415	441	22	-	-	PUNCT
dpc-1415	441	23	iv	iv	NUM
dpc-1415	441	24	melanoma	melanoma	NOUN
dpc-1415	441	25	receiving	receive	VERB
dpc-1415	441	26	immunotherapy	immunotherapy	NOUN
dpc-1415	441	27	and	and	CCONJ
dpc-1415	441	28	its	its	PRON
dpc-1415	441	29	association	association	NOUN
dpc-1415	441	30	with	with	ADP
dpc-1415	441	31	survival	survival	NOUN
dpc-1415	441	32	:	:	PUNCT
dpc-1415	441	33	a	a	DET
dpc-1415	441	34	systematic	systematic	ADJ
dpc-1415	441	35	review	review	NOUN
dpc-1415	441	36	and	and	CCONJ
dpc-1415	441	37	meta	meta	ADJ
dpc-1415	441	38	-	-	PUNCT
dpc-1415	441	39	analysis	analysis	NOUN
dpc-1415	441	40	.	.	PUNCT
dpc-1415	442	1	j	j	PROPN
dpc-1415	442	2	clin	clin	PROPN
dpc-1415	442	3	oncol	oncol	PROPN
dpc-1415	442	4	2015;33(7):773e81	2015;33(7):773e81	NUM
dpc-1415	442	5	.	.	PUNCT
dpc-1415	443	1	doi	doi	NOUN
dpc-1415	443	2	:	:	PUNCT
dpc-1415	443	3	10.1200/	10.1200/	NUM
dpc-1415	443	4	jco.2014.57.4756	jco.2014.57.4756	PROPN
dpc-1415	443	5	.	.	PUNCT
dpc-1415	444	1	pmid	pmid	PROPN
dpc-1415	444	2	:	:	PUNCT
dpc-1415	444	3	25605840	25605840	NUM
dpc-1415	444	4	.	.	PUNCT
dpc-1415	445	1	43	43	NUM
dpc-1415	445	2	.	.	PUNCT
dpc-1415	446	1	nardin	nardin	ADV
dpc-1415	446	2	c	c	X
dpc-1415	446	3	,	,	PUNCT
dpc-1415	446	4	jeand’heur	jeand’heur	NOUN
dpc-1415	446	5	a	a	PRON
dpc-1415	446	6	,	,	PUNCT
dpc-1415	446	7	bouiller	bouiller	NOUN
dpc-1415	446	8	k	k	PROPN
dpc-1415	446	9	,	,	PUNCT
dpc-1415	446	10	et	et	PROPN
dpc-1415	446	11	al	al	PROPN
dpc-1415	446	12	.	.	PROPN
dpc-1415	446	13	vitiligo	vitiligo	PROPN
dpc-1415	446	14	under	under	ADP
dpc-1415	446	15	anti	anti	ADJ
dpc-1415	446	16	-	-	ADJ
dpc-1415	446	17	programmed	programmed	ADJ
dpc-1415	446	18	cell	cell	NOUN
dpc-1415	446	19	death-1	death-1	NUM
dpc-1415	446	20	therapy	therapy	NOUN
dpc-1415	446	21	is	be	AUX
dpc-1415	446	22	associated	associate	VERB
dpc-1415	446	23	with	with	ADP
dpc-1415	446	24	increased	increase	VERB
dpc-1415	446	25	survival	survival	NOUN
dpc-1415	446	26	in	in	ADP
dpc-1415	446	27	melanoma	melanoma	NOUN
dpc-1415	446	28	patients	patient	NOUN
dpc-1415	446	29	.	.	PUNCT
dpc-1415	447	1	j	j	PROPN
dpc-1415	447	2	am	be	AUX
dpc-1415	447	3	acad	acad	ADJ
dpc-1415	447	4	dermatol	dermatol	NOUN
dpc-1415	447	5	.	.	PUNCT
dpc-1415	448	1	2020;82(3):770	2020;82(3):770	X
dpc-1415	448	2	-	-	SYM
dpc-1415	448	3	772	772	NUM
dpc-1415	448	4	.	.	PUNCT
dpc-1415	449	1	doi	doi	NOUN
dpc-1415	449	2	:	:	PUNCT
dpc-1415	449	3	10.1016	10.1016	NUM
dpc-1415	449	4	/	/	SYM
dpc-1415	449	5	j.jaad.2019.11.017	j.jaad.2019.11.017	NOUN
dpc-1415	449	6	.	.	PUNCT
dpc-1415	450	1	pmid	pmid	NOUN
dpc-1415	450	2	:	:	PUNCT
dpc-1415	450	3	31734192	31734192	NUM
dpc-1415	450	4	.	.	PUNCT
dpc-1415	451	1	44	44	NUM
dpc-1415	451	2	.	.	PUNCT
dpc-1415	452	1	roujeau	roujeau	PROPN
dpc-1415	452	2	jc	jc	PROPN
dpc-1415	452	3	,	,	PUNCT
dpc-1415	452	4	stern	stern	ADJ
dpc-1415	452	5	rs	rs	NOUN
dpc-1415	452	6	.	.	PUNCT
dpc-1415	453	1	severe	severe	ADJ
dpc-1415	453	2	adverse	adverse	ADJ
dpc-1415	453	3	cutaneous	cutaneous	ADJ
dpc-1415	453	4	reactions	reaction	NOUN
dpc-1415	453	5	to	to	ADP
dpc-1415	453	6	drugs	drug	NOUN
dpc-1415	453	7	.	.	PUNCT
dpc-1415	454	1	n	n	PRON
dpc-1415	454	2	engl	engl	PROPN
dpc-1415	454	3	j	j	PROPN
dpc-1415	454	4	med	med	PROPN
dpc-1415	454	5	.	.	PUNCT
dpc-1415	454	6	1994;331:1272	1994;331:1272	NUM
dpc-1415	454	7	-	-	SYM
dpc-1415	454	8	1285	1285	NUM
dpc-1415	454	9	.	.	PUNCT
dpc-1415	455	1	doi	doi	NOUN
dpc-1415	455	2	:	:	PUNCT
dpc-1415	455	3	10.1056/	10.1056/	NUM
dpc-1415	455	4	nejm199411103311906	nejm199411103311906	PROPN
dpc-1415	455	5	.	.	PROPN
dpc-1415	455	6	doi	doi	PROPN
dpc-1415	455	7	:	:	PUNCT
dpc-1415	455	8	10.1056	10.1056	NUM
dpc-1415	455	9	/	/	SYM
dpc-1415	455	10	nejm19941110331	nejm19941110331	PROPN
dpc-1415	455	11	1906	1906	NUM
dpc-1415	455	12	.	.	PUNCT
dpc-1415	456	1	pmid	pmid	NOUN
dpc-1415	456	2	:	:	PUNCT
dpc-1415	456	3	7794310	7794310	NUM
dpc-1415	456	4	.	.	PUNCT
dpc-1415	457	1	45	45	NUM
dpc-1415	457	2	.	.	PUNCT
dpc-1415	457	3	logan	logan	PROPN
dpc-1415	457	4	it	it	PRON
dpc-1415	457	5	,	,	PUNCT
dpc-1415	457	6	zaman	zaman	PROPN
dpc-1415	457	7	s	s	PROPN
dpc-1415	457	8	,	,	PUNCT
dpc-1415	457	9	hussein	hussein	PROPN
dpc-1415	457	10	l	l	PROPN
dpc-1415	457	11	,	,	PUNCT
dpc-1415	457	12	et	et	PROPN
dpc-1415	457	13	al	al	PROPN
dpc-1415	457	14	.	.	PROPN
dpc-1415	457	15	combination	combination	NOUN
dpc-1415	457	16	therapy	therapy	NOUN
dpc-1415	457	17	of	of	ADP
dpc-1415	457	18	ipilimumab	ipilimumab	NOUN
dpc-1415	457	19	and	and	CCONJ
dpc-1415	457	20	nivolumab	nivolumab	ADV
dpc-1415	457	21	-	-	PUNCT
dpc-1415	457	22	associated	associate	VERB
dpc-1415	457	23	toxic	toxic	ADJ
dpc-1415	457	24	epidermal	epidermal	ADJ
dpc-1415	457	25	necrolysis	necrolysis	NOUN
dpc-1415	457	26	(	(	PUNCT
dpc-1415	457	27	ten	ten	NUM
dpc-1415	457	28	)	)	PUNCT
dpc-1415	457	29	in	in	ADP
dpc-1415	457	30	a	a	DET
dpc-1415	457	31	patient	patient	NOUN
dpc-1415	457	32	with	with	ADP
dpc-1415	457	33	metastatic	metastatic	ADJ
dpc-1415	457	34	melanoma	melanoma	NOUN
dpc-1415	457	35	:	:	PUNCT
dpc-1415	457	36	a	a	DET
dpc-1415	457	37	case	case	NOUN
dpc-1415	457	38	report	report	NOUN
dpc-1415	457	39	and	and	CCONJ
dpc-1415	457	40	literature	literature	PROPN
dpc-1415	457	41	review	review	PROPN
dpc-1415	457	42	.	.	PUNCT
dpc-1415	458	1	j	j	PROPN
dpc-1415	458	2	immunother	immunother	PROPN
dpc-1415	458	3	.	.	PUNCT
dpc-1415	459	1	2020;43(3):89	2020;43(3):89	NOUN
dpc-1415	459	2	-	-	SYM
dpc-1415	459	3	92	92	NUM
dpc-1415	459	4	.	.	PUNCT
dpc-1415	460	1	doi	doi	NOUN
dpc-1415	460	2	:	:	PUNCT
dpc-1415	460	3	10.1097	10.1097	NUM
dpc-1415	460	4	/	/	SYM
dpc-1415	460	5	cji.0000000000000302	cji.0000000000000302	NUM
dpc-1415	460	6	.	.	PUNCT
dpc-1415	461	1	pmid	pmid	NOUN
dpc-1415	461	2	:	:	PUNCT
dpc-1415	461	3	31651559	31651559	NUM
dpc-1415	461	4	.	.	PUNCT
dpc-1415	462	1	46	46	NUM
dpc-1415	462	2	.	.	PUNCT
dpc-1415	462	3	mirzas	mirzas	PROPN
dpc-1415	462	4	,	,	PUNCT
dpc-1415	462	5	hill	hill	PROPN
dpc-1415	462	6	e	e	PROPN
dpc-1415	462	7	,	,	PUNCT
dpc-1415	462	8	ludlow	ludlow	PROPN
dpc-1415	462	9	sp	sp	PROPN
dpc-1415	462	10	,	,	PUNCT
dpc-1415	462	11	et	et	PROPN
dpc-1415	462	12	al	al	PROPN
dpc-1415	462	13	.	.	PROPN
dpc-1415	463	1	checkpoint	checkpoint	NOUN
dpc-1415	463	2	inhibitor	inhibitor	NOUN
dpc-1415	463	3	-	-	PUNCT
dpc-1415	463	4	associated	associate	VERB
dpc-1415	463	5	drug	drug	NOUN
dpc-1415	463	6	reaction	reaction	NOUN
dpc-1415	463	7	with	with	ADP
dpc-1415	463	8	eosinophilia	eosinophilia	PROPN
dpc-1415	463	9	and	and	CCONJ
dpc-1415	463	10	systemic	systemic	ADJ
dpc-1415	463	11	symptom	symptom	NOUN
dpc-1415	463	12	syndrome	syndrome	NOUN
dpc-1415	463	13	.	.	PUNCT
dpc-1415	464	1	melanoma	melanoma	NOUN
dpc-1415	464	2	res	re	NOUN
dpc-1415	464	3	.	.	PUNCT
dpc-1415	465	1	2017;27(3):271	2017;27(3):271	NOUN
dpc-1415	465	2	-	-	SYM
dpc-1415	465	3	273	273	NUM
dpc-1415	465	4	.	.	PUNCT
dpc-1415	466	1	doi	doi	NOUN
dpc-1415	466	2	:	:	PUNCT
dpc-1415	466	3	10.1097/	10.1097/	NUM
dpc-1415	466	4	cmr.0000000000000326	cmr.0000000000000326	NOUN
dpc-1415	466	5	.	.	PUNCT
dpc-1415	467	1	pmid	pmid	NOUN
dpc-1415	467	2	:	:	PUNCT
dpc-1415	467	3	28146044	28146044	NUM
dpc-1415	467	4	.	.	PUNCT
dpc-1415	468	1	47	47	NUM
dpc-1415	468	2	.	.	PUNCT
dpc-1415	468	3	di	di	PROPN
dpc-1415	468	4	palma	palma	NOUN
dpc-1415	468	5	-	-	PUNCT
dpc-1415	468	6	grisi	grisi	PROPN
dpc-1415	468	7	jc	jc	PROPN
dpc-1415	468	8	,	,	PUNCT
dpc-1415	468	9	vijayagopal	vijayagopal	PROPN
dpc-1415	468	10	k	k	PROPN
dpc-1415	468	11	,	,	PUNCT
dpc-1415	468	12	muslimani	muslimani	PROPN
dpc-1415	468	13	ma	ma	PROPN
dpc-1415	468	14	.	.	PROPN
dpc-1415	468	15	case	case	NOUN
dpc-1415	468	16	reports	report	NOUN
dpc-1415	468	17	of	of	ADP
dpc-1415	468	18	dress	dress	NOUN
dpc-1415	468	19	syndrome	syndrome	NOUN
dpc-1415	468	20	and	and	CCONJ
dpc-1415	468	21	symptoms	symptom	NOUN
dpc-1415	468	22	consistent	consistent	ADJ
dpc-1415	468	23	with	with	ADP
dpc-1415	468	24	dress	dress	NOUN
dpc-1415	468	25	syndrome	syndrome	NOUN
dpc-1415	468	26	following	follow	VERB
dpc-1415	468	27	treatment	treatment	NOUN
dpc-1415	468	28	with	with	ADP
dpc-1415	468	29	recently	recently	ADV
dpc-1415	468	30	marked	mark	VERB
dpc-1415	468	31	monoclonal	monoclonal	NOUN
dpc-1415	468	32	antibodies	antibody	NOUN
dpc-1415	468	33	.	.	PUNCT
dpc-1415	469	1	autoimmune	autoimmune	PROPN
dpc-1415	469	2	dis	dis	PROPN
dpc-1415	469	3	.	.	PUNCT
dpc-1415	470	1	2019;2019:7595706	2019;2019:7595706	NUM
dpc-1415	470	2	.	.	PUNCT
dpc-1415	471	1	doi	doi	PROPN
dpc-1415	471	2	:	:	PUNCT
dpc-1415	471	3	10.1155/2019/7595706	10.1155/2019/7595706	NUM
dpc-1415	471	4	.	.	PUNCT
dpc-1415	472	1	pmid	pmid	NOUN
dpc-1415	472	2	:	:	PUNCT
dpc-1415	472	3	31308976	31308976	NUM
dpc-1415	472	4	.	.	PUNCT
dpc-1415	473	1	48	48	NUM
dpc-1415	473	2	.	.	PUNCT
dpc-1415	474	1	horii	horii	PROPN
dpc-1415	474	2	m	m	PROPN
dpc-1415	474	3	,	,	PUNCT
dpc-1415	474	4	kobayashi	kobayashi	PROPN
dpc-1415	474	5	t	t	PROPN
dpc-1415	474	6	,	,	PUNCT
dpc-1415	474	7	maeda	maeda	PROPN
dpc-1415	474	8	s	s	PROPN
dpc-1415	474	9	,	,	PUNCT
dpc-1415	474	10	et	et	PROPN
dpc-1415	474	11	al	al	PROPN
dpc-1415	474	12	.	.	PROPN
dpc-1415	474	13	stevens	stevens	PROPN
dpc-1415	474	14	-	-	PUNCT
dpc-1415	474	15	johnson	johnson	PROPN
dpc-1415	474	16	syndrome	syndrome	PROPN
dpc-1415	474	17	associated	associate	VERB
dpc-1415	474	18	with	with	ADP
dpc-1415	474	19	radiation	radiation	NOUN
dpc-1415	474	20	recall	recall	NOUN
dpc-1415	474	21	dermatitis	dermatitis	PROPN
dpc-1415	474	22	in	in	ADP
dpc-1415	474	23	a	a	DET
dpc-1415	474	24	patient	patient	NOUN
dpc-1415	474	25	treated	treat	VERB
dpc-1415	474	26	with	with	ADP
dpc-1415	474	27	immune	immune	ADJ
dpc-1415	474	28	checkpoint	checkpoint	NOUN
dpc-1415	474	29	inhibitor	inhibitor	NOUN
dpc-1415	474	30	.	.	PUNCT
dpc-1415	475	1	j	j	PROPN
dpc-1415	475	2	dermatol	dermatol	NOUN
dpc-1415	475	3	.	.	PUNCT
dpc-1415	476	1	2019	2019	NUM
dpc-1415	476	2	;	;	PUNCT
dpc-1415	477	1	46(11):e434	46(11):e434	X
dpc-1415	477	2	-	-	SYM
dpc-1415	477	3	e436	e436	PROPN
dpc-1415	477	4	.	.	PUNCT
dpc-1415	478	1	doi	doi	NOUN
dpc-1415	478	2	:	:	PUNCT
dpc-1415	478	3	10.1111/1346	10.1111/1346	NUM
dpc-1415	478	4	-	-	SYM
dpc-1415	478	5	8138.15027	8138.15027	NUM
dpc-1415	478	6	.	.	PUNCT
dpc-1415	479	1	pmid	pmid	NOUN
dpc-1415	479	2	:	:	PUNCT
dpc-1415	479	3	31342541	31342541	NUM
dpc-1415	479	4	.	.	PUNCT
dpc-1415	480	1	49	49	NUM
dpc-1415	480	2	.	.	PUNCT
dpc-1415	480	3	dasanu	dasanu	PROPN
dpc-1415	480	4	ca	can	AUX
dpc-1415	480	5	.	.	PUNCT
dpc-1415	481	1	late	late	ADJ
dpc-1415	481	2	-	-	PUNCT
dpc-1415	481	3	onset	onset	NOUN
dpc-1415	481	4	stevens	stevens	PROPN
dpc-1415	481	5	-	-	PUNCT
dpc-1415	481	6	johnson	johnson	PROPN
dpc-1415	481	7	syndrome	syndrome	NOUN
dpc-1415	481	8	due	due	ADP
dpc-1415	481	9	to	to	ADP
dpc-1415	481	10	nivolumab	nivolumab	NOUN
dpc-1415	481	11	use	use	NOUN
dpc-1415	481	12	for	for	ADP
dpc-1415	481	13	hepatocellular	hepatocellular	ADJ
dpc-1415	481	14	carcinoma	carcinoma	NOUN
dpc-1415	481	15	.	.	PUNCT
dpc-1415	482	1	j	j	PROPN
dpc-1415	482	2	oncol	oncol	ADJ
dpc-1415	482	3	pharm	pharm	NOUN
dpc-1415	482	4	pract	pract	PROPN
dpc-1415	482	5	.	.	PUNCT
dpc-1415	483	1	2019;25(8):2052	2019;25(8):2052	NUM
dpc-1415	483	2	-	-	PUNCT
dpc-1415	483	3	2055	2055	NUM
dpc-1415	483	4	.	.	PUNCT
dpc-1415	484	1	doi	doi	NOUN
dpc-1415	484	2	:	:	PUNCT
dpc-1415	484	3	10.1177/1078155219830166	10.1177/1078155219830166	NUM
dpc-1415	484	4	.	.	PUNCT
dpc-1415	485	1	pmid	pmid	NOUN
dpc-1415	485	2	:	:	PUNCT
dpc-1415	485	3	30782092	30782092	NUM
dpc-1415	485	4	.	.	PUNCT
dpc-1415	486	1	50	50	NUM
dpc-1415	486	2	.	.	PUNCT
dpc-1415	487	1	hwang	hwang	PROPN
dpc-1415	487	2	sj	sj	PROPN
dpc-1415	487	3	,	,	PUNCT
dpc-1415	487	4	carlos	carlos	PROPN
dpc-1415	487	5	g	g	PROPN
dpc-1415	487	6	,	,	PUNCT
dpc-1415	487	7	wakade	wakade	NOUN
dpc-1415	487	8	d	d	NOUN
dpc-1415	487	9	,	,	PUNCT
dpc-1415	487	10	et	et	PROPN
dpc-1415	487	11	al	al	PROPN
dpc-1415	487	12	.	.	PROPN
dpc-1415	487	13	ipilimumab	ipilimumab	ADV
dpc-1415	487	14	-	-	PUNCT
dpc-1415	487	15	induced	induce	VERB
dpc-1415	487	16	acute	acute	NOUN
dpc-1415	487	17	generalized	generalize	VERB
dpc-1415	487	18	exanthematous	exanthematous	ADJ
dpc-1415	487	19	pustulosis	pustulosis	NOUN
dpc-1415	487	20	in	in	ADP
dpc-1415	487	21	a	a	DET
dpc-1415	487	22	patient	patient	NOUN
dpc-1415	487	23	with	with	ADP
dpc-1415	487	24	metastatic	metastatic	ADJ
dpc-1415	487	25	melanoma	melanoma	NOUN
dpc-1415	487	26	.	.	PUNCT
dpc-1415	488	1	melanoma	melanoma	NOUN
dpc-1415	488	2	res	re	NOUN
dpc-1415	488	3	.	.	PUNCT
dpc-1415	489	1	2016;26(4):417	2016;26(4):417	NUM
dpc-1415	489	2	-	-	PUNCT
dpc-1415	489	3	420	420	NUM
dpc-1415	489	4	.	.	PUNCT
dpc-1415	490	1	doi	doi	NOUN
dpc-1415	490	2	:	:	PUNCT
dpc-1415	490	3	10.1097/	10.1097/	NUM
dpc-1415	490	4	cmr.0000000000000261	cmr.0000000000000261	X
dpc-1415	490	5	.	.	PUNCT
dpc-1415	491	1	pmid	pmid	NOUN
dpc-1415	491	2	:	:	PUNCT
dpc-1415	491	3	27031538	27031538	NUM
dpc-1415	491	4	.	.	PUNCT
dpc-1415	492	1	51	51	NUM
dpc-1415	492	2	.	.	PUNCT
dpc-1415	492	3	page	page	NOUN
dpc-1415	492	4	b	b	PROPN
dpc-1415	492	5	,	,	PUNCT
dpc-1415	492	6	borradori	borradori	PROPN
dpc-1415	492	7	l	l	NOUN
dpc-1415	492	8	,	,	PUNCT
dpc-1415	492	9	beltraminelli	beltraminelli	PROPN
dpc-1415	492	10	h	h	NOUN
dpc-1415	492	11	,	,	PUNCT
dpc-1415	492	12	et	et	PROPN
dpc-1415	492	13	al	al	PROPN
dpc-1415	492	14	.	.	PROPN
dpc-1415	492	15	acute	acute	PROPN
dpc-1415	492	16	generalized	generalize	VERB
dpc-1415	492	17	exanthematous	exanthematous	ADJ
dpc-1415	492	18	pustulosis	pustulosis	NOUN
dpc-1415	492	19	associated	associate	VERB
dpc-1415	492	20	with	with	ADP
dpc-1415	492	21	ipilimumab	ipilimumab	NOUN
dpc-1415	492	22	and	and	CCONJ
dpc-1415	492	23	nivolumab	nivolumab	NOUN
dpc-1415	492	24	.	.	PUNCT
dpc-1415	493	1	j	j	PROPN
dpc-1415	493	2	eur	eur	PROPN
dpc-1415	493	3	acad	acad	PROPN
dpc-1415	493	4	dermatol	dermatol	NOUN
dpc-1415	493	5	venereol	venereol	NOUN
dpc-1415	493	6	.	.	PUNCT
dpc-1415	494	1	2018;32(7):e256	2018;32(7):e256	NUM
dpc-1415	494	2	-	-	PUNCT
dpc-1415	494	3	e257	e257	PROPN
dpc-1415	494	4	..	..	PUNCT
dpc-1415	494	5	doi	doi	NOUN
dpc-1415	494	6	:	:	PUNCT
dpc-1415	494	7	10.1111	10.1111	NUM
dpc-1415	494	8	/	/	SYM
dpc-1415	494	9	jdv.14282	jdv.14282	PROPN
dpc-1415	494	10	.	.	PUNCT
dpc-1415	495	1	pmid	pmid	NOUN
dpc-1415	495	2	:	:	PUNCT
dpc-1415	495	3	28430376	28430376	NUM
dpc-1415	495	4	.	.	PUNCT
dpc-1415	496	1	52	52	NUM
dpc-1415	496	2	.	.	PUNCT
dpc-1415	497	1	perret	perret	PROPN
dpc-1415	497	2	re	re	PROPN
dpc-1415	497	3	,	,	PUNCT
dpc-1415	497	4	josselin	josselin	PROPN
dpc-1415	497	5	n	n	CCONJ
dpc-1415	497	6	,	,	PUNCT
dpc-1415	497	7	knol	knol	PROPN
dpc-1415	497	8	ac	ac	PROPN
dpc-1415	497	9	,	,	PUNCT
dpc-1415	497	10	et	et	PROPN
dpc-1415	497	11	al	al	PROPN
dpc-1415	497	12	.	.	PUNCT
dpc-1415	498	1	histopathological	histopathological	ADJ
dpc-1415	498	2	aspects	aspect	NOUN
dpc-1415	498	3	of	of	ADP
dpc-1415	498	4	cutaneous	cutaneous	ADJ
dpc-1415	498	5	erythematous	erythematous	ADJ
dpc-1415	498	6	-	-	PUNCT
dpc-1415	498	7	papular	papular	ADJ
dpc-1415	498	8	eruptions	eruption	NOUN
dpc-1415	498	9	induced	induce	VERB
dpc-1415	498	10	by	by	ADP
dpc-1415	498	11	immune	immune	ADJ
dpc-1415	498	12	checkpoint	checkpoint	NOUN
dpc-1415	498	13	inhibitors	inhibitor	NOUN
dpc-1415	498	14	for	for	ADP
dpc-1415	498	15	the	the	DET
dpc-1415	498	16	treatment	treatment	NOUN
dpc-1415	498	17	of	of	ADP
dpc-1415	498	18	metastatic	metastatic	ADJ
dpc-1415	498	19	melanoma	melanoma	NOUN
dpc-1415	498	20	.	.	PUNCT
dpc-1415	499	1	int	int	NOUN
dpc-1415	499	2	j	j	PROPN
dpc-1415	499	3	dermatol	dermatol	NOUN
dpc-1415	499	4	.	.	PUNCT
dpc-1415	500	1	2017;56(5):527	2017;56(5):527	NUM
dpc-1415	500	2	-	-	PUNCT
dpc-1415	500	3	533	533	NUM
dpc-1415	500	4	.	.	PUNCT
dpc-1415	500	5	doi	doi	NOUN
dpc-1415	500	6	:	:	PUNCT
dpc-1415	500	7	10.1111	10.1111	NUM
dpc-1415	500	8	/	/	SYM
dpc-1415	500	9	ijd.13540	ijd.13540	PROPN
dpc-1415	500	10	.	.	PUNCT
dpc-1415	501	1	pmid	pmid	NOUN
dpc-1415	501	2	:	:	PUNCT
dpc-1415	501	3	28188628	28188628	NUM
dpc-1415	501	4	.	.	PUNCT
dpc-1415	502	1	53	53	NUM
dpc-1415	502	2	.	.	PUNCT
dpc-1415	503	1	munoz	munoz	PROPN
dpc-1415	503	2	j	j	PROPN
dpc-1415	503	3	,	,	PUNCT
dpc-1415	503	4	guillot	guillot	ADJ
dpc-1415	503	5	b	b	NOUN
dpc-1415	503	6	,	,	PUNCT
dpc-1415	503	7	girard	girard	PROPN
dpc-1415	503	8	c	c	PROPN
dpc-1415	503	9	,	,	PUNCT
dpc-1415	503	10	et	et	PROPN
dpc-1415	503	11	al	al	PROPN
dpc-1415	503	12	.	.	PUNCT
dpc-1415	504	1	first	first	ADJ
dpc-1415	504	2	report	report	NOUN
dpc-1415	504	3	of	of	ADP
dpc-1415	504	4	ipilimumab	ipilimumab	ADV
dpc-1415	504	5	-	-	PUNCT
dpc-1415	504	6	induced	induce	VERB
dpc-1415	504	7	grover	grover	NOUN
dpc-1415	504	8	disease	disease	NOUN
dpc-1415	504	9	.	.	PUNCT
dpc-1415	505	1	br	br	PROPN
dpc-1415	505	2	j	j	PROPN
dpc-1415	505	3	dermatol	dermatol	NOUN
dpc-1415	505	4	.	.	PUNCT
dpc-1415	506	1	2014;171(5):1236	2014;171(5):1236	NUM
dpc-1415	506	2	-	-	SYM
dpc-1415	506	3	1237	1237	NUM
dpc-1415	506	4	.	.	PUNCT
dpc-1415	507	1	doi	doi	NOUN
dpc-1415	507	2	:	:	PUNCT
dpc-1415	507	3	10.1111	10.1111	NUM
dpc-1415	507	4	/	/	SYM
dpc-1415	507	5	bjd.13058	bjd.13058	NOUN
dpc-1415	507	6	.	.	PUNCT
dpc-1415	508	1	pmid	pmid	NOUN
dpc-1415	508	2	:	:	PUNCT
dpc-1415	508	3	24749658	24749658	NUM
dpc-1415	508	4	.	.	PUNCT
dpc-1415	509	1	54	54	NUM
dpc-1415	509	2	.	.	PUNCT
dpc-1415	510	1	uemura	uemura	PROPN
dpc-1415	510	2	m	m	PROPN
dpc-1415	510	3	,	,	PUNCT
dpc-1415	510	4	faisal	faisal	PROPN
dpc-1415	510	5	f	f	PROPN
dpc-1415	510	6	,	,	PUNCT
dpc-1415	510	7	haymaker	haymaker	NOUN
dpc-1415	510	8	c	c	PROPN
dpc-1415	510	9	,	,	PUNCT
dpc-1415	510	10	et	et	PROPN
dpc-1415	510	11	al	al	PROPN
dpc-1415	510	12	.	.	PUNCT
dpc-1415	511	1	a	a	DET
dpc-1415	511	2	case	case	NOUN
dpc-1415	511	3	report	report	NOUN
dpc-1415	511	4	of	of	ADP
dpc-1415	511	5	grover	grover	NOUN
dpc-1415	511	6	’s	’s	PART
dpc-1415	511	7	disease	disease	NOUN
dpc-1415	511	8	from	from	ADP
dpc-1415	511	9	immunotherapy	immunotherapy	NOUN
dpc-1415	511	10	—	—	PUNCT
dpc-1415	511	11	a	a	DET
dpc-1415	511	12	skin	skin	NOUN
dpc-1415	511	13	toxicity	toxicity	NOUN
dpc-1415	511	14	induced	induce	VERB
dpc-1415	511	15	by	by	ADP
dpc-1415	511	16	inhibition	inhibition	NOUN
dpc-1415	511	17	of	of	ADP
dpc-1415	511	18	ctla-4	ctla-4	NOUN
dpc-1415	511	19	but	but	CCONJ
dpc-1415	511	20	not	not	PART
dpc-1415	511	21	pd-1	pd-1	ADV
dpc-1415	511	22	.	.	PUNCT
dpc-1415	512	1	j	j	PROPN
dpc-1415	512	2	immunother	immunother	ADJ
dpc-1415	512	3	cancer	cancer	NOUN
dpc-1415	512	4	.	.	PUNCT
dpc-1415	513	1	2016;4:55	2016;4:55	NOUN
dpc-1415	513	2	.	.	PUNCT
dpc-1415	514	1	doi	doi	NOUN
dpc-1415	514	2	:	:	PUNCT
dpc-1415	514	3	10.1186	10.1186	NUM
dpc-1415	514	4	/	/	SYM
dpc-1415	514	5	s40425	s40425	NOUN
dpc-1415	514	6	-	-	PUNCT
dpc-1415	514	7	016	016	NUM
dpc-1415	514	8	-	-	PUNCT
dpc-1415	514	9	0157	0157	NUM
dpc-1415	514	10	-	-	SYM
dpc-1415	514	11	6	6	NUM
dpc-1415	514	12	.	.	PUNCT
dpc-1415	515	1	pmid	pmid	NOUN
dpc-1415	515	2	:	:	PUNCT
dpc-1415	515	3	27660709	27660709	NUM
dpc-1415	515	4	.	.	PUNCT
dpc-1415	516	1	55	55	NUM
dpc-1415	516	2	.	.	PUNCT
dpc-1415	517	1	sheik	sheik	PROPN
dpc-1415	517	2	s	s	PROPN
dpc-1415	517	3	,	,	PUNCT
dpc-1415	517	4	goddard	goddard	PROPN
dpc-1415	517	5	al	al	PROPN
dpc-1415	517	6	,	,	PUNCT
dpc-1415	517	7	luke	luke	PROPN
dpc-1415	517	8	jj	jj	PROPN
dpc-1415	517	9	,	,	PUNCT
dpc-1415	517	10	et	et	PROPN
dpc-1415	517	11	al	al	PROPN
dpc-1415	517	12	.	.	PROPN
dpc-1415	517	13	drug	drug	NOUN
dpc-1415	517	14	-	-	PUNCT
dpc-1415	517	15	induced	induce	VERB
dpc-1415	517	16	dermatomyositis	dermatomyositis	NOUN
dpc-1415	517	17	following	follow	VERB
dpc-1415	517	18	ipilimumab	ipilimumab	NOUN
dpc-1415	517	19	therapy	therapy	NOUN
dpc-1415	517	20	.	.	PUNCT
dpc-1415	518	1	jama	jama	PROPN
dpc-1415	518	2	dermatol	dermatol	NOUN
dpc-1415	518	3	.	.	PUNCT
dpc-1415	519	1	2015;151(1):195	2015;151(1):195	NOUN
dpc-1415	519	2	-	-	SYM
dpc-1415	520	1	199	199	NUM
dpc-1415	520	2	.	.	PUNCT
dpc-1415	520	3	doi	doi	NOUN
dpc-1415	520	4	:	:	PUNCT
dpc-1415	520	5	10.1001	10.1001	NUM
dpc-1415	520	6	/	/	SYM
dpc-1415	520	7	jamadermatol.2014.2233	jamadermatol.2014.2233	PROPN
dpc-1415	520	8	.	.	PUNCT
dpc-1415	521	1	pmid	pmid	NOUN
dpc-1415	521	2	:	:	PUNCT
dpc-1415	521	3	25321335	25321335	NUM
dpc-1415	521	4	.	.	PUNCT
dpc-1415	522	1	review	review	VERB
dpc-1415	522	2	|	|	ADV
dpc-1415	522	3	dermatol	dermatol	ADJ
dpc-1415	522	4	pract	pract	NOUN
dpc-1415	522	5	concept	concept	NOUN
dpc-1415	522	6	2021;11(1):e2021155	2021;11(1):e2021155	NUM
dpc-1415	522	7	11	11	NUM
dpc-1415	522	8	56	56	NUM
dpc-1415	522	9	.	.	PUNCT
dpc-1415	523	1	yamaguchi	yamaguchi	PROPN
dpc-1415	523	2	y	y	PROPN
dpc-1415	523	3	,	,	PUNCT
dpc-1415	523	4	abe	abe	PROPN
dpc-1415	523	5	r	r	PROPN
dpc-1415	523	6	,	,	PUNCT
dpc-1415	523	7	haga	haga	NOUN
dpc-1415	523	8	n	n	CCONJ
dpc-1415	523	9	,	,	PUNCT
dpc-1415	523	10	et	et	PROPN
dpc-1415	523	11	al	al	PROPN
dpc-1415	523	12	.	.	PUNCT
dpc-1415	524	1	a	a	DET
dpc-1415	524	2	case	case	NOUN
dpc-1415	524	3	of	of	ADP
dpc-1415	524	4	drug	drug	NOUN
dpc-1415	524	5	associated	associate	VERB
dpc-1415	524	6	dermatomyositis	dermatomyositis	PROPN
dpc-1415	524	7	following	follow	VERB
dpc-1415	524	8	ipilimumab	ipilimumab	NOUN
dpc-1415	524	9	therapy	therapy	NOUN
dpc-1415	524	10	.	.	PUNCT
dpc-1415	525	1	eur	eur	PROPN
dpc-1415	525	2	j	j	PROPN
dpc-1415	525	3	dermatol	dermatol	NOUN
dpc-1415	525	4	.	.	PUNCT
dpc-1415	526	1	2016;26(3):320	2016;26(3):320	NOUN
dpc-1415	526	2	-	-	SYM
dpc-1415	526	3	321	321	NUM
dpc-1415	526	4	.	.	PUNCT
dpc-1415	527	1	doi	doi	NOUN
dpc-1415	527	2	:	:	PUNCT
dpc-1415	527	3	10.1684	10.1684	NUM
dpc-1415	527	4	/	/	SYM
dpc-1415	527	5	ejd.2016.2770	ejd.2016.2770	NOUN
dpc-1415	527	6	.	.	NOUN
dpc-1415	527	7	pmid	pmid	NOUN
dpc-1415	527	8	:	:	PUNCT
dpc-1415	527	9	27210586	27210586	NUM
dpc-1415	527	10	.	.	PUNCT
dpc-1415	528	1	57	57	NUM
dpc-1415	528	2	.	.	X
dpc-1415	528	3	le	le	PROPN
dpc-1415	529	1	burel	burel	PROPN
dpc-1415	529	2	s	s	PART
dpc-1415	529	3	,	,	PUNCT
dpc-1415	529	4	champiat	champiat	PROPN
dpc-1415	529	5	s	s	PROPN
dpc-1415	529	6	,	,	PUNCT
dpc-1415	529	7	routier	routier	X
dpc-1415	529	8	e	e	NOUN
dpc-1415	529	9	,	,	PUNCT
dpc-1415	529	10	et	et	PROPN
dpc-1415	529	11	al	al	PROPN
dpc-1415	529	12	.	.	PROPN
dpc-1415	529	13	onset	onset	PROPN
dpc-1415	529	14	of	of	ADP
dpc-1415	529	15	connective	connective	ADJ
dpc-1415	529	16	tissue	tissue	NOUN
dpc-1415	529	17	disease	disease	NOUN
dpc-1415	529	18	following	follow	VERB
dpc-1415	529	19	anti	anti	ADJ
dpc-1415	529	20	-	-	ADJ
dpc-1415	529	21	pd-1	pd-1	ADJ
dpc-1415	529	22	/	/	SYM
dpc-1415	529	23	pd	pd	ADJ
dpc-1415	529	24	-	-	PROPN
dpc-1415	529	25	l1	l1	PROPN
dpc-1415	529	26	cancer	cancer	NOUN
dpc-1415	529	27	immunotherapy	immunotherapy	NOUN
dpc-1415	529	28	.	.	PUNCT
dpc-1415	530	1	ann	ann	PROPN
dpc-1415	530	2	rheum	rheum	PROPN
dpc-1415	530	3	dis	dis	PROPN
dpc-1415	530	4	.	.	PUNCT
dpc-1415	531	1	2018;77(3):468	2018;77(3):468	NUM
dpc-1415	531	2	-	-	SYM
dpc-1415	531	3	470	470	NUM
dpc-1415	531	4	.	.	PUNCT
dpc-1415	532	1	doi	doi	NOUN
dpc-1415	532	2	:	:	PUNCT
dpc-1415	532	3	10.1136	10.1136	NUM
dpc-1415	532	4	/	/	SYM
dpc-1415	532	5	annrheum	annrheum	NOUN
dpc-1415	532	6	dis-2016	dis-2016	NOUN
dpc-1415	532	7	-	-	PUNCT
dpc-1415	532	8	210820	210820	NUM
dpc-1415	532	9	.	.	PUNCT
dpc-1415	533	1	pmid	pmid	NOUN
dpc-1415	533	2	:	:	PUNCT
dpc-1415	533	3	28242618	28242618	NUM
dpc-1415	533	4	.	.	PUNCT
dpc-1415	534	1	58	58	NUM
dpc-1415	534	2	.	.	PUNCT
dpc-1415	535	1	gambichler	gambichler	PROPN
dpc-1415	535	2	t	t	PROPN
dpc-1415	535	3	,	,	PUNCT
dpc-1415	535	4	strutzmann	strutzmann	PROPN
dpc-1415	535	5	s	s	NOUN
dpc-1415	535	6	,	,	PUNCT
dpc-1415	535	7	tannapfel	tannapfel	NOUN
dpc-1415	535	8	a	a	X
dpc-1415	535	9	,	,	PUNCT
dpc-1415	535	10	et	et	PROPN
dpc-1415	535	11	al	al	PROPN
dpc-1415	535	12	.	.	PUNCT
dpc-1415	536	1	paraneoplastic	paraneoplastic	ADJ
dpc-1415	536	2	acral	acral	ADJ
dpc-1415	536	3	vascular	vascular	ADJ
dpc-1415	536	4	syndrome	syndrome	NOUN
dpc-1415	536	5	in	in	ADP
dpc-1415	536	6	a	a	DET
dpc-1415	536	7	patient	patient	NOUN
dpc-1415	536	8	with	with	ADP
dpc-1415	536	9	metastatic	metastatic	ADJ
dpc-1415	536	10	melanoma	melanoma	NOUN
dpc-1415	536	11	under	under	ADP
dpc-1415	536	12	immune	immune	ADJ
dpc-1415	536	13	checkpoint	checkpoint	NOUN
dpc-1415	536	14	blockade	blockade	NOUN
dpc-1415	536	15	.	.	PUNCT
dpc-1415	537	1	bmc	bmc	ADJ
dpc-1415	537	2	cancer	cancer	NOUN
dpc-1415	537	3	.	.	PUNCT
dpc-1415	538	1	2017;17(1):327	2017;17(1):327	NOUN
dpc-1415	538	2	.	.	PUNCT
dpc-1415	539	1	doi	doi	NOUN
dpc-1415	539	2	:	:	PUNCT
dpc-1415	539	3	10.1186	10.1186	NUM
dpc-1415	539	4	/	/	SYM
dpc-1415	539	5	s12885	s12885	NOUN
dpc-1415	539	6	-	-	PUNCT
dpc-1415	539	7	017	017	NUM
dpc-1415	539	8	-	-	PUNCT
dpc-1415	539	9	3313	3313	NUM
dpc-1415	539	10	-	-	SYM
dpc-1415	539	11	6	6	NUM
dpc-1415	539	12	.	.	PUNCT
dpc-1415	540	1	pmid	pmid	NOUN
dpc-1415	540	2	:	:	PUNCT
dpc-1415	540	3	28499411	28499411	NUM
dpc-1415	540	4	.	.	PUNCT
dpc-1415	541	1	59	59	NUM
dpc-1415	541	2	.	.	PUNCT
dpc-1415	541	3	cappelli	cappelli	PROPN
dpc-1415	541	4	lc	lc	PROPN
dpc-1415	541	5	,	,	PUNCT
dpc-1415	541	6	gutierrez	gutierrez	PROPN
dpc-1415	541	7	ak	ak	PROPN
dpc-1415	541	8	,	,	PUNCT
dpc-1415	541	9	baer	baer	PROPN
dpc-1415	541	10	an	an	PROPN
dpc-1415	541	11	,	,	PUNCT
dpc-1415	541	12	et	et	PROPN
dpc-1415	541	13	al	al	PROPN
dpc-1415	541	14	.	.	PUNCT
dpc-1415	541	15	inflammatory	inflammatory	ADJ
dpc-1415	541	16	arthritis	arthritis	NOUN
dpc-1415	541	17	and	and	CCONJ
dpc-1415	541	18	sicca	sicca	VERB
dpc-1415	541	19	syndrome	syndrome	NOUN
dpc-1415	541	20	induced	induce	VERB
dpc-1415	541	21	by	by	ADP
dpc-1415	541	22	nivolumab	nivolumab	NOUN
dpc-1415	541	23	and	and	CCONJ
dpc-1415	541	24	ipilimumab	ipilimumab	VERB
dpc-1415	541	25	.	.	PUNCT
dpc-1415	542	1	ann	ann	PROPN
dpc-1415	542	2	rheum	rheum	PROPN
dpc-1415	542	3	dis	dis	PROPN
dpc-1415	542	4	.	.	PUNCT
dpc-1415	543	1	2017;76(1):43	2017;76(1):43	NUM
dpc-1415	543	2	-	-	SYM
dpc-1415	543	3	50	50	NUM
dpc-1415	543	4	.	.	PUNCT
dpc-1415	544	1	doi	doi	NOUN
dpc-1415	544	2	:	:	PUNCT
dpc-1415	544	3	10.1136	10.1136	NUM
dpc-1415	544	4	/	/	SYM
dpc-1415	544	5	annrheumdis-2016	annrheumdis-2016	NOUN
dpc-1415	544	6	-	-	PUNCT
dpc-1415	544	7	209595	209595	NUM
dpc-1415	544	8	.	.	PUNCT
dpc-1415	545	1	pmid	pmid	NOUN
dpc-1415	545	2	:	:	PUNCT
dpc-1415	545	3	27307501	27307501	NUM
dpc-1415	545	4	.	.	PUNCT
dpc-1415	546	1	60	60	NUM
dpc-1415	546	2	.	.	PUNCT
dpc-1415	547	1	curry	curry	PROPN
dpc-1415	547	2	jl	jl	PROPN
dpc-1415	547	3	,	,	PUNCT
dpc-1415	547	4	tetzlaff	tetzlaff	PROPN
dpc-1415	547	5	mt	mt	PROPN
dpc-1415	547	6	,	,	PUNCT
dpc-1415	547	7	nagarajan	nagarajan	NOUN
dpc-1415	547	8	p	p	PRON
dpc-1415	547	9	,	,	PUNCT
dpc-1415	547	10	et	et	PROPN
dpc-1415	547	11	al	al	PROPN
dpc-1415	547	12	.	.	PUNCT
dpc-1415	548	1	diverse	diverse	ADJ
dpc-1415	548	2	types	type	NOUN
dpc-1415	548	3	of	of	ADP
dpc-1415	548	4	dermatologic	dermatologic	ADJ
dpc-1415	548	5	toxicities	toxicity	NOUN
dpc-1415	548	6	from	from	ADP
dpc-1415	548	7	immune	immune	ADJ
dpc-1415	548	8	checkpoint	checkpoint	NOUN
dpc-1415	548	9	blockade	blockade	NOUN
dpc-1415	548	10	therapy	therapy	NOUN
dpc-1415	548	11	.	.	PUNCT
dpc-1415	549	1	j	j	PROPN
dpc-1415	549	2	cutan	cutan	PROPN
dpc-1415	549	3	pathol	pathol	PROPN
dpc-1415	549	4	.	.	PUNCT
dpc-1415	550	1	2017;44(2):158	2017;44(2):158	NUM
dpc-1415	550	2	-	-	PUNCT
dpc-1415	550	3	176	176	NUM
dpc-1415	550	4	.	.	PUNCT
dpc-1415	551	1	doi	doi	NOUN
dpc-1415	551	2	:	:	PUNCT
dpc-1415	551	3	10.1111	10.1111	NUM
dpc-1415	551	4	/	/	SYM
dpc-1415	551	5	cup.12858	cup.12858	PROPN
dpc-1415	551	6	.	.	PUNCT
dpc-1415	552	1	pmid	pmid	NOUN
dpc-1415	552	2	:	:	PUNCT
dpc-1415	552	3	27859479	27859479	NUM
dpc-1415	552	4	.	.	PUNCT
dpc-1415	553	1	61	61	NUM
dpc-1415	553	2	.	.	PUNCT
dpc-1415	554	1	bousquet	bousquet	PROPN
dpc-1415	554	2	e	e	PROPN
dpc-1415	554	3	,	,	PUNCT
dpc-1415	554	4	zarbo	zarbo	X
dpc-1415	554	5	a	a	NOUN
dpc-1415	554	6	,	,	PUNCT
dpc-1415	554	7	tournier	tournier	NOUN
dpc-1415	554	8	e	e	NOUN
dpc-1415	554	9	,	,	PUNCT
dpc-1415	554	10	et	et	PROPN
dpc-1415	554	11	al	al	PROPN
dpc-1415	554	12	.	.	PUNCT
dpc-1415	554	13	development	development	NOUN
dpc-1415	554	14	of	of	ADP
dpc-1415	554	15	papulopustular	papulopustular	ADJ
dpc-1415	554	16	rosacea	rosacea	NOUN
dpc-1415	554	17	during	during	ADP
dpc-1415	554	18	nivolumab	nivolumab	NOUN
dpc-1415	554	19	therapy	therapy	NOUN
dpc-1415	554	20	for	for	ADP
dpc-1415	554	21	metastatic	metastatic	ADJ
dpc-1415	554	22	cancer	cancer	NOUN
dpc-1415	554	23	.	.	PUNCT
dpc-1415	555	1	acta	acta	PROPN
dpc-1415	555	2	derm	derm	PROPN
dpc-1415	555	3	venereol	venereol	NOUN
dpc-1415	555	4	.	.	PUNCT
dpc-1415	556	1	2017;97(4):539	2017;97(4):539	NOUN
dpc-1415	556	2	-	-	SYM
dpc-1415	556	3	540	540	NUM
dpc-1415	556	4	.	.	PUNCT
dpc-1415	557	1	doi	doi	NOUN
dpc-1415	557	2	:	:	PUNCT
dpc-1415	557	3	10.2340/00015555	10.2340/00015555	NUM
dpc-1415	557	4	-	-	SYM
dpc-1415	557	5	2566	2566	NUM
dpc-1415	557	6	.	.	PUNCT
dpc-1415	558	1	pmid	pmid	NOUN
dpc-1415	558	2	:	:	PUNCT
dpc-1415	558	3	27826614	27826614	NUM
dpc-1415	558	4	.	.	PUNCT
dpc-1415	559	1	62	62	NUM
dpc-1415	559	2	.	.	PUNCT
dpc-1415	560	1	suozzi	suozzi	PROPN
dpc-1415	560	2	kc	kc	PROPN
dpc-1415	560	3	,	,	PUNCT
dpc-1415	560	4	stahl	stahl	PROPN
dpc-1415	560	5	m	m	PROPN
dpc-1415	560	6	,	,	PUNCT
dpc-1415	560	7	ko	ko	PROPN
dpc-1415	560	8	cj	cj	PROPN
dpc-1415	560	9	,	,	PUNCT
dpc-1415	560	10	et	et	PROPN
dpc-1415	560	11	al	al	PROPN
dpc-1415	560	12	.	.	PROPN
dpc-1415	560	13	immune	immune	NOUN
dpc-1415	560	14	-	-	PUNCT
dpc-1415	560	15	related	relate	VERB
dpc-1415	560	16	sarcoidosis	sarcoidosis	NOUN
dpc-1415	560	17	observed	observe	VERB
dpc-1415	560	18	incombination	incombination	NOUN
dpc-1415	560	19	ipilimumab	ipilimumab	ADV
dpc-1415	560	20	and	and	CCONJ
dpc-1415	560	21	nivolumab	nivolumab	ADP
dpc-1415	560	22	therapy	therapy	NOUN
dpc-1415	560	23	.	.	PUNCT
dpc-1415	561	1	jaad	jaad	PROPN
dpc-1415	561	2	case	case	NOUN
dpc-1415	561	3	rep	rep	PROPN
dpc-1415	561	4	.	.	PROPN
dpc-1415	561	5	2016;2(3):264	2016;2(3):264	NUM
dpc-1415	561	6	-	-	PUNCT
dpc-1415	561	7	268	268	NUM
dpc-1415	561	8	.	.	PUNCT
dpc-1415	562	1	doi	doi	NOUN
dpc-1415	562	2	:	:	PUNCT
dpc-1415	562	3	10.1016	10.1016	NUM
dpc-1415	562	4	/	/	SYM
dpc-1415	562	5	j.jdcr.2016.05.002	j.jdcr.2016.05.002	PROPN
dpc-1415	562	6	.	.	PUNCT
dpc-1415	563	1	pmid	pmid	NOUN
dpc-1415	563	2	:	:	PUNCT
dpc-1415	563	3	27486590	27486590	NUM
dpc-1415	563	4	.	.	PUNCT
dpc-1415	564	1	63	63	NUM
dpc-1415	564	2	.	.	PUNCT
dpc-1415	564	3	martínez	martínez	PROPN
dpc-1415	564	4	leboráns	leboráns	PROPN
dpc-1415	564	5	l	l	PROPN
dpc-1415	564	6	,	,	PUNCT
dpc-1415	564	7	esteve	esteve	PROPN
dpc-1415	564	8	martínez	martínez	PROPN
dpc-1415	564	9	a	a	PROPN
dpc-1415	564	10	,	,	PUNCT
dpc-1415	564	11	victoria	victoria	PROPN
dpc-1415	564	12	martínez	martínez	PROPN
dpc-1415	564	13	am	be	AUX
dpc-1415	564	14	,	,	PUNCT
dpc-1415	564	15	et	et	PROPN
dpc-1415	564	16	al	al	PROPN
dpc-1415	564	17	.	.	PUNCT
dpc-1415	565	1	cutaneous	cutaneous	ADJ
dpc-1415	565	2	sarcoidosis	sarcoidosis	NOUN
dpc-1415	565	3	in	in	ADP
dpc-1415	565	4	a	a	DET
dpc-1415	565	5	melanoma	melanoma	NOUN
dpc-1415	565	6	patient	patient	NOUN
dpc-1415	565	7	under	under	ADP
dpc-1415	565	8	ipilimumab	ipilimumab	NOUN
dpc-1415	565	9	therapy	therapy	NOUN
dpc-1415	565	10	.	.	PUNCT
dpc-1415	566	1	dermatol	dermatol	NOUN
dpc-1415	566	2	ther	ther	ADV
dpc-1415	566	3	.	.	PUNCT
dpc-1415	567	1	2016;29(5):306–308	2016;29(5):306–308	X
dpc-1415	567	2	.	.	PUNCT
dpc-1415	568	1	doi	doi	NOUN
dpc-1415	568	2	:	:	PUNCT
dpc-1415	568	3	10.1111	10.1111	NUM
dpc-1415	568	4	/	/	SYM
dpc-1415	568	5	dth.12380	dth.12380	NOUN
dpc-1415	568	6	.	.	NOUN
dpc-1415	569	1	pmid	pmid	NOUN
dpc-1415	569	2	:	:	PUNCT
dpc-1415	569	3	27357143	27357143	NUM
dpc-1415	569	4	.	.	PUNCT
dpc-1415	570	1	64	64	NUM
dpc-1415	570	2	.	.	PUNCT
dpc-1415	571	1	reule	reule	NOUN
dpc-1415	571	2	rb	rb	PROPN
dpc-1415	571	3	,	,	PUNCT
dpc-1415	571	4	north	north	NOUN
dpc-1415	571	5	jp	jp	NOUN
dpc-1415	571	6	.	.	PUNCT
dpc-1415	572	1	cutaneous	cutaneous	ADJ
dpc-1415	572	2	and	and	CCONJ
dpc-1415	572	3	pulmonary	pulmonary	ADJ
dpc-1415	572	4	sarcoidosislikereaction	sarcoidosislikereaction	NOUN
dpc-1415	572	5	associated	associate	VERB
dpc-1415	572	6	with	with	ADP
dpc-1415	572	7	ipilimumab	ipilimumab	NOUN
dpc-1415	572	8	.	.	PUNCT
dpc-1415	573	1	j	j	PROPN
dpc-1415	573	2	am	be	AUX
dpc-1415	573	3	acad	acad	ADJ
dpc-1415	573	4	dermatol	dermatol	NOUN
dpc-1415	573	5	.	.	PUNCT
dpc-1415	574	1	2013;69(5):e272	2013;69(5):e272	NOUN
dpc-1415	574	2	-	-	PUNCT
dpc-1415	574	3	273	273	NUM
dpc-1415	574	4	.	.	PUNCT
dpc-1415	575	1	doi	doi	NOUN
dpc-1415	575	2	:	:	PUNCT
dpc-1415	575	3	10.1016	10.1016	NUM
dpc-1415	575	4	/	/	SYM
dpc-1415	575	5	j.jaad.2013.07.028	j.jaad.2013.07.028	PROPN
dpc-1415	575	6	.	.	PUNCT
dpc-1415	576	1	pmid	pmid	NOUN
dpc-1415	576	2	:	:	PUNCT
dpc-1415	576	3	24124863	24124863	NUM
dpc-1415	576	4	.	.	PUNCT
dpc-1415	577	1	65	65	NUM
dpc-1415	577	2	.	.	PUNCT
dpc-1415	578	1	birnbaum	birnbaum	PROPN
dpc-1415	578	2	mr	mr	PROPN
dpc-1415	578	3	,	,	PUNCT
dpc-1415	578	4	ma	ma	PROPN
dpc-1415	578	5	mw	mw	PROPN
dpc-1415	578	6	,	,	PUNCT
dpc-1415	578	7	fleisig	fleisig	NOUN
dpc-1415	578	8	s	s	X
dpc-1415	578	9	,	,	PUNCT
dpc-1415	578	10	et	et	PROPN
dpc-1415	578	11	al	al	PROPN
dpc-1415	578	12	.	.	PROPN
dpc-1415	578	13	nivolumab	nivolumab	ADV
dpc-1415	578	14	-	-	PUNCT
dpc-1415	578	15	related	relate	VERB
dpc-1415	578	16	cutaneous	cutaneous	ADJ
dpc-1415	578	17	sarcoidosisin	sarcoidosisin	NOUN
dpc-1415	578	18	a	a	DET
dpc-1415	578	19	patient	patient	NOUN
dpc-1415	578	20	with	with	ADP
dpc-1415	578	21	lung	lung	NOUN
dpc-1415	578	22	adenocarcinoma	adenocarcinoma	NOUN
dpc-1415	578	23	.	.	PUNCT
dpc-1415	579	1	jaad	jaad	NOUN
dpc-1415	579	2	case	case	PROPN
dpc-1415	579	3	rep	rep	PROPN
dpc-1415	579	4	.	.	PROPN
dpc-1415	579	5	2017;3(3):208	2017;3(3):208	NUM
dpc-1415	579	6	-	-	SYM
dpc-1415	579	7	211	211	NUM
dpc-1415	579	8	.	.	PUNCT
dpc-1415	580	1	doi	doi	NOUN
dpc-1415	580	2	:	:	PUNCT
dpc-1415	580	3	10.1016	10.1016	NUM
dpc-1415	580	4	/	/	SYM
dpc-1415	580	5	j.jdcr.2017.02.015	j.jdcr.2017.02.015	PROPN
dpc-1415	580	6	.	.	PUNCT
dpc-1415	581	1	pmid	pmid	NOUN
dpc-1415	581	2	:	:	PUNCT
dpc-1415	581	3	28443311	28443311	NUM
dpc-1415	581	4	.	.	PUNCT
dpc-1415	582	1	66	66	NUM
dpc-1415	582	2	.	.	PUNCT
dpc-1415	582	3	zarbo	zarbo	PROPN
dpc-1415	582	4	a	a	PROPN
dpc-1415	582	5	,	,	PUNCT
dpc-1415	582	6	belum	belum	PROPN
dpc-1415	582	7	vr	vr	PROPN
dpc-1415	582	8	,	,	PUNCT
dpc-1415	582	9	sibaud	sibaud	NOUN
dpc-1415	582	10	v	v	NOUN
dpc-1415	582	11	,	,	PUNCT
dpc-1415	582	12	et	et	PROPN
dpc-1415	582	13	al	al	PROPN
dpc-1415	582	14	.	.	PROPN
dpc-1415	582	15	immune	immune	NOUN
dpc-1415	582	16	-	-	PUNCT
dpc-1415	582	17	related	relate	VERB
dpc-1415	582	18	alopecia	alopecia	NOUN
dpc-1415	582	19	(	(	PUNCT
dpc-1415	582	20	areata	areata	ADJ
dpc-1415	582	21	and	and	CCONJ
dpc-1415	582	22	universalis	universali	VERB
dpc-1415	582	23	)	)	PUNCT
dpc-1415	582	24	in	in	ADP
dpc-1415	582	25	cancer	cancer	NOUN
dpc-1415	582	26	patients	patient	NOUN
dpc-1415	582	27	receiving	receive	VERB
dpc-1415	582	28	immune	immune	ADJ
dpc-1415	582	29	checkpoint	checkpoint	NOUN
dpc-1415	582	30	inhibitors	inhibitor	NOUN
dpc-1415	582	31	.	.	PUNCT
dpc-1415	583	1	br	br	PROPN
dpc-1415	583	2	j	j	PROPN
dpc-1415	583	3	dermatol	dermatol	NOUN
dpc-1415	583	4	.	.	PUNCT
dpc-1415	584	1	2017;176(6):1649	2017;176(6):1649	NUM
dpc-1415	584	2	-	-	SYM
dpc-1415	584	3	1652	1652	NUM
dpc-1415	584	4	.	.	PUNCT
dpc-1415	585	1	doi	doi	NOUN
dpc-1415	585	2	:	:	PUNCT
dpc-1415	585	3	10.1111	10.1111	NUM
dpc-1415	585	4	/	/	SYM
dpc-1415	585	5	bjd.15237	bjd.15237	PROPN
dpc-1415	585	6	.	.	PUNCT
dpc-1415	586	1	pmid	pmid	NOUN
dpc-1415	586	2	:	:	PUNCT
dpc-1415	586	3	27943234	27943234	NUM
dpc-1415	586	4	.	.	PUNCT
dpc-1415	587	1	67	67	NUM
dpc-1415	587	2	.	.	PUNCT
dpc-1415	588	1	apalla	apalla	PROPN
dpc-1415	588	2	z	z	PROPN
dpc-1415	588	3	,	,	PUNCT
dpc-1415	588	4	sibaud	sibaud	NOUN
dpc-1415	588	5	v.	v.	ADP
dpc-1415	588	6	immunotherapy	immunotherapy	NOUN
dpc-1415	588	7	-	-	PUNCT
dpc-1415	588	8	mediated	mediate	VERB
dpc-1415	588	9	dermatological	dermatological	ADJ
dpc-1415	588	10	adverse	adverse	ADJ
dpc-1415	588	11	events	event	NOUN
dpc-1415	588	12	:	:	PUNCT
dpc-1415	588	13	the	the	DET
dpc-1415	588	14	urgent	urgent	ADJ
dpc-1415	588	15	need	need	NOUN
dpc-1415	588	16	for	for	ADP
dpc-1415	588	17	a	a	DET
dpc-1415	588	18	common	common	ADJ
dpc-1415	588	19	,	,	PUNCT
dpc-1415	588	20	clinically	clinically	ADV
dpc-1415	588	21	meaningful	meaningful	ADJ
dpc-1415	588	22	,	,	PUNCT
dpc-1415	588	23	management	management	NOUN
dpc-1415	588	24	strategy	strategy	NOUN
dpc-1415	588	25	.	.	PUNCT
dpc-1415	589	1	support	support	NOUN
dpc-1415	589	2	care	care	NOUN
dpc-1415	589	3	cancer	cancer	NOUN
dpc-1415	589	4	.	.	PUNCT
dpc-1415	590	1	2020;28(12):55975599	2020;28(12):55975599	X
dpc-1415	590	2	.	.	X
dpc-1415	590	3	doi	doi	NOUN
dpc-1415	590	4	:	:	PUNCT
dpc-1415	590	5	10.1007	10.1007	NUM
dpc-1415	590	6	/	/	SYM
dpc-1415	590	7	s00520	s00520	NOUN
dpc-1415	590	8	-	-	PUNCT
dpc-1415	590	9	020	020	NUM
dpc-1415	590	10	-	-	PUNCT
dpc-1415	590	11	05701	05701	NUM
dpc-1415	590	12	-	-	PUNCT
dpc-1415	590	13	9	9	NUM
dpc-1415	590	14	.	.	PUNCT
dpc-1415	591	1	pmid	pmid	NOUN
dpc-1415	591	2	:	:	PUNCT
dpc-1415	591	3	32827054	32827054	NUM
dpc-1415	591	4	.	.	PUNCT